

CUMULATIVE INDEX

Notes

This index covers the chapters in all four volumes in the *Clinical Pain Management* series. Page references are prefixed by a code indicating the volume in which the page referred can be found. The codes are as follows:

- A Acute Pain
- Ch Chronic Pain
- C Cancer Pain
- P Practice and Procedures

An *F* following a page reference indicates that the reference is to a figure; a *T* indicates that the reference is to a table.

To save space in the index, the following abbreviations have been used:

- APS – Acute Pain Service(s)
- CAM – complementary and alternative medicine
- CBT – cognitive-behavioral therapy
- CPSP – chronic postsurgical pain
- CRPS – complex regional pain syndrome
- ICU(s) – intensive care unit
- MRI – magnetic resonance imaging
- NHS – National Health Service
- NSAIDs – nonsteroidal anti-inflammatory drugs
- PCA – patient-controlled analgesia
- SCS – spinal cord stimulation
- TENS – transcutaneous electrical nerve stimulation

A α -fiber(s)

- classification **A:** 4 *T*
- local anesthetic sensitivity **A:** 116 *T*
- postnatal development **A:** 33, **A:** 34 *T*
- abatacept, rheumatoid
 - arthritis **Ch:** 522–4 *T*, **Ch:** 524
- Abbey Pain Scale **A:** 147
- abbreviated measures, chronic
 - pain **Ch:** 183
- abdomen
 - chronic pain syndromes **P:** 385
 - nerve blocks **P:** 275–9
 - physical examination **Ch:** 583
- abdominal aortic surgery, epidural
 - analgesia **A:** 263
- abdominal malignancy, celiac plexus
 - block **P:** 341
- abdominal migraine **A:** 414
 - characteristics **A:** 414; **Ch:** 565
 - prophylaxis **A:** 414

abdominal pain

- acute **A:** 413–7
 - analgesia **A:** 363, **A:** 414
 - conservative management **A:** 414
 - diagnosis **A:** 413
 - elderly, perception of **A:** 510
 - emergency department **A:** 363
 - etiology **A:** 413
 - red flags **A:** 413
 - yellow flags **A:** 414
- cardiac failure **Ch:** 565
- chronic **Ch:** 549–69
 - clinical history **Ch:** 551
 - etiology **Ch:** 549–51
 - evaluation **Ch:** 551
- continuous, labor pain **A:** 465
- functional *see* functional abdominal
 - pain (FAP)
- HIV-associated **Ch:** 358
- nerve injury/entrapment **Ch:** 565

pancreatic cancer **C:** 35

- porphyrias **A:** 421
- see also individual diseases/disorders*

abdominal skin reflex (ASR) **A:** 39

- abdominal surgery, postoperative
 - epidural analgesia **P:** 312–3

abdominoperineal surgery, postoperative epidural analgesia **P:** 318, **P:** 320

- aberrant behavior, opioids **Ch:** 222,
Ch: 223 *T*

A β -fiber(s)

- characteristics **A:** 4 *T*
- inflammation, response to **Ch:** 28
- innocuous stimuli response **Ch:** 27
- local anesthetic sensitivity **A:** 116 *T*
- neuropathic pain **Ch:** 13
- peripheral neuropathy **P:** 77 *T*
- persistent musculoskeletal
 - pain **Ch:** 29–30

- A β -fiber(s) (*continued*)
 postamputation pain **Ch**: 420
 postnatal development **A**: 33, **A**: 34 *T*
 TENS **P**: 194
- abnormal posture, spasticity **Ch**: 442,
Ch: 444
- abnormal temporal summation
 testing **P**: 50
- abscess(es)
 epidural analgesia-induced *see*
 epidural abscess
 peridiverticular, diverticular
 disease **Ch**: 562
- absolute efficacy, CBT **Ch**: 297
- absolute risk **Ch**: 69, **Ch**: 69 *T*
- absorption **P**: 146
- absorption, drug
 definition **C**: 107
 local anesthetics *see* local anesthetic(s)
 NSAIDs **A**: 69
 oral drug administration **A**: 202
- acalculous cholecystitis, HIV-associated
 pain **Ch**: 358
- acceleration–deceleration injury *see*
 whiplash
- acceptance
 chronic pain **P**: 168–9
 pain, mindfulness and **P**: 170–1
- acceptance and commitment therapy
 (ACT) **P**: 169
- Access to Controlled Medicines
 Program (ACMP), opioids for
 nonmalignant pain **P**: 110
- accident and emergency *see* emergency
 departments (ED)
- Accident Rehabilitation and
 Compensation Insurance
 Corporation, low back pain
 management **A**: 454
- accountable officers (AO) **C**: 414
- accounting staff, pediatric APS **P**: 643
- Accreditation Council for Graduate
 Medical Education (ACGME),
 palliative care accreditation **C**: 413
- Accutherm **P**: 441
- aceclofenac **A**: 77
- ACE inhibitors, NSAID
 interactions **A**: 74 *T*
- acetaminophen *see* paracetamol
 (acetaminophen)
- acetanilide **A**: 85
- acetylcholine, myofascial pain **Ch**: 605
- acetyl L-carnitine
 chemotherapy-induced peripheral
 neuropathy **C**: 402
 HIV-related peripheral
 neuropathy **A**: 413
- acetylsalicylic acid *see* aspirin
 (acetylsalicylic acid)
- Achieving a balance in national opioids
 control policy: guidelines for
 assessment* **C**: 84
- Achilles bursitis **Ch**: 530
- Achilles tendon enthesitis **P**: 357
- Achilles tendonitis **Ch**: 530
- Achilles tendonosis **P**: 357
- Achilles tendon rupture **P**: 357
- acidosis, labor pain **A**: 465–6
- acid phosphatase test **C**: 257
- acid reflux **Ch**: 543
- acid-sensing ion channels (ASIC),
 somatic nociceptors **A**: 4–6
- acquired immunodeficiency syndrome
 (AIDS) *see* AIDS
- acquired tolerance **C**: 105
- acromioclavicular joint, intra-articular
 injection **P**: 351, **P**: 352 *F*
- ACTH *see* adrenocorticotrop
 hormone (ACTH)
- action potentials **A**: 114
- action potential stimulation
 therapy **P**: 196
- activated charcoal therapy, paracetamol
 overdose **A**: 92
- activated protein C (drotrecogin alfa),
 sepsis **A**: 350
- activation
 acute neck pain treatment **Ch**: 494
 low back pain management **A**: 450
 mechanical back pain
 management **A**: 454
- activation, action potential **Ch**: 28
- active escape, neuropathic pain
 models **Ch**: 7
- active listening **P**: 100
- active negotiation, patient beliefs **A**: 295
- active placebo **P**: 520
 neuropathic pain clinical trials **P**: 524
- active skill practicing, CBT **Ch**: 294–5
- activity, definition **P**: 221
- activity avoidance, pain-related
 fear **P**: 180
- activity meters **P**: 103
- activity schedules, pediatric headache
 therapy **Ch**: 630
- acupressure (Shiatsu) **C**: 272, **C**: 277–8
- acupuncture **P**: 206–19
 acute pain **A**: 280–2
 cancer-related **C**: 272
 clinical effectiveness **A**: 282–5,
A: 283 *T*
 indications **A**: 280
 adverse effects **Ch**: 310
 angina pectoris **A**: 284
- applied anatomy **P**: 194
- breast cancer **C**: 273
 case example **Ch**: 316–7
- cancer pain **C**: 271–4
 clinical trial evidence **C**: 272–3
- central neuropathic pain **Ch**: 379–80
- chemotherapy-induced nausea **C**: 274
- chronic pain **Ch**: 307–10
- complications **C**: 274
- contraindications **A**: 282; **C**: 274
- definition **A**: 280
- dental pain, acute **A**: 283 *T*, **A**: 284–5
de qi **A**: 281–2
- dosage **A**: 281–2
- dysmenorrhea **A**: 283 *T*, **A**: 284,
A: 417; **Ch**: 574
- dyspnea **C**: 274
- efficacy studies **Ch**: 309
- elbow pain **A**: 438
- fibromyalgia syndrome **Ch**: 309,
Ch: 607
- functional abdominal pain **Ch**: 635
- historical aspects **A**: 280; **Ch**: 308–9;
C: 271–2; **P**: 206
- imaging studies **P**: 209
- labor pain **A**: 283 *T*, **A**: 284, **A**: 468
- low back pain **A**: 282–4, **A**: 283 *T*,
A: 451 *T*, **A**: 452
- mechanism of action **A**: 280–1;
C: 273; **P**: 208–9
- metastatic disease **C**: 273
- multiple sclerosis **Ch**: 332
- musculoskeletal problems **A**: 281
- myofascial pain **Ch**: 608
- neck pain, chronic **Ch**: 494
- needle stimulation **Ch**: 309
- needling technique **A**: 281
- neurologic disease pain **Ch**: 331
- neuropathic pain **A**: 281
- neurophysiology **C**: 273; **P**: 208–9
 general effects **P**: 209
 heterosegmental effects **P**: 209
 local effects **P**: 209
 segmental effects **P**: 209
- nociceptive pain **A**: 281
- non-pain symptoms **C**: 273–4
- osteoarthritis **P**: 358–9
- point selection **A**: 281
- postamputation pain **Ch**: 423–4
- postoperative nausea and
 vomiting **C**: 273–4
- postoperative pain **A**: 284; **C**: 272
- precautions **A**: 282
- procedure-related pain **C**: 216
- research **P**: 208
- scientific basis **Ch**: 310
- segmental **P**: 212

- sham **P**: 208
 spinal cord injury pain **Ch**: 395–7,
Ch: 397 *T*
 Taoist philosophy **Ch**: 308
 techniques **Ch**: 309–10; **P**: 209–17
 electrical current **Ch**: 309,
Ch: 309 *F*
 timing **A**: 281–2
 traditional Chinese approach **C**: 271
 traditional theories **P**: 206–8
 trauma **A**: 285
 treatment course **C**: 272
 trigger point needling **P**: 209
 vegetative reactions **P**: 210–1
see also Western medical acupuncture
 acupuncture-like TENS *see* AL-TENS
 acupuncture meridians **C**: 273;
P: 206–7, **P**: 207 *F*
 acupuncture points **A**: 280
 development **P**: 206–7
 myofascial trigger points
 overlap **P**: 206–7, **P**: 207 *F*
 selection **A**: 281
 acute chest syndrome, sickle cell
 disease **A**: 419
 acute confusional migraine,
 children **Ch**: 629–30
 acute coronary syndrome **A**: 417
 acute interstitial nephritis,
 NSAID-induced **C**: 136
 acute pain
 abdominal *see* abdominal pain
 anxiety and **P**: 147
 assessment *see* acute pain assessment
 cardiac **A**: 417–8
 children *see* pediatric acute pain
 cryoanalgesia **P**: 383
 early intervention benefits **P**: 656
 elderly *see* elderly
 history taking **A**: 136–8
 analgesic use **A**: 138
 associated symptoms **A**: 137
 communication with
 patients **A**: 137
 emotional effects **A**: 137, **A**: 138
 functional impact
 assessment **A**: 138
 intensity **A**: 138
 key elements **A**: 137
 nature of pain **A**: 137
 nociceptive *vs.* neuropathic **A**: 138,
A: 138 *T*
 pain descriptions **A**: 137
 phantom sensations **A**: 138
 rest *vs.* movement-related
 intensity **A**: 138
 reviews **A**: 137
- sites of pain **A**: 137
 litigation sources **P**: 678 *T*
 management
 chronic opioid therapy
 patients **P**: 115–6
 chronic pain risk reduction **P**: 580
 in developing world *see* developing
 world, acute pain management
 fast-track recovery **P**: 580
 guidelines/reports **P**: 580
 humanitarian **P**: 579
 inadequate, recognition of **P**: 580–1
 quality indicators/
 measures **P**: 673 *T*
 untreated severe pain
 avoidance **P**: 579–80
 vital organ function
 preservation **P**: 580
see also acute pain service(s) (APS)
 measurement **A**: 138–48
 pain intensity scales **A**: 136 *T*,
A: 139–47
 medical disorders and **A**: 410–29
 neurological disorders **A**: 410–29
 nociceptors activated **P**: 44
 postoperative *see* acute postoperative
 pain
 sympathetic block
 indications **P**: 324–5
 TENS *see* transcutaneous electrical
 nerve stimulation (TENS)
- acute pain assessment **A**: 135–53
 children *see* pediatric acute pain
 chronic pain development risk **P**: 656
 frequency of **A**: 136
 functional assessment **A**: 147–8
 meta-analysis **A**: 149
 objectives **A**: 136 *T*
 research **A**: 148–9
 analgesia comparisons **A**: 148–9
 PCA **A**: 149
 tool validation **A**: 148
 treatment adverse effects **A**: 137
- Acute pain management: scientific
 evidence **P**: 666–7
- Acute pain management in the
 perioperative setting **P**: 666
- acute pain service(s) (APS) **P**: 579–603
 adaptation **P**: 614
 analgesic regimen selection **P**: 586–8
 analgesic technique selection
P: 586–7
 patient factors **P**: 587
- audit *see* audit, APS
 availability **P**: 606
 benefits **P**: 583–5
 persistent pain reduction **P**: 584
- postoperative patient
 outcome **P**: 583–4
 changing role **P**: 581–2
 children *see* pediatric acute pain
 services
 chronic pain service
 cooperation **P**: 583
 collaboration **P**: 597–8
 communication **P**: 597–8
 complex pain management
 issues **P**: 581–2
 development **P**: 581–5
 direct costs **P**: 584
 documentation
 standardization **P**: 588,
P: 590–1 *F*, **P**: 592–3 *F*
 drug selection **P**: 587–8
 economic considerations **P**: 584–5
 education **P**: 585–6
 medical staff **P**: 585–6
 nursing staff **P**: 585–6
 equipment selection **P**: 587–8
 expansion **P**: 583
 field/disaster situations **A**: 384–5
 training **A**: 384–5
 future developments **P**: 598
 growth **P**: 581–5
 guideline standardization **P**: 588–95,
P: 594–5 *F*, **P**: 596–7 *F*
 indirect costs **P**: 584
 initiation **P**: 583
 integration, other clinical
 services **P**: 598
 monitoring regimens **P**: 585
 monitoring standardization **P**: 589–95
 back pain **P**: 595
 block height **P**: 593–5
 hypotension **P**: 591–3
 motor blockade **P**: 593–5
 respiratory depression **P**: 589–91
 sensory blockade **P**: 593–5
- NHS
 implementation *see* acute pain
 service implementation, NHS
 policy background **P**: 605, **P**: 605 *T*
 organization **P**: 585–98
 organizational change **P**: 604–18
 organizational models **P**: 582–3
 anesthesiologist-based/
 nurse-supported **P**: 582
 Nordic countries **P**: 582
 nurse-based/anesthesiologist-
 led **P**: 582
 nurse practitioner model **P**: 582–3
 UK **P**: 582
- out of hours cover
 arrangements **P**: 598

- acute pain service(s) (APS) (*continued*)
- pain assessment
 - standardization **P:** 588–9
 - pain control, post-discharge **P:** 606
 - patients *see* patient education
 - PCA **P:** 295
 - pediatric *see* pediatric acute pain services
 - prescription standardization **P:** 588, **P:** 590–1 *F*, **P:** 592–3 *F*
 - protocol standardization **P:** 588–95
 - quality improvement **P:** 595–7
 - referral problems **P:** 612
 - regulatory changes **P:** 614
 - resources required **P:** 583
 - role **P:** 579–603
 - service provision **P:** 581
- acute pain service director **P:** 583
- acute pain service implementation, NHS
- challenges, addressing **P:** 612–4
 - change, path of least resistance **P:** 610
 - dissemination programmes **P:** 608
 - evaluation **P:** 608
 - existing values/norms, challenges to **P:** 610–1, **P:** 611
 - inter-professional working difficulties **P:** 611–2, **P:** 611
 - local adaptation **P:** 608
 - “lowest common denominator” approach **P:** 608
 - national performance agendas and **P:** 610
 - organization change
 - literature **P:** 607–12
 - content issues **P:** 607–8, **P:** 612–3
 - context issues **P:** 608–10, **P:** 613
 - lessons from **P:** 613
 - process issues **P:** 610–4
 - partial **P:** 608
 - political mandates **P:** 610
 - problems **P:** 605–7
 - professional boundaries in **P:** 612
 - service reorganizations and **P:** 609–10
 - trust mergers **P:** 609–10
 - at turbulent time **P:** 609
 - 1980s **P:** 609
 - 1990s **P:** 609
- acute pain service nurse, PCA **A:** 221
- acute pain service referral
 - form **P:** 631–4, **P:** 636–7 *F*
- acute phase protein **P:** 68–9
- acute phase reaction **P:** 68–9
- acute postoperative pain
- catastrophizing **A:** 294
 - C-fiber injury **A:** 156
 - children **A:** 480, **A:** 488–9
 - consequences of **A:** 328
 - definition **A:** 309
 - depression **A:** 294
 - elderly, perception of **A:** 510
 - management *see* acute postoperative pain management
 - mechanisms **A:** 155
 - mood **A:** 293–4
 - postoperative peripheral nociception **A:** 156
 - predictors **A:** 156–7
 - preoperative inputs **A:** 156
 - prevalence **A:** 292
 - psychological factors **A:** 293–5
 - resource implications **A:** 292
 - severity, progression to CPSP **A:** 563
 - threat value **A:** 294
 - underestimation, healthcare providers **A:** 295
- acute postoperative pain management **A:** 327–42
- acupuncture **A:** 284
- analgesic timing **A:** 329
- children **A:** 481
- continuous local anesthetic infiltration **A:** 332
- disadvantages **A:** 332
 - ultrasound-guided catheter placement **A:** 332
- continuous peripheral neural blockade *see* continuous peripheral neural blockade (CPNB)
- early period **A:** 335
- future work **A:** 336
- hypnosis **A:** 315–6
- inadequate, consequences of **A:** 328
- intra-articular analgesia **A:** 331
- intraperitoneal instillation **A:** 331
- multimodal techniques **A:** 156, **A:** 156 *F*, **A:** 329–35, **A:** 330 *T*
- ideal **A:** 329
 - pain perception **A:** 329
 - see also specific techniques*
- neuraxial analgesia **A:** 264
- numbers needed to treat **A:** 328
- opioids **A:** 329–30
- PCA **A:** 221–2
- peripheral nerve blocks **A:** 331
- short duration **A:** 331
- post-discharge **A:** 335–6
- preoperative considerations **A:** 328–9
- anxiolytic therapy **A:** 294
 - patient education **A:** 328–9
- preventive analgesia *see* preventive analgesia
- procedure-specific **A:** 328
- surgical considerations **A:** 336
- TENS **A:** 277, **A:** 278
- topical analgesia **A:** 330–1
- wound infiltration **A:** 330–1
- see also individual drugs*
- acute renal failure (ARF), NSAID-induced **A:** 71; **C:** 135–6
- mechanisms **C:** 135–6, **C:** 136 *F*
 - reduced circulation volumes **C:** 136
- acute tolerance (tachyphylaxis) **C:** 105
- adalimumab, rheumatoid arthritis **Ch:** 521, **Ch:** 522–4 *T*
- adaptation **C:** 49–50
- addiction
- characteristics **P:** 113
 - definition **A:** 540; **Ch:** 222, **Ch:** 653–4; **C:** 106, **C:** 157
 - fear of
 - cancer patients **C:** 106
 - by healthcare provider **A:** 295
 - PCA users **A:** 295
 - opioids *see* opioid addiction
 - see also* substance abuse/misuse
- additive effects, clinical trials **P:** 518
- additives, local anesthetics **A:** 118–9
- adductor tendonosis, soft-tissue injection **P:** 356
- A δ -fiber(s)
- acupuncture **A:** 280–1; **P:** 194, **P:** 208
 - acute pain **P:** 44
 - characteristics/structure **A:** 4, **A:** 4 *T*, **A:** 6 *T*
 - local anesthetic sensitivity **A:** 116 *T*
 - peripheral neuropathy **P:** 77 *T*
 - peripheral nociceptors **Ch:** 27, **Ch:** 28, **Ch:** 29
 - peripheral sensitization **A:** 21
 - persistent musculoskeletal pain **Ch:** 29–30
 - in spinal cord **A:** 8–9
- adenine **Ch:** 49
- Adenomatous Polyp Prevention on Vioxx (APPROVe) trial **Ch:** 195–6
- adenomyosis **Ch:** 574
- adenosine
 - field/disaster situations **A:** 380
 - peripheral nociceptor sensitization **Ch:** 29
- adhesiolysis
- adhesions **Ch:** 578
 - endoscopic *see* endoscopic adhesiolysis
 - epidural fibrosis **P:** 429
 - epidurosopic **P:** 431, **P:** 431 *F*
- adhesions **Ch:** 578
- adhesive capsulitis (frozen shoulder) management **Ch:** 529

- natural history **A:** 437
 soft-tissue injection **P:** 355
- adjustment disorders **Ch:** 617–8
- adolescents
 chronic pain assessment **P:** 455–6
 chronic pain outcome
 measurement **Ch:** 181
 hypnosis **P:** 485
 PCA **A:** 222
- adrenaline *see* epinephrine (adrenaline)
- adrenocorticotrophic hormone (ACTH)
 acupuncture **C:** 273
 fibromyalgia syndrome **Ch:** 603
 labor pain **A:** 466
 suppression, epidural
 steroid-induced **P:** 423
- advance statements **C:** 96–7
- A&E *see* emergency departments (ED)
- aerobic fitness assessment **P:** 222
- affective changes,
 opioid-induced **C:** 154
- affective disorders, clinical trial
 exclusion **P:** 545
- afferent input, spinal cord pain
 transmission **A:** 33
- affinity, drug **C:** 105
- Affymetrix, high-density genome-wide
 screening **Ch:** 71
- Africa, palliative care services **C:** 86,
C: 88–9, **C:** 90 *F*
 historical aspects **C:** 88–9
 initiatives **C:** 88
 opioid usage **C:** 89, **C:** 90 *F*
 organizational provision **C:** 89,
C: 89 *T*
- African Americans, chronic pain
 epidemiology **Ch:** 66–9
- after sensations, neuropathic
 pain **Ch:** 136, **Ch:** 141 *T*
- A γ fiber(s)
 characteristics **A:** 4 *T*
 local anesthetic sensitivity **A:** 116 *T*
- Agency for Health Care Policy and
 Research (AHCPR)
 acute low back pain
 management **A:** 453–4
 biofeedback meta-analysis **P:** 164
- AGENT-2 (Angiogenic Gene Therapy)
 trial **Ch:** 541–2
- aging population *see* elderly
- agitation
 end of life care **C:** 335
 pain misinterpretation **C:** 43
- agonist **C:** 105
- agonist–antagonist **C:** 105
- agranulocytosis,
 NSAID-induced **Ch:** 198
- AIDS
 associated pain *see* HIV-associated
 pain
 defining illnesses **Ch:** 352, **Ch:** 353
 diagnosis **Ch:** 151 *T*
 highly active antiretroviral
 treatment **Ch:** 352
see also HIV infection
- airway obstruction, tumors **C:** 312
- alar ligament tears **Ch:** 159
- albumin, plasma
 age-related changes **A:** 506 *T*, **A:** 508
 local anesthetic binding **A:** 120
- alcohol
 chronic pancreatitis **Ch:** 553
 abstinence **Ch:** 554
 paracetamol interactions **A:** 87
 sympathetic blocks **P:** 327
- alcohol abuse
 history taking **C:** 39
 as prognostic factor **C:** 42–3
 screening **C:** 42–3
- alcoholic neuropathy **A:** 412; **Ch:** 341;
P: 77
- alcohol neurolysis **C:** 227, **C:** 228 *T*;
P: 337–8
- celiac plexus block **P:** 341
 concentration effects **C:** 227, **C:** 227 *T*
 intrathecal **P:** 339, **P:** 340
 toxicity **C:** 231 *T*
 nerve regeneration **C:** 227
 neurolytic celiac plexus
 blockade **C:** 228
 peripheral **P:** 256, **P:** 338
 phenol neurolysis vs. **C:** 228; **P:** 257
- alfentanil **A:** 60
- burn pain **A:** 403, **A:** 404
- cancer patients
 procedure-related pain **C:** 217
 subcutaneous drug
 infusion **P:** 127 *T*
- context-sensitive half-times **A:** 58
- cryoanalgesia **P:** 382
- dyspnea palliation **C:** 313
- intranasal administration **A:** 208 *T*
- intravenous challenges **P:** 63
- neuropathic pain **Ch:** 209
- pharmacodynamics, elderly **A:** 508–9
- pharmacokinetics **A:** 59 *T*
- spinal cord injury pain **Ch:** 394
- volume of distribution **A:** 58
- algometer testing (pressure
 algometry) **P:** 48
- alkaline phosphatase tests **C:** 257
- alkalinization, local anesthetics **A:** 119
- alleles **Ch:** 49
 dominant **Ch:** 53
- recessive **Ch:** 53
- allergic dermatitis,
 vulvodynia **Ch:** 587–8
- allergies/allergic reactions
 continuous peripheral neural
 blockade **A:** 242
 local anesthetic-induced **A:** 123,
A: 242; **Ch:** 232
 paracetamol-induced **Ch:** 200
 procaine-induced **A:** 123
 TENS-induced **P:** 198
- Allied and Complementary Medicine
 (AMED) **P:** 570 *T*
- allocation bias **P:** 554
- allocation concealment, clinical
 trials **P:** 519
 quality assessment **P:** 571
- allodynia **Ch:** 135
 assessment **Ch:** 138
 brain areas **Ch:** 16
 CPSP **Ch:** 407
 cryoanalgesia-induced **P:** 381
 definition **A:** 20–1; **Ch:** 135, **Ch:** 336,
Ch: 375; **P:** 44
 fibromyalgia syndrome **Ch:** 599–600,
Ch: 604
 history-taking **P:** 8
 to mechanical stimulation **P:** 44
 neuropathic pain **Ch:** 3–4
 opioid-induced, cancer
 patients **P:** 129
 peripheral neuropathies **Ch:** 336
 postherpetic neuralgia **Ch:** 431
 residual limb pain **Ch:** 419
 TENS contraindications **A:** 277
- almotriptan, migraine **Ch:** 455–6,
Ch: 460 *T*
- aloe **Ch:** 315 *T*
- alosetron, irritable bowel
 syndrome **Ch:** 559–60
- levo-alpha-acetylmethadol,
 opioid-tolerant patients **A:** 550
- α_1 -acid glycoprotein
 age-related changes **A:** 508
 local anesthetic binding **A:** 120
- alpha-2 adrenoceptor(s)
 nitrous oxide effects **A:** 97
 postnatal development **A:** 38
- alpha-2 adrenoceptor agonists **A:** 101–3
 acute pain **A:** 102–3
 adverse effects **A:** 102
 chemical properties **A:** 101
 clinical effects **A:** 101–2
 fibromyalgia syndrome **Ch:** 608
 ICUs **A:** 102, **A:** 348
 mechanism of action **A:** 101–2
 neuraxial analgesia **A:** 259

- alpha-2 adrenoceptor agonists
(*continued*)
neuropathic pain, acute **A:** 102
opioid-tolerant patients **A:** 549
perioperative systemic use **A:** 102
pharmacokinetics **A:** 101 *T*
physical properties **A:** 101
postoperative pain
management **A:** 334
spasticity pain **Ch:** 445
spinal administration **Ch:** 287
toxicity **A:** 102
see also individual drugs
- AL-TENS **A:** 274 *T*; **C:** 239 *T*
application sites **P:** 197
mechanism of action **C:** 237–8,
C: 240 *F*
qualities **P:** 199, **P:** 199 *T*
stimulator settings **P:** 198
- alternative medicine *see* complementary
and alternative medicine (CAM)
- alvimopan, constipation **C:** 324
- Alzheimer's disease (AD)
nonverbal pain assessment **C:** 370–1
pain in **Ch:** 643
placebo-based trials **P:** 504
- AM404 **C:** 125
- ambulation, labor pain **A:** 469
- AMED (Allied and Complementary
Medicine) **P:** 570 *T*
- American Academy of Neurology,
quantitative sensory testing **P:** 78
- American Boards of Clinical
Hypnosis **P:** 493
- American Chronic Pain Association,
chronic pain experience
survey **Ch:** 171
- American College of Obstetricians and
Gynecologists (ACOG),
hysterectomy criteria **Ch:** 585
- American College of Rheumatology
fibromyalgia syndrome
classification **Ch:** 600
juvenile fibromyalgia syndrome
diagnostic criteria **Ch:** 625
rheumatoid arthritis scores **Ch:** 520–1
- American Pain Society (APS)
quality improvement
guidelines **P:** 672, **P:** 673 *T*
revision **P:** 672
Quality of Care Task Force **P:** 672
- American Society for Clinical
Hypnosis **P:** 493
- American Society of Anesthesiologists,
Acute pain management in the
perioperative setting
guidelines **P:** 666
- American Society of
Cardiologists **Ch:** 539
- American Society of Interventional Pain
Physicians **P:** 624
- American Society of Regional
Anesthesia and Pain
Medicine **P:** 624
- Americans with Disabilities Act
(ADA) **P:** 623
- amethocaine **A:** 125; **C:** 217
- Ametop **A:** 488
- amifostine **C:** 402
- amino amide local anesthetics
A: 124–7
- amino-ester local anesthetics **A:** 124
- aminoglycosides, NSAID
interactions **A:** 74 *T*
- amitriptyline **Ch:** 244 *T*
acute pain **A:** 105
atypical facial pain **Ch:** 475
central neuropathic pain **Ch:** 379,
Ch: 379–82 *T*
central poststroke pain **Ch:** 380
CRPS **Ch:** 369
dosage **P:** 138
elderly **C:** 369
adverse effects **A:** 516
neuropathic pain **Ch:** 647
fibromyalgia syndrome **Ch:** 245,
Ch: 607
- HIV-related peripheral
neuropathy **Ch:** 355–6
- interstitial cystitis **Ch:** 557
- juvenile fibromyalgia
syndrome **Ch:** 625
- migraine prophylaxis **Ch:** 459–61,
Ch: 461 *T*
- neuropathic pain **Ch:** 234, **Ch:** 345,
Ch: 345 *T*
cancer patients **C:** 205
gabapentin *vs.* **Ch:** 345
topical application **Ch:** 234
pediatric headache **Ch:** 632
dosages **Ch:** 632
postamputation pain **Ch:** 422–3
postbreast cancer surgery
pain **C:** 404–5
postherpetic neuralgia **A:** 105;
Ch: 433
spinal cord injury pain **Ch:** 394,
Ch: 396 *T*
tension-type headache
prophylaxis **Ch:** 461–2
- ammonium compounds,
neurolysis **C:** 228
- AMPA receptors
anticonvulsant effects **A:** 103
- central sensitization **A:** 25; **Ch:** 12,
Ch: 31
nociception **A:** 9–10
postnatal development **A:** 33, **A:** 34 *T*
- amphetamines
cancer-related fatigue **C:** 329
contraindications **C:** 184–5
depression **C:** 332
opioid-induced sedation **C:** 184
- amputation
pediatric hypnoanalgesia **P:** 484
prevention **A:** 564
- amygdala, neuropathic pain
imaging **Ch:** 16
- amyloid neuropathy, primary,
diagnosis **Ch:** 151 *T*
- amyloidosis
familial Mediterranean fever **Ch:** 562
neuropathy **Ch:** 342
- AN-132 **P:** 59
- anakinra, rheumatoid arthritis **Ch:** 521,
Ch: 522–4 *T*
- analgesia/analgesics
abdominal pain, acute **A:** 363, **A:** 414
adjuvant
breakthrough pain **C:** 290
children **C:** 351–4
age-related changes **A:** 45–6
analgesic efficacy **A:** 45, **A:** 46 *F*
metabolic function **A:** 46
receptor expression **A:** 45
transmitter function **A:** 45–6
“as required” **C:** 111
burn pain **A:** 403–4
cancer pain
subcutaneous drug
infusion **P:** 125–6, **P:** 130–1
tolerance development **P:** 539
- children
mild/moderate pain **P:** 464–5,
P: 465 *T*
moderate to severe pain **P:** 465–9
pharmacology **A:** 481–8
- chronic use of, pain history **A:** 138
- comparisons, pain
assessment **A:** 148–9
- consumption measurement **A:** 190
- CPSP **A:** 563, **A:** 564
- depression **Ch:** 242
- in elderly *see* elderly
- emergency departments **A:** 361–3
choice of **A:** 361
- epidural *see* epidural analgesia
- fibromyalgia syndrome **Ch:** 607
- ICUs **A:** 347–8
- labor pain **A:** 469
- lumbar radiculopathy **Ch:** 511

- nonopioids *see* nonopioid analgesics
number needed to treat **A**: 89 *T*
opioid-induced **C**: 154
tolerance **C**: 156
oral administration **C**: 109–11
children **C**: 349
overuse, pediatric headaches **Ch**: 630
pediatric cancer pain **C**: 347–9
pharmacokinetics, age-related
changes **A**: 45
porphyrias **A**: 421–2
postamputation pain **Ch**: 421
postbreast cancer surgery pain **C**: 404
presurgical, postamputation pain
prevention **Ch**: 424
reduced effect, increased nociceptive
inputs **C**: 106
refusal **C**: 94
by relatives **C**: 96
regimen selection, APS **P**: 586–8
rheumatoid arthritis **A**: 87; **Ch**: 521
routes of administration **C**: 110–1
children **C**: 349–50; **P**: 463–4
stimulation-induced *see* stimulation-
induced analgesia
sublingual administration,
breakthrough pain **C**: 291
substance abuse/misuse **C**: 384–5
systemic, topical analgesics
vs. **Ch**: 230
technique selection, APS **P**: 586–8
topical *see* topical analgesics
see also individual drugs
analgesic ceiling, paracetamol **A**: 332–3
analgesic efficacy **P**: 539
analgesic gap, local anesthetics **A**: 245
analgesic responsiveness
cancer patients **P**: 539
definition **P**: 539
analysis bias **P**: 554–5
anandamide, peripheral nociceptor
sensitization **Ch**: 29
anastrozole **C**: 265
androgenic hormones, endometriosis
treatment **Ch**: 575
anemia, cancer patients **C**: 311
anesthesia/anesthetic(s)
CPSP **A**: 563, **A**: 564
elderly **C**: 368
general *see* general anesthesia
local *see* local anesthetic(s)
anesthesia training **P**: 582
anesthesiology staff, pediatric
APS **P**: 642
aneurysms, spinal pain *vs.* **Ch**: 155–6,
Ch: 156 *T*
angelica (Dong qai) **Ch**: 315 *T*
- anger
assessment **C**: 56
chronic pain and **Ch**: 293; **P**: 621–2
management strategies **C**: 56
angina pectoris
acupuncture **A**: 284
elderly, pain perception **A**: 509–10
refractory *see* refractory angina
pectoris
TENS **A**: 280; **P**: 195, **P**: 197–8
angina plan **Ch**: 539–40
angiogenesis, sports injuries **A**: 528
Angiogenic Gene Therapy (AGENT-2)
trial **Ch**: 541–2
angiography, trigeminal
neuralgia **Ch**: 473
angioplasty, refractory angina
pectoris **Ch**: 539–40
angular cheilitis **C**: 316
anhedonia, chronic pain **P**: 621–2
animal models/studies
acupuncture **A**: 281
anticonvulsants **A**: 103
cancer- induced bone pain **C**: 4–5
cancer pain **P**: 540
chemotherapy-induced peripheral
neuropathy **C**: 8, **C**: 400
chronic pancreatitis **Ch**: 553
CPSP **A**: 561
neuropathic pain *see* neuropathic
pain
neurostimulation **Ch**: 269
nitrous oxide **A**: 97
opioid-induced hyperalgesia **Ch**: 219
opioid tolerance, acute **A**: 543
postamputation pain **Ch**: 421
preemptive analgesia **A**: 565
somatic pain, cancer- induced **C**: 4
spinal cord injury pain spinal
generator **Ch**: 390
visceral pain **Ch**: 41, **Ch**: 42–3,
Ch: 276
cancer- induced **C**: 9
- ankle
acute pain **A**: 441
intra-articular injection **P**: 353
joint anatomy **P**: 353
soft-tissue disorders **Ch**: 530
soft-tissue injection **P**: 357
ankle blocks **P**: 289–90, **P**: 290 *F*
anatomy **P**: 289–90
complications **P**: 291
indications **P**: 289
see also individual blocks
ankylosing spondylitis, neck
pain **Ch**: 488
anorectal pain, HIV infection **Ch**: 359
- anorexia and cachexia *see* anorexia
cachexia syndrome (ACS)
anorexia cachexia syndrome
(ACS) **C**: 326–8
causes **C**: 326
clinical findings **C**: 327
investigations **C**: 327
management **C**: 327
nonpharmacological **C**: 327
pharmacological **C**: 327–8
potential therapies **C**: 328
neurohormonal mechanisms **C**: 327,
C: 327 *F*
noncancer illness **C**: 326
pathophysiology **C**: 326–7
starvation *vs.* **C**: 327
anserine bursitis **Ch**: 530; **P**: 356
antagonist **C**: 105
anterior cingulate cortex (ACC)
affective-motivational dimension of
pain **Ch**: 242–3
functional imaging **Ch**: 16
neuropathic pain **Ch**: 16
anterior cingulate gyrus
hypnotic analgesia **P**: 149
pain perception **P**: 146
anterior cruciate ligament repair,
femoral nerve blocks **A**: 240
anterior insula (aINS)
pain neuroimaging **P**: 86–8
placebo effect **P**: 506
anterior knee pain syndrome **Ch**: 530
antiarrhythmics **Ch**: 263–4
neuropathic cancer pain **C**: 208
see also individual drugs
antibiotics
pharyngitis **A**: 418
septic arthritis **A**: 434
anticholinergics
end of life care **C**: 335
irritable bowel syndrome **Ch**: 559–60
see also individual drugs
anticoagulants
cardiac surgery **A**: 262
epidural analgesia and **A**: 518
neurolytic blocks and **P**: 338
SCS contraindication **P**: 407
spinal hematoma induction **A**: 261
sympathetic block
contraindication **P**: 326
see also individual drugs
anticonvulsants **A**: 103–5
acute pain **A**: 104–5
adverse effects **A**: 103–4; **C**: 369
burn pain **A**: 403–4
chemical properties **A**: 103
children **C**: 354

- anticonvulsants (*continued*)
 clinical effects **A:** 103
 CPSP **A:** 565
 CRPS, children **Ch:** 627
 diabetic neuropathy **Ch:** 330
 elderly
 liver function **A:** 516
 neuropathic pain **A:** 516; **Ch:** 647;
 C: 369
 field/disaster situations **A:** 380
 mechanism of action **A:** 103; **Ch:** 632
 migraine prophylaxis **A:** 104–5
 neurologic disease pain **Ch:** 330
 neuropathic pain
 acute **A:** 104
 central **Ch:** 380
 peripheral **Ch:** 346–7
 opioid-tolerant patients **A:** 549
 pediatric headache **Ch:** 632, **Ch:** 633 *T*
 perioperative use **A:** 104
 pharmacokinetics **A:** 103 *T*
 physical properties **A:** 103
 postamputation pain **Ch:** 415
 postherpetic neuralgia **Ch:** 433–5,
 Ch: 434 *T*
 postoperative pain
 management **A:** 335
 spinal cord injury pain **Ch:** 394,
 Ch: 396 *T*
 vulvodynia **Ch:** 590
see also antiepileptics; *individual drugs*
- anti-cyclic citrullinated protein
 (anti-CCP) **P:** 69–70
- antidepressant discontinuation
 syndrome **Ch:** 247–8
 diagnostic criteria **Ch:** 247 *T*
- antidepressants **P:** 137–9
 acute pain **A:** 105
 adverse effects **P:** 138–9
 anxiety, cancer patients **C:** 333
 burning mouth syndrome **Ch:** 476
 children **C:** 351–3
 chronic lower back pain **Ch:** 508
 chronic pancreatitis **Ch:** 554
 clinical uses **P:** 137
 contraindications **P:** 137–8
 CRPS **Ch:** 369
 depression
 cancer patients **C:** 332
 chronic pain patients **Ch:** 616
 diabetic neuropathy **Ch:** 329–30
 dosing **P:** 138
 efficacy **P:** 134–5
 elderly **Ch:** 647; **C:** 369
 fibromyalgia syndrome **Ch:** 607
 mechanism of action **C:** 205
 metabolism **P:** 138
 neurologic disease pain **Ch:** 329–30
 neuropathic pain **Ch:** 345–6
 cancer patients **C:** 205–6
 opioid-tolerant patients **A:** 549
 persistent somatoform pain
 disorder **Ch:** 619
 pharmacokinetics **A:** 105 *T*
 pharmacokinetic variability **P:** 138
 pharmacology **C:** 205
 rheumatoid arthritis **Ch:** 521
 spinal cord injury pain **Ch:** 394–5,
 Ch: 396 *T*
 treatment schedule **P:** 138
see also individual drugs/drug classes
- antidiarrheals
 cancer patients **C:** 326 *T*
 irritable bowel syndrome **Ch:** 559–60
see also individual drugs
- antiemetics
 opioid therapy and **C:** 113, **C:** 191
 PCA and **A:** 227; **P:** 296
- antiepileptics **Ch:** 254–63, **Ch:** 256 *T*;
 P: 135–7
 adverse effects **C:** 206; **P:** 136–7
 clinical pharmacology **C:** 206
 clinical uses **P:** 135
 contraindications **P:** 135
 CRPS **Ch:** 369
 dosing schedule **P:** 135–6
 efficacy **P:** 134–5
 fibromyalgia syndrome **Ch:** 607–8
 mechanism of action **C:** 206
 metabolism **P:** 135
 migraine **Ch:** 461 *T*
 neuropathic cancer pain **C:** 206–7
 new drugs **C:** 207
 older drugs **C:** 206
 neuropathic orofacial pain **Ch:** 472
 renal function impairment and **P:** 135
 terminology **P:** 134–5
 treatment schedule **P:** 135–6
 trigeminal neuralgia **P:** 135
see also individual drugs
- antifungals
 vulvodynia **Ch:** 590
see also individual drugs
- antihistamines
 cough **C:** 315
 opioid-induced pruritus **C:** 192
 vulvodynia **Ch:** 590
- anti-inflammatory agents
 CRPS **Ch:** 369
 inflammatory bowel disease **Ch:** 561
 osteoarthritis **Ch:** 526
 pancreatic cancer pain **Ch:** 551
see also individual drugs
- antineuropathic agents
 brachial plexus neuropathy **C:** 406
 CRPS **Ch:** 369
- antineutrophil cytoplasmic antibodies
 (ANCA) **P:** 70
- antinuclear antibody (ANA) **P:** 70
- antioxidants
 chronic pancreatitis pain **Ch:** 554
 local anesthetics **A:** 118
- antiplatelet drugs
 epidural analgesia
 contraindication **A:** 518
 spinal hematoma **A:** 261, **A:** 518
see also individual drugs
- anti-proliferative factor (APF),
 interstitial cystitis **Ch:** 557–8
- antipsychotics
 agitation **C:** 335
 delirium
 cancer patients **C:** 334
 opioid-induced **C:** 187
- antireflux valves, PCA **A:** 226; **P:** 294
- antiretrovirals
 carbamazepine interactions **Ch:** 355
 HIV infection **Ch:** 353, **Ch:** 353 *T*,
 Ch: 354
 peripheral neuropathy
 induction **Ch:** 341–2
see also individual drugs
- antiretroviral toxic neuropathy
 (ATN) **Ch:** 355
 causes **Ch:** 354
 management guidelines **Ch:** 356–7
 new patient assessment **Ch:** 356–7
 prevalence **Ch:** 354
 treatment **Ch:** 355–6
 drug interactions **Ch:** 355
- anti-RNP antibodies **P:** 70
- antisiphon valve, PCA **P:** 294
- anti-Smith antibodies **P:** 70
- anti-SSA/Ro **P:** 70
- anti-SS-B/La **P:** 70
- antitussives **C:** 315
- antivirals, herpes zoster **Ch:** 432,
 Ch: 433
- anxiety
 acute pain and **P:** 147
 assessment, chronic pain
 patients **Ch:** 173–4
 cancer patients **C:** 332–3
 etiology **C:** 332–3
 family's future **C:** 49
 management **C:** 333
 nonpharmacological
 management **C:** 333
 pharmacological
 management **C:** 333
 prevalence **C:** 332

- quality of life **C**: 49
 risk assessment **C**: 57–8
 children **A**: 309
 CPSP development **A**: 563
 cryoanalgesia contraindication **P**: 381
 functional abdominal pain **Ch**: 634
 labor pain **A**: 466
 opioid unresponsiveness **P**: 129
 pain-relationship, children **P**: 480–1
 PCA and **A**: 222
 phantom pain **Ch**: 418
 predisposing factors **C**: 57
 presurgical assessment **P**: 246–8,
 P: 247 *F*
 non-health related impacts **P**: 246,
 P: 250 *F*
 questionnaires **P**: 247–8
 worry checklists **P**: 247 *F*, **P**: 248
 relaxation-induced **P**: 162
 spinal cord injury **Ch**: 400
 subcutaneous drug infusion
 contraindication **P**: 122
 substance abuse/misuse **Ch**: 657
 symptoms **C**: 57
 anxiety disorders
 chronic pain **Ch**: 170, **Ch**: 616–20
 see also individual diseases/disorders
 anxiety scores, family caregiver **C**: 65
 anxiety sensitivity, children **A**: 309
 anxiolytics
 dyspnea **C**: 313–4
 elderly **C**: 368
 opioid therapy and **A**: 549; **C**: 113–4
 opioid-tolerant patients **A**: 549
 preoperative, postoperative pain
 and **A**: 294
 apatite-associated destructive
 arthritis **Ch**: 526
 apazone (azapropazone) **A**: 76
 apical periodontitis **Ch**: 477
 aplastic anemia, NSAID-induced **A**: 73;
 Ch: 198
 apoptosis, neuropathic pain **Ch**: 10
 dorsal horn **Ch**: 12
 appetite loss, depression **Ch**: 615
 applied psychophysiology,
 definition **P**: 478–9
 applied relaxation **P**: 161
 Applied Social Science Index and
 Abstracts (ASSIA) **P**: 570 *T*
 appraisal support, professional
 teams **C**: 75
 arepripitant **C**: 320 *T*
 arachidonic acid metabolites, peripheral
 sensitization **A**: 22–3
 arachnoiditis **P**: 423
 arginine salts, oral NSAIDs **A**: 202
 argumentation avoidance, motivational
 interviewing **P**: 100
 aromatherapy **C**: 277–8
 elderly **C**: 370
 arsenical polyneuropathy **Ch**: 341
 arterial laceration, epidural steroid
 injections **P**: 422–3
 arterial *p*CO₂, respiratory
 depression **P**: 589
 arteria radicularis magna damage,
 epidural steroid injection **P**: 422–3
 artery of Adamkiewicz damage,
 epidural steroid injection **P**: 422–3
 arthritis
 crystal **A**: 434
 interleukin-1B **Ch**: 29
 interleukin-6 **Ch**: 29
 septic *see* septic arthritis
 spinal pain **Ch**: 156
 tumor necrosis factor- α **Ch**: 29
 see also osteoarthritis; rheumatoid
 arthritis
 arthrography, articular pain **A**: 433
 arthroscopic meniscal debridement,
 osteoarthritis **Ch**: 528
 arthroscopic washouts,
 osteoarthritis **Ch**: 528
 articaïne **A**: 127
 articular cartilage injuries **A**: 530
 articular pain
 acute *see* joint pain, acute
 chronic *see* joint pain, chronic
 artificial disk implants **P**: 442
 artificial saliva, xerostomia **C**: 316
 arylacetic acids **A**: 77–8;
 see also individual drugs
 arylpropionic acids **A**: 76–7;
 see also individual drugs
 ascending pathways, postnatal
 nociception development **A**: 38
 ascending tract conduction block,
 neurostimulation **Ch**: 270
 aseptic meningitis, NSAID-
 induced **A**: 72
 Asia Pacific region, palliative care
 services **C**: 86
 aspartate, nociception **A**: 9–10
 aspirin (acetylsalicylic acid) **A**: 75–6
 asthma induction **A**: 71
 buccal/sublingual
 administration **A**: 207–8
 children **P**: 464
 cancer pain **C**: 348
 elderly, cancer pain **C**: 365
 emergency departments **A**: 365
 gastrointestinal injury risk **C**: 129,
 C: 131–3
 intravenous administration **A**: 205–6
 ischemic cardiac chest pain **A**: 365
 low-dose, cardiovascular protective
 effects **A**: 71–2, **A**: 75–6
 metabolism **A**: 70
 migraine **A**: 365
 numbers needed to treat **A**: 89 *T*
 platelet aggregation prevention **A**: 76
 properties **A**: 75 *T*
 Reye's syndrome **A**: 73, **A**: 76; **Ch**: 631
 sports injuries **A**: 532–3
 tension-type headache **Ch**: 458
 thromboxane inhibition **A**: 76
 WHO essential drug list **A**: 395 *T*
 assay sensitivity **P**: 516
 dental pain model **P**: 533
 documenting **P**: 533
 downside **P**: 516, **P**: 534
 improving **P**: 533
 pulpotomy **P**: 533
 upside **P**: 516, **P**: 534
 assessment (of pain) *see* pain
 assessment
 ASSIA (Applied Social Science Index
 and Abstracts) **P**: 570 *T*
 Association for Applied
 Psychophysiology and
 Biofeedback **P**: 493
 Association for Palliative Medicine,
 outside license drug use **C**: 415–6
 Association of Paediatric Anaesthetists,
 newborn pain survey **P**: 629–30
 association studies **Ch**: 57
 asthma
 aspirin adverse effects **A**: 71
 NSAID cross-sensitivity **A**: 71, **A**: 483;
 Ch: 196–7
 astrocytes **A**: 11
 ASTRONAUT study **C**: 366
 asymmetric diabetic
 neuropathy **Ch**: 339
 atlantooccipital blocks, neck
 pain **Ch**: 152
 ATP, peripheral nociceptor
 sensitization **Ch**: 29
 ATP 1A2 gene/protein **Ch**: 630
 atropine, renal colic **A**: 415
 attention
 pain-related fear **P**: 178–9
 phantom pain **Ch**: 418
 attentional distraction **C**: 300
 attentional techniques, CBT **A**: 298;
 Ch: 296
 atypical facial pain (AFP) **Ch**: 474–5
 comorbidities **Ch**: 474
 definition **Ch**: 474
 differential diagnosis **Ch**: 474–5

- atypical facial pain (AFP) (*continued*)
 epidemiology **Ch:** 474
 management **Ch:** 475
 pathophysiology **Ch:** 474
 risk factors **Ch:** 474
 symptomatology **Ch:** 474
- atypical odontalgia **Ch:** 474, **Ch:** 475
 definition **Ch:** 475
 epidemiology **Ch:** 475
 management **Ch:** 475, **Ch:** 476 *F*
 pathophysiology **Ch:** 475
 symptomatology **Ch:** 475
- audit, APS **P:** 595–7
 outcome **P:** 596
 pediatric unit **P:** 644
 process **P:** 596
 structure **P:** 596
- aura, migraine **Ch:** 450–1
- auranofin (oral gold), rheumatoid arthritis **Ch:** 522–4 *T*
- auricular electrical stimulation, burn pain **A:** 404–5
- auriculoacupuncture **C:** 272
 elderly **C:** 370
 neuropathic pain **C:** 272
- auriculotemporal nerve
 cryoanalgesia **P:** 385
- auscultation, abdominal pain **Ch:** 551
- Australasian Triage Scale **A:** 140
- Australian and New Zealand College of Anesthetists and Faculty of Pain Medicine, Acute pain management: scientific evidence guidelines **P:** 666–7
- “autogenic feedback” **P:** 158
- autogenic training **P:** 160, **P:** 480 *T*
- autoimmune neuropathies **Ch:** 342
- autoimmune screens, peripheral neuropathy **P:** 79
- autonomic indicators, ICU pain assessment **A:** 345
- autonomic nervous system,
 acupuncture **A:** 280–1
- avoidance behavior **P:** 177
 chronic pain **Ch:** 174
 interview **P:** 181
 pain-related fear **P:** 178
- avulsion fractures **A:** 529
- axillary artery **P:** 268
- axillary brachial plexus block *see*
 brachial plexus blocks
- axon convergence theory, referred pain **A:** 11
- axonotmesis, cryoanalgesia **P:** 380
- axotomy, postnatal development effects **A:** 44
- azapropazone (apazone) **A:** 76
- azathioprine, rheumatoid arthritis **Ch:** 522–4 *T*
- Baastrup’s disease **Ch:** 505–6
- back, myofascial trigger points
P: 211 *F*
- back exercises
 acute low back pain **A:** 451–2,
A: 451 *T*
 chronic low back pain **Ch:** 509
- background infusion, PCA **A:** 220
- background pain, burns patients **A:** 401
- backlash, subcutaneous drug infusion **P:** 124
- back pain
 children, cancer-related **C:** 346
 chronic lower *see* chronic lower back pain (CLBP)
 economic costs **Ch:** 77
 epidural analgesia-induced **P:** 313
 low *see* low back pain (LBP)
 meningeal carcinomatosis **C:** 32
 monitoring, APS **P:** 595
 pancreatic cancer **C:** 35
- Back Performance Scale **P:** 222
- back schools **A:** 451 *T*, **A:** 452
- back-to-work programs, chronic lower back pain **Ch:** 510
- baclofen
 cancer neuropathic pain **C:** 209
 central neuropathic pain **Ch:** 380
 CRPS, children **Ch:** 627
 intrathecal *see* intrathecal baclofen
 neurologic disease pain **Ch:** 330,
Ch: 331
 spasticity pain **Ch:** 444
 spinal administration **Ch:** 285–6,
Ch: 287, **Ch:** 288
 spinal cord injury pain **Ch:** 393,
Ch: 395, **Ch:** 396 *T*
- bacterial infections
 oral, cancer patients **C:** 317
 septic arthritis **A:** 433
- balanced analgesia *see* multimodal analgesia
- balanced placebo design **P:** 503,
P: 503 *F*
- balloon animation,
 biofeedback **P:** 486 *F*
- balloon distension, animal visceral pain models **Ch:** 41
- Bandolier **P:** 564
- Bangladesh, healthcare spending **A:** 391 *T*
- barcoding, PCA **A:** 226; **P:** 294
- baroreceptor inhibition,
 opioid-induced **A:** 57
- barriers, to pain relief *see* pain relief barriers
- Barriers questionnaire, family caregivers **C:** 64–5
- base of skull metastases, pain syndromes **C:** 29–30
 clinical features **C:** 29, **C:** 31 *T*
 radiographic investigations **C:** 30,
C: 31 *F*
- Bath Adolescent Pain Questionnaire (BAPQ) **P:** 456
- battlefields *see* field/disaster situations
- Baxter patient-controlled intranasal analgesia on-demand system **P:** 307, **P:** 308 *T*
- B-cell inhibitors, rheumatoid arthritis **Ch:** 522–4 *T*, **Ch:** 524
- Beck Depression Inventory (BDI),
 chronic pain **Ch:** 125–6, **Ch:** 172 *T*
 emotional distress assessment **Ch:** 173
- bed rest, low back pain **A:** 451,
A: 451 *T*
- behavior(s)
 assessment *see* behavioral assessment (of pain)
 cognitive deficit patients **Ch:** 646
 dying person **C:** 392
 ex-neonatal ICU patients **A:** 43
 facial expressions **P:** 32
 hyperalgesia **A:** 20–1
 as hypothetical construct **P:** 32
 opioid addiction
 risk **Ch:** 656, **Ch:** 656 *T*
 treatment **Ch:** 657
 persistent visceral pain
 models **Ch:** 42–3
 substance abuse disorder **A:** 545
 tests, neuropathic pain models **Ch:** 5,
Ch: 6–7, **Ch:** 6 *F*
- behavioral adjustment, chronic pain **P:** 622
- behavioral assessment (of pain) **A:** 144–5; **P:** 31–2
 children **P:** 32
 acute pain **A:** 480; **P:** 450–3,
P: 451 *T*
 chronic pain **P:** 32
 clinical use **A:** 144
 direct observation **A:** 145
 elderly **A:** 512
 ICUs **A:** 345, **A:** 346 *T*
 physiological responses *vs.* **A:** 144–5
 surrogates **A:** 147
 therapeutic response **A:** 147
- behavioral conditioning,
 opioids **Ch:** 218

- behavioral deconditioning, chronic pain **P:** 620
- behavioral interventions, cancer treatment-related side effects **C:** 302
- Behavioral Pain Assessment Scale **A:** 346 *T*
- Behavioral Pain Scale (BPS) **A:** 479 *T*
- behavioral pain scales, dementia/delirium patients **C:** 43
- behavioral therapies
interstitial cystitis treatment **Ch:** 557
irritable bowel syndrome treatment **Ch:** 559–60
vulvodynia **Ch:** 591
see also individual therapies
- Belize, healthcare spending **A:** 391 *T*
- benorilate **A:** 75
- benzocaine **A:** 125, **A:** 128
dyspepsia **A:** 417
- benzodiazepines
agitation **C:** 335
anxiety **C:** 333
burn pain **A:** 403
delirium
cancer patients **C:** 334
opioid-induced **C:** 187
elderly **C:** 365
myofascial pain **Ch:** 608
neurologic disease pain **Ch:** 330
opioid-tolerant patients **A:** 549
spinal cord injury pain **Ch:** 393
temporomandibular disorder **Ch:** 469–70
- benztropine, morphine vs. **Ch:** 211
- bereavement support **C:** 334
- Bertolotti's syndrome **Ch:** 506–7
- best practice **P:** 681
- βarrestin2 gene, opioid response **C:** 174
- beta-blockers
ischemic cardiac chest pain **A:** 365
migraine prophylaxis **Ch:** 459–61, **Ch:** 461 *T*
NSAID interactions **A:** 74 *T*
pediatric headache **Ch:** 631–2
- β-cyclodextrin linkage, NSAIDs **A:** 202
- β-endorphin(s), labor pain **A:** 466
- betamethasone
epidural steroid injections **P:** 419
postoperative nausea and vomiting **A:** 106
- beta-2 adrenoceptor(s)
antagonists *see* beta-blockers
temporomandibular disorders **Ch:** 469
- bethanecol **C:** 316
- B fiber(s)
characteristics **A:** 4 *T*
local anesthetic sensitivity **A:** 116 *T*
- Biacuplasty (transdiscal annuloplasty) **P:** 441
- bicipital tendonitis **Ch:** 529 *T*
- bicipital tendonosis, proximal **P:** 354
- Bier's block *see* intravenous regional anesthesia (Bier's block)
- bile duct dilation, opioid-induced **C:** 192
- biliary colic **A:** 415–6
cholecystectomy **A:** 415
emergency departments **A:** 364
pharmacological pain management **A:** 415
- biliary tract, opioid-induced effects **C:** 155, **C:** 192
- biliary tree, HIV-associated pain **Ch:** 358
- binary data **P:** 572
- bioavailability (F) **C:** 107
subcutaneous **C:** 110
- biochemistry, pain diagnosis **P:** 67–74
chronic pain **Ch:** 151, **Ch:** 151 *T*
- biofeedback **P:** 153–66
approaches **P:** 149–50, **P:** 154–7
anxiety reduction **P:** 154
general **P:** 154
indirect **P:** 157
specific **P:** 154–7
autogenic training and **P:** 160
certification **P:** 493
children *see* biofeedback, children
chronic low back pain **P:** 163
chronic pain **P:** 149–50, **P:** 165
chronic pelvic pain **Ch:** 584
“coaching model” **P:** 159
definition **Ch:** 315; **P:** 153, **P:** 480 *T*
evidence base **P:** 164–5
feedback **P:** 153–4
imagery and **P:** 160
indications **P:** 162–4
labor pain **A:** 468
meta-analyses **P:** 164
migraine **P:** 164
motivation sources **P:** 154
patient education **P:** 158–9
pediatric *see* biofeedback, children
phantom limb pain **P:** 163
practice **P:** 159
process **P:** 153–4
psychophysiological
assessment **P:** 154, **P:** 155 *T*
adaptation **P:** 155
baseline data collection **P:** 155
muscle discrimination **P:** 157
muscle scanning **P:** 156
profiles **P:** 156, **P:** 156 *F*
reactivity **P:** 155–6
recommendations **P:** 157
recovery assessment **P:** 156
stimulus conditions **P:** 155
as relaxation aid **Ch:** 295; **P:** 157–8
relaxation-induced anxiety **P:** 162
response identification/
amplification **P:** 153–4
sensor placement **P:** 153–4
stimulated work conditions **P:** 159
temporomandibular joint disorders **P:** 164–5
termination **P:** 162
training **P:** 493
treatment considerations **P:** 158–62
break determination **P:** 159
observation sharing **P:** 159
self-control baseline **P:** 159
strategy reviews **P:** 159
treatment session, typical **P:** 159
vulvodynia **Ch:** 591
whiplash injuries **P:** 149–50
- biofeedback, children **P:** 485–90
body awareness **P:** 490
case examples **P:** 488–9, **P:** 489–90
chronic pain **P:** 486–7
contraindications **P:** 493
control training phase **P:** 490
definitions **P:** 485–7
delivery formats **P:** 486 *F*
discern training phase **P:** 490
generalize training phase **P:** 490
headache **Ch:** 633
integration **P:** 491
locus of control **P:** 486
modalities **P:** 487 *T*
parental involvement **P:** 488
physiologic change monitoring **P:** 488
physiologic modality **P:** 488
psychophysiological stress
profiling **P:** 486
self-hypnosis in **P:** 491
skills transfer **P:** 491
symptom diary **P:** 488
teaching **P:** 487–90
practice **P:** 487
schedule **P:** 487
techniques **P:** 488
- Biofeedback Certification Institute of America **P:** 493
- Biofeedback Foundation of Europe **P:** 493
- biomedical framework, treatment interventions **P:** 96
- biomedical outcomes, chronic pain **Ch:** 181

- biomedical reductionism **P**: 655
- biopsychosocial model (of pain) **Ch**: 115–6, **Ch**: 181; **C**: 297
- children **Ch**: 624
- compensation injuries **Ch**: 116
- treatment interventions **P**: 96
- variable interactions **Ch**: 115–6
- low correlation **Ch**: 116–7, **Ch**: 116 *F*
- biotoxins **A**: 116, **A**: 129
- BioTrace software **P**: 486 *F*
- bispectral analysis, ICUs **A**: 345
- bisphosphonates
- bone metastases **C**: 265–6
- breakthrough pain **C**: 290
- elderly, cancer pain **C**: 369
- hypercalcemia **C**: 321
- metastatic bone pain **C**: 290, **C**: 369
- bladder
- opioid effects **C**: 192
- phantom pain **C**: 36
- spasms, cancer patients **C**: 36
- bleeding
- cryoanalgesia-induced **P**: 381
- diverticular disease **Ch**: 562
- gastrointestinal *see* gastrointestinal bleeding
- NSAID-induced **A**: 483
- postoperative **A**: 72
- bleeding diathesis, cryoanalgesia
- contraindication **P**: 381
- bleeding disorders, SCS
- contraindication **P**: 407
- blinding, clinical trials **P**: 520, **P**: 571
- cancer pain **P**: 542
- chronic pain **Ch**: 184
- blindness, epidural steroid injection-induced **P**: 422
- block randomization **P**: 554
- blood–brain barrier, spinal drug administration **Ch**: 285, **Ch**: 285 *F*, **Ch**: 286 *F*
- blood flow
- cryotherapy **A**: 535–6
- phantom pain **Ch**: 420
- blood pressure
- NSAID-induced changes **A**: 72
- TENS **P**: 201
- blood tests
- joint pain **A**: 432–3
- needle phobia **P**: 246
- nonarticular pain **A**: 433
- peripheral neuropathy **Ch**: 337; **P**: 78–9
- valproate, pretreatment **P**: 137
- blowing bubbles, relaxation **P**: 482
- blunting, definition **A**: 310–1
- blunt pressure, neuropathic pain assessment **Ch**: 138
- blunt trauma, cartilage **A**: 530
- body fat, age-related changes **A**: 506 *T*, **A**: 508
- body fluid screening, substance abuse/misuse **C**: 381
- body-line drawings, pain location **P**: 4–5
- body temperature regulation **C**: 331
- body water, age-related changes **A**: 506 *T*
- Bolam concept **P**: 679, **P**: 681
- Bolivia, healthcare spending **A**: 391 *T*
- bone(s)
- infection, radiography **Ch**: 146
- innervation **Ch**: 26
- MRI **Ch**: 148
- structure **A**: 528
- tumors, radiography **Ch**: 146
- bone injuries **A**: 528–30
- epiphyseal **A**: 530
- healing, speed of **A**: 528
- overuse **A**: 529–30
- periosteal **A**: 529
- surgical fixation **A**: 529
- see also* fracture(s)
- bone metastases
- diagnostic criteria **C**: 257–8
- hypercalcemia **C**: 319
- incidence **C**: 257 *T*
- osteoblasts **C**: 256–7
- osteoclast activation **C**: 256–7
- pathophysiology **C**: 256–7
- persistent musculoskeletal pain **Ch**: 26
- sacral **C**: 29 *T*
- vertebral *see* vertebral metastases
- bone pain, cancer- induced *see* cancer- induced bone pain (CIBP)
- bone scans
- cancer patient assessment **C**: 40
- chronic pain **Ch**: 149
- CRPS **Ch**: 149, **Ch**: 367
- joint pain **A**: 433
- knee pain **A**: 440
- malignant bone tumors **C**: 257
- osteoarthritis **Ch**: 526
- rheumatoid arthritis **Ch**: 520
- Bonferroni correction **Ch**: 72
- Bonica model, multidisciplinary pain management **P**: 620
- borborygmi **C**: 323
- border zone spinal pain *see* spinal cord injury (SCI) pain, at-level neuropathic pain
- Borrelia burgdorferi* antibody **P**: 70
- bortezomib **C**: 402
- botanical therapies *see* herbal medicine
- “bottom-to-top” model, fibromyalgia syndrome **Ch**: 604
- botulinum toxin
- esophageal motor disorders **Ch**: 543
- focal spasticity **Ch**: 446–7
- myofascial pain **Ch**: 608
- neurologic disease pain **Ch**: 332
- spinal cord injury pain **Ch**: 393
- temporomandibular disorder **Ch**: 469–70
- vulvodynia **Ch**: 591
- bowel obstruction, advanced
- cancer **C**: 321–3
- clinical features **C**: 322
- incidence **C**: 321
- management **C**: 322–3
- “dip and suck”
- indispensable **C**: 322
- nonsurgical **C**: 322–3
- surgical intervention **C**: 322
- pathophysiology **C**: 321
- vomiting management **C**: 322, **C**: 323 *F*
- bowel rest, inflammatory bowel disease **Ch**: 561
- bowel toxicity, radiotherapy-induced **C**: 259
- BPI *see* Brief Pain Inventory (BPI)
- BPS (Behavioral Pain Scale) **A**: 479 *T*
- brachial plexopathy *see* brachial plexus neuropathy (BPM)
- brachial plexus **P**: 265, **P**: 266 *F*, **P**: 471
- testing (four P’s) **P**: 266 *T*
- brachial plexus blocks **P**: 264–5
- anatomy **P**: 265, **P**: 266 *F*
- axillary **A**: 237–8; **P**: 268–9
- affecting factors **A**: 237
- catheter placement **A**: 237–8
- children **P**: 471
- complications **P**: 270 *T*
- continuous **P**: 269
- distensions **P**: 269
- emergency departments **A**: 368
- field/emergency situations **A**: 382 *T*
- forearm fractures **A**: 368
- landmarks **P**: 268, **P**: 269 *F*
- multiple injections **P**: 268, **P**: 269, **P**: 269 *F*
- practical steps/technique **P**: 268–9, **P**: 269 *F*
- transarterial technique **P**: 268
- vascular flow **A**: 237
- children **A**: 490; **P**: 471
- complications **P**: 270 *T*
- continuous **A**: 332

- children **P:** 471
 elderly **A:** 519
 “immobile needle” technique **P:** 265
 indications **P:** 265
 infraclavicular approach,
 children **P:** 471
 interscalene **P:** 265
 acute pain **A:** 238 *T*, **A:** 239
 complications **P:** 265, **P:** 270 *T*
 continuous, postoperative
 pain **A:** 332
 contraindications **A:** 243
 field/emergency situations **A:** 382 *T*
 intravenous opioids *vs.* **A:** 239
 landmarks **P:** 265
 neurological complications **A:** 246
 posterior approach **A:** 239
 practical steps/technique **P:** 265,
 P: 267 *F*
 shoulder surgery **A:** 239
 stimulating catheters **A:** 244
 periclavicular **A:** 238–9
 efficacy **A:** 238–9
 subclavian approach **A:** 239
 stellate ganglion block-induced **P:** 329
 supraclavicular approach,
 children **P:** 471
 techniques **P:** 264
see also individual techniques
- brachial plexus neuropathy
 (BPM) **Ch:** 343–4
 cancer patients **C:** 32
 definition **P:** 76
 neuralgic amyotrophy **Ch:** 343
 radiotherapy-induced **Ch:** 343–4;
 C: 405
 incidence **C:** 405
 time–incidence relationship **C:** 405
 treatment **C:** 406
 tumor-induced neuropathy
 vs. **C:** 405
 traumatic lesions **Ch:** 343
- bradycardia
 clonidine-induced **A:** 102, **A:** 487
 opioid-induced **A:** 57
- bradykinin(s), peripheral
 sensitization **A:** 23; **Ch:** 29
- brain, nociception **A:** 12–4, **A:** 13 *F*
- brain-derived neurotrophic factor
 (BDNF)
 neuropathic pain **Ch:** 10, **Ch:** 14
 Trk receptors **Ch:** 12
 nociception **A:** 10–1
 peripheral sensitization **A:** 24
- brain processing alterations,
 neuropathic pain **Ch:** 133
- brain stem, central sensitization **P:** 88–9
- brain tumors
 headache **Ch:** 455
 pediatric cancer pain **C:** 346
 radiotherapy **C:** 252–3
- branched chain amino acids
 (BCAA) **C:** 328
- breakthrough pain
 burns patients **A:** 401
 cancer patients **C:** 286–95; **P:** 539
 antineoplastic treatment **C:** 289
 as prognostic indicator **C:** 288
 baseline therapy
 optimization **C:** 289–90,
 C: 290 *F*
 bone pain **C:** 28
 characteristics **C:** 287–8
 children **C:** 346
 clinical trials **P:** 539
 comorbid condition
 treatment **C:** 289
 dying person **C:** 393
 elderly **C:** 368
 management **C:** 288
 model **C:** 287 *F*
 nonpharmacologic
 therapies **C:** 292, **C:** 292 *T*
 opioid titration **C:** 43
 parenteral formulations **C:** 292
 precipitating factor
 treatment **C:** 289
 prevalence **C:** 287
 primary interventions **C:** 288
 rescue medication **P:** 541–2
 subtypes **C:** 287
 symptomatic
 interventions **C:** 289–91
 transmucosal
 formulations **C:** 291–2
 treatment strategies **C:** 288 *T*
- chronic opioid therapy
 patients **P:** 113, **P:** 116
 definition **C:** 43, **C:** 287; **P:** 539
 labor analgesia **A:** 469
 management, algorithm use **P:** 635
 rescue dosing *see* rescue analgesia/
 dosing
- breast, phantom pain **C:** 404
- breast cancer
 acupuncture **Ch:** 316–7; **C:** 273
 CAM **Ch:** 316–7
 elderly **C:** 360
 metastatic
 hypnosis **C:** 276, **C:** 301
 pain prevalence **C:** 18
 radiotherapy **C:** 254
 metastatic bone pain
 chemotherapy **C:** 264
- hormone treatment **C:** 265
 postoperative chronic pain *see*
 postbreast cancer surgery pain
 (PBCSP)
 prevalence **Ch:** 409
 supportive psychotherapy **C:** 298–9
 TENS **C:** 241
- breastfeeding *see* lactation
- breast reconstruction, postoperative
 pain **C:** 404
- breast surgery
 catastrophizing **A:** 294
 CPSP *see* postbreast cancer surgery
 pain (PBCSP)
 postoperative symptoms **A:** 559
 preventive analgesia **A:** 185
- breath control training **P:** 480 *T*
- breathing, noisy, end of life **C:** 335
- breathing techniques, children **A:** 314
- breathlessness *see* dyspnea
- Brief Pain Inventory (BPI) **A:** 147; **P:** 17
 acute pain **A:** 147
 advantages **A:** 147
 cancer pain **C:** 42; **P:** 21
 chronic pain **Ch:** 172 *T*, **Ch:** 173
 clinical trial outcomes **P:** 523
 content **P:** 33–4 *T*
 disadvantages **A:** 147
 neuropathic pain **Ch:** 139–40
 validation **A:** 147
- Brief Symptom Inventory (BSI) **Ch:** 127
- British Columbia Major Depression
 Inventory **Ch:** 173
- British Pain Society, SCS
 guidelines **P:** 413
- brivudin, herpes zoster **Ch:** 432
- bromfenac **A:** 77
- bronchial carcinoma
 radiotherapy **C:** 252
 unilateral facial pain **C:** 32
- bronchoalveolar carcinoma **C:** 315
- bronchodilators, dyspnea **C:** 314
- bronchorrhea, bronchoalveolar
 carcinoma **C:** 315
- buccal drug administration **A:** 207–8
 children **P:** 463–4
 delivery systems **P:** 308
 nonopioid analgesics **A:** 207–8
 opioid analgesics **A:** 208
see also individual drugs
- bulking agents, cancer patients **C:** 324
- bupivacaine **A:** 127
 cardiotoxicity **A:** 122, **A:** 127, **A:** 487
 children
 adverse effects **A:** 487
 dental surgery **A:** 489
 herniorrhaphy **A:** 489

- bupivacaine (*continued*)
 inguinal blocks **A**: 489
 penile block **A**: 490
 strabismus surgery **A**: 489
 clearance **A**: 120
 clinical profile **A**: 119 *T*, **A**: 125
 continuous peripheral nerve
 blocks **A**: 245
 epidural analgesia **P**: 313
 caudal **A**: 491
 children **A**: 491, **A**: 492
 labor **A**: 470, **A**: 471 *T*, **A**: 472 *F*
 pharmacodynamic
 interactions **P**: 316
 pharmacokinetic
 interactions **P**: 316
 safety **P**: 315
 fentanyl and
 labor pain **A**: 471, **A**: 471 *F*
 neuraxial analgesia **A**: 258
 half-life, elderly patients **A**: 515
 intra-articular analgesia **A**: 331
 isoforms, toxicity **A**: 122
 lumbar sympathetic block **P**: 332
 minimum local analgesic
 concentration **A**: 471, **A**: 471 *F*
 myotoxicity **A**: 124
 peripheral nerve blocks **P**: 256
 physicochemical properties **A**: 119 *T*,
A: 125
 postoperative pain
 management **A**: 331
 spinal administration **Ch**: 287
 sympathetic blocks **P**: 326–7
 transient radicular irritation
 induction **A**: 122
 as WHO essential drug **A**: 395 *T*
 wounds **A**: 367
- buprenorphine **A**: 61; **C**: 159–60
 adverse effects **A**: 61; **Ch**: 212; **C**: 159
 bioavailability **C**: 159
 breakthrough pain **Ch**: 212; **C**: 291
 buccal/sublingual
 administration **A**: 208
 cancer pain **C**: 159–60, **C**: 169 *T*
 cancer related/induced-neuropathic
 pain **C**: 204, **C**: 206
 clinical studies **C**: 204
 chronic noncancer pain **Ch**: 212
 dose escalation **Ch**: 212
 double-blind vs. deceptive design
 study **P**: 503–4
 elderly **C**: 367
 equianalgesic doses **A**: 547 *T*
 intranasal administration **A**: 208,
A: 208 *T*
 mechanism of action **A**: 550; **Ch**: 212
- opioid-induced hyperalgesia **Ch**: 219
 opioid tolerance **A**: 550–1; **Ch**: 219
 pharmacodynamics **C**: 159
 pharmacokinetics **A**: 59 *T*, **A**: 550–1;
C: 159
 pharmacology **C**: 204
 potency **A**: 61
 respiratory depression
 induction **A**: 61
 routes of administration/
 formulations **A**: 61; **C**: 159
 subcutaneous infusion **P**: 127 *T*
 cancer patients **P**: 126
 substance abuse disorder **A**: 550–1
 tolerance **C**: 159–60
 transdermal administration **A**: 207;
C: 159
 adverse effects **Ch**: 209
 cancer pain **C**: 159–60
 chronic noncancer pain **Ch**: 212
 elderly **C**: 368
 opioid-tolerant patients **A**: 551
- bupropion **Ch**: 247
 adverse effects **Ch**: 247
 HIV-related peripheral
 neuropathy **A**: 413
 mechanism of action **Ch**: 247
 neuropathic pain **Ch**: 247
 spinal cord injury pain **Ch**: 394–5
- burn(s) **A**: 399–400
 local cell death **A**: 400
 pain *see* burn pain
 prevalence **A**: 399–400
 wound depth **A**: 400
 wound dressings **A**: 402, **A**: 405
- burning mouth syndrome **Ch**: 474,
Ch: 475–6
 definition **Ch**: 475
 differential diagnosis **Ch**: 476
 epidemiology **Ch**: 475–6
 management **Ch**: 476
 pathophysiology **Ch**: 476
 symptomatology **Ch**: 476
- burning pain sensation **P**: 5
 neuropathic orofacial pain **Ch**: 471
- burn pain **A**: 399–409
 assessment **A**: 401–2
 background pain **A**: 401
 procedural pain vs. **A**: 402
 reduction of **A**: 401
 breakthrough pain **A**: 401
 characteristics **A**: 400–1
 consciousness influence **A**: 400
 evolution of **A**: 401
 intensity prediction **A**: 400
 mechanisms **A**: 399–401
 central **A**: 400–1
- peripheral **A**: 400
 neuropathic pain **A**: 401
 nociceptive pain **A**: 401
 procedural pain **A**: 401, **A**: 402
 background pain vs. **A**: 402
 psychological factors **A**: 401
 treatment **A**: 402–5
 general anesthesia **A**: 404
 inhalational anesthesia **A**: 402,
A: 404
 local anesthesia **A**: 400–1, **A**: 404
 local cooling **A**: 402
 during maneuvers **A**: 402
 nonopioid analgesia **A**: 403–4
 nonpharmacological
 approaches **A**: 404–5
 opioids **A**: 400–1, **A**: 402–3
 PCA **A**: 402
see also individual drugs
- bupirone, cancer patients
 anxiety **C**: 333
 dyspnea **C**: 314
- butorphanol **P**: 307
 acute pain **A**: 61
 cancer pain **C**: 162
 intranasal administration **A**: 208 *T*;
P: 307
- butyl amino-benzoate (BAB) **A**: 129
- cachexia *see* anorexia cachexia
 syndrome (ACS)
- CACNA1A gene/protein **Ch**: 630
- caffeine, opioid-induced
 sedation **C**: 185
- CAGE-AID **Ch**: 128
- CAGE questionnaire
 alcoholism diagnosis **C**: 42–3
 drug addiction **Ch**: 655
- calcitonin **A**: 106–7
 acute pain **A**: 106–7
 adverse effects **A**: 106
 chemical properties **A**: 106
 clinical effects **A**: 106
 elderly **C**: 369
 hypercalcemia **C**: 321
 mechanism of action **A**: 106
 osteoporotic vertebral crush
 fractures **A**: 107
 phantom limb pain **A**: 107
 pharmacokinetics **A**: 106 *T*
 physical properties **A**: 106
 postamputation pain **Ch**: 423
- calcitonin gene-related peptide (CGRP)
 acupuncture **P**: 209
 capsaicin-induced release **Ch**: 232
 joint innervation **Ch**: 26
 migraine **Ch**: 453

- muscle innervation **Ch**: 26
 nociception **A**: 9
 opioid-tolerant patients **A**: 544
 peripheral sensitization **A**: 21
 peripheral vascular disease **Ch**: 275–6
 persistent musculoskeletal pain **Ch**: 31
 calcitonin receptors **A**: 106
 calcium-activated K channels **Ch**: 9
 calcium/calmodulin-dependent protein kinase (CaMKII)
 capsaicin **A**: 26
 postnatal development **A**: 35 *T*
 sensitization **A**: 25 *F*, **A**: 26
 calcium channel $\alpha_2\delta_1$ subunit ligands **P**: 135
 calcium channel blockers, pediatric headache **Ch**: 631–2, **Ch**: 632 *T*
 calcium crystal arthropathies **A**: 434
 calcium hydroxyapatite dihydrate deposition disease **A**: 434
 calcium pyrophosphate dihydrate deposition disease **A**: 434; **Ch**: 526
 calor, musculoskeletal pain **A**: 431–2
 CaMKII *see* calcium/calmodulin-dependent protein kinase (CaMKII)
 camphor **C**: 330
 Canadian C-spine rules **Ch**: 491
 Canadian Occupational Performance Measure (COPM) **P**: 226
 cancer
 global burden **C**: 81
 non-pain symptoms
 control **C**: 310–42
 gastrointestinal problems **C**: 316–7
 psychiatric problems **C**: 331–4
 psychological problems **C**: 331–4
 respiratory symptoms **C**: 311
see also individual symptoms
 Cancer and Supportive Care Networks **C**: 417
 cancer bone pain, syndromes **C**: 28–9
 cancer-directed therapy, pain induction **C**: 7
 cancer-induced bone pain (CIBP)
 animal models **C**: 4–5
 blood-borne metastasis **C**: 256
 causes **C**: 257 *T*
 clinical presentation **C**: 257
 diagnostic criteria **C**: 257–8
 dorsal horn alteration **C**: 5
 etiology **C**: 256–7
 hormone treatment **C**: 265–6
 management **C**: 256–69, **C**: 267 *F*
 evidence-based
 evaluation **C**: 258–64
 incidence pain **C**: 258
 pharmacological **C**: 258
 surgery **C**: 266–7
 metastatic *see* metastatic bone pain
 neuropathic **C**: 5
 pathological features **C**: 5, **C**: 6 *F*
 pathophysiology **C**: 4–5, **C**: 256–7
 peripheral activation **C**: 5
 prognosis **C**: 266 *F*, **C**: 267
 radiotherapy *see* radiotherapy
 response to drugs **C**: 5
 tumor infiltration **C**: 256
 cancer-induced/related neuropathic pain
 drug sequencing **C**: 209
 drug synergy **C**: 209
 drug treatment **C**: 200–12
 dosing schedules **C**: 201 *T*
 topical **C**: 209
see also individual drugs
 etiology **C**: 201
 models **C**: 7–9
 limitations **C**: 7
 pain behaviors **C**: 7–8
 reproducible tumor confinement **C**: 7
 nerve compression **C**: 7
 models **C**: 7–8
 paroxysmal **C**: 290
 pathophysiology **C**: 5–7, **C**: 201
 prevalence **C**: 5–6, **C**: 200
 secondary **C**: 7
 symptoms **C**: 7
 therapy-related **C**: 7
 WHO management guidelines **C**: 209
 cancer-induced somatic pain
 animal models **C**: 4
 definition **C**: 41
 pathophysiology **C**: 4–5
 cancer pain
 analgesic requirements **P**: 539
 animal models **P**: 540
 assessment **C**: 38–47
 historical aspects **C**: 38
 intensity *see* pain intensity
 measurement
 multidimensional **C**: 42–3, **C**: 43 *T*
 pain–other symptom integration **C**: 44
 categorization **P**: 540
 characterization **C**: 41, **C**: 41 *T*
 multiple sites **C**: 41
 children *see* pediatric cancer pain
 chronic, opioid tolerance *see* opioid tolerance
 clinical management
 guidelines **C**: 116–7, **C**: 117 *T*
 criticism **C**: 116–7
 online **C**: 117 *T*
 WHO *see* World Health Organization (WHO)
 clinical trials *see* cancer pain clinical trials
 community setting management *see* community setting cancer pain management
 depression and *see* depression
 elderly *see* elderly
 epidemiology **C**: 13–26
 assessment tools **C**: 14
 future challenges **C**: 23
 pain measurement **C**: 14
 pain–other factors
 relationship **C**: 18–21
 etiology **C**: 28 *T*, **C**: 151; **P**: 539
 history taking **C**: 39–40, **C**: 39 *T*
 alcohol/drug abuse **C**: 39
 cognitive failure **C**: 39
 concurrent medical conditions **C**: 40
 mood disorders **C**: 39
 previous treatments **C**: 39
 sexual **C**: 55
 intensity measurement *see* pain intensity measurement
 investigations **C**: 40
 management
 historical aspects **C**: 82
 teamworking in *see* teamworking, cancer pain management
see also individual drugs
 meaning of **P**: 146–7
 measurement **C**: 38–47
 mechanisms **C**: 27–8
 neurolytic blocks **P**: 338
 neuropathic *see* cancer-induced/related neuropathic pain
 nociceptive inputs **C**: 3
 pain evaluation **C**: 41–4
 pathophysiology **C**: 3–12
 patient beliefs **A**: 295
 patient evaluation **C**: 39–40
 patients' experience **P**: 540, **P**: 540 *F*
 pediatric pain services **P**: 650
 physical examination **C**: 40
 prevalence **C**: 14–8, **C**: 28 *T*; **P**: 538
 advanced disease **C**: 14–8, **C**: 19–21 *T*
 assessment **C**: 13–4
 bereaved carer studies **C**: 14–8, **C**: 19–21 *T*
 early disease **C**: 14, **C**: 15–8 *T*
 metastatic disease effects **C**: 18

- cancer pain (*continued*)
- primary tumor site C: 18, C: 22 *T*, C: 28 *T*
 - time of diagnosis C: 14
 - psychological evaluation
 - confidentiality C: 51
 - coping mechanisms C: 55–6
 - effective communication
 - skills C: 52
 - ethical issues C: 51
 - family C: 48–62
 - moral issues C: 51
 - objectives C: 50–1
 - opioid therapy selection **Ch**: 215
 - patient C: 48–62
 - psychosocial assessment C: 50–2
 - carers C: 52
 - family C: 52
 - friends C: 52
 - individual C: 51
 - physical resources C: 52
 - social resources C: 52
 - public attitudes to C: 49
 - somatic *see* cancer-induced somatic pain
 - spinal drug administration **Ch**: 288, **Ch**: 288–9
 - staging C: 43–4
 - suffering and P: 540
 - undertreated, international
 - scope **Ch**: 102
- cancer pain clinical trials P: 538–51
- accrual rate, decreased P: 546
 - adverse effects
 - duration P: 546
 - incidence P: 546–7
 - intensity P: 546
 - analgesia
 - requirements P: 539
 - second level dose P: 548
 - consent P: 548–9
 - control/comparison group P: 542
 - drug interactions P: 541–2
 - duration P: 546
 - ethics P: 547–9
 - exclusion criteria P: 545
 - factors difficult to control P: 546–7
 - fundamentals P: 542
 - inclusion criteria P: 545
 - loss to follow-up P: 547
 - opioid switching P: 542
 - oral equianalgesic dose
 - conversion P: 541
 - outcome measures P: 540
 - pain assessment P: 540–1
 - instruments P: 541
 - intensity scales P: 540–1
 - tools P: 540–1
 - pain fluctuation P: 539–40
 - baseline drift P: 540
 - patient accretion P: 545
 - patient compliance P: 547
 - patient information P: 548–9
 - patient withdrawals P: 547
 - polypharmacy in P: 541–2
 - sample size calculation P: 546
 - study design issues P: 542–5
 - blinding P: 542
 - cluster-randomized trials P: 544–5
 - crossover studies P: 543–4, P: 544 *F*
 - enriched enrollment designs P: 544, P: 544 *F*
 - historical control study
 - design P: 542
 - parallel study design P: 543, P: 543 *F*
 - patient selection P: 545
 - patient stratification P: 545
 - randomized controlled trials P: 543
 - sequential trials P: 542–3
 - study size P: 546
 - supplementary treatment P: 547
 - cancer pain syndromes C: 27–37; *see also individual syndromes*
 - cancer-related mucositis A: 418–9; C: 317
 - cancer-related suicide C: 57
 - psychiatrist referral C: 57
 - risk evaluation C: 57
 - risk factors C: 21–3, C: 332
 - management C: 332
 - Cancer Relief India C: 87
 - cancer survivors, pain C: 399–410; *see also individual diseases/disorders*
 - candesartan, migraine
 - prophylaxis **Ch**: 459–61, **Ch**: 461 *T*
 - candidate genes
 - chronic pain **Ch**: 71
 - cosegregating gene
 - identification **Ch**: 55–6
 - candidiasis, oral C: 316–7
 - risk factors C: 316
 - treatment C: 316–7
 - cannabinoid(s)
 - anorexia cachexia syndrome C: 328
 - cancer pain C: 275
 - multiple sclerosis **Ch**: 380
 - neurologic disease pain **Ch**: 331
 - topical, mechanisms of action **Ch**: 232
 - cannabinoid receptors
 - CB₁ subtype **Ch**: 16
 - CB₂ subtype **Ch**: 14
 - neuropathic pain **Ch**: 13, **Ch**: 14, **Ch**: 16
 - cannabis
 - central neuropathic pain
 - treatment **Ch**: 381–2 *T*
 - mechanism of action A: 15
 - nociception modulation A: 15
 - CanSupport C: 87
 - capacity, definition P: 221
 - capnography, biofeedback P: 487 *T*
 - capsaicin
 - adverse effects **Ch**: 231, **Ch**: 233
 - calcium/calmodulin-dependent protein kinase A: 26
 - clinical uses/indications **Ch**: 234
 - CRPS **Ch**: 369
 - doxepin and **Ch**: 234
 - HIV-associated distal symmetrical polyneuropathy **Ch**: 234
 - low back pain **Ch**: 236
 - mechanisms of action **Ch**: 232, **Ch**: 347
 - neurologic disease pain **Ch**: 329
 - neuropathic pain **Ch**: 234
 - assessment **Ch**: 138, **Ch**: 139 *T*
 - cancer patients C: 209
 - orofacial **Ch**: 472
 - osteoarthritis **Ch**: 527
 - peripheral neuropathic pain **Ch**: 347
 - peripheral nociceptor
 - sensitization **Ch**: 29
 - postbreast cancer surgery pain C: 275, C: 404–5
 - postherpetic neuralgia **Ch**: 234, **Ch**: 343, **Ch**: 435
 - protein kinase activation A: 26
 - pruritus, cancer patients C: 330
 - carbamazepine **Ch**: 255, **Ch**: 256 *T*
 - adverse effects **Ch**: 256, **Ch**: 257 *T*; C: 369; P: 136
 - antiretroviral drug
 - interactions **Ch**: 355
 - central neuropathic pain **Ch**: 379, **Ch**: 379–82 *T*
 - clinical trials **Ch**: 255
 - clomipramine and **Ch**: 255
 - contraindications P: 135
 - CRPS **Ch**: 369
 - diabetic neuropathy **Ch**: 255, **Ch**: 257 *T*
 - dosage/treatment schedule **Ch**: 257 *T*; P: 136
 - efficacy **Ch**: 261 *T*
 - elderly, cancer pain C: 369
 - indications **Ch**: 257 *T*
 - metabolism P: 135
 - multiple sclerosis A: 411
 - pediatric headache **Ch**: 632, **Ch**: 633 *T*
 - pharmacology **Ch**: 254–5

- postherpetic neuralgia **Ch:** 255
 sodium channel blockade **Ch:** 254–5
 spinal cord injury pain **Ch:** 394
 trigeminal neuralgia **Ch:** 255,
 Ch: 256 *T*, **Ch:** 257 *T*, **Ch:** 346,
 Ch: 473; **P:** 136
 carbocysteine **C:** 315
 carbonated salt preparations, local
 anesthetics **A:** 118–9
 carboplatin **C:** 401
 cardiac arrhythmia, sympathetic block-
 induced **P:** 335
 cardiac failure, abdominal pain **Ch:** 565
 cardiac pacemakers, TENS
 caution **A:** 277; **P:** 195
 cardiac pain, acute **A:** 417–8
 cardiac plexus neurons **Ch:** 538–9
 spinal cord stimulation **Ch:** 274–5
 cardiac rehabilitation, refractory angina
 pectoris **Ch:** 539–40
 cardiac surgery
 CPSP **A:** 559 *T*
 epidural analgesia **A:** 263
 patient-controlled **A:** 263
 ICUs **A:** 351
 intrathecal analgesia **A:** 263
 neuraxial analgesia **A:** 262
 cardiovascular compromise, continuous
 spinal analgesia **A:** 260–1
 cardiovascular drugs, local anesthetic
 interactions **A:** 124
 cardiovascular system
 alpha-2 adrenoreceptor
 agonists **A:** 102
 aspirin, low-dose benefits **A:** 71–2
 local anesthetic effects **A:** 122, **A:** 257
 low-dose aspirin benefits **A:** 75–6
 NSAID-induced adverse
 effects **A:** 71–2, **A:** 334, **A:** 516;
 Ch: 195–8; **C:** 136–8
 opioid effects **C:** 155
 caregiving, definition **C:** 63–4
 carers *see* family caregiver
 care withdrawal **A:** 350–1
 carpal fractures **A:** 528
 carpal tunnel syndrome **P:** 357–8
 corticosteroid injections **P:** 358,
 P: 358 *F*
 diagnosis **Ch:** 529 *T*
 nerve conduction studies **Ch:** 149–50
 pregnancy **A:** 462
 carpometacarpal joint, first, intra-
 articular injection **P:** 352
 carryover effects **P:** 520, **P:** 555–6
 Cartesian definitions **Ch:** 88
 cartilage debridement,
 osteoarthritis **Ch:** 528
 cartilage deterioration, osteoarthritis
 vs. **A:** 436
 case–control studies, chronic pain
 epidemiology **Ch:** 70
 case formulation **P:** 95–106
 biopsychological model **P:** 97
 assessment material in **P:** 97
 conceptualization **P:** 98–100, **P:** 99 *F*
 conceptual model development **P:** 98,
 P: 99 *F*
 engaging the patient **P:** 100–1
 measurements in **P:** 97
 motivation enhancement/
 clarification **P:** 101
 patient goal establishment **P:** 100–1
 preferred interventions **P:** 97
 process **P:** 96–7
 results judging **P:** 97–8
 case study **P:** 97–8, **P:** 98 *T*
 norms **P:** 97–8
 standardization sample **P:** 97
 shared understanding
 development **P:** 100
 stakeholder establishment **P:** 101
 targets **P:** 100
 case managers, pediatric persistent pain
 services **P:** 649
 case study, single-subject designs
 vs. **P:** 103
 Cataphoresis machine **P:** 193–4
 catastrophizing
 acute postoperative pain **A:** 294
 breast surgery **A:** 294
 children **A:** 310
 chronic pelvic pain **Ch:** 582
 CPSP development **A:** 563
 definition **A:** 293, **A:** 310
 pain-related fear **P:** 178
 catechol-*O*-methyl transferase (COMT)
 CPSP **A:** 561
 fibromyalgia syndrome **Ch:** 603
 opioid response variability **C:** 174
 pharmacogenetics **Ch:** 62 *T*
 polymorphism **Ch:** 242–3; **P:** 85–6
 temporomandibular
 disorders **Ch:** 469
 categorical-rated scale (CRS),
 elderly **C:** 361
 cathartic drugs **C:** 190
 catheter(s)
 axillary brachial plexus
 blocks **A:** 237–8
 continuous peripheral neural
 blockade **A:** 243–4
 kits **A:** 243–4
 epidural analgesia **A:** 260
 children **P:** 473
 thoracic **A:** 260
 sciatic nerve block **A:** 240
 cauda equina **P:** 417
 cauda equina compression *see* spinal
 cord compression, cancer patients
 cauda equina syndrome **A:** 448–9;
 Ch: 505
 chiropractic therapy **Ch:** 313
 surgery **Ch:** 512
 caudal analgesia, developing
 world **A:** 396
 caudal epidural analgesia, children
 acute pain **A:** 490–1
 anatomy **P:** 472
 anesthetic spread **A:** 490, **A:** 491 *T*
 catheters **P:** 472–3
 complications **A:** 490–1
 drug combinations **A:** 491
 indications **P:** 472
 local anesthetic **P:** 473
 method **P:** 472–3
 procedures **A:** 490
 causalgia, sympathetic blocks **Ch:** 151
 causality **C:** 98
 cavernous sinus syndrome **C:** 31 *T*
 CBT *see* cognitive-behavioral therapy
 (CBT)
 CCL2 chemokine (MCP-1)
 microglia activation **Ch:** 14
 neuropathic pain **Ch:** 10, **Ch:** 14
 CCR2, neuropathic pain **Ch:** 10,
 Ch: 14
 CD4 T-cells, HIV infection **Ch:** 352–3
 ceiling effect **C:** 105
 nonopioid drugs **C:** 111
 opioids, chronic noncancer
 pain **Ch:** 217–8; **P:** 116
 celecoxib **A:** 78, **A:** 79
 cardiovascular risks **Ch:** 195–6; **C:** 137
 elderly **C:** 366
 oral administration **A:** 202–3
 properties **A:** 75 *T*
 rheumatoid arthritis **Ch:** 198
 temporomandibular
 disorder **Ch:** 469–70
 celiac ganglionectomy, chronic
 pancreatitis **Ch:** 556
 celiac plexus **P:** 341
 celiac plexus block **P:** 341–2
 anatomy **P:** 341
 chronic pancreatitis **Ch:** 554–5
 complications **P:** 342
 fluoroscopic guidance **P:** 341
 indications **P:** 341
 pancreatic cancer **P:** 341
 technique **P:** 341–2, **P:** 342 *F*
 cell culture, pain research **Ch:** 61 *T*

- cell membrane electrical
gradient **A:** 114
- cellular electrophysiology **A:** 114
- Cental Europe, palliative care
services **C:** 86
- Center for Epidemiological
Studies-Depression (CES-D) scale,
chronic pain patients **Ch:** 172 *T*,
Ch: 173, **Ch:** 241–2
- CENTRAL (Cochrane Central Register
Controlled Trials) **P:** 570 *T*
- central dysthesia syndrome *see* spinal
cord injury (SCI) pain, below-level
neuropathic pain
- central hyperexcitability **P:** 44
- central hypogastric pain **C:** 35
- central nerve blocks, children **P:** 472–4
- central nervous system (CNS)
age-related changes **A:** 506 *T*, **A:** 507
indometacin adverse effects **A:** 72
ketamine adverse effects **A:** 99
local anesthetic toxicity **A:** 122, **A:** 257
NSAID-induced adverse effects **A:** 72,
A: 516
opioid effects **C:** 154–5
- central nervous system depressants,
local anesthetic interactions **A:** 123
- central neuropathic itch **Ch:** 237
- central neuropathic pain **Ch:** 374–87
concomitant non-neuropathic
pain **Ch:** 375
definition **C:** 200
etiology **Ch:** 374
lesions **Ch:** 375
non-neuropathic pain and **Ch:** 375
pathophysiology **Ch:** 378–9
cold-signaling pathway **Ch:** 378
lemniscal sensory pathway **Ch:** 378
lesion sites **Ch:** 378
phantom limb pain *vs.* **Ch:** 378
spinal-thalamic-cortical pathway
dysfunction **Ch:** 378
spinoreticulothalamic
system **Ch:** 378–9
spinothalamic pathway **Ch:** 378
thalamic pain syndromes **Ch:** 379
thermal sensations **Ch:** 378
subtypes **Ch:** 375, **Ch:** 375–8;
see also individual types
treatment **Ch:** 259, **Ch:** 379–83
adverse effects **Ch:** 379
dosages **Ch:** 379
drug interactions **Ch:** 379
efficacy of **Ch:** 375
intrathecal therapy **Ch:** 380
parenteral therapy **Ch:** 380
patient expectations **Ch:** 379
- pharmacological
management **Ch:** 379,
Ch: 379–82 *T*
surgery **Ch:** 380–3
- central pain syndromes, laser-evoked
potentials **P:** 51
- central poststroke pain
(CPSP) **Ch:** 377–8
acute **A:** 411
complex regional pain syndrome
development **A:** 411
development **Ch:** 377
lateral medullary infarctions **Ch:** 377
lesion distribution effects **Ch:** 377
severity **Ch:** 377–8
somatosensory disturbances **Ch:** 378
spontaneous pain **Ch:** 378–9
studies **Ch:** 377
thalamic infarctions **Ch:** 377
right-sided **Ch:** 377–8
thalamic pain syndrome **Ch:** 377
treatment **Ch:** 262, **Ch:** 380
- central sensitization **A:** 24–7
brain stem **P:** 88–9
definition **A:** 25
dorsal horn plasticity *see* dorsal horn
plasticity
excitatory postsynaptic
potentials **A:** 25
experimental demonstration **A:** 25
imaging **P:** 88–9
mechanisms **P:** 44
opioid effects **A:** 168
persistent musculoskeletal
pain **Ch:** 26
protein kinases **A:** 26–7
calcium/calmodulin-dependent
protein kinase **A:** 26
extracellular signal-regulated
kinases **A:** 26–7
mitogen-activated protein
kinase **A:** 26–7
- central spinal pain *see* spinal cord
injury (SCI) pain
- central summation **P:** 52
- central venous cannulation, substance
abuse disorder **A:** 546
- cerebral blood flow (CBF)
imaging **P:** 84
fibromyalgia syndrome **Ch:** 604,
Ch: 604 *T*
- cerebral metastasis, headache
management **C:** 253
- cerebral origin spasticity **Ch:** 441–2,
Ch: 441 *T*
- cerebrospinal fluid examination,
peripheral neuropathies **Ch:** 337
- cerebrospinal fluid (CSF) leaks,
intrathecal drug delivery **P:** 376
- cerebrovascular disorders, neck
pain **Ch:** 490
- cervical dorsal root ganglion
percutaneous radiofrequency
lesioning **P:** 397–9
cervical radicular pain **P:** 399
chronic intractable pain **P:** 399
contraindications **P:** 397
diagnostic root blocks **P:** 397–8,
P: 397 *F*
efficacy **P:** 398–9
indications **P:** 397
side effects **P:** 398
technique **P:** 397–8, **P:** 398 *F*
tunnel-vision projection **P:** 397–8
pulsed radiofrequency lesions **P:** 398
- cervical dystonia, spinal accessory nerve
block **P:** 261
- cervical hematoma, stellate ganglion
block-induced **P:** 329
- cervical intervertebral discs, referred
pain **Ch:** 486
- cervical medial branch blocks, neck
pain diagnosis **Ch:** 162
- cervical pain **P:** 395
- cervical plexus, superficial
branches **P:** 262
- cervical plexus block **P:** 261–2
deep (Labat method) **P:** 262–4
anatomy **P:** 262
complications **P:** 264
landmarks **P:** 262, **P:** 264 *F*
practical steps/technique **P:** 262–3,
P: 264 *F*
indications **P:** 262
superficial **P:** 262
anatomy **P:** 262, **P:** 263 *F*
landmarks **P:** 262
practical steps/technique **P:** 262
single injection technique **P:** 262,
P: 263 *F*
superficial injection
technique **P:** 262, **P:** 263 *F*
- cervical radicular pain, referred **Ch:** 485
- cervical radiculopathy,
myelography **Ch:** 148
- cervical referred pain **Ch:** 485–9
cervical intervertebral disks **Ch:** 486
cervical radicular pain **Ch:** 485
convergence **Ch:** 485
definition **Ch:** 485
intraspinous muscles **Ch:** 486
pain maps **Ch:** 485–6, **Ch:** 485 *F*,
Ch: 486 *F*, **Ch:** 487 *F*
patterns **Ch:** 485–6

- somatic **Ch**: 485
 vertebral etiology **Ch**: 486, **Ch**: 487 *F*
 zygapophyseal joints **Ch**: 486
- cervical roots **P**: 262
- cervical spine, rheumatoid arthritis **Ch**: 520
- cervical spondylosis
 headache **Ch**: 454
 radiography **Ch**: 488, **Ch**: 491–2
- cervical zygapophyseal blocks **P**: 365–6
 intra-articular **P**: 365–6
 C2-3 joints **P**: 366
 needle placement **P**: 366 *F*
 medial branch blocks **P**: 366, **P**: 366 *F*,
P: 367 *F*
 results **P**: 367
- cervical zygapophyseal joints, neck
 pain **Ch**: 152
 diagnosis **Ch**: 162
- cervicobrachialgia **P**: 395–6
- cervicogenic headache **P**: 396
- cervicothoracic sympathetic
 chain **P**: 327, **P**: 328 *F*
 block *see* stellate ganglion block
- cesarean section, CPSP **A**: 559 *T*
- C-fiber(s)
 acupuncture **A**: 280–1; **P**: 209
 acute pain **P**: 44
 acute postoperative pain **A**: 156
 burn pain **A**: 400
 characteristics/structure **A**: 4, **A**: 4 *T*,
A: 6 *T*
 local anesthetic sensitivity **A**: 116 *T*
 neuropathic pain **Ch**: 13, **Ch**: 134
 peripheral neuropathy **Ch**: 336–7;
P: 44, **P**: 77 *T*
 peripheral nociceptors **Ch**: 27
 sensitization **Ch**: 29
 peripheral sensitization **A**: 21
 persistent visceral pain **Ch**: 39
 postnatal development **A**: 33, **A**: 34 *T*
 functional contacts **A**: 33
 hyperalgesia **A**: 39
 wind up-like pain **Ch**: 136
- c-Fos, persistent musculoskeletal
 pain **Ch**: 30
- chamomile **Ch**: 314 *T*
- chapparral **Ch**: 315 *T*
- Charcot–Marie–Tooth (CMT) disease,
 diagnosis **Ch**: 151 *T*
- Charcot–Marie–Tooth (CMT) disease
 type 2B **P**: 79
- Charcot–Marie–Tooth (CMT) disease
 type 4F **P**: 79
- Charité artificial disk **P**: 442
- Checklist for Interpersonal Pain
 Behavior (CHIP) **A**: 145
- Checklist of Nonverbal Pain
 Indicators **C**: 392
- chemical hyperalgesia, neuropathic
 pain **Ch**: 141 *T*
- chemical knee synovectomy **P**: 359
- chemically induced writhing
 model **Ch**: 41
- chemical neurolysis **C**: 225–34
 agents **C**: 226 *T*, **C**: 227–8;
see also individual agents
 clinical applications **C**: 228–31
 historical aspects **C**: 225–6, **C**: 226 *T*
 pathophysiology **C**: 226–7, **C**: 227 *T*
 surgical sectioning vs. **C**: 226,
C: 226 *T*
- chemical stimuli
 human visceral pain models **Ch**: 41
 persistent visceral pain **Ch**: 38
- chemokines
 neuropathic pain **Ch**: 10
see also individual chemokines
- chemoreceptors **A**: 4–6
- chemotherapy
 metastatic bone pain **C**: 264–5,
C: 264 *T*
 indications **C**: 264
 nausea and vomiting *see*
 chemotherapy-induced nausea
 and vomiting
 neuropathic pain induction *see*
 chemotherapy-induced
 peripheral neuropathy (CIPN)
 neurotoxic agents **C**: 400
 neurotoxicity **C**: 399–400
- chemotherapy-induced nausea and
 vomiting
 acupuncture **C**: 274
 hypnosis **C**: 276
 management plan **C**: 322 *F*
 TENS **C**: 243
- chemotherapy-induced peripheral
 neuropathy (CIPN) **C**: 399–402
 animal models **C**: 8, **C**: 400
 assessment **C**: 401
 standardization **C**: 401
 axonopathy **C**: 8, **C**: 400–1
 “coasting” **C**: 400–1
 diagnostic features **C**: 400
 grading scales **C**: 401, **C**: 401 *T*
 mechanisms **C**: 399–401
 neuroimmune responses **C**: 8
 neuronopathy **C**: 400–1
 neurotoxic agents **C**: 400, **C**: 401–2
 pain distribution **C**: 400
 pathophysiology **C**: 7
 presentation **C**: 399–401
 prevention **C**: 402
- treatment **C**: 8–9, **C**: 402
 as unique pain syndrome **C**: 4
- chest pain
 cardiac **Ch**: 539–42
 acute ischemic **A**: 364–5, **A**: 418
 chronic **Ch**: 537–48
 anatomy **Ch**: 538–9
 assessment **Ch**: 538
 clinical history **Ch**: 538
 epidemiology **Ch**: 537–8
 etiology **Ch**: 537–8, **Ch**: 538 *T*,
Ch: 544 *T*
 costs **Ch**: 538
 esophageal **Ch**: 543
 TENS **P**: 195, **P**: 201
 musculoskeletal **Ch**: 544
 radiotherapy **C**: 252
 referred **Ch**: 544
 somatic **Ch**: 543
 visceral
 gastric **Ch**: 543
 great vessels **Ch**: 542
 pericardium **Ch**: 542
- chest radiography, dyspnea **C**: 311
- chickenpox (varicella) **Ch**: 429–30,
Ch: 430 *F*
- Child Depression Inventory,
 breakthrough pain **C**: 346
- child life specialists, pediatric
 APS **P**: 643
- children
 acute pain *see* pediatric acute pain
 avoidant attitude development **A**: 309
 biofeedback *see* biofeedback,
 children
 buccal drug administration **P**: 463–4
 cancer pain *see* pediatric cancer pain
 chronic pain **Ch**: 623–40
 archetype disorders **Ch**: 624
 assessment **Ch**: 125; **P**: 455–6
 epidemiology **Ch**: 624
 management goals **Ch**: 624
 pathophysiology **Ch**: 623–4
 psychological assessment **Ch**: 125
- desire to protect **C**: 54
- distress assessment **P**: 453
- distress reduction, parental
 involvement **P**: 480–1
- epidural analgesia *see* epidural
 analgesia
- epidural space estimation **P**: 473
- helping parents talk to **C**: 54–5
- hypnosis *see* hypnosis
 with ill relative, behavioral
 changes **C**: 54
- inhalational drug
 administration **P**: 464

- children (*continued*)
- intramuscular drug
 - administration **A:** 485; **C:** 350; **P:** 464
 - intranasal drug administration **A:** 485; **P:** 463–4
 - intravenous drug
 - administration **A:** 481–2, **A:** 482 *T*, **A:** 485; **C:** 350; **P:** 464
 - local anesthetic procedures **P:** 469–74
 - local anesthetic sensitivity **A:** 120–1
 - mind/body skills *see* mind/body skills
 - neuraxial drug administration **P:** 464
 - nurse-controlled analgesia **A:** 484, **A:** 493; **P:** 467, **P:** 467 *T*
 - opioid tolerance **C:** 354–5
 - opioid use *see* opioid(s)
 - oral drug administration **C:** 349; **P:** 463
 - pain assessment **P:** 447–61
 - critical care patients **P:** 453
 - cultural considerations **P:** 458
 - developmental disabilities **P:** 456
 - ethnic considerations **P:** 458
 - intensive care **P:** 453
 - parental role **P:** 458
 - postoperative **P:** 451–3
 - procedural **P:** 451
 - pain intensity measurement **P:** 20
 - behavioral indicators **P:** 20
 - limitations **P:** 20
 - physiological indicators **P:** 20
 - self-report **P:** 20
 - toys **P:** 16, **P:** 17 *F*
 - pain management **P:** 462–77
 - management plan **P:** 462, **P:** 463 *T*
 - multimodal analgesia **P:** 462
 - pain-related fear assessment **P:** 453
 - pain study **A:** 478
 - parental behavior effects, presurgery **P:** 252–3
 - parental distress effects **P:** 252
 - PCA **C:** 350; **P:** 294, **P:** 296–7, **P:** 467, **P:** 467 *T*
 - phantom limb pain **Ch:** 408
 - psychological evaluation **C:** 54–5
 - psychological preparation, painful procedures **P:** 252–3
 - psychosocial needs **C:** 54
 - rectal drug administration **C:** 350; **P:** 463
 - subcutaneous drug
 - administration **C:** 350; **P:** 464
 - sublingual drug
 - administration **P:** 463–4
 - TENS caution **P:** 196
 - Children and Infants Postoperative Pain Scale (CHIPPS) **A:** 479 *T*
 - Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS)
 - burn pain assessment **A:** 402
 - procedural pain, children **A:** 481 *T*; **P:** 20, **P:** 451, **P:** 452 *T*
 - Chinese herbs **C:** 275
 - CHIP (Checklist for Interpersonal Pain Behavior) **A:** 145
 - CHIPPS (Children and Infants Postoperative Pain Scale) **A:** 479 *T*
 - chiropractic therapy **Ch:** 311–3
 - adverse effects/risk **Ch:** 313
 - clinical uses/indications **Ch:** 312
 - Cochrane review **Ch:** 312
 - efficacy **Ch:** 312
 - historical aspects **Ch:** 311–2
 - low back pain, case study **Ch:** 316
 - neurologic disease pain **Ch:** 331
 - pain validation **Ch:** 312
 - spine care team **Ch:** 502–3
 - “subluxation complex” **Ch:** 312
 - value of **Ch:** 312
 - chlamydial infections, recurrent
 - cystitis **Ch:** 579–80
 - chloroprocaine **A:** 124, **A:** 125
 - chlorpromazine, migraine **A:** 366, **A:** 366 *T*
 - children **Ch:** 631 *T*
 - cholecystectomy
 - biliary colic **A:** 415
 - CPSP **A:** 559 *T*, **A:** 562
 - cholecystitis, acalculous, HIV **Ch:** 358
 - cholecystokinin (CCK)
 - acupuncture **C:** 273
 - neuropathic pain **Ch:** 12–3, **Ch:** 14 *F*, **Ch:** 15–6
 - nocebo effect **P:** 505–6
 - nociception modulation **A:** 17
 - opioid effectiveness **C:** 202–3
 - cholestasis, cancer patients **C:** 330
 - cholestyramine **C:** 330
 - choline magnesium trisalicylate (Trilisate), children **C:** 348
 - cholinesterase, local anesthetic metabolism **A:** 120
 - chondromalacia **A:** 530
 - chondroprotective agents, osteoarthritis **Ch:** 527
 - chromosomes **Ch:** 49
 - chronic back pain
 - gray matter volume loss **P:** 89
 - lower back *see* chronic lower back pain (CLBP)
 - magnetic resonance volumetry **P:** 89
 - multidisciplinary treatment **P:** 223
 - neurodegeneration **P:** 89
 - opioids **P:** 117
 - chronic constriction injury (CCI)
 - postnatal development effects **A:** 44
 - sciatic nerve **Ch:** 4–5
 - chronic fatigue syndrome **Ch:** 42, **Ch:** 602
 - chronic intractable pain, radiofrequency lesioning **P:** 399
 - chronic lower back pain (CLBP) **Ch:** 501–17
 - activity limitation assessment **P:** 222
 - biofeedback **P:** 163
 - chronic pain syndrome *vs.* **Ch:** 503
 - definition **Ch:** 503
 - diagnosis **Ch:** 157–9
 - CT **Ch:** 157
 - disk algorithms **Ch:** 157, **Ch:** 158 *F*
 - disk stimulation **Ch:** 157, **Ch:** 159 *T*
 - lumbar zygapophyseal joint
 - pain **Ch:** 157, **Ch:** 158–9
 - medial branch blocks **Ch:** 159
 - MRI **Ch:** 148, **Ch:** 157
 - sacroiliac joint pain **Ch:** 159
 - synovial joint algorithm **Ch:** 158–9, **Ch:** 160 *F*
 - differential diagnosis **Ch:** 503
 - disability **Ch:** 502, **Ch:** 503–4
 - disk algorithms **Ch:** 157, **Ch:** 158 *F*
 - elderly **Ch:** 642
 - etiology **Ch:** 507–8
 - discogenic origin **Ch:** 505
 - osteopathic view **Ch:** 508
 - patient mindset **Ch:** 507, **Ch:** 507 *T*
 - exercise **P:** 223
 - fusion surgery **P:** 438–9
 - graded exposure *in vivo*, increased pain **P:** 186
 - history taking **Ch:** 504
 - initial assessment **Ch:** 503–7
 - goals **Ch:** 503
 - pain severity **Ch:** 502, **Ch:** 504
 - intervertebral disk
 - degeneration **P:** 416, **P:** 438
 - treatments **P:** 417
 - manual medicine **P:** 237
 - match/mismatch model of pain **P:** 179
 - pain overprediction **P:** 179
 - patient history **Ch:** 507
 - patient presentation **Ch:** 502
 - physical examination **Ch:** 504–7, **Ch:** 506 *T*
 - red flag screening **Ch:** 504, **Ch:** 504 *T*
 - treatment **Ch:** 508–11
 - aims **Ch:** 508
 - approach to **Ch:** 502

- back-to-work programs **Ch:** 510
injection therapy **Ch:** 511
multidisciplinary
 approach **Ch:** 502–3
NSAIDs **Ch:** 198, **Ch:** 199 *T*
pain rehabilitation
 programs **Ch:** 503
pharmacological **Ch:** 508
physical **Ch:** 509–10
realistic pain reduction **Ch:** 508
selective serotonin reuptake
 inhibitors **Ch:** 247
spinal manipulation **Ch:** 509
spine care team **Ch:** 502–3
surgery **Ch:** 512
thermal **P:** 224
topical analgesics **Ch:** 236–7
traction **Ch:** 510
tricyclic antidepressants **Ch:** 244–5
yellow flag screening **Ch:** 504,
 Ch: 504 *T*
- chronic masticatory
 neuralgia **Ch:** 257 *T*
- chronic muscle pain, trigger points
 in **P:** 163
- chronic obstructive pulmonary disease
(COPD), COX-2
 inhibitors **Ch:** 196–7
- chronic pain
 acceptance of **P:** 168–9
 adult survivors, childhood
 cancers **C:** 346
 adverse impact of **Ch:** 66
 anger and **P:** 621–2
 assessment **P:** 3–4
 children **P:** 455–6
 nonmalignant pain **P:** 21
 biofeedback **P:** 149–50, **P:** 165
 children **P:** 486–7
 biological markers **Ch:** 70–1
 children *see* children
 as construct **Ch:** 116, **Ch:** 117
 cryoanalgesia **P:** 383–7
 daily functioning
 assessment **Ch:** 172–3, **Ch:** 172 *T*
 daily living effects **Ch:** 66, **Ch:** 171
 definitions **Ch:** 117, **Ch:** 181
 depression and *see* depression
 development
 healthcare provider beliefs **A:** 296
 transition prevention,
 NSAIDs **A:** 70
 diagnostic procedures **Ch:** 145–68
 biochemical tests **Ch:** 151,
 Ch: 151 *T*
 known pathology **Ch:** 154–6,
 Ch: 154 *T*
- therapeutic utility **Ch:** 163
unknown pathology **Ch:** 155 *T*,
 Ch: 156–7
utility **Ch:** 162–3
see also individual diseases/disorders;
individual procedures/techniques
- direct cost estimation **P:** 624–5
disability assessment **Ch:** 172–3,
 Ch: 172 *T*
disbelief, feelings **P:** 171–2
economics *see* economics (chronic
 pain)
elderly *see* elderly
emotional distress
 assessment **Ch:** 173–4
emotional state, patient **Ch:** 170–1
epidemiology **Ch:** 65–74
 age **Ch:** 66–9
 candidate genes **Ch:** 71
 case–control studies **Ch:** 70
 cohort studies **Ch:** 70
 cross-sectional studies **Ch:** 67–8 *T*,
 Ch: 69–70
 ethnicity/culture/race **Ch:** 66–9
 false discovery rate controls **Ch:** 72
 future work **Ch:** 72
 gender **Ch:** 66–9
 high-density genome-wide
 screening **Ch:** 71
 molecular methods **Ch:** 70–2;
 see also individual methods
 multiple comparisons **Ch:** 72
 pathway-based approach **Ch:** 71
 population stratification **Ch:** 72
 prevalence **Ch:** 66–9, **Ch:** 67–8 *T*
 principles **Ch:** 69
 sex hormones **Ch:** 66
 socioeconomic
 considerations **Ch:** 69
 statistics **Ch:** 71–2
 study design **Ch:** 69–70;
 see also individual studies
- frustrations, patient **P:** 3
historical aspects **Ch:** 86
history-taking **P:** 3–11
 back/spinal pain **P:** 8
 drugs **P:** 6
 herbal medicines **P:** 5–6
 hyperalgesia **P:** 8
 nervous system disorders **P:** 8
indirect cost estimation **P:** 624–5
litigation sources **P:** 678 *T*
meaningful change **P:** 22–3
measurement **Ch:** 117–9
 individuality in **Ch:** 118
muscle tension perception **P:** 157
muscle tension resting levels **P:** 155
- opioid ligand binding studies
 P: 90
outcome measurement *see* chronic
 pain outcome measurement
patient definition **P:** 3
PCA, opioid-tolerant
 patients **P:** 297–8
pelvic *see* chronic pelvic pain (CPP)
physical examination *see* physical
 examination, chronic pain
 patients
physician–patient interview *see*
 physician–patient interview,
 chronic pain
physiotherapy, patient
 education **P:** 223
postsurgical *see* chronic postsurgical
 pain (CPSP)
prevalence **Ch:** 66–9, **Ch:** 67–8 *T*,
 Ch: 87
 cross-sectional studies **Ch:** 67–8 *T*,
 Ch: 69–70
psychological assessment **Ch:** 122–31
 applicability **Ch:** 129
 disability outcome
 predictions **Ch:** 127–8
 ethics **Ch:** 123
 inadequate, effects of **Ch:** 122–3
 invasive procedure outcome
 prediction **Ch:** 127–8
 liabilities/claims **Ch:** 128
 objectives **Ch:** 123
 pain assessment
 measures **Ch:** 124–5
 pain center evaluation,
 standard **Ch:** 123–5
 pain center questionnaire **Ch:** 123,
 Ch: 124 *T*
 psychological status
 measures **Ch:** 125–7
 structured clinical
 interview **Ch:** 123–4
 substance abuse/misuse **Ch:** 128–9
 treatment plan **Ch:** 123
 see also individual measures/
 instruments
- psychological effects **Ch:** 169–77
 assessment effects **Ch:** 170
 behavioral avoidance **Ch:** 174
 community pain surveys **Ch:** 171,
 Ch: 171 *F*
 environmental
 avoidance **Ch:** 174–5
 experiential avoidance **Ch:** 174
 historical aspects **Ch:** 170
 model development **Ch:** 170
 pain avoidance **Ch:** 174

- chronic pain (*continued*)
- patients seeking
 - treatment **Ch:** 170–1
 - processes in **Ch:** 174–5
 - psychophysiological
 - assessment **P:** 155 *T*
 - quality of life reduction **P:** 620
 - risk factors **Ch:** 69
 - signs/symptoms **P:** 620
 - social context **P:** 171–2
 - pressure on patient **P:** 172
 - “self,” understanding of **P:** 171
 - treatment environment **P:** 171–2
 - spousal responses **P:** 171
 - substance abuse disorder **A:** 542
 - sympathetic block indications **P:** 325
 - TENS *see* transcutaneous electrical nerve stimulation (TENS)
 - yellow flags **A:** 296
 - see also individual diseases/disorders*
- chronic pain outcome
- measurement **Ch:** 178–89
 - biomedical outcomes **Ch:** 181
 - blinding **Ch:** 184
 - CBT **Ch:** 298
 - concurrent treatments **Ch:** 184, **Ch:** 184 *F*
 - consensus measures **Ch:** 182
 - control groups **Ch:** 183–4
 - data analysis/presentation **Ch:** 184–6
 - graphical representation **Ch:** 186
 - data collection **Ch:** 183
 - difficulties **Ch:** 181–4
 - chronological issues **Ch:** 181
 - pain complexity **Ch:** 181
 - population problems **Ch:** 181–2
 - end points **Ch:** 185
 - future work **Ch:** 186
 - measurement necessity **Ch:** 178–81
 - neuropathic pain
 - assessment **Ch:** 139–40
 - “N of 1” studies **Ch:** 183
 - number needed to treat
 - Ch:** 185–6, **Ch:** 185 *F*, **Ch:** 186
 - pain measurement **Ch:** 184–5
 - practical considerations **Ch:** 182–3
 - abbreviated measures **Ch:** 183
 - data collection **Ch:** 183
 - published guidelines **Ch:** 183
 - sensitivity **Ch:** 182–3
 - psychological outcomes **Ch:** 181
 - reasons for **Ch:** 178–81
 - social outcomes **Ch:** 181
 - specific treatment
 - determination **Ch:** 179
 - stakeholders **Ch:** 179, **Ch:** 179 *T*
- treatment benefit
- determination **Ch:** 179–81
 - effectiveness measure **Ch:** 180, **Ch:** 180 *T*
 - efficacy measure **Ch:** 180
 - efficiency measure **Ch:** 180–1
 - utility measure **Ch:** 180
 - treatment guide **Ch:** 179
 - treatment safety **Ch:** 179
- chronic pain programs **P:** 620–1
- cost–benefit issues **P:** 621
 - “detoxification” **P:** 621
 - multidisciplinary pain clinical evaluation **P:** 620
 - return to work **P:** 621
- Chronic Pain Questionnaire (CPQ), depression **Ch:** 241–2
- chronic pain service, APS cooperation **P:** 583
- chronic pain syndrome **P:** 222
- Chronic Pain Values Inventory (CPVI) **P:** 170
- chronic pelvic pain (CPP) **Ch:** 570–98
- clinical evaluation **Ch:** 582–3
 - clinical history **Ch:** 582–3
 - definition **Ch:** 571
 - depression **Ch:** 582
 - diagnostic studies **Ch:** 583
 - epidemiology **Ch:** 571
 - etiology **Ch:** 571–2, **Ch:** 573 *T*
 - gastroenterologic **Ch:** 573 *T*, **Ch:** 579
 - musculoskeletal **Ch:** 573 *T*, **Ch:** 580–1
 - peripheral causes **Ch:** 572–8, **Ch:** 573 *T*
 - physical abuse **Ch:** 582
 - sexual abuse **Ch:** 582
 - urologic **Ch:** 573 *T*, **Ch:** 579–80
 - see also individual diseases/disorders*
- gynecologic cyclic pain **Ch:** 572, **Ch:** 573 *T*
- gynecologic noncyclic pain **Ch:** 573 *T*, **Ch:** 578–9
- idiopathic **Ch:** 581–2
- management **Ch:** 583–7
- alternative medicine **Ch:** 587
 - hysterectomy *see* hysterectomy
 - injection therapy **Ch:** 584
 - multidisciplinary **Ch:** 587
 - pharmacological **Ch:** 583–4
 - physical therapy **Ch:** 584
 - psychological therapies **Ch:** 587
 - surgery **Ch:** 584–5
- myofascial pain **Ch:** 573 *T*, **Ch:** 580–1
- symptoms/signs **Ch:** 581
 - treatment **Ch:** 581
- neuroanatomy **Ch:** 571–2, **Ch:** 571 *T*
- visceral innervation **Ch:** 571–2
- neuropathic pain **Ch:** 573 *T*, **Ch:** 581
- pathophysiology **Ch:** 571–2
- physical examination **Ch:** 583
- psychological factors **Ch:** 582
- chronic pelvic pain syndrome (CPPS) **Ch:** 563
- chronic postsurgical pain (CPSP) **A:** 558–69; **Ch:** 405–13
- acute postsurgical pain severity **A:** 563
 - bilateral surgery and **A:** 561
 - climate of blame **Ch:** 409–10
 - cognitive perceptions **Ch:** 410
 - definitions **A:** 292, **A:** 559
 - preoperative pain confusion **A:** 559
 - problems **A:** 559; **Ch:** 405–6
 - working definition **A:** 559
 - evolutionary perspective **Ch:** 407
 - future directions **Ch:** 410
 - genetics **A:** 561
 - historical aspects **A:** 558–9
 - implications **A:** 560
 - incidence **A:** 559, **A:** 559 *T*
 - age-related **A:** 560–1
 - mechanisms **A:** 560; **Ch:** 406–7
 - cognitive perceptions **Ch:** 410
 - complexity
 - implications **Ch:** 409–10
 - cortical remapping **Ch:** 407
 - nervous system changes **Ch:** 407
 - neuronal plasticity **Ch:** 407
 - medical factors **A:** 561–3
 - analgesia **A:** 563
 - anesthesia **A:** 563
 - concomitant treatments **A:** 562–3
 - post-cancer surgery **C:** 402–5
 - predictors **A:** 156–7
 - preoperative pain and **A:** 156–7, **A:** 561–2
 - prevention **A:** 563–6
 - analgesia choice **A:** 564
 - anesthetic choice **A:** 564
 - organizational barriers **A:** 565–6
 - perioperative pain
 - management **A:** 564–5
 - preemptive analgesia **A:** 565
 - surgery, reduction of **A:** 564
 - psychosocial factors **A:** 563
 - risk factors **A:** 560–3
 - demographics **A:** 560–1
 - inappropriate surgery **A:** 559
 - surgeons’ experience and **A:** 562
 - surgery, reasons for **A:** 562–3
 - surgical type **A:** 562; **Ch:** 406–7
 - syndromes **Ch:** 407–9
 - range of **Ch:** 406

- see also individual surgical techniques*
- chronic renal failure,
 NSAID-induced **C**: 135
- chronic vulvovaginitis **Ch**: 587
- chronological issues, outcome
 measurement **Ch**: 181
- Churg–Strauss neuropathy **Ch**: 151 *T*,
 Ch: 342
- ciclosporin, NSAID interactions **A**: 74 *T*
- cimetidine, porphyria **A**: 421
- CINAHL (Cumulative Index to Nursing
 and Allied Health
 Literature) **P**: 570 *T*
- cinchocaine **A**: 125
- CINODs (COX inhibitors and NO
 donors; NO-NSAIDs) **C**: 138
- Cipla Cancer Palliative Care
 Centre **C**: 87
- circumcision, penile block **A**: 490
- cirrhosis, pharmacokinetics
 effects **C**: 108
- cisplatin, neuropathy induction **C**: 7,
 C: 401
- citalopram **Ch**: 244 *T*
 dosage/treatment schedule **P**: 138
 fibromyalgia syndrome **Ch**: 246–7
 mechanism of action **Ch**: 246
 neuropathic pain **Ch**: 246, **Ch**: 346
 pediatric headache **Ch**: 632
 pharmacology **Ch**: 246
 tension-type headache
 prophylaxis **Ch**: 461–2
- citrulline moiety **P**: 69–70
- classical conditioning, placebo
 response **P**: 504
- classification and regression tree
 (CART) modeling **Ch**: 72
- clearance (Cl), drugs
 definition **C**: 107
 elderly **C**: 365
 hepatic function and **C**: 108
- climatic conditions, pain
 perception **P**: 13–4
- clinical governance **P**: 680–1
- clinical guidelines, best practice **P**: 681
- Clinical Incident Reporting **P**: 677
- Clinical Nurse Specialist (CNS) **C**: 418
- clinical practice, clinical trials
 vs. **Ch**: 180 *T*
- clinical practice guidelines (CPG)
 evidence-based, definition **P**: 665–6
 postoperative pain
 management **P**: 665–9
 see also individual guidelines
- Clinical Scoring System (CSS) **A**: 479 *T*
- Clinical Standards Advisory Group
 (CSAG) **A**: 454
- clinical trial registries **P**: 570 *T*, **P**: 574
- clinical trials
 active placebos **P**: 520
 acute pain **P**: 514–28
 additive effects **P**: 518
 assay sensitivity *see* assay sensitivity
 baseline pain **P**: 519
 blinding **P**: 520
 cancer pain *see* cancer pain clinical
 trials
 chronic pain **P**: 514–28
 screening periods **P**: 519
 clinical practice *vs.* **Ch**: 180 *T*
 control choice **P**: 516–8
 crossover studies *see* crossover studies
 definition **P**: 514–5, **P**: 552
 design **P**: 516
 difficulty, children **A**: 478
 drop outs **P**: 524–5
 duplicate publication **P**: 563
 end points, meaningful **P**: 520–1
 patient's assessment **P**: 521
 self-report measures **P**: 520
 enriched enrollment **P**: 519–20
 evoked pain **P**: 521, **P**: 522 *T*
 exclusions, sensitivity **Ch**: 183
 explanatory attitudes **P**: 515, **P**: 515 *T*
 Good Clinical Practice
 Guidelines **P**: 554
 good practice **P**: 531
 intention-to-treat **P**: 524–5, **P**: 525 *T*
 interpretation problems **P**: 533
 intrathecal opioids **Ch**: 184
 long-term **P**: 524
 neuropathic pain *see* neuropathic pain
 clinical trials
 outcomes **P**: 520–4
 clinically important changes **P**: 524
 global assessment **P**: 523–4
 health-related quality of life **P**: 523
 onset of analgesia **P**: 522–3
 remedication time **P**: 522
 repeated measurements **P**: 522
 rescue analgesia
 consumption **P**: 522, **P**: 523 *F*
 time to meaningful pain
 relief **P**: 522
- pain mechanism-based
 inclusion **P**: 519–20
- parallel studies *see* parallel studies
- patient inclusion **P**: 519–20
- per-protocol analysis **P**: 524–5,
 P: 525 *T*
- placebo response, knowledge of **P**: 518
- pragmatic attitudes **P**: 515, **P**: 515 *T*
- primary efficacy variable
 definition **P**: 515–6
- publication **P**: 525
 selective **P**: 563
- quality of life assessment **P**: 524
- randomization methods **P**: 519
- registration **P**: 525
- relative potency **P**: 516–8
- responder analysis **P**: 524
- sample size estimation **P**: 524,
 P: 524 *T*
- side effects assessment **P**: 523
- statistical issues **P**: 524–5
- study purpose **P**: 515
- success rate **P**: 502
- surrogate end point **P**: 515–6
- synergy **P**: 518, **P**: 518 *F*
- treatment choice **P**: 516–8
- unblinding **P**: 520
- clivus syndrome **C**: 31 *T*
- clodronate **C**: 265–6
- clomipramine
 carbamazepine and **Ch**: 255
 dosage/treatment schedule **P**: 138
 peripheral neuropathic pain **Ch**: 345
- clonazepam
 burning mouth syndrome **Ch**: 476
 CRPS, children **Ch**: 627
 elderly **C**: 369
 neuropathic pain **Ch**: 345 *T*, **Ch**: 346
 opioid-induced myoclonus **C**: 188
- clonidine
 adverse effects **A**: 102
 bradycardia **A**: 102, **A**: 487
 dose-related **A**: 379–80
 hypotension **A**: 487
 in neonates **A**: 487
 sedation **A**: 102, **A**: 487
- burn pain **A**: 403–4
- central neuropathic pain **Ch**: 379,
 Ch: 380
- chemical properties **A**: 101
- children **A**: 486–7; **P**: 469
 administration **A**: 487
 doses **P**: 469 *T*
- continuous peripheral neural
 blockade **A**: 245
- field/disaster situations **A**: 379–80
- ICU analgesia **A**: 348
- intra-articular analgesia **A**: 331
- intrathecal delivery
 complications **P**: 377
- migraine prophylaxis **Ch**: 459–61,
 Ch: 461 *T*
- neuraxial analgesia **A**: 259
- neurologic disease pain **Ch**: 331
- neuropathic pain **Ch**: 345 *T*
- neurotoxicity **P**: 469
- opioid-tolerant patients **A**: 549

- clonidine (*continued*)
 acute pain treatment **P**: 115–6
 PCA **P**: 298
 PCA **A**: 224; **P**: 295
 perioperative use, PCAs **A**: 102
 pharmacokinetics **A**: 101 *T*
 children **A**: 487
 physical properties **A**: 101
 as premedication **A**: 102
 spasticity pain **Ch**: 445
 spinal administration **Ch**: 287
 spinal cord injury pain **Ch**: 395,
Ch: 396 *T*
 spinal cord stimulation and **Ch**: 269
 clopidogrel, epidural analgesia
 contraindication **A**: 518
 Clorpactin, interstitial cystitis **Ch**: 557
 closed tidal irrigation,
 osteoarthritis **Ch**: 528
 clotting abnormalities, subcutaneous
 drug infusion and **P**: 122
 cluster headache
 clinical features **Ch**: 452
 epidemiology **Ch**: 452
 pathophysiology **Ch**: 454
 prophylaxis **Ch**: 462
 treatment **Ch**: 462
 cluster-randomized trials, cancer
 pain **P**: 544–5
 C-nociceptors *see* C-fiber(s)
 coagulation disorders, continuous
 peripheral neural blockade
 contraindications **A**: 242
 coanalgesics
 adverse effects **C**: 181
 cancer pain clinical trials **P**: 541
 elderly **Ch**: 647
 opioid adverse effect
 management **C**: 181–2
 WHO analgesic ladder **C**: 113
 cocaine **A**: 124
 characteristics **A**: 125
 historical aspects **A**: 113
 as topical anesthesia **A**: 128
 coccygodynia, cryoanalgesia **P**: 387
 Cochrane Central Register Controlled
 Trials (CENTRAL) **P**: 570 *T*
 Cochrane Collaboration **P**: 677–8
 Back Review Group, low back
 pain **A**: 447
 codeine **A**: 60; **C**: 157
 adverse effects **A**: 485; **C**: 157
 cancer pain **C**: 157
 children **A**: 485; **C**: 348, **C**: 352 *T*;
P: 464–5, **P**: 465 *T*
 cough **C**: 315
 elderly **C**: 367
 intramuscular administration **A**: 485
 metabolism **A**: 46, **A**: 60
 neuropathic pain **Ch**: 209
 noninflammatory joint pain **A**: 435
 number needed to treat **A**: 89 *T*
 oral administration **A**: 485
 paracetamol and **A**: 87–8; **Ch**: 200
 pediatric headache **Ch**: 632 *T*
 pharmacodynamics **C**: 157
 pharmacokinetics **A**: 59 *T*, **A**: 485;
C: 157
 pulpitis **Ch**: 477
 rheumatoid arthritis **Ch**: 521
 routes of administration/
 formulations **C**: 157
 children **A**: 485
 sports injuries **A**: 532–3
 WHO essential drug list **A**: 395 *T*
 codifiability **P**: 608
 coding region, genes **Ch**: 49–51
 codons **Ch**: 51, **Ch**: 52 *F*
 cognitive-behavioral model of fear of
 movement/(re)injury **P**: 177
 cognitive-behavioral therapy (CBT)
 acute pain **A**: 299–301
 aims **A**: 300
 medical interventions, with **A**: 300
 minimal intervention
 strategies **A**: 300
 multimodal techniques **A**: 300
 study problems **A**: 300
 adherence importance **Ch**: 297
 anxiety, cancer patients **C**: 333
 assumptions **C**: 299
 behavioral changes **Ch**: 296
 burn pain **A**: 405
 cancer pain **C**: 299–303
 acute *vs.* chronic pain **C**: 303
 efficacy, evidence for **C**: 301–2
 individual studies **C**: 301
 models **C**: 303
 symptom limitations **C**: 304
 systemic reviews/
 meta-analyses **C**: 301–2
 tailoring **C**: 302–3
 children
 acute pain **A**: 317–8
 cancer pain **C**: 306, **C**: 347
 CRPS **Ch**: 371, **Ch**: 626
 functional abdominal pain **Ch**: 634
 general anesthesia *vs.* **C**: 306
 interventions **A**: 317
 mechanism of actions **A**: 317–8
 parental involvement **A**: 317
 chronic pain **Ch**: 292–302; **P**: 622
 acute medical settings **Ch**: 294
 aims **Ch**: 293–4
 evidence base **Ch**: 297–300
 exposure **Ch**: 296
 future work **Ch**: 300
 generalization **Ch**: 297
 goal setting **Ch**: 295
 maintenance strategies **Ch**: 297
 meta-analysis *see* meta-analysis,
 CBT in chronic pain
 program components **Ch**: 295–6
 response prevention **Ch**: 296
 therapeutic methods **Ch**: 296–7
 contextual *see* contextual
 cognitive-behavioral therapy
 (CCBT)
 coping skills/techniques **C**: 299,
C: 305–6
 CRPS **Ch**: 371
 definition **A**: 299
 depression
 cancer patients **C**: 332
 chronic pain patients **Ch**: 616
 exercise/fitness training **Ch**: 295–6
 fibromyalgia syndrome **Ch**: 606–7
 functional abdominal pain **Ch**: 634
 generalized anxiety
 disorder **Ch**: 616–7
 goals **C**: 299
 historical aspects **Ch**: 292–3; **P**: 167–8
 low back pain
 acute **A**: 451 *T*, **A**: 453
 chronic **Ch**: 510, **Ch**: 510–1
 maladaptive thoughts **C**: 299
 neuropathic pain **Ch**: 346 *T*
 operant behavioral therapy
vs. **P**: 224–5
 operant principles **Ch**: 296
 opioid-tolerant patients **A**: 549
 panic disorder **Ch**: 617
 patient education **Ch**: 295
 pediatric headache **Ch**: 633
 persistent somatoform pain
 disorder **Ch**: 619
 posttraumatic stress disorder **Ch**: 617
 principles **Ch**: 294–7
 problem solving **Ch**: 297
 procedure-related pain, cancer
 patients **C**: 216
 children **C**: 216, **C**: 305–6
 efficacy **C**: 305–6
 program components **C**: 300
 refractory angina pectoris **Ch**: 540
 relaxation in **Ch**: 295
 requirements **Ch**: 294–5
 active skill practicing **Ch**: 294–5
 collaborative engagement **Ch**: 294
 consultative engagement **Ch**: 294
 empathic discussion **Ch**: 294

- integration **Ch:** 295
 limitation recognition **Ch:** 294
 qualified staff **Ch:** 294
 synergy **Ch:** 295
 rotator cuff disorders **Ch:** 529
 spinal cord injury pain **Ch:** 397 *T*,
 Ch: 400
 strategies **C:** 300
 syndrome X **Ch:** 542
 vulvodynia **Ch:** 591
 cognitive content, pain measures **P:** 31
 cognitive defects/dysfunction
 chronic pain presentation **Ch:** 293
 elderly patient pain **Ch:** 643
 postoperative pain **Ch:** 643
 NSAID-induced **A:** 515
 opioid-induced **A:** 515; **Ch:** 216
 cognitive defusion **P:** 169
 cognitive failure
 cancer patients, history taking **C:** 39
 opioid-induced **C:** 185
 cognitive fusion **P:** 169
 cognitive impairment
 cancer pain trial exclusion **P:** 545
 fMRI **A:** 511–2
 pain assessment **A:** 511–2; **C:** 371
 dying person **C:** 392, **C:** 392 *F*
 placebo trials **A:** 511–2
 reported pain **A:** 511
 strong opioids **C:** 113
 cognitive pain measures **P:** 31
 cognitive processes, pain measures **P:** 31
 cognitive restructuring **Ch:** 296–7;
 C: 300
 cognitive strategies, pain measures **P:** 31
 cognitive therapy *see* cognitive-
 behavioral therapy (CBT)
 cohort studies, chronic pain
 epidemiology **Ch:** 70
 colchicine
 gout **A:** 434
 pericarditis **Ch:** 542
 cold, chronic lower back pain **Ch:** 510
 cold hyperalgesia, neuropathic
 pain **Ch:** 135, **Ch:** 141 *T*
 cold packs, commercial **A:** 536
 cold pain, thermotest **P:** 48–9
 cold pressor testing **Ch:** 219
 cold response, transient receptor
 potential ion channel A1 **Ch:** 9
 cold sensations, neuropathic pain
 assessment **Ch:** 137–8
 cold-signaling pathway, central
 neuropathic pain **Ch:** 378
 cold treatment *see* cryotherapy
 colitis, persistent visceral pain **Ch:** 42
 collaborative engagement, CBT **Ch:** 294
 collagenases, tissue healing/
 repair **A:** 528
 collagen deposition, tissue healing/
 repair **A:** 528
 collective ethics **P:** 547–8
 colon
 cancer- induced visceral pain **C:** 9
 diverticular disease **Ch:** 562
 Colorectal Adenoma Prevention with
 Celecoxib (APC) trial, National
 Cancer Institute **Ch:** 195–6
 colorectal cancer, radiotherapy
 C: 254
 colored analog scale (CAS) **C:** 371
 combat support hospitals
 (CSH) **A:** 376–7, **A:** 376 *F*
 combined opioid–opioid analgesia
 (COOA) **Ch:** 214
 combined spinal–epidural (CSE)
 analgesia **A:** 210, **A:** 260
 leg surgery **A:** 260
 obstetrics **A:** 260
 COMFORT scale, children **A:** 479 *T*,
 A: 480, **A:** 481 *T*
 critical care **P:** 20, **P:** 453, **P:** 454–5 *T*
 “Comfort Zone” **P:** 647
 comfrey **Ch:** 315 *T*
 “comma sign,” ganglion impar
 block **P:** 345
 commercial cold packs **A:** 536
 Commission of Specialist in Pain
 Therapy and Palliative Care,
 Romania **C:** 84–5
 Commission on Accreditation of
 Rehabilitation Facilities
 (CARF) **P:** 623
 interdisciplinary pain rehabilitation
 programs **Ch:** 129; **P:** 623–5
 interdisciplinary team member
 recommendations **P:** 624
 team size guidelines **P:** 624
 Commission on Narcotic Drugs,
 Economic and Social
 Council **C:** 83
 commissurotomy, central neuropathic
 pain **Ch:** 380–3
 communication
 acute pain history **A:** 137
 healthcare provider education
 A: 297
 impaired, children **A:** 480
 painful procedure psychological
 preparation **P:** 252
 unhelpful **C:** 52
 community setting cancer pain
 management **C:** 411–21
 case history **C:** 417–9
 at home medication
 provision **C:** 414–5
 United Kingdom **C:** 414
 United States **C:** 414–5
 out-of-hours medication
 provision **C:** 416–7
 case history **C:** 419
 “crisis pack” **C:** 417
 drug access problems **C:** 417
 “just-in-case” pack **C:** 417
 on-call pharmacy services **C:** 417
 work practices **C:** 417
 outside license drug use **C:** 415–6
 “specialist only” drugs **C:** 416
 specialist vs. generalist
 prescribing **C:** 416
 United Kingdom **C:** 416
 United States **C:** 416
 see also palliative care
 comparator drugs, cancer pain clinical
 trials **P:** 548
 compatibility, APS
 recommendations **P:** 610
 compensation injuries, biopsychosocial
 model (of pain) **Ch:** 116
 “compensation neurosis” **P:** 678–9
 competitive antagonist **C:** 105
 complaints
 procedure **P:** 681
 reasons for **P:** 678
 types **P:** 678–9, **P:** 678 *T*
 complementary and alternative
 medicine (CAM) **Ch:** 303–19
 breast cancer, case
 examples **Ch:** 316–7
 cancer pain **C:** 270–85
 children **C:** 270–1
 elderly **C:** 369–70
 reasons for use **C:** 271
 usage **C:** 270–1
 case examples **Ch:** 316–7
 costs **Ch:** 305
 definitions **Ch:** 305–6; **C:** 270
 dying person **C:** 394
 fibromyalgia syndrome **Ch:** 607
 low back pain **Ch:** 502–3
 case examples **Ch:** 316
 medical profession’s attitude
 to **Ch:** 305; **C:** 271
 neurologic disease pain **Ch:** 332
 patient use of **Ch:** 304–7
 pregnancy, case example **Ch:** 316
 prevalence **Ch:** 304–5
 procedural pain, children **A:** 493
 scope of **Ch:** 306–7, **Ch:** 306 *F*
 training programs **Ch:** 305
see also individual therapies/types

- complementary therapies *see*
 complementary and alternative
 medicine (CAM)
- complex regional pain syndrome
 (CRPS) **Ch:** 362–73, **Ch:** 343
- central poststroke pain **A:** 411
- children **Ch:** 626–8
 age at onset **Ch:** 626
 clinical presentation **Ch:** 626
 early nerve injury effects **A:** 45
 etiology **Ch:** 626
 gender differences **Ch:** 626
 management goals **Ch:** 626
 mobilization **Ch:** 626–7
 pharmacological therapy **Ch:** 627
 physical therapy **Ch:** 371, **Ch:** 626
 prognosis **Ch:** 627–8
 psychological
 interventions **Ch:** 371, **Ch:** 627
 sympathetic blockade **Ch:** 627
 treatment **Ch:** 371, **Ch:** 626–7
- diagnosis **Ch:** 150–1, **Ch:** 277,
Ch: 363–7
 criteria **Ch:** 363–7, **Ch:** 363,
Ch: 364 *T*
- edema **Ch:** 366
- electrodermal activity training **P:** 488
- electrodiagnosis **Ch:** 367
- epidemiology **Ch:** 363
- historical aspects **Ch:** 362–3
- imaging **Ch:** 149, **Ch:** 367–8
- laboratory tests **Ch:** 367–8
- management **Ch:** 368–71
 biopsychosocial
 consequences **Ch:** 370–1
 disuse effects reversal **Ch:** 370,
Ch: 370 *T*
 epidural analgesia **Ch:** 370
 intervention therapies,
 traditional **Ch:** 369–70
 pain **Ch:** 368–70
 pharmacotherapy **Ch:** 368–9
 placebos **Ch:** 369
 psychological
 interventions **Ch:** 370–1
 somatic nerve blockade **Ch:** 369
 spinal cord stimulation **Ch:** 277,
Ch: 370
 topical therapy **Ch:** 368–9
 of underlying pathology **Ch:** 368
- movement disorders **Ch:** 367
- residual limb pain **Ch:** 419–20
- results judging, case study **P:** 97–8,
P: 98 *T*
- sensory changes **Ch:** 365, **Ch:** 365 *T*
- sudomotor changes **Ch:** 366–7,
Ch: 366 *T*
- sympathetic blocks **Ch:** 369;
C: 229–30; **P:** 325
 clinical trials **P:** 325
 diagnostic **Ch:** 151
 taxonomy **Ch:** 363
 vasomotor changes **Ch:** 365–6
 cold vs. warm **Ch:** 365
 diagnostic value **Ch:** 365
 skin blood flow **Ch:** 365
 temperature asymmetry **Ch:** 366
- complex regional pain syndrome type I
 (CRPS-I) **Ch:** 343
 treatment **Ch:** 234, **Ch:** 258
- complex regional pain syndrome type
 II (CRPS-II) **Ch:** 343
- comprehensive pain rehabilitation
 programs, North
 America **P:** 619–27
 accreditation **P:** 623–5
 clinical effectiveness **P:** 624
 cost-effectiveness **P:** 624
 cost-utility analysis **P:** 625
 family issues **P:** 623
 financial issues **P:** 623
 interdisciplinary team
 members **P:** 624
 medical utilization **P:** 623
 medication issues **P:** 622
 national advisory committees **P:** 623
 treatment “success” **P:** 625
 work issues **P:** 622–3
- compression
 neuropathic pain **Ch:** 4 *T*
 sports injury management **A:** 532
- computed tomography (CT) **Ch:** 147
 atypical facial pain **Ch:** 474
 base of skull metastases **C:** 30, **C:** 31 *F*
 cancer patient assessment **C:** 40
 chronic pain **Ch:** 147
 chronic pelvic pain **Ch:** 583
 cryoanalgesia **P:** 382
 discogenic pain **Ch:** 157
 headache **Ch:** 454
 malignant bone tumors **C:** 257
 malignant psoas syndrome **C:** 34 *F*
 neck pain **Ch:** 492
 pancreatic cancer **Ch:** 551
 pulmonary emboli **C:** 311–2
 urolithiasis, recurrent **Ch:** 564
- COMT gene/protein **Ch:** 62 *T*
- conceptual diagrams **P:** 98, **P:** 99 *F*
- concurrent validity, pain measures **P:** 37
- confidence intervals,
 meta-analysis **A:** 149
- confidentiality, psychological
 evaluation **C:** 51
- confrontation **P:** 177
- confusion
 causes, terminally ill patients **C:** 333–4
 opioid-induced, children **C:** 353 *T*
see also delirium
- Confusion Assessment Method
 (CAM) **C:** 186
- congenital abnormalities,
 radiography **Ch:** 146
- congenital insensitivity to pain **Ch:** 344
- congestive heart failure
 epidural steroid injection
 contraindication **P:** 424
 NSAID-induced **Ch:** 195–6
- consciousness, burn pain **A:** 400
- conscious sedation **C:** 218–9
- complications **C:** 219
- contraindications **C:** 219
- definition **C:** 218–9
- precautions/guidelines **C:** 219
- consent
 cancer patients **C:** 94–5
 clinical trials
 cancer pain **P:** 548–9
 dental pain model **P:** 531
 patients without capacity **P:** 555
 drug testing **C:** 385
 epiduroscopy **P:** 430
 informed *see* informed consent
 lack of **P:** 680
 opioids, chronic noncancer
 pain **Ch:** 221–2; **P:** 112–3
- Consolidated Standard of Reporting
 Trials (CONSORT) **P:** 562–3,
P: 563 *F*
- constipation
 cancer patients **C:** 323–4
 clinical findings **C:** 323
 investigations **C:** 323
 management **C:** 324
 pathophysiology **C:** 323
 definition **C:** 189
 dying person **C:** 394–5
 opioid-induced **A:** 57; **Ch:** 216;
C: 155, **C:** 189–90
 cancer patients **C:** 323
 children **C:** 351, **C:** 353 *T*
 clinical presentation/
 findings **C:** 189
 diagnostic criteria **C:** 189–90
 elderly **C:** 367
 epidemiology **C:** 181 *T*, **C:** 189
 etiology **C:** 189
 investigations **C:** 189–90
 management **C:** 190
 pathophysiology **C:** 189
 prevention **C:** 190
- construct validity, pain measures **P:** 37

- contact dermatitis,
acupuncture **Ch**: 310
- content, context and process (CCP)
framework **P**: 607
- context effect **P**: 500
- contextual cognitive-behavioral therapy
(CCBT) **P**: 167–76
- chronic pain model **P**: 168 *F*
- definitions **P**: 168
- focus exercise **P**: 173
- perspective exercise **P**: 173
- treatment outcome, chronic
pain **P**: 172–4, **P**: 174 *F*
case study **P**: 173
depression **P**: 173
follow-up **P**: 173
- continuous data **P**: 572
- continuous epidural analgesia **A**: 260
analgesic efficacy, PCA vs. **A**: 222
children **A**: 491
gastrointestinal surgery **A**: 264
- continuous interscalene nerve block,
postoperative pain **A**: 332
- continuous labor support **A**: 468
- continuous paravertebral blockade *see*
paravertebral blockade
- continuous peripheral neural blockade
(CPNB) **A**: 236–54; **P**: 258
adjuvant drugs **A**: 245
aim **A**: 237
analgesic gap **A**: 245
bolus dose **A**: 245
clinical use **A**: 238 *T*
complications **A**: 246–7
catheter-related **A**: 247
infection **A**: 247
- contraindications **A**: 242–3
allergies **A**: 242
block-specific **A**: 243
coagulation disorders **A**: 242
infections **A**: 243
preexisting neurological
problems **A**: 243
- doses **A**: 245
- drugs **A**: 244–5
choice of **A**: 244–5
see also individual drugs
- equipment **A**: 243–4
catheterization kits **A**: 243–4
pumps **A**: 244
- field/disaster situations **A**: 377,
A: 380–1, **A**: 383
- historical aspects **A**: 236
- infusion rates **A**: 245
- local anesthetics **A**: 244–5
- lockout interval **A**: 245
- monitoring **A**: 237
- multidisciplinary teams **A**: 237
- neurological complications **A**: 246–7
incidence **A**: 246
permanent brain damage **A**: 246
post-orthopedic surgery **A**: 246
- patient refusal **A**: 242
- postoperative analgesia **A**: 237, **A**: 246
post-hip surgery **A**: 241
post-knee surgery **A**: 241
- systemic opioids vs. **A**: 237
- toxicity **A**: 245
- trunk **A**: 241–2
- types **A**: 237–42
- ultrasound imaging **A**: 244
- upper limb **A**: 237–9
see also individual blocks
- continuous popliteal block,
postoperative pain **A**: 332
- continuous quality improvement
(CQI) **P**: 670–1, **P**: 672 *F*
care improvement plan development/
implementation **P**: 671
evaluation study **P**: 670
interdisciplinary committee **P**: 670
reevaluation **P**: 671
- continuous renal replacement therapy
(CRRT) **A**: 349
- continuous spinal analgesia
(CSA) **A**: 260–1
cardiovascular compromise **A**: 260–1
microcatheters **A**: 261
orthopedic surgery **A**: 260–1
- continuous subcutaneous infusions
(CSCI) **C**: 110
indications **P**: 122
usage assumption **P**: 121–2
- contractions, labor pain **A**: 464–5
- contracture, spasticity pain **Ch**: 443,
Ch: 443 *F*
- control groups, chronic pain outcome
measurement **Ch**: 183–4
- controlled dissociation **P**: 147
- controlled drugs (CDs)
United Kingdom
audit trail **C**: 414
guidance development **C**: 414,
C: 415 *T*
legislation **C**: 414
prescriptions **C**: 414
record-keeping/monitoring **C**: 414
unwanted, collection/
destruction **C**: 414
- United States
insurance plans **C**: 414–5
lack of availability **C**: 415
legislation **Ch**: 106
payment/co-payment issues **C**: 415
- prescription regulations **C**: 415
- controlled release (CR)
morphine **Ch**: 211–2; **C**: 161
- controlled release (CR)
oxycodone **A**: 203–4
- controlled release (CR)
oxymorphone **A**: 203–4; **C**: 161
- Controlled Substances Act
(USA) **Ch**: 106, **Ch**: 111
- control population selection,
case–control studies **Ch**: 70
- conus medularis **P**: 417
- convergence, cervical referred
pain **Ch**: 485
- cooling, burn pain **A**: 402
- coping/coping strategies
cancer patients **C**: 49–50
mechanisms assessment **C**: 55–6
children **A**: 310–1, **A**: 313
definition **C**: 50
identification, chronic pain **Ch**: 124
pain measurement **P**: 31
- coping model, surgical patients **P**: 252
- Coping Strategies Questionnaire
(CSQ) **Ch**: 127
- coproxamol
adverse effects **Ch**: 201
elderly **C**: 367
withdrawal **A**: 88
- cordectomy **Ch**: 380–3
- cordomyelotomy **Ch**: 397
- cordotomy **Ch**: 397, **Ch**: 397 *T*;
P: 244
radiotherapy-induced brachial plexus
neuropathy **C**: 406
- Cornell scale for depression in
dementia (CSDD) **C**: 371
- coronary circulatory insufficiency,
thoracic sympathetic block **P**: 330
- cortex
electroencephalography **A**: 38
near-infrared spectroscopy **A**: 38
nociception **A**: 12–3
pain modulation **P**: 146
- cortical hyperexcitability,
migraine **Ch**: 452–3
- cortical reorganization/remapping
CPSP **Ch**: 407
postamputation pain **Ch**: 421
- cortical spreading depression,
migraine **Ch**: 453
- corticosteroid(s) **A**: 105–6
acute pain **A**: 106
adverse effects **A**: 105
airway obstruction,
tumor-induced **C**: 312
anorexia cachexia syndrome **C**: 327–8

- corticosteroid(s) (*continued*)
- bowel obstruction, advanced
 - cancer **C**: 322–3
 - breakthrough pain **C**: 290
 - chemical properties **A**: 105
 - children, cancer pain **C**: 354
 - clinical effects **A**: 105
 - degenerative tendinopathies **A**: 535
 - dying person **C**: 394
 - epidural injections *see* epidural steroid injections
 - forearm soft-tissue disorders **Ch**: 530
 - injections *see* corticosteroid injections
 - interstitial cystitis **Ch**: 557
 - mechanism of action **A**: 105, **A**: 533 *F*, **A**: 534
 - nausea and vomiting
 - cancer patients **C**: 320 *T*
 - opioid-related **A**: 258
 - NSAID interactions **A**: 74 *T*
 - osteoarthritis **Ch**: 527
 - pericarditis **Ch**: 542
 - perioperative period **A**: 106
 - physical properties **A**: 105
 - in pregnancy **A**: 462
 - rheumatoid arthritis **Ch**: 524
 - sickle cell disease pain **A**: 420–1
 - spinal cord injury pain **Ch**: 393
 - sports injuries **A**: 534–5
 - duration **A**: 535
 - local anesthetic, with **A**: 535
 - oral **A**: 534
 - studies **A**: 534–5
 - transdermal **A**: 535
 - vulvodynia **Ch**: 590
- corticosteroid injections **P**: 349–50
- chronic lower back pain **Ch**: 511
 - elbow pain, acute **A**: 438
 - epidural *see* epidural steroid injections
 - historical aspects **P**: 349–50
 - rheumatoid arthritis **P**: 349–50
 - sports injuries **A**: 534
 - postinjection flare **A**: 535
- cortisol
- fibromyalgia syndrome **Ch**: 603
 - labor pain **A**: 466
- CORTRA analysis, neuraxial analgesia **A**: 265
- co segregating gene identification *see* genetics
- cost(s), outcome measurement **Ch**: 181
- cost–benefit analysis, economic evaluation **Ch**: 80
- calculation **Ch**: 79–80
- cost–consequence analysis, economic evaluation **Ch**: 81
- cost–effectiveness
- chronic pain outcome measurement **Ch**: 180
 - neuraxial analgesia **A**: 264–5
- cost–effectiveness analysis, economic evaluation **Ch**: 80
- costochondritis **Ch**: 544
- cost of illness studies **Ch**: 77
- cost–utility analysis (CUA) **Ch**: 81, **Ch**: 180–1
- pain rehabilitation programs **P**: 625
- cough, cancer patients **C**: 314–5
- antineoplastic treatment **C**: 314–5
 - clinical findings **C**: 314
 - history/examination **C**: 314
 - management **C**: 314
 - palliative treatment **C**: 315
 - suppression, opioid-induced **C**: 155, **C**: 315
- counterirritants, pruritus **C**: 330
- counter-irritation effects, manual medicine **P**: 235–6
- counting thoughts, children **A**: 313
- counts, definition **P**: 572
- COX-2 selective inhibitors *see* cyclooxygenase 2 (COX-2) selective inhibitors
- CPNB *see* continuous peripheral neural blockade (CPNB)
- CPSP *see* chronic postsurgical pain (CPSP)
- cracked-tooth syndrome **Ch**: 477
- cranial blood vessels, migraine **Ch**: 453
- cranial diabetic neuropathy **Ch**: 339
- cranial nerve cancer pain syndromes **C**: 29–30
- cranial nerve examination, peripheral neuropathy **P**: 78
- C-reactive protein (CRP) **P**: 69
- bacterial infections **P**: 69
 - inflammatory joint disease **P**: 69
 - joint pain **A**: 433
- creatine kinase (CK) **P**: 68
- CRIES (CRying, Increased vital signs, Expression, and Sleeplessness) **A**: 145, **A**: 479 *T*, **A**: 480
- critical analysis of errors, APS **P**: 595–6
- critical care pain assessment, children **P**: 453
- Crohn's disease **Ch**: 561
- acute pain **A**: 416–7
 - presenting symptoms **Ch**: 561
- crossover studies **P**: 520
- cancer pain clinical trials **P**: 543–4, **P**: 544 *F*
 - disadvantages **P**: 555
 - drop outs **P**: 525
- drug safety evaluation
- limitations **P**: 557
- limitation/problems **P**: 520
- neuropathic pain clinical trials **P**: 555–7, **P**: 556 *F*
- randomization **P**: 521 *T*
- treatment vs. carryover effect designs **P**: 544 *F*
- unintentional unblinding **P**: 556
- cross-sectional studies, chronic pain **Ch**: 67–8 *T*, **Ch**: 69–70
- cross-tolerance
- definition **A**: 540; **C**: 105
 - opioids **C**: 106
 - incomplete **C**: 156
- CRPS *see* complex regional pain syndrome (CRPS)
- CRying, Increased vital signs, Expression, and Sleeplessness (CRIES) **A**: 145, **A**: 479 *T*, **A**: 480
- cryoanalgesia **C**: 231; **P**: 379–88
- acute pain **P**: 383
 - advantages/disadvantages **C**: 232 *T*
 - chronic neuropathic pain **P**: 381
 - chronic pain **P**: 383–7
 - chronic pelvic pain **Ch**: 581
 - complications **P**: 381
 - contraindications **P**: 381
 - defrosting **P**: 382
 - diagnostic block **P**: 382
 - equipment preparation **P**: 381–2
 - freeze-thaw cycles, number of **P**: 380–1
 - freezing **P**: 382
 - imaging **P**: 382
 - indications **P**: 381
 - nerve regeneration **P**: 380
 - neuromas **P**: 381
 - pain relief duration **P**: 380
 - patient preparation **P**: 381
 - physical determinants for success **P**: 380–1
 - fast freezing rates **P**: 380
 - slow freezing rates **P**: 380
 - physics **P**: 379–80, **P**: 380 *F*
 - physiology **P**: 380
 - postoperative pain **P**: 383
 - principles **P**: 257
 - probe temperature **P**: 380–1
 - procedural pain analgesia **P**: 382
 - risks **P**: 381
 - technical data **P**: 379–80
 - techniques **P**: 382–3
 - nerve localization **P**: 382
 - nerve stimulation **P**: 382
 - palpation **P**: 382
 - percutaneous (closed) **P**: 382

- preoperative (open) **P:** 382
 probe insertion **P:** 382
 treatment duration **P:** 380–1
see also individual nerves
 cryoglobulinemia **Ch:** 151 *T*
 cryomachines **P:** 379–80
 cryoneurolysis *see* cryoanalgesia
 cryoprobes **P:** 379–80, **P:** 380 *F*
 positioning **P:** 381
 size **P:** 381
 temperature **P:** 380–1
 cryotherapy **A:** 535–6
 ankle pain **A:** 441
 contraindications **A:** 536
 local immersion **A:** 536
 physiological effects **A:** 535–6
 blood flow **A:** 535–6
 edema **A:** 535–6
 muscle responses **A:** 536
 nerve conduction **A:** 536
 techniques **A:** 536
 crystal arthritis **A:** 434
 CSA *see* continuous spinal analgesia (CSA)
 CSAG (Clinical Standards Advisory Group) **A:** 454
 CSE *see* combined spinal–epidural (CSE) analgesia
 cue-controlled relaxation **P:** 161–2
 Cumulative Index to Nursing and Allied Health Literature (CINAHL) **P:** 570 *T*
 cumulative sum technique, pediatric APS audit **P:** 644
 cupula of the pleura **P:** 327
 curative model **Ch:** 101, **Ch:** 101 *T*
 accountability, lack of **Ch:** 108
 analgesia prioritization failure **Ch:** 103
 current opioid misuse measure (COMM) **Ch:** 620
 cutaneous field stimulation **P:** 194
 cutaneous hypersensitivity, opioid-induced **P:** 129
 cutpoints, pain measure validity **P:** 37–8
 cyclic AMP (cAMP), intracellular signaling **A:** 22
 cyclizine, nausea and vomiting **A:** 228; **C:** 320 *T*
 cyclobenzaprine
 juvenile fibromyalgia syndrome **Ch:** 625
 temporomandibular disorder **Ch:** 469–70
 cyclooxygenase(s) (COX)
 NSAID mechanism of action **A:** 69
 paracetamol effects **Ch:** 200
 single nucleotide polymorphisms **C:** 127
 splice variants **C:** 127
 cyclooxygenase 1 (COX-1) **A:** 69; **C:** 126–7
 in inflammation **C:** 126
 cyclooxygenase 2 (COX-2) **A:** 69; **C:** 126–7
 cyclooxygenase 1 vs. **A:** 69
 inflammation **A:** 174
 cyclooxygenase 2 (COX-2) selective inhibitors **A:** 78–9
 acute pancreatitis **A:** 416
 asthma induction **A:** 71
 cardiovascular risks **Ch:** 195; **C:** 136–7
 children
 acute pain **A:** 483
 cancer pain **C:** 348
 chronic obstructive pulmonary disease **Ch:** 196–7
 definition **C:** 127
 dysmenorrhea, primary **A:** 417
 elderly
 acute pain **A:** 515–6
 chronic pain **Ch:** 647
 as first-line drug **A:** 75
 gastrointestinal adverse effects **A:** 71; **Ch:** 196; **C:** 133
 postoperative pain management **A:** 332, **A:** 333–4
 preventive analgesia **A:** 175
 renal complications **Ch:** 197
 spinal, persistent musculoskeletal pain **Ch:** 31
 sports injuries **A:** 533
 thrombotic risk **C:** 136
see also individual drugs
 cyclooxygenase 3 (COX-3) **C:** 127
 paracetamol effect **C:** 124
 cyclooxygenase-inhibitors and NO-donors (CINODs); NO-NSAIDs) **C:** 138
 cyclophosphamide, rheumatoid arthritis **Ch:** 522–4 *T*
 cyclosporine
 interstitial cystitis **Ch:** 557
 rheumatoid arthritis **Ch:** 522–4 *T*
 CYP2D6
 absent activity **A:** 223
 codeine metabolism **A:** 60
 opioid metabolism **C:** 173
 pharmacogenetics **Ch:** 62 *T*
 cyproheptadine, spasticity pain **Ch:** 445
 Cyr-Wartman Screen **Ch:** 128
 cystitis
 infectious, recurrent **Ch:** 579–80
 interstitial *see* interstitial cystitis (IC)
 intestinal **Ch:** 42
 persistent visceral pain **Ch:** 42
 cytochrome P450
 codeine metabolism **A:** 46
 paracetamol metabolism **Ch:** 201
 cytochrome P450 2D6 **Ch:** 62 *T*
 cytochrome P450 3A4 (CYP3A4), opioid metabolism **C:** 173
 cytokine(s)
 critical illness **A:** 348
 neuropathic pain **Ch:** 10
 peripheral sensitization **A:** 23
see also individual cytokines
 cytokines, cancer-induced bone pain **C:** 5
 cytomegalovirus infection, HIV patients **Ch:** 342, **Ch:** 357
 cytosine **Ch:** 49
 cytostatic drug-induced peripheral neuropathy **Ch:** 341
 daily functioning assessment, chronic pain **Ch:** 172–3, **Ch:** 172 *T*
 daily living effects, chronic pain **Ch:** 66, **Ch:** 171
 elderly **Ch:** 642, **Ch:** 644
 daily pain ratings, chronic pelvic pain **Ch:** 583
 danthron **C:** 325 *T*
 dantrolene, spasticity pain **Ch:** 445
 data and ethic monitoring committee, clinical trials **P:** 562
 databases
 bibliographic **P:** 570 *T*
 pediatric APS **P:** 644–5
 data mining, pain research **Ch:** 61 *T*
 day-surgery
 children **A:** 489
 NSAIDs **A:** 70
 deafferentation pain *see* spinal cord injury (SCI) pain
 death receptors, neuropathic pain **Ch:** 10
 de-briefing, hypnosis **P:** 482 *T*
Decade of Pain Control and Research **P:** 655
 deception, placebo effect **P:** 503, **P:** 503 *T*
 decision-making
 by healthcare professional **C:** 96
 patient's involvement **C:** 95
 patients who have capacity, western society **C:** 95
 patients who lack capacity **C:** 96–7
 by relatives
 patients who have capacity **C:** 95–6

- decision-making (*continued*)
 patients who lack capacity C: 96
 process C: 67 *T*
- Declaration of Helsinki
 clinical trial ethics P: 553
 patient information P: 531
 placebo ethics P: 508, P: 559
 revised, results publication P: 525
- deep brain stimulation
 (DBS) Ch: 279–80
 cancer pain C: 246
 central neuropathic pain Ch: 383
 spinal cord injury pain Ch: 397 *T*
- deepening stage, hypnosis P: 482 *T*,
 P: 483
- deep inferior epigastric perforator
 (DIEP) free flaps C: 404
- deep joint effusions,
 ultrasound Ch: 148–9
- deep pain tolerance, age-related
 changes P: 20
- deep partial thickness burns A: 400
- deep peroneal nerve block P: 290 *F*,
 P: 291
- deep referred pain, persistent
 musculoskeletal pain Ch: 30
- deep sedation C: 219
- deep tissue, nociceptors Ch: 26–9
- defibrillation devices, SCS
 contraindication P: 407
- deficiency states, peripheral
 neuropathies Ch: 340–1
- deformities Ch: 146
- degenerative diseases/disorders
 lumbar spine A: 446
 persistent musculoskeletal
 pain Ch: 24–5
- degenerative tendinopathies A: 535
- dehydration, dying person
 C: 394–5
- deliberate tampering, PCA A: 226
- delirium
 agitated C: 186
 definition C: 185–6
 drug-induced C: 361
 hypoactive C: 186
 ICU pain assessment A: 345
 mixed C: 186
 opioid-induced C: 185–7
 clinical presentation C: 186
 diagnostic criteria C: 186
 epidemiology C: 186
 etiology C: 186
 examination C: 186
 management C: 186–7
 pathophysiology C: 186
 prognosis C: 187
- pain assessment A: 512, A: 512 *T*;
 C: 43
- pain overestimation C: 186
- palliative care patients C: 333
 causes C: 333–4
 clinical features C: 333
 environmental
 manipulation C: 333
 management C: 333
 pharmacological
 management C: 333–4
- Delirium Rating Scale (DRS) C: 40
- delta-opioid agonists C: 154
- delta (δ) opioid receptors A: 54; C: 152
 endogenous ligands A: 55
 location A: 55
 neuraxial analgesia A: 256
 spinal cord A: 15
- dementia
 pain assessment A: 145–7; C: 43
 pain perception Ch: 643
 self-assessment tools Ch: 646
- demyelination, neuropathic
 pain Ch: 4 *T*
- denial assessment, cancer
 patients C: 55–6
- Denny–Brown syndrome Ch: 344
- dental injections, neuropathic orofacial
 pain Ch: 470–1
- dental pain Ch: 476–7
 acute A: 418
 atypical facial pain vs. Ch: 474
 clinical trials *see* dental pain model
 differential diagnosis Ch: 477
 epidemiology Ch: 476
 management Ch: 477; P: 195, P: 200
 pathophysiology Ch: 477
 pulpitis Ch: 477
 sinusitis vs. Ch: 477
 symptomatology Ch: 477
see also individual disorders
- dental pain model P: 529–37
 advantages P: 530, P: 535
 assay sensitivity P: 533
 baseline pain intensity
 as confounding factor P: 533–4,
 P: 533 *F*
 surgical intervention in P: 533–4
 baseline pain variations P: 530–1
 consent P: 531
 crossover studies P: 530
 definition P: 529–30
 disadvantages P: 530–1, P: 535
 drugs evaluated P: 530
 exclusion criteria P: 532
 good clinical trial practice P: 531
 inclusion criteria P: 532
- monitoring P: 531
 operative procedures P: 531–2
 parallel group design P: 530
 patient information P: 531
 patient understanding of
 instructions P: 532
 placebo controls P: 534, P: 535 *F*
 postoperative pain natural
 course P: 530–1
 practical tips P: 535
 protocol P: 531
 protocol compliance P: 532
 rescue analgesia P: 534–5
 single-dose studies P: 530–1
 trial duration P: 530–1
- dental surgery, children A: 489
- dentine hypersensitivity Ch: 477
- depigmentation, soft-tissue
 injection-induced P: 354
- deployable rapid assembly shelter and
 surgical hospital
 (DRASH) A: 376–7
- depression
 addiction Ch: 657
 cancer patients C: 331–2; P: 147
 diagnosis C: 56–7, C: 331–2
 elderly C: 369
 history taking C: 39
 management C: 332
 nonpharmacological therapy C: 332
 pharmacological therapy C: 332
 predisposing factors C: 56
 prevalence C: 21, C: 331–2
 risk assessment C: 56–7
 somatic features C: 331–2
- chest pain, chronic Ch: 538
- chronic pain Ch: 241–53, Ch: 615–6
 diagnosis Ch: 616
 epidemiology Ch: 66, Ch: 241–2
 experimental pain studies Ch: 242
 functional imaging Ch: 242–3
 overdiagnosis Ch: 293
 prevalence P: 147
 suicide risk Ch: 616
 treatment Ch: 616; P: 621
 underdiagnosis Ch: 293
- chronic pelvic pain Ch: 582
- depressed mood vs. C: 56
- functional abdominal pain Ch: 634
- placebo effect P: 507
- postoperative pain and A: 294
- spinal cord injury patients Ch: 400
- symptoms Ch: 615
 tension-type headache Ch: 453
see also antidepressants
- depression scores, family
 caregiver C: 65

- de qi, acupuncture **A:** 281–2
- de Quervain's stenosing tenosynovitis **Ch:** 529 *T*; **P:** 355
- descending inhibitory pathway, tricyclic antidepressants **Ch:** 243
- descending modulation
neurostimulation **Ch:** 270
persistent musculoskeletal pain **Ch:** 31–2
- descending modulatory system **P:** 88
- descending pathways
hyperalgesia *see* hyperalgesia
postnatal nociception development **A:** 38
TENS A: 274
- desensitization, pediatric CRPS **Ch:** 627
- desipramine **Ch:** 244 *T*
postherpetic neuralgia **Ch:** 433
- desmopressin, renal colic **A:** 415
- developed world
field/disaster situations **A:** 375
low back pain **A:** 445
resources, developing world *vs.* **A:** 391, **A:** 391 *T*
- developing world, acute pain management **A:** 389–98
analgesia availability/effectiveness **A:** 390
barriers to pain relief **A:** 390–3
case studies **A:** 397
cost-effectiveness analysis **A:** 396
drug administration **A:** 392–3
problems **A:** 393
training lack **A:** 393
drug cost/availability **A:** 396
drug storage/transport **A:** 391
emergency situations **A:** 390
geography and **A:** 390
healthcare spending **A:** 391 *T*
hospitals, fear of **A:** 393
local anesthesia **A:** 395–6
epidural analgesia **A:** 396
plexus blockade **A:** 396
single shot caudal analgesia **A:** 396
spinal analgesia **A:** 395–6
wound local infiltration **A:** 396
- obstetric pain **A:** 390
- “off licence” drugs **A:** 396
- opioid availability **A:** 391–2
fear of **A:** 392
governmental restrictions **A:** 392
overseas visitor observations **A:** 396–7
pain assessment **A:** 394
pain incidence/prevalence **A:** 389–90
surgical **A:** 390
traumatic **A:** 389–90
patient factors **A:** 393
- pharmacological therapy **A:** 394–5
modes of delivery **A:** 395
PCA A: 395
WHO analgesic ladder A: 394, **A:** 394 *F*
WHO essential drug list A: 395, **A:** 395 *T*
- population and **A:** 390
prescribing problems **A:** 393
psychological interventions **A:** 394
resources **A:** 391, **A:** 391 *T*
rural-based populations **A:** 390
solutions **A:** 393–6
techniques **A:** 393–6
training lack **A:** 393
understaffing issues **A:** 393
western medicine distrust **A:** 393
- developmental disabilities, pediatric pain assessment **P:** 456
- dexamethasone
airway obstruction, tumors **C:** 312
anorexia cachexia syndrome **C:** 327–8
children **C:** 354
dying person **C:** 394
epidural injection **P:** 419
migraine **A:** 366
opioid-related nausea and vomiting **A:** 258
pharmacokinetics **A:** 105 *T*
pharyngitis **A:** 418
postoperative nausea and vomiting **A:** 106
children **A:** 493
sports injuries **A:** 533–4
transdermal delivery **A:** 535
superior vena caval obstruction **C:** 312
- dexamphetamine
children, cancer pain **C:** 353–4
opioid-induced sedation **C:** 184
- dexketoprofen
intravenous administration **A:** 205–6
oral administration **A:** 202–3
- dexmedetomidine
chemical properties **A:** 101
field/disaster situations **A:** 379–80
ICUs A: 102, **A:** 348
limitations **A:** 334
neuraxial analgesia **A:** 259
opioid-tolerant patients **A:** 549
perioperative use **A:** 102
pharmacokinetics **A:** 101 *T*
physical properties **A:** 101
postoperative pain management **A:** 334
preventive analgesia **A:** 185
- dextroamphetamine *see* dexamphetamine
- dextromethorphan
central neuropathic pain **Ch:** 381–2 *T*
cough **C:** 315
intramuscular administration **A:** 184
neuropathic pain **Ch:** 345 *T*
opioid tolerance reduction **A:** 184–5
pediatric headache **Ch:** 632
postamputation pain **Ch:** 423
postoperative pain management **A:** 334–5
preventive analgesia **A:** 165 *T*, **A:** 175, **A:** 180
reduced analgesic requirements **A:** 184
surgical procedures **A:** 184
- dextropropoxyphene
elderly **A:** 513; **C:** 367
osteoarthritis **Ch:** 527
paracetamol and **A:** 88
rheumatoid arthritis **Ch:** 521
- dextrose, porphyrias **A:** 421
- diabetes mellitus
epidural steroid complications **P:** 423
epidural steroid injection caution **P:** 424
- diabetic amyotrophy (lower limb asymmetric motor neuropathy) **Ch:** 339
- diabetic neuropathy **Ch:** 339
acute mononeuropathy **Ch:** 339
acute painful **Ch:** 340
asymmetric **Ch:** 339
as clinical trial model **P:** 558
cranial **Ch:** 339
diagnosis, biochemical tests **Ch:** 151 *T*
distal symmetric sensorimotor polyneuropathy **Ch:** 340
lower limb asymmetric motor neuropathy **Ch:** 339
management
anticonvulsants **Ch:** 330
antidepressants **Ch:** 244
nerve conduction studies **Ch:** 149–50
pathogenesis **Ch:** 340
peripheral nerves **Ch:** 339
small-fiber **Ch:** 340
TENS P: 195
thoracoabdominal radiculopathy **Ch:** 339–40
treatment-induced **Ch:** 340
- diabetic polyneuropathy, neuraxial analgesia contraindication **A:** 256
- Diagnostic and Statistical Manual for Mental Disorder, 4th edition (**DSM-IV**)

- delirium definition **C:** 185
depression **Ch:** 242
irritable bowel syndrome
 diagnosis **Ch:** 550
psychiatric diagnoses **Ch:** 615,
 Ch: 615 *T*
 substance abuse definition **C:** 380
diagnostic blocks **Ch:** 152–3
 controls **Ch:** 153
 headache **Ch:** 152
 lower back pain **Ch:** 152, **Ch:** 158–9
 neck pain **Ch:** 152
 neuropathic pain **Ch:** 152
 techniques **Ch:** 152
 visceral pain **Ch:** 152
 see also individual blocks
dialysis, pharmacokinetic effects **C:** 108
diamorphine **A:** 59
 children **A:** 485
 pharmacokinetics **A:** 485
 cough **C:** 315
 epidural analgesia **A:** 485; **P:** 319
 intranasal administration **A:** 208,
 A: 485; **P:** 307
 intrathecal administration **A:** 485
 complications **P:** 377
 metabolism **A:** 59
 neuropathic pain **C:** 204
 oral administration **A:** 485
 parenteral administration **A:** 485
 routes of administration **A:** 59
 children **A:** 485
 spinal administration **Ch:** 287
 subcutaneous administration **A:** 205
 cancer patients **P:** 127 *T*
diaphragmatic breathing **Ch:** 295;
 P: 160
 children **P:** 481–2
diaphragmatic pumps, intrathecal drug
 delivery **P:** 371, **P:** 372
diarrhea, cancer patients **C:** 324–6
 clinical findings **C:** 324
 history taking **C:** 324
 investigations **C:** 324
 management **C:** 324–6, **C:** 326 *T*
 pathophysiology **C:** 324
diasters *see field/disaster situations*
diathesis, depression **Ch:** 293
diazepam
 agitation **C:** 335
 dyspnea **C:** 314
 spasticity pain **Ch:** 444–5
diclofenac **A:** 77
 adverse effects **A:** 71
 cardiac surgery **A:** 351
 children **A:** 482–3; **P:** 465 *T*
 doses **A:** 483 *T*
 intravenous administration **A:** 205–6
 mechanism of action **A:** 77
 metabolism **A:** 70
 numbers needed to treat **A:** 89 *T*
 opioid-sparing effect **C:** 181–2
 preparations **A:** 77
 properties **A:** 75 *T*
 rectal administration **A:** 204
 serum transaminase levels **A:** 71
 subcutaneous infusion, cancer
 patients **P:** 130
 thrombogenicity **C:** 136, **C:** 137–8
 topical
 osteoarthritis **Ch:** 235–6
 soft-tissue injuries **Ch:** 235
 transdermal administration **A:** 206–7
didanosine, neuropathy **Ch:** 341–2,
 Ch: 355
dietary fiber, constipation **C:** 324
dietary therapy
 fibromyalgia syndrome **Ch:** 607
 functional abdominal pain **Ch:** 634
 inflammatory bowel disease **Ch:** 561
 irritable bowel syndrome **Ch:** 559–60
 pediatric headache **Ch:** 630
 rheumatoid arthritis **Ch:** 525
 vulvodynia **Ch:** 591
diffuse infiltrative lymphocytosis
 (DILS), HIV patients **Ch:** 357
diffuse intraductal calcium deposition,
 chronic pancreatitis **Ch:** 553
diffuse noxious inhibitory controls
 (DNIC)
 acupuncture **P:** 209
 fibromyalgia neuronal
 plasticity **Ch:** 605, **Ch:** 605 *F*
 manual medicine **P:** 235–6
 persistent musculoskeletal
 pain **Ch:** 31–2
diffusion tensor imaging (DTI) **P:** 89,
 P: 89 *F*
diflunisal **A:** 76
digoxin, NSAID interactions **A:** 74 *T*
dihydrocodeine
 oral administration **A:** 203
 rheumatoid arthritis **Ch:** 521
dihydroergotamine, migraine
 acute episodes **Ch:** 455
 emergency department **A:** 366
 prophylaxis **Ch:** 459–61, **Ch:** 461 *T*
diltiazem, ischemic cardiac chest
 pain **A:** 365
dimethyl sulfoxide (DMSO), interstitial
 cystitis **Ch:** 557
diphenhydramine
 migraine, children **Ch:** 631 *T*
 nausea and vomiting **A:** 228
dipyron (metamizole) **A:** 76; **C:** 125
 agranulocytosis associations **C:** 125
 biliary colic **A:** 415
 in cancer pain **C:** 125
 intravenous administration **A:** 205–6
 PCA **P:** 296
 renal colic **A:** 415
disability
 assessment, chronic pain **Ch:** 172–3,
 Ch: 172 *T*;
 see also individual instruments
 chronic lower back pain **Ch:** 502,
 Ch: 503–4
 chronic pain presentation **Ch:** 293
 as construct **Ch:** 116
 definition **P:** 221
 measurement **Ch:** 119
discogenic low back pain
 artificial disk implants **P:** 442
 epidural steroid injections **P:** 422
 investigations **Ch:** 157
 radiofrequency lesioning **C:** 232
Discomfort Scale for Dementia of the
 Alzheimer Type
 (DS-DAT) **A:** 145–6
“discomfort threshold,”
 neurostimulation **Ch:** 270
discTRODE **P:** 439, **P:** 439 *F*
 effectiveness **P:** 441
 efficacy **P:** 441
 intradiscal electrothermal therapy
 vs. **P:** 441
Disease Assessment Score (DAS28),
 rheumatoid arthritis **Ch:** 520–1
disease-modifying antirheumatic drugs
 (DMARDs) **Ch:** 521, **Ch:** 522–4 *T*
 B-cell inhibitors **Ch:** 522–4 *T*, **Ch:** 524
 biological **Ch:** 521–4
 definition **Ch:** 521
 interleukin 1 inhibitors **Ch:** 521,
 Ch: 522–4 *T*
 T-cell costimulation
 inhibitors **Ch:** 522–4 *T*, **Ch:** 524
 timing of **Ch:** 521
 tumor necrosis factor- α
 inhibitors **Ch:** 521, **Ch:** 522–4 *T*
 see also individual drugs
disk displacement with reduction,
 temporomandibular
 disorders **Ch:** 468
disk stimulation **Ch:** 153–4
 chronic lower back pain **Ch:** 157,
 Ch: 159 *T*
 neck pain **Ch:** 160
dislocations **A:** 366
disposable devices, PCA **A:** 218; **P:** 304
dissociation **C:** 300–1

- distal lumbar plexus block *see* fascia iliaca compartment block
- distal symmetrical polyneuropathy (DSP), HIV-associated **Ch:** 355
management guidelines **Ch:** 356–7
patient assessment **Ch:** 356–7
prevalence **Ch:** 354
treatment **Ch:** 355–6
- distal symmetric sensorimotor polyneuropathy, diabetic **Ch:** 340
- distraction
attentional **C:** 300
cancer patients **C:** 277
efficacy **C:** 301
elderly **C:** 370
children **A:** 313
cancer patients **C:** 277, **C:** 347
failures of **A:** 313
hypnosis *vs.* **P:** 148–9
preprocedural **P:** 252
procedural pain **A:** 313
techniques **A:** 313
low hypnotizable subjects **P:** 147
surgical patients **P:** 251
- distress
assessment, children **P:** 553
CPSP development **A:** 563
- Distress Scale for Ventilated Newborn Infants (DSVNI) **A:** 479 *T*
- diuretics, NSAID interactions **A:** 74 *T*
- divalproex **Ch:** 263
adverse effects **Ch:** 263
diabetic neuropathy **Ch:** 263
efficacy **Ch:** 261 *T*
migraine prophylaxis **Ch:** 459–61
- divergent validity, pain measures **P:** 37
- diverticular disease **Ch:** 562
- DNA **Ch:** 48–9, **Ch:** 50 *F*
- DNA microarrays **Ch:** 58–9, **Ch:** 71
- DNA polymorphisms **Ch:** 62 *T*
- DNA re-sequencing **Ch:** 62 *T*
- docetaxel **C:** 402
- doctors
attitudes to pain in elderly **C:** 362
cancer pain estimation **C:** 364
see also healthcare professionals/providers
- doctrine of double effect **C:** 97–8
conditions **C:** 98
end of life issues **C:** 391
euthanasia **C:** 98
foreseen harms **C:** 98
intention **C:** 98
pain relief-life shortening issues **C:** 97
“doctrine of similars,”
homeopathy **Ch:** 310–1
- dominant alleles **Ch:** 53
- domperidone **C:** 320 *T*
- donation after cardiac death (DCD) **A:** 351
- donepezil **C:** 185
- Dong qai (angelica) **Ch:** 315 *T*
- dopamine D₂ receptor antagonists, opioid-related nausea and vomiting **A:** 258
- dorsal column, sensory homunculus **P:** 406
- dorsal column stimulators, pediatric CRPS **Ch:** 627
- dorsal horn
alterations, cancer-induced bone pain **C:** 5
central sensitization **P:** 89
neurotransmitters **A:** 9–11, **A:** 10 *T*
persistent visceral pain **Ch:** 40
postnatal development **A:** 34 *T*
- dorsal horn plasticity **A:** 24–5
G-protein coupled receptors **A:** 25–6
initiation **A:** 25–6, **A:** 25 *F*
ligand-gated ion channels **A:** 25–6
low-frequency stimuli **A:** 25
voltage-gated calcium channels **A:** 25–6
wind up **A:** 24
- dorsal nerve of penis **P:** 291, **P:** 470
block *see* penile block, children
- dorsal root entry zone (DREZ)
lesioning
central neuropathic pain **Ch:** 380–3
spinal cord injury pain **Ch:** 397, **Ch:** 397 *T*
- dorsal root ganglion (DRG)
lumbar *see* lumbar dorsal root ganglion
postamputation pain **Ch:** 420
postnatal nociception
development **A:** 33
- dorsal root ganglionitis **Ch:** 344
- dorsal root stimulation,
neurostimulation computer models **Ch:** 270–1, **Ch:** 273 *F*
- dorsolateral funiculus (DLF), persistent musculoskeletal pain **Ch:** 31
- dose escalation, tolerance
development **P:** 539
- dose–response curves **C:** 105, **C:** 105 *F*
- dothiepin, rheumatoid arthritis **Ch:** 521
- double-blind design **P:** 554
- double-blind procedure **P:** 520
- double dummy **P:** 524
- double effect principle *see* doctrine of double effect
- doula **A:** 468
- downside assay sensitivity **P:** 516, **P:** 534
- Down syndrome, pain
assessment **C:** 371
- doxepin
capsaicin and **Ch:** 234
pruritus **Ch:** 232; **C:** 330
- doxycycline, urethral syndrome **Ch:** 580
- “drawer” sign **A:** 431
- “drawer” test **A:** 431
- driving
opioids and **Ch:** 216; **C:** 185
spinal cord stimulation
patients **C:** 245–6
TENS caution **P:** 195–6
- dronabinol, central neuropathic pain **Ch:** 381–2 *T*
- droperidol
field/disaster situations **A:** 380
nausea and vomiting **A:** 227–8
opioid-related **A:** 258
PCA and **P:** 296
pruritus **A:** 228
- Drosophila melanogaster*,
research **Ch:** 61 *T*
- drotrecogin alfa (activated protein C), sepsis **A:** 350
- drug(s)
absorption *see* absorption, drug
addiction *see* addiction
affinity **C:** 105
clearance *see* clearance (Cl), drugs
cost/availability, developing
world **A:** 396
efficacy (intrinsic activity) **A:** 54; **C:** 105
history-taking, chronic pain
patients **P:** 6
hoarding, problematic opioid
use **P:** 117
induced neuropathies **Ch:** 5–6
lipid solubility, age-related
changes **C:** 365
neuropathic pain **Ch:** 4 *T*
potency **A:** 54; **C:** 105
routes of administration **A:** 201–16, **A:** 202 *T*
historical aspects **A:** 201–2
PCA *see* patient-controlled
analgesia (PCA)
*see also individual routes; specific
drugs*
side effects, patient information **C:** 94
withdrawal symptoms *see* withdrawal
symptoms
see also individual drugs

- drug abuse/misuse, personality disorders **Ch:** 618
- Drug Abuse Screening Test (DAST-20) **Ch:** 128
- drug allergies, history-taking **P:** 6
- drug development studies, phases **P:** 553 *T*
- drug-in-adhesive matrix system, fentanyl **A:** 207
- drug-induced reactions, subcutaneous drug infusion **P:** 125
- drug-related neuropathy, clinical trial model **P:** 558
- drug-seeking behavior **A:** 543; **C:** 107
- drug transporters, opioid response variability **C:** 170–3
- dry mouth *see* xerostomia
- dual channel TENS **C:** 243
- ductal hypertension/obstruction surgery, chronic pancreatitis **Ch:** 556
- duloxetine **Ch:** 244 *T*
- adverse effects **Ch:** 245
- CRPS **Ch:** 369
- dosage **P:** 138
- fibromyalgia syndrome **Ch:** 245
- neuropathic pain **Ch:** 245
- peripheral neuropathic pain **Ch:** 345 *T*, **Ch:** 346
- pharmacology **Ch:** 245
- spinal cord injury pain **Ch:** 394–5, **Ch:** 396 *T*
- duodenal ulcers **Ch:** 565
- duodenitis **Ch:** 42
- dura, accidental penetration **P:** 473
- dural sac **P:** 417
- dural tap **P:** 473
- SCS-induced **P:** 411
- dying person **C:** 389–98
- case history **C:** 419
- dying trajectory **C:** 390, **C:** 390 *F*
- family caregiver **C:** 390–1
- interdisciplinary team **C:** 390
- nonpain symptom management **C:** 394
- opioids **C:** 392–3
- pain
- adverse effects **C:** 394–5
- etiology **C:** 390
- prevalence **C:** 390
- sensory aspects **C:** 391
- pain assessment **C:** 392, **C:** 392 *F*
- nonverbal patients **C:** 392
- pain management
- adjuvant drugs **C:** 393–4
- challenges in **C:** 391–2
- clinical interventions, efficacy **C:** 390–1
- communication in **C:** 391
- drug routes of administration **C:** 393, **C:** 393–4
- nonpharmacological **C:** 394
- treatment choices **C:** 393–5
- polypharmacy **C:** 393–4
- quality of life **C:** 391, **C:** 392
- “total pain” **C:** 390, **C:** 392
- unique care **C:** 389–91
- dying state **C:** 389–90
- dynamic analgesia
- assessing **P:** 589
- definition **P:** 579–80
- epidural **P:** 312
- dynamic hyperalgesia, neuropathic pain **Ch:** 135, **Ch:** 141 *T*
- dynorphin receptors, cancer-induced bone pain **C:** 5
- dynorphins **A:** 55; **C:** 153
- dysesthesia(e)
- brachial plexopathy, cancer patients **C:** 32
- definition **Ch:** 136, **Ch:** 375
- intrathecal neurolysis-induced **C:** 231 *T*
- malignant paraplegia **C:** 30–1
- neuropathic pain **Ch:** 136, **Ch:** 138
- peripheral neuropathy **Ch:** 336
- spinal cord compression **C:** 30–1
- vulvodynia **Ch:** 588
- dysesthetic skin, TENS
- contraindication **P:** 195
- dysfunctional labor **A:** 467, **A:** 467 *F*
- dyskinesia, movement disorders **Ch:** 327
- dysmenorrhea **Ch:** 572
- acupuncture **A:** 283 *T*, **A:** 284, **A:** 417; **Ch:** 574
- definition **Ch:** 572
- endometriosis **Ch:** 575
- pathophysiology **Ch:** 572
- primary **A:** 417; **Ch:** 572–4
- diagnosis **Ch:** 572
- onset **Ch:** 572
- pharmacological therapy **Ch:** 572–4
- risk factors **A:** 417
- TENS **A:** 278, **A:** 280, **A:** 417; **Ch:** 574; **P:** 201
- treatment **Ch:** 572–4
- secondary **Ch:** 574
- examination **Ch:** 572
- onset **Ch:** 572
- dyspepsia
- acute **A:** 417
- treatment **A:** 417
- NSAID-induced **A:** 70–1; **C:** 128–9
- dysphagia, cancer patients **C:** 317–8
- clinical findings **C:** 317
- etiology **C:** 317
- investigations **C:** 317
- management **C:** 317–8
- neurogenic **C:** 317
- neurological problems and **C:** 317
- dysphoria
- nitrous oxide-induced **A:** 97
- opioid-induced **A:** 56; **C:** 154
- children **C:** 353 *T*
- dyspnea **C:** 311
- cancer patients
- acupuncture **C:** 274
- causes **C:** 311–3
- clinical findings **C:** 311
- drug treatment **C:** 313–4
- emotional component **C:** 311
- history/examination **C:** 311
- investigations **C:** 311–2
- management **C:** 312–3
- nebulized drugs **C:** 314
- palliation **C:** 313–4
- supportive care **C:** 312
- definition **C:** 311
- pathophysiology **C:** 311
- ear acupuncture *see*
- auriculoacupuncture
- early receptor potential (ERP), hypnotic analgesia **P:** 149
- Eastern Europe, palliative care services **C:** 86
- Ebers Papyrus **A:** 201–2
- Échelle Douleur Enfant San Salvadour (DESS) **P:** 456
- echinaca **Ch:** 314 *T*
- ecomaps, psychological evaluation **C:** 51
- economics (chronic pain) **Ch:** 75–85
- age in **Ch:** 78
- aging populations **Ch:** 76
- analgesia direct costs **Ch:** 77–8
- chest pain **Ch:** 538
- cost of illness studies **Ch:** 77
- demand and supply gap **Ch:** 77
- economic evaluation **Ch:** 79–81
- definition **Ch:** 79
- new treatment effects **Ch:** 80
- quality adjusted life years **Ch:** 80, **Ch:** 81 *F*
- techniques **Ch:** 80–1
- see also individual techniques*
- effectiveness **Ch:** 81–2
- efficiency **Ch:** 76–7, **Ch:** 82
- definition **Ch:** 76

- equity **Ch:** 76–7, **Ch:** 82–3
 definition **Ch:** 76
 fair distribution **Ch:** 76
 indirect costs **Ch:** 78–9
 NSAID-induced adverse effects **Ch:** 79
 prescription costs **Ch:** 77–8
 primary care cost estimations **Ch:** 78
 productivity costs **Ch:** 77, **Ch:** 78–9
 lost working days **Ch:** 78
 resource limitations **Ch:** 76
 self-medication costs **Ch:** 77–8
 strategy development **Ch:** 81–3
 United States **Ch:** 66
- ectopic discharges
 definition **Ch:** 7
 peripheral neuropathies **Ch:** 336–7
- edema
 CRPS **Ch:** 366, **Ch:** 366–7
 cryotherapy **A:** 535–6
 organ failure **A:** 349
- Edmonton Classification System for Cancer Pain (ECS-CP) **C:** 44, **C:** 45 *T*
- Edmonton Symptom Assessment System (ESAS), cancer patients
 anxiety diagnosis **C:** 39
 depression diagnosis **C:** 39
 pain intensity **C:** 42
- education
 family *see* family education
 family caregiver **C:** 67–8, **C:** 363
 healthcare professionals *see* healthcare professionals/providers
 patients *see* patient education
- effectiveness
 definition **Ch:** 180
 economic measure **Ch:** 81–2
 efficacy *vs.* **Ch:** 180 *T*
 number needed to treat **Ch:** 185
- effect size **P:** 572
- efficacy, effectiveness *vs.* **Ch:** 180 *T*
- efficacy (intrinsic activity), drugs **A:** 54; **C:** 105
- efficiency
 definition **Ch:** 180–1
 economics **Ch:** 76, **Ch:** 76–7, **Ch:** 82
- eicosapentaenoic acid (EPA) **C:** 328
- elbow
 intra-articular injection **P:** 352
 nerve blocks **P:** 270–1
 anatomy **P:** 270–1
 indications **P:** 270
 soft-tissue injection **P:** 355
- elbow pain **A:** 437–8
 clinical features **A:** 437
 entities **A:** 437
- investigations **A:** 437–8
 lateral *see* lateral epicondylitis
 management **A:** 438
 medial *see* medial epicondylitis
 surgery **A:** 438
- elderly
 acute pain **A:** 504–25
 analgesia **A:** 513–6
 analgesic techniques **A:** 516–9
 assessment **A:** 510–3
 behavioral assessment **A:** 512
 non-oral drug absorption **A:** 505–7
 NSAIDs **A:** 73
 pain measurement **A:** 512–3
 reporting of **A:** 510–2
 self-reporting **A:** 512
- analgesic misconceptions **C:** 363
- angina **A:** 509–10
- arthritic pain management **Ch:** 199
- body fat changes **A:** 506 *T*, **A:** 508
- cancer pain **C:** 359–78
 ageist attitudes **C:** 360
 analgesia, additional **C:** 368–70
 assessment **C:** 361–2
 bone metabolism affecting drugs **C:** 369
 carer knowledge/
 experience **C:** 363–4
 characteristics **C:** 360–1
 control of **C:** 362–3
 doctors' attitudes **C:** 362
 drug side effect knowledge/
 experience **C:** 364
 healthcare professionals' attitudes **C:** 362–3
 hospital admissions **C:** 360
 incidence **C:** 360
 measurement instruments **C:** 361
 nonpharmacological management **C:** 369–70
 nurses' attitudes **C:** 362–3
 nursing home patients **C:** 371–2
 pain overestimation, carers **C:** 363
 pain relief measurement **C:** 361
 palliative care interventions **C:** 360
 patient knowledge/
 experience **C:** 364
 patients' attitudes **C:** 362
 public attitude effects **C:** 364
 quality of life **C:** 360, **C:** 361, **C:** 363
 reluctance to report **C:** 362
 simple analgesia **C:** 365–6
- cardiac output changes **A:** 506 *T*, **A:** 507–8
 drug distribution **A:** 507–8
- cerebral drug uptake **A:** 507
- chronic back pain **Ch:** 642
- chronic pain **Ch:** 641–51
 assessment **Ch:** 644–6
 assessment barriers **Ch:** 644–5, **Ch:** 645 *T*
 attitudes to **Ch:** 644
 CAM **C:** 369–70
 coanalgesics **Ch:** 647
 comorbidities **Ch:** 642, **Ch:** 646
 daily life effects **Ch:** 642
 economics **Ch:** 76
 epidemiology **Ch:** 641–2
 management
 considerations **Ch:** 646–8
 nonpharmacological interventions **Ch:** 646
 NSAIDs **Ch:** 647
 opioids **Ch:** 647
 outcome measurement **Ch:** 181–2
 pain management,
 paracetamol **Ch:** 646–7
 physiotherapy/exercise **Ch:** 648
 polypharmacy **Ch:** 646
 prevalence **Ch:** 642
 psychological influences **Ch:** 643–4
 psychological strategies **Ch:** 647–8
 self-reporting **Ch:** 644
 social circumstances **Ch:** 643–4
 delirium **A:** 512, **A:** 512 *T*
 dose response **A:** 505
 emergency departments **A:** 361
 epidural analgesia *see* epidural analgesia
 herpes zoster **Ch:** 430–1, **Ch:** 436
 impaired cognition **Ch:** 646
 local anesthetic sensitivity **A:** 121
 muscle mass changes **A:** 506 *T*, **A:** 508
 nighttime pain **C:** 361
 nonverbal patient assessment **A:** 512; **C:** 370–1
 nursing home patients **Ch:** 642; **C:** 371–2
 pain prevalence **C:** 371
 undertreatment risk **C:** 371
- obesity **A:** 508
- opioids *see* opioid(s)
- pain definitions **C:** 360
 pain etiology **C:** 360
 pain intensity measurement **P:** 20
 pain mechanisms **Ch:** 643
 pain perception **P:** 20
 abdominal pain **A:** 510
 pain perception changes **A:** 509–10, **A:** 511 *T*; **P:** 20
 pain thresholds **A:** 509
 pain tolerance **A:** 509; **C:** 360
 PCA **P:** 298–9
 pharmacodynamics **A:** 505–9; **C:** 365

- elderly (*continued*)
- pharmacokinetics **A:** 505–9; **C:** 365
 - distribution **C:** 365
 - drug distribution **A:** 505–7
 - hepatic clearance **A:** 508
 - non-oral absorption **A:** 505–7
 - oral absorption **A:** 505
 - systemic **A:** 505–7
 - physiological changes **A:** 506 *T*; **Ch:** 642–3
 - physiological simulations **A:** 509
 - bolus dose **A:** 510 *F*
 - infusion **A:** 511 *F*
 - minimum effective analgesic concentration **A:** 509
 - population increases **Ch:** 641–2
 - postoperative pain **Ch:** 643
 - assessment **Ch:** 645–6
 - perception **A:** 510
 - postoperative pain, inadequate relief **A:** 504
 - protein binding changes **A:** 508
 - renal clearance **A:** 508
 - residential home patients **C:** 371–2
 - resignation to pain **C:** 372
 - terminal dependency period **C:** 360
 - visceral pain **Ch:** 642
 - WHO analgesic ladder **Ch:** 646
- electrical skin burns, TENS-induced **P:** 198
- electrical stimulation
- neuropathic pain
 - assessment **Ch:** 139 *T*
 - peripheral nociceptors **Ch:** 27
- Electrical Stimulation versus Coronary Bypass Surgery (ESBY) study **Ch:** 541
- electroacupuncture
- clinical trial evidence **C:** 272
 - definition **A:** 280
 - mechanism of action **P:** 209
 - technique **Ch:** 309, **Ch:** 309 *F*; **C:** 272
- electroanesthetic equipment, history **P:** 193–4
- electrodermal activity (EDA)
- biofeedback **P:** 487 *T*
 - complex regional pain syndrome **P:** 488
 - needle phobia **P:** 489
- electrodermal response, biofeedback **P:** 486 *F*
- electrodes
- neurostimulation **Ch:** 270
 - displacement of **Ch:** 280
 - TENS *see* transcutaneous electrical nerve stimulation (TENS)
- electrodiagnosis, CRPS **Ch:** 367
- electroencephalography (EEG) **P:** 84
- biofeedback **P:** 487 *T*
 - postnatal development **A:** 38
- electrolyte testing **P:** 68
- electromagnetic field therapy, rotator cuff disorders **Ch:** 529
- electromyographic-assisted relaxation **P:** 157–8, **P:** 487 *T*
- recurrent headache **P:** 163
- electromyography (EMG) **P:** 157–8
- CRPS **Ch:** 367
 - lumbar disk herniation **Ch:** 150, **Ch:** 150 *T*
 - machine variability **P:** 158
 - mechanism **Ch:** 149
 - peripheral neuropathies **Ch:** 337
 - postnatal development **A:** 36–8
- electrophysiology
- hyperalgesia **A:** 20–1
 - neuropathic orofacial pain **Ch:** 471, **Ch:** 472 *F*
- eletriptan, migraine **Ch:** 455–6, **Ch:** 460 *T*
- children **Ch:** 631 *T*
- elevation, sports injury management **A:** 532
- elimination half-life ($t_{1/2}$) **C:** 107
- eltenac, osteoarthritis **Ch:** 236
- EMBASE **P:** 570 *T*
- emergency departments (ED) **A:** 360–73
- abdominal pain, acute **A:** 363
 - analgesia
 - age-related issues **A:** 361
 - choice of **A:** 361
 - delivery systems **A:** 361
 - systemic **A:** 361–3
 - see also individual drugs*
 - children **A:** 361
 - abdominal pain **A:** 363
 - fractures **A:** 367
 - dislocations **A:** 367
 - elderly pain management **A:** 361
 - fracture reduction **A:** 367
 - migraine **A:** 365–6
 - numerical rating scale use **A:** 140
 - pain prevalence **A:** 361
 - renal colic **A:** 363–4
 - wounds **A:** 366–7
- emergency resuscitation **A:** 351
- emergency situations *see* field/disaster situations
- emergent reperfusion, ischemic cardiac chest pain **A:** 365
- emetic (vomiting) pattern generator **C:** 318, **C:** 318 *F*
- EMLA (eutectic mixture of local anesthetics) **A:** 128; **Ch:** 234
- adverse effects **A:** 488
- children **A:** 487–8
 - administration **A:** 487–8
- peripheral neuropathies **Ch:** 347
- postbreast cancer surgery pain **C:** 404–5
- postoperative pain **Ch:** 237
- procedure-related pain, cancer patients **C:** 216
- children **C:** 349–50
- emotional conflict, tension-type headache **Ch:** 453
- emotional distress
 - assessment, chronic pain **Ch:** 173–4
 - pain and **C:** 303
- emotional experiences
 - chronic pain presentation **Ch:** 293
 - chronic pelvic pain **Ch:** 582
 - phantom pain **Ch:** 418
- emotional Stroop task, pain-related fear **P:** 178–9
- empathic discussion, CBT **Ch:** 294
- empowerment, patient **C:** 297
- enantiomers, local anesthetics **A:** 117, **A:** 117 *F*
- endocrine system, placebo effect **P:** 505 *F*, **P:** 507
- end-of-dose failure **C:** 287; **P:** 539
- epidemiology **C:** 288
- end of life care
 - cancer patients **C:** 334–5
 - agitation management **C:** 335
 - home care **C:** 334
 - multiprofessional care team **C:** 334
 - pain relief **C:** 334
 - prognosis estimations **C:** 334
 - secretion management **C:** 335
 - symptoms control **C:** 334
 - ICU patients **A:** 344, **A:** 350–1
 - organ donation **A:** 351
 - palliative analgesia **A:** 351
- End-of-Life Nursing Education Consortium (ELNEC-Oncology) **C:** 413
- End of Life Strategy **C:** 417
- endogenous opiates, hypnotic analgesia **P:** 149
- endogenous opioids **C:** 153
 - activation, acute pain **Ch:** 242–3
 - binding characteristics **C:** 153 *T*
 - precursor molecules **C:** 153
- endometrial carcinoma
 - hormone treatment **C:** 265
 - metastatic bone pain management **C:** 265
- endometriosis **Ch:** 574–7
 - bowel affecting **Ch:** 579

- diagnosis **Ch:** 575
 etiology **Ch:** 575
 incidence **Ch:** 574–5
 pain outcome **Ch:** 576–7
 symptoms/signs **Ch:** 575
 treatment **Ch:** 575–6
 medical **Ch:** 575
 surgery **Ch:** 576
- endomorphin-1 **C:** 153
- endorphins
 acupuncture **Ch:** 310
 mu opioid receptor binding **A:** 55;
 C: 153
- endoscopes, epiduroscopy **P:** 428 *F*
- endoscopic adhesiolysis **P:** 244
 efficacy **P:** 434
 low back pain with sciatica **P:** 433
- endoscopic retrograde
 cholangiopancreatography (ERCP)
 chronic pancreatitis **Ch:** 553
 procedural-related pain
 control **C:** 218
- endoscopic thoracic sympathectomies,
 refractory angina pectoris **Ch:** 540
- endoscopy
 chronic pancreatitis pain **Ch:** 554
 post cholecystectomy
 syndrome **Ch:** 563–4
- endothelins (ET), cancer-induced bone
 pain **C:** 5
- end zone spinal pain *see* spinal cord
 injury (SCI) pain, at-level
 neuropathic pain
- energy healing **Ch:** 307, **Ch:** 307 *T*,
 Ch: 316
 adverse effects **Ch:** 316
 research **Ch:** 316
- enhanced external counter pulsation
 (EECP), refractory angina
 pectoris **Ch:** 541
- enkephalins
 delta opioid receptor binding **A:** 55;
 C: 153
 joint innervation **Ch:** 26
- enriched enrollment, clinical
 trials **P:** 519–20
 cancer pain **P:** 544, **P:** 544 *F*
 neuropathic pain **P:** 558
- enteropathy, NSAID-induced **C:** 134
- entonox
 burn pain **A:** 402
 labor pain **A:** 469–70
 procedure-related pain **C:** 218
 advantages/disadvantages **C:** 218
- entrapment neuropathies **Ch:** 134
- environmental avoidance, chronic pain
 patients **Ch:** 174–5
- environmental reinforcers, chronic
 pain **Ch:** 123
- ephedra (Ma huang) **Ch:** 315 *T*
- epicondylitis, lateral *see* lateral
 epicondylitis
- epidermolysis bullosa, topical
 opioids **Ch:** 237
- epididymitis **Ch:** 563
- epidural abscess **P:** 318
 epidural steroid injection-
 induced **P:** 422, **P:** 423
 monitoring **P:** 593
 SCS-induced **P:** 411
- epidural analgesia **P:** 311–21, **P:** 244
 abdominal aortic surgery **A:** 263
 abscess induction *see* epidural abscess
 adverse effect reduction **P:** 313
 anticoagulant drugs and **A:** 518
 APS **P:** 587
 cardiac surgery **A:** 263
 ICU patients **A:** 351
 catastrophic complications **P:** 313
 catheter placement **A:** 260
 children **A:** 491–2; **P:** 318, **P:** 472–3,
 P: 473–4
 anatomy **P:** 473
 cancer pain **C:** 354
 catheters **P:** 473
 caudal approach *see* caudal epidural
 analgesia, children
 complications **P:** 474
 drugs/infusions **A:** 492; **P:** 473–4,
 P: 474 *T*
 epidural space identification **P:** 473
 indications **P:** 473
 local anesthetic-opioid
 combinations **A:** 492; **P:** 474
 local anesthetics **A:** 492
 monitoring **P:** 474
 peripheral nerve block *vs.* **P:** 472
 technique **P:** 473
 complications **P:** 593
 continuous *see* continuous epidural
 analgesia
 cost-effectiveness **A:** 265
 CRPS **Ch:** 370
 developing world **A:** 396
 discharge information **P:** 586, **P:** 594
 drug combinations **P:** 313, **P:** 314 *F*
 alternatives **P:** 319
 safety **P:** 315
 drug delivery **A:** 209
 effectiveness, epinephrine in **P:** 314 *F*,
 P: 315
 efficacy optimization **P:** 313
 elderly **A:** 507, **A:** 517–8
 cardiovascular system **A:** 517
- ICUs **A:** 517
- local anesthetic/opioid
 combinations **A:** 518
- local anesthetics **A:** 517
 monitoring **A:** 518
 opioids **A:** 518
 PCA **A:** 517
- excessive doses **P:** 313
- femoral nerve blocks *vs.* **A:** 240
- field/emergency situations **A:** 382 *T*
- gastrointestinal surgery **A:** 264
- hypotension **P:** 591
- ICU patients **A:** 349–50, **A:** 517;
 P: 318
- indications/uses **P:** 312
- intensive care unit patients **P:** 318
- in labor **P:** 318
- low back pain management **A:** 451 *T*,
 A: 453
- lumbar *see* lumbar epidural analgesia
- motor block development **P:** 593–5
 informal testing **P:** 594
- obstetric pain **P:** 316–8, **P:** 319
- opioid-induction, pruritus **A:** 257–8
- opioids **A:** 209
 elderly **A:** 518
 extended release epidural
 morphine **A:** 209
 onset of analgesia **A:** 209
 urinary retention **A:** 258
 see also individual drugs
- patient controlled *see* patient-
 controlled epidural analgesia
 (PCEA)
- personnel **P:** 319, **P:** 320
- post-abdominoperineal
 surgery **P:** 318, **P:** 320
- postamputation pain
 prevention **Ch:** 424
- post-lower limb surgery **P:** 318
- postoperative cardiopulmonary
 outcomes **P:** 312–3
- postoperative pain **A:** 332; **P:** 316–8,
 P: 319
 analgesic mixture **P:** 316
 catheter site tenderness **P:** 317
 catheter tip levels **P:** 316
 closed system **P:** 317, **P:** 317 *F*
 contraindications/relative
 contraindications **P:** 316
 discontinuation **P:** 317
 education program **P:** 319
 indications **P:** 316
 monitoring **P:** 317, **P:** 319
 pain management program
 requirements **P:** 319
 patient-controlled **P:** 317

- epidural analgesia (*continued*)
 procedure P: 316
 sterile techniques P: 317
 preprinted flow sheets P: 592–3 *F*
 preprinted standard orders P: 592–3 *F*
 prescription P: 316–8
 pulmonary postoperative
 complication reduction P: 312
 risks to patient P: 313
 safety P: 313
 sensory block development P: 593–5
 informal testing P: 594
 sickle cell disease pain A: 421
 spinal cord blood flow P: 315–6
 thoracic *see* thoracic epidural
 analgesia (TEA)
 thoracic surgery A: 263
 thoracic vs. lumbar P: 312–3
 vaginal delivery P: 312, P: 318, P: 320
 drug regime P: 318
 procedure P: 319
- epidural blood vessel trauma,
 epiduroscopy P: 428
- epidural catheters, children P: 473
- epidural fibrosis
 adhesiolysis P: 429
 nerve root strangulation P: 429
 radiculopathy P: 429
 surgically-induced P: 429
- epidural hematoma P: 318
 epidural steroid injection
 complication P: 422–3
 monitoring P: 593
- epidural neurolytic blockade C: 230–1
 phenol C: 230
- epidural space
 age-related changes P: 428
 estimation, children P: 473
- epidural spinal cord
 compression C: 29 *T*
- epidural steroid injections P: 416–26
 anatomy P: 417–8
 back pain P: 416–26
 caudal approach P: 418
 complications P: 423
 indications P: 417
 complications P: 422–3
 injectate-related P: 423
 needle malpositioning P: 422
 procedure-related P: 422
 contraindications P: 423–4
 absolute P: 424
 relative P: 424
 drugs used P: 419
 duration P: 417
 failure P: 419, P: 419 *T*
 fluoroscopy in P: 419
- historical aspects P: 416–7
 indications P: 417
 interlaminar approach P: 418
 complications P: 422
 indications P: 417
 local anesthetic test dose P: 419
 pharmacological mixtures P: 419
 radicular low back pain *see* lumbar
 radiculopathy
 routes of administration P: 418
 “safety triangle” P: 418
 side effects P: 422–3
 small unmyelinated C-fibers P: 417
 transforaminal approach P: 418
 complications P: 422–3
 indications P: 417
 preganglionic P: 418
 selective subdural nerve root block
 vs. P: 418
- epidural test dose, children P: 473
- epiduroscopic adhesiolysis P: 431,
 P: 431 *F*
- epilepsy, TENS contraindications A: 277
- epileptiform neuralgia C: 206
- epileptiform seizures, multiple
 sclerosis Ch: 326
- epinephrine (adrenaline)
 continuous peripheral neural
 blockade A: 245
 cryoanalgesia P: 382
 epidural analgesia P: 313
 coughing pian during P: 314 *F*,
 P: 315
 effectiveness P: 314 *F*, P: 315
 epidural blood flow P: 315
 optimal doses P: 315
 pharmacodynamic
 interactions P: 316
 pharmacokinetic
 interactions P: 316
 platelets, effects on P: 315
 safety P: 315
 spinal cord blood flow P: 315–6
 thoracic A: 258
 labor pain A: 466
 local anesthetics and A: 118
 neuraxial analgesia A: 258
- epiphyseal injuries A: 530
- episodic pain Ch: 221;
see also breakthrough pain
- epsilon (ϵ) opioid receptor A: 54
- equianalgesic doses A: 547 *T*
- equinovarus foot, spasticity
 Ch: 442
- equivalence trials P: 516
 assumptions P: 516
 neuropathic pain P: 559–60
- ergot alkaloids, migraine A: 366;
 Ch: 455
- ergotamine, migraine Ch: 455
- ERKs *see* extracellular signal-regulated
 kinases (ERKs)
- error variance, pain measures P: 36
- erythema
 musculoskeletal pain A: 431–2
 topical local anesthetic-
 induced Ch: 232
- erythrocyte sedimentation rate
 (ESR) P: 69
 joint pain A: 433
 osteoarthritis Ch: 526
 spinal neoplasia Ch: 155
- erythromelalgia, hereditary Ch: 342
- erythromycin
 nausea and vomiting C: 320 *T*
 urethral syndrome Ch: 580
- erythropoietin
 fatigue, cancer-related C: 329
 uremic itch C: 331
- escape behaviors, pain-related
 fear P: 178
- escitalopram, pediatric
 headache Ch: 632
- esmolol, ischemic cardiac chest
 pain A: 365
- esophageal candidiasis C: 316
- esophageal motor disorders Ch: 543
- esophageal pain
 chest Ch: 543
 HIV infection Ch: 358, Ch: 359 *T*
- esophageal spasm A: 417
- esophageal stents C: 215 *F*
- esophagitis, persistent pain Ch: 42
- Essaic C: 274
- estrogens
 fibromyalgia syndrome Ch: 603
 vulvodynia Ch: 590
- etanercept, rheumatoid
 arthritis Ch: 521, Ch: 522–4 *T*
- ethamsylate C: 315
- ethanol *see* alcohol
- ethical issues Ch: 99–114
 accountability lack Ch: 108–9
 curative model problems Ch: 108
 legal redress Ch: 109
 analgesia knowledge lack Ch: 104–5
 addiction fears Ch: 104–5
 opioid use Ch: 104
 restrictive prescribing laws Ch: 105
 analgesia prioritization
 failure Ch: 103–4
 curative model Ch: 103
 disease process focus Ch: 103–4
 pseudoaddiction Ch: 103–4

- training lack **Ch**: 103
- barriers to pain relief *see* pain relief barriers
- cancer pain clinical trials **P**: 547–9
rescue medication **P**: 541–2
- cancer pain management **C**: 93–100
blame **C**: 99
dying person **C**: 391
substance abuse/misuse and **C**: 384, **C**: 386
- collective **P**: 547–8
- consent *see* consent
- curative medicine model **Ch**: 101, **Ch**: 101 *T*
- diagnostic blocks **Ch**: 153
- first do no harm principle **Ch**: 100
- healthcare professional, moral obligations **C**: 97
- individual **P**: 547–8
- intrusive questioning **C**: 95
- neuropathic pain clinical trials **P**: 553
- opioid analgesics **Ch**: 100
- pain, identifiable causes of **Ch**: 100
- pain definition **Ch**: 88
- pain undertreatment **Ch**: 94
- palliative medicine model **Ch**: 101 *T*
- physician's duty to relieve suffering **Ch**: 101–2
- placebos *see* placebo
- post-clinical trial access to treatment **P**: 562
- prolongation of life **C**: 97–9
common-sense approach **C**: 97
“double effect” **C**: 97
foreseen harms **C**: 98
intention **C**: 98
media's role **C**: 97
moral failures **C**: 98–9
public acceptance **C**: 98
- psychological assessment
cancer patients **C**: 51
chronic pain patients **Ch**: 123
- regulatory scrutiny fear **Ch**: 105–8
- sham surgery **P**: 509
- total pain **C**: 95
- undertreated pain **Ch**: 102
see also decision-making
- ethnicity
children and pain **A**: 311–2
chronic pain **Ch**: 66–9
pain perception **P**: 13
- ethosuxamide **C**: 8–9
- etidocaine **A**: 125, **A**: 127
metabolism **A**: 120
- etodolac **A**: 75 *T*, **A**: 77
- etoricoxib **A**: 75 *T*, **A**: 79
congestive heart failure **Ch**: 195–6
- thrombotic risk **Ch**: 195–6; **C**: 137
- E-TRANS **P**: 304–5
- euphoria
nitrous oxide-induced **A**: 97
opioid-induced **A**: 56
- European Association for Palliative Care (EAPC)
opioid adverse effect management guidelines **C**: 181
opioid switching
recommendations **C**: 169
- European Medicines Agency
website **P**: 564
- European Organization for Research and Treatment of Cancer (EORTC), elderly pain assessment **C**: 361
- European Society of Cardiology
cardiac rehabilitation **Ch**: 539
refractory angina pectoris
definition **Ch**: 539
- European Society of Regional Anesthesia and Pain Therapy, Postoperative pain management - good clinical practice guidelines *see* Postoperative pain management - good clinical practice
- European Union Clinical Trials Directive, neuropathic pain trials **P**: 552–3
- eutectic mixture of local anesthetics *see* EMLA (eutectic mixture of local anesthetics)
- euthanasia **C**: 98, **C**: 391
- evaluation, innovations **P**: 608
- event rate measure, neuropathic pain clinical trials **P**: 561
- evoked pain
clinical trials **P**: 521, **P**: 522 *T*
neuropathic **Ch**: 134
- excitatory modulation, spinal cord pain transmission **A**: 33, **A**: 34 *T*
- excitatory postsynaptic potentials (EPSPs), central sensitization **A**: 25
- exercise therapy **P**: 223–4
acute neck pain **Ch**: 494
cancer-related fatigue **C**: 329
CBT **Ch**: 295–6
chronic lower back pain **Ch**: 509; **P**: 223
fear-avoidance beliefs **Ch**: 509
chronic neck pain **Ch**: 494, **Ch**: 495 *T*
- elbow pain **A**: 438
- elderly **Ch**: 648
- fibromyalgia syndrome **Ch**: 606; **P**: 223
- knee pain **A**: 440
- manual medicine and **P**: 237
- myofascial pain **Ch**: 608
- noninflammatory joint pain **A**: 435
- osteoarthritis **Ch**: 527; **P**: 223
prognosis **P**: 223–4
- rheumatoid arthritis **P**: 223
- rotator cuff disease **P**: 223
- rotator cuff disorders **Ch**: 529
- shoulder pain **A**: 437
- spinal cord injury pain **Ch**: 397 *T*
- wrist pain **A**: 439
- exons **Ch**: 49–51
- experiential avoidance **Ch**: 174
- experimental invasive sensory testing **Ch**: 25
- expert medicolegal report **P**: 677–85
clinician's competency **P**: 679
concerns **P**: 679–80
examination **P**: 683–4
altered sensation **P**: 683
locomotion assessment **P**: 684
musculoskeletal **P**: 683–4
neurological **P**: 683–4
- functional capacity, individual **P**: 679
- history taking **P**: 683
sickness records **P**: 683
social/domestic framework **P**: 683
socioeconomic difficulties **P**: 683, **P**: 684 *T*
- illness behavior assessment **P**: 684
- incidence/complication, nature of **P**: 680
- informed consent **P**: 680
- joint statements **P**: 684
- lack of consent **P**: 680
- “litigious” patient
characteristics **P**: 683
- malingerer/false claims **P**: 680
- “off label” drug use **P**: 680
- personal loss and suffering **P**: 679
- report
conclusion **P**: 682–5
future progress assessment **P**: 682
layout **P**: 682
opinion **P**: 684–5
preparation **P**: 682–3
prognosis
recommendations **P**: 684, **P**: 685 *T*
source information **P**: 682, **P**: 683
structure **P**: 684
standards of care **P**: 679
treatment suitability **P**: 679–80
- explanatory studies **P**: 515, **P**: 515 *T*
- exposure, CBT **Ch**: 296
- expression analysis **Ch**: 63

- extended release epidural morphine (EREM) **A:** 209
- extensor spasms, spasticity **Ch:** 442–3, **Ch:** 442 *F*
- extensor tenosynovitis **P:** 355
- external beam radiotherapy, bone pain **C:** 258–9
- extracellular matrix, tissue repair **A:** 528
- extracellular signal-regulated kinases (ERKs)
- central sensitization **A:** 26–7
 - intracellular signaling **A:** 22
 - microglia activation **Ch:** 14–5
 - peripheral sensitization **A:** 21
 - postnatal development **A:** 35, **A:** 35 *T*
- extracorporeal shock wave treatment (ESWT), shoulder pain **A:** 437
- extradural neurolysis **P:** 341
- complications **P:** 341
- extremely low birth weight (ELBW) infants, persistent visceral pain **Ch:** 43
- eye movement desensitization and reprocessing (EMDR) **Ch:** 617
- Eysenck Personality Questionnaire **Ch:** 486
- Fabry's disease **Ch:** 151 *T*, **Ch:** 342
- Face, Legs, Arms, Cry, Consolability (FLACC) scale
- acute pain assessment **A:** 145, **A:** 146 *F*
 - children **A:** 145, **A:** 480, **A:** 481 *T*
 - in dementia **A:** 145–6
 - postoperative pain assessment **P:** 451–3
 - procedural pain assessment **P:** 20, **P:** 451, **P:** 452 *T*
- face scales, acute pain assessment **P:** 448–9
- photographs **P:** 448
 - schematized pictures **P:** 448
- Faces Pain Scale (FPS) **A:** 143 *F*; **P:** 16 *F*
- acute pain assessment
 - children **A:** 142, **A:** 145; **P:** 448–9
 - elderly **A:** 512
 - chronic pain assessment, elderly **Ch:** 644
 - cognitive impairment **C:** 371
- Faces Pain Scale-Revised (FPS-R) **P:** 15–6, **P:** 16 *F*
- acute pain assessment **P:** 448–9, **P:** 449 *F*
 - chronic pain assessment **P:** 455–6
 - cultural/ethnic considerations **P:** 458
 - school-aged children **P:** 449
- facet joint pain, radiofrequency lesioning **C:** 232
- facet joint disease **Ch:** 505
- facet joint injections *see* zygapophyseal joint blocks/injections
- facet joint syndrome **P:** 361
- facial affective scale (FAS), cognitive impairment **C:** 371
- facial hyperalgesia, chronic pain syndromes **P:** 383
- facial pain **Ch:** 467–83
- bronchial cancer **C:** 32
 - persistent idiopathic **Ch:** 474–6
 - see also individual diseases/disorders*
- factitious disorder **Ch:** 620
- factor VIII replacement, hemophilia **A:** 419
- failed back surgery syndrome (FBSS)
- deep brain stimulation **C:** 246
 - epidural steroid injections **P:** 421
 - caudal approach **P:** 421
 - transforaminal approach **P:** 421 - SCS **C:** 244; **P:** 405
- failure of values-based action **Ch:** 174
- falls, elderly **C:** 361
- false positives **P:** 501–2
- diagnostic blocks **Ch:** 153
 - nerve conduction studies **Ch:** 150
- famciclovir, herpes zoster **Ch:** 432
- familial amyloid neuropathy **Ch:** 151 *T*
- familial clustering, complex multifactorial disorders **Ch:** 53, **Ch:** 60–1
- familial hemiplegic migraine (FHM) **Ch:** 630
- familial Mediterranean fever (FMF) **Ch:** 562
- family
- acute pain management, children **A:** 481
 - as “attorney” **C:** 96
 - barriers to pain relief **Ch:** 103
 - of cancer patients
 - education needs **C:** 52–3
 - importance of **C:** 52–3
 - needs **C:** 53
 - palliative care concerns **C:** 52–3
 - psychological evaluation **C:** 53–4
 - psychological state **C:** 53
 - psychosocial assessment **C:** 52
 - carers *see* family caregiver
 - CBT involvement **Ch:** 297
 - as co-clients **C:** 53
 - comprehensive pain rehabilitation programs **P:** 623
 - conflict of needs **C:** 54
- emotional risk, predisposing factors **C:** 53
- ICU pain assessment **A:** 345
- see also* parent(s)
- family caregiver, cancer patients
- anxiety scores **C:** 65
 - burden of caring **C:** 52
 - definition **C:** 63–4
 - demographics **C:** 364
 - depression scores **C:** 65
 - dying person **C:** 390–1
 - financial burden **C:** 65
 - health status scores **C:** 65
 - pain education program **C:** 67–8, **C:** 363
 - pain experience
 - communication problems **C:** 64
 - impact of cancer **C:** 65
 - perceptions **C:** 64
 - pain management **C:** 63–70
 - barriers to **C:** 64–5
 - clinical practice implications **C:** 68
 - implementation difficulties **C:** 66, **C:** 66 *T*
 - processes **C:** 66–7, **C:** 67 *T*
 - research implications **C:** 68
 - skills **C:** 66–8, **C:** 67 *T*
 - pain overestimation **C:** 64, **C:** 363
 - pain underestimation **C:** 64
 - palliative care patient, impact of caring for **C:** 65
 - psychosocial assessment **C:** 52
 - quality of life **C:** 65
 - strain on **C:** 65
- family education
- cancer patient needs **C:** 52–3
 - juvenile fibromyalgia syndrome **Ch:** 625
 - pediatric headache **Ch:** 630
- famotidine
- functional abdominal pain **Ch:** 634
 - peptic ulcer prophylaxis **C:** 133
- FAS *see* Functional Activity Scale (FAS)
- fascia iliaca **P:** 470
- fascia iliaca compartment block **P:** 280
- children **A:** 490; **P:** 470–1
 - anatomy **P:** 470
 - indications **P:** 470
 - local anesthetic solution **P:** 471
 - method **P:** 470–1
 - indications **A:** 238 *T*
- fasciculation, peripheral neuropathy **P:** 78
- fatigue, cancer patients **C:** 328–9
- management **C:** 329
 - treatable causes **C:** 328
- fear(s)

- addiction **C**: 106
hospitals, developing world **A**: 393
labor pain **A**: 466
measures of **P**: 31
opioid-related *see* opioid(s)
pain-related *see* pain-related fear
tolerance **C**: 106
- fear-avoidance
chronic lower back pain, exercise therapy **Ch**: 509
chronic pain development **A**: 296
exaggerated pain model **Ch**: 296; **P**: 177
psychological factors **A**: 293
- Fear-Avoidance Beliefs Questionnaire (FABQ) **Ch**: 173–4; **P**: 180
- feet *see* foot
- felbinac **A**: 77, **A**: 207
- femoral neck fractures **A**: 366
- femoral nerve **P**: 282
- femoral nerve block **A**: 238 *T*, **A**: 240; **P**: 282
anterior cruciate ligament repair **A**: 240
children **A**: 490
complications **P**: 282
continuous *see* epidural analgesia
femoral neck fractures **A**: 366
field/emergency situations **A**: 382 *T*
hip replacement surgery **A**: 241
knee surgery **A**: 240
practical steps/technique **P**: 282, **P**: 282 *F*
- femoral nerve pain, pregnancy **A**: 462
- fenamates **A**: 78;
see also individual drugs
- fenoprofen **A**: 76
- fentanyl **A**: 60; **C**: 160
adverse effects **C**: 160
children **A**: 484
cognitive dysfunction **A**: 515
elderly **C**: 368
atypical odontology **Ch**: 475
breakthrough pain **C**: 291
buccal/sublingual administration **A**: 208
bupivacaine and **A**: 258
labor pain **A**: 471, **A**: 471 *F*
burn pain **A**: 403
cancer pain **C**: 160, **C**: 169 *T*
cancer related/induced-neuropathic pain **C**: 202, **C**: 203–4
clinical studies **C**: 203–4
children **A**: 484; **C**: 349, **C**: 352 *T*; **P**: 466 *T*, **P**: 467–8
chronic noncancer pain **Ch**: 212
dyspnea **C**: 313
- elderly **A**: 513; **C**: 368
- emergency departments **A**: 362
- epidural analgesia **P**: 313
children **P**: 474 *T*
labor pain **A**: 471, **A**: 471 *F*
pharmacodynamic interactions **P**: 316
pharmacokinetic interactions **P**: 316
safety **P**: 315
- equianalgesic doses **A**: 547 *T*
- fracture reduction **A**: 367
- inhalational administration **A**: 209
- interindividual response variability **C**: 174
- intranasal administration **A**: 208, **A**: 208 *T*; **P**: 306
- intrathecal administration **A**: 210
labor pain **A**: 469
metabolism **A**: 60; **C**: 203
Middle East usage **C**: 88
morphine vs. **Ch**: 209
neuropathic pain **Ch**: 209
- oral transmucosal administration *see* oral transmucosal fentanyl citrate (OTFC)
- osteoarthritis **Ch**: 212
- PCA
children **A**: 484; **P**: 467–8
dose **A**: 219
field/disaster situations **A**: 381–2
renal disorder patients **P**: 298
- pharmacodynamics **C**: 160
elderly **A**: 508–9
- pharmacokinetics **A**: 59 *T*; **C**: 160
children **A**: 484
elderly **A**: 505
- pharmacology **C**: 203
- potency **A**: 60
- procedure-related pain **C**: 217
- routes of administration/formulations **C**: 110, **C**: 160
- sedation **C**: 184
- subcutaneous drug infusion, cancer patients **P**: 127 *T*
- sublingual administration **C**: 291; **P**: 308
- tracheal administration **P**: 304
- transdermal administration **A**: 60, **A**: 207; **P**: 304
cancer related-induced neuropathic pain **C**: 203
children, cancer pain **C**: 349
elderly **C**: 367
field/disaster situations **A**: 381–2
iontophoretic delivery **A**: 207, **A**: 219
- nausea induction **C**: 191
- patient-controlled systems **A**: 207, **A**: 223; **P**: 306
respiratory effects **A**: 207
transdermal reservoir **A**: 207
- fentanyl buccal tablet **A**: 208; **P**: 308
breakthrough pain **C**: 160, **C**: 292
cancer pain **C**: 160
- ferritin **P**: 68
- fetal position, labor pain **A**: 467
- fetal stimulation, TENS
contraindication **P**: 195
- fever, dying person **C**: 394
- feverfew **Ch**: 314 *T*
- fibrinogen **P**: 69
- fibroblasts, tissue repair **A**: 528
- fibromyalgia *see* fibromyalgia syndrome (FMS)
- fibromyalgia syndrome (FMS) **Ch**: 599–613
allodynia **Ch**: 599–600, **Ch**: 604
American College of Rheumatology classification **Ch**: 600
associated conditions **Ch**: 602
persistent visceral pain and **Ch**: 42
children *see* juvenile fibromyalgia syndrome
cultural factors **Ch**: 602
diagnosis **Ch**: 600–1
epidemiology **Ch**: 602
genetics **Ch**: 603
hyperalgesia **Ch**: 599–600, **Ch**: 604
intravenous ketamine test **P**: 62
laser-evoked potentials **P**: 51
low back pain and **Ch**: 507
management **Ch**: 259–60, **Ch**: 605–6
analgesics **Ch**: 604, **Ch**: 607
antidepressants **Ch**: 607
growth hormone **Ch**: 608
nonpharmacological **Ch**: 606–7
personalized therapy **Ch**: 606
pharmacological **Ch**: 258, **Ch**: 607–8
muscle anomalies **Ch**: 603
neuroendocrine modifications **Ch**: 603–4
neuronal plasticity **Ch**: 604–5
cerebral blood flow **Ch**: 604, **Ch**: 604 *T*
diffuse noxious inhibitory control system **Ch**: 605, **Ch**: 605 *F*
pathophysiology **Ch**: 603–5
persistent musculoskeletal pain and **Ch**: 26
PET studies **P**: 90
prognosis **Ch**: 609
risk factors **Ch**: 602

- fibromyalgia syndrome (FMS)
(continued)
 sociocultural factors **Ch:** 602
 subtypes **Ch:** 601
 tender point location **Ch:** 600,
Ch: 600 *F*, **Ch:** 601
see also myofascial pain
- field/disaster situations **A:** 374–88
 acute pain service teams **A:** 384–5
 challenges **A:** 376–7
 service differences **A:** 377
 supplies **A:** 377
- combat support hospitals **A:** 376–7,
A: 376 *F*
- continuous peripheral neural
 blockade **A:** 377, **A:** 380–1,
A: 383
 definition **A:** 375–6
 deployable rapid assembly shelter and
 surgical hospital **A:** 376–7
 developed world **A:** 375
 developing world **A:** 390
 evacuation, patient condition
 for **A:** 383–4
 geography/terrain difficulties **A:** 376
 historical aspects **A:** 374–5
 morphine **A:** 375
 opium **A:** 375
 slow developments **A:** 375
- maladaptive pain **A:** 383
 medication issues **A:** 378
 military service differences **A:** 377
 multimodal analgesia **A:** 379–80
 advantages **A:** 379
 anticonvulsants **A:** 380
 NMDA antagonists **A:** 379
 NSAIDs **A:** 379
 wound packs **A:** 379
see also individual drugs
- novel pain control methods **A:** 381–3
 long-release formulations **A:** 383
 monitoring equipment **A:** 383
 patient-controlled delivery
 systems **A:** 381–2
- PCA **A:** 377, **A:** 381–2, **A:** 383
 peripheral nerve blocks **A:** 380–1
 personnel **A:** 377–8
 importance of **A:** 377
 safety provision **A:** 377
- protocols/guidelines **A:** 378–9
 evacuation changes **A:** 378–9,
A: 378 *T*
- regional anesthesia **A:** 380–1
 equipment **A:** 381, **A:** 381 *F*
 resources **A:** 377–83
 supply selection **A:** 377
 transport **A:** 376–7
- weather extremes **A:** 376
- first do no harm principle **Ch:** 100
 first pass clearance **C:** 107
 elderly **C:** 365
- fitness training, CBT **Ch:** 295–6
 Fitzgerald hypothesis **A:** 71–2
 fixation, sports injuries **A:** 529
- fixed effect model, statistics **P:** 572
- FLACC *see* Face, Legs, Arms, Cry,
 Consolability (FLACC) scale
- flecainide, cancer neuropathic
 pain **C:** 208–9
- FlexiCore Intervertebral Disk **P:** 442
- flexor reflex afferents (FRA),
 spasticity **Ch:** 440–1
- flexor spasms, spasticity
 pain **Ch:** 442–3, **Ch:** 443 *F*
- flexor tenosynovitis, soft-tissue
 injection **P:** 355–6
- “floor effect,” study
 sensitivity **Ch:** 182–3
- fluconazole, candidiasis **C:** 316–7
- flufenamic acid, sports
 injuries **A:** 533–4
- fluid intake, constipation **C:** 324
- fluid restriction, hypotension
 and **P:** 592–3
- fluid retention, NSAID-induced **C:** 135
- flunarizine, migraine
 prophylaxis **Ch:** 459–61, **Ch:** 461 *T*
 children **Ch:** 630
- fluoroscopy
 cryoanalgesia **P:** 382
 epidural steroid injections **P:** 419
- 5fluorouracil, herpes zoster **Ch:** 432
- fluoxetine **Ch:** 244 *T*
 dosage/treatment schedule **P:** 138
 fibromyalgia syndrome **Ch:** 246–7,
Ch: 607
 mechanism of action **Ch:** 246
 neuropathic pain **Ch:** 246, **Ch:** 346
 cancer patients **C:** 205
 pediatric headache **Ch:** 632
 pharmacology **Ch:** 246
- flurbiprofen **A:** 76; **Ch:** 235
- flushing, opioid-induced **A:** 57
- flvoxamine, neuropathic pain **Ch:** 346
- fMRI *see* functional magnetic resonance
 imaging (fMRI)
- focal myofascial pain, lower back
 pain **Ch:** 505
- focal neuropathic pain, topical
 lidocaine **Ch:** 233
- focal spasticity **Ch:** 441–2
 cerebral origin **Ch:** 441–2
 general spasticity *vs.* **Ch:** 441–2
 pain management **Ch:** 446–7
- surgery **Ch:** 447
- follicle-stimulating hormone (FSH),
 ovarian remnant
 syndrome **Ch:** 577
- follow-up completeness, clinical trial
 quality assessment **P:** 571
- food allergies, rheumatoid
 arthritis **Ch:** 525
- Food and Drug Administration (FDA)
 herbal medicines **Ch:** 313
 topical analgesics **Ch:** 231
 website **P:** 564
- food avoidance, interstitial
 cystitis **Ch:** 557
- food diaries, functional abdominal
 pain **Ch:** 634
- foot
 posturing, spasticity **Ch:** 442
 soft-tissue injection **P:** 357
- foot pain **A:** 441
 clinical features **A:** 441
 investigations **A:** 441
 management **A:** 441
 spasticity **Ch:** 442
- foramen sphenopalatinum **P:** 394
- foraminal stenosis **P:** 418
- forearm fractures **A:** 367–8
 hematoma block **A:** 367–8
 reduction anesthesia **A:** 368
- forearm soft-tissue
 disorders **Ch:** 529–30
 diagnosis **Ch:** 529–30
 epidemiology **Ch:** 529–30
 occupation **Ch:** 529
 prevalence **Ch:** 529–30
 treatment **Ch:** 530
see also individual disorders
- foreign body removal,
 epiduroscopy **P:** 435
- FP10 **C:** 414
- fracktalkine **Ch:** 14
- fracture(s)
 fixation **A:** 529
 healing **A:** 528
 immobilization **A:** 532
 limb bones **A:** 528
 lumbar spine diseases/
 disorders **A:** 446
 neck pain **Ch:** 488
 radiography *see* radiography
 reduction **A:** 367
 children **A:** 367
 nonpharmacological
 methods **A:** 367
 spinal pain **Ch:** 156
 stress **A:** 529–30; **Ch:** 149
 transverse **A:** 528

- whiplash **Ch:** 489
see also individual fractures
- French-Language Society of Pediatric Anesthesiologists, pediatric APS data **P:** 644–5
- frontal cortex, neuropathic pain imaging **Ch:** 16
- frontal lobe, pain perception **P:** 146
- frontal-posterior neck placement **P:** 163
- frovatriptan, migraine **Ch:** 460 *T*
- frozen shoulder *see* adhesive capsulitis (frozen shoulder)
- frustration, chronic pain **Ch:** 293
- full thickness burns **A:** 400
- full thickness skin wounding **A:** 44
- functional abdominal pain (FAP) **Ch:** 633–5
 diagnosis **Ch:** 633–4
 warning signs **Ch:** 633
- food diaries **Ch:** 634
- lactose intolerance **Ch:** 634
- prevalence **Ch:** 633
- psychological symptoms **Ch:** 634
- symptom remission **Ch:** 633
- treatment **Ch:** 634–5
 acupuncture **Ch:** 635
 dietary changes **Ch:** 634
 pharmacological **Ch:** 634
 psychological interventions **Ch:** 634
- Functional Activity Scale (FAS) **A:** 138, **A:** 148
 advantages **A:** 148
 disadvantages **A:** 148
 dynamic analgesia **P:** 589
- functional bowel disorders (FBD) **A:** 44
- Functional Capacity Evaluation (FCE) **Ch:** 119–20
- functional contextualism **P:** 168
- Functional Disability Inventory (FDI), pediatric chronic pain **P:** 455–6
- functional imaging **P:** 84, **P:** 84 *F*
 depression **Ch:** 242–3
 persistent visceral pain **Ch:** 40–1
- functional magnetic resonance imaging (fMRI) **P:** 84
 blood oxygen level dependent (BOLD) **P:** 85, **P:** 85 *F*, **P:** 86 *F*
 cognitive impairment **A:** 511–2
 CRPS **Ch:** 367–8
 fibromyalgia syndrome **Ch:** 604
 guided imagery **A:** 316
 hypnosis **A:** 315
 movement disorders **Ch:** 367
 neck pain **Ch:** 492
 nociception **A:** 13–4, **A:** 13 *F*
 pain intensity-stimulus intensity findings **A:** 292
- placebo effect **P:** 506
- positron emission tomography *vs.* **P:** 87 *T*
- functional restoration programs **P:** 658
- functioning, definition **P:** 221
- funicular pain, spinal cord compression **C:** 30
- funnel plot, publication bias **P:** 574
- furosemide **C:** 314
- futility, clinical trials **P:** 562
- GABA
 neuropathic pain **Ch:** 12–3
 nociception modulation **A:** 15
 peripheral nerve injury **Ch:** 12
 TENS **A:** 275
- GABA A agonists
 neurotoxicity **Ch:** 288
 spinal administration **Ch:** 287–8
- GABA_A receptor, postnatal development **A:** 34 *T*, **A:** 35–6
- GABA B agonists, spinal administration **Ch:** 287
- gabapentin **Ch:** 256 *T*, **Ch:** 257–8
 adverse effects **A:** 103; **Ch:** 257 *T*, **Ch:** 260, **Ch:** 394; **P:** 137
 applications **A:** 164
 burn pain **A:** 400–1, **A:** 403–4
 cancer-induced bone pain **C:** 5
 central neuropathic pain **Ch:** 379–82 *T*
 chemotherapy-induced peripheral neuropathy **C:** 8–9, **C:** 402
 chronic masticatory neuralgia **Ch:** 257 *T*
 combination therapies **Ch:** 260
 contraindications **P:** 135
 CPSP prevention **A:** 565
 CRPS **Ch:** 369
 diabetic neuropathy **Ch:** 257–8, **Ch:** 257 *T*
 dosage/treatment schedule **Ch:** 257 *T*; **P:** 136
 efficacy **Ch:** 257 *T*, **Ch:** 260
 elderly **A:** 516; **Ch:** 647
 fibromyalgia syndrome **Ch:** 257 *T*, **Ch:** 258
 field/disaster situations **A:** 380
 Guillain-Barré syndrome **A:** 411–2; **Ch:** 258
 HIV-associated neuropathic pain **Ch:** 356
 HIV-related peripheral neuropathy **A:** 413
 interactions **Ch:** 260
 mechanism of action **A:** 164; **Ch:** 346
 metabolism **P:** 135
- morphine and **Ch:** 258
- neurologic disease pain **Ch:** 330
- neuropathic pain **Ch:** 257 *T*
 amitriptyline *vs.* **Ch:** 345
 cancer patients **C:** 206, **C:** 207
 clinical trials, sample size **P:** 554
 orofacial **Ch:** 472
 peripheral **Ch:** 345 *T*, **Ch:** 346
 non-neuropathic pain **Ch:** 258
- opioids and **Ch:** 213
 opioid-tolerant patients **A:** 549
- pediatric headache **Ch:** 632, **Ch:** 633 *T*
- perioperative use **A:** 104
- peripheral nociceptor sensitization **Ch:** 29
- pharmacokinetics **A:** 103 *T*; **Ch:** 257
- pharmacology **Ch:** 257
- porphyria **A:** 422
- postamputation pain **Ch:** 423
- postbreast cancer surgery pain **C:** 404–5
- postherpetic neuralgia **Ch:** 257, **Ch:** 257 *T*, **Ch:** 258, **Ch:** 433, **Ch:** 434 *T*
 dosages **Ch:** 434 *T*
- postoperative pain management **A:** 335
- preventive analgesia **A:** 164–8
 doses **A:** 168
 studies **A:** 159 *F*
- pruritus, cancer patients **C:** 330
- spinal cord injury **Ch:** 257 *T*, **Ch:** 258, **Ch:** 380, **Ch:** 394, **Ch:** 396 *T*
- vulvodynia **Ch:** 590
- galanin
 joint innervation **Ch:** 26
 peripheral nociceptor sensitization **Ch:** 10, **Ch:** 29
- galanin, nociception modulation **A:** 17
- gallium nitrate **C:** 321
- gamma-aminobutyric acid (GABA) *see* GABA
- ganglion impar block **C:** 230; **P:** 345
 superior hypogastric plexus block *vs.* **P:** 345
- garlic **Ch:** 314 *T*
- gas-driven constant flow pumps, intrathecal drug delivery **P:** 371
- gas exchange, dyspnea **C:** 311
- Gasserian ganglion **P:** 392
 radiofrequency lesioning **P:** 392–4
 applied anatomy **P:** 392–3
 complications **P:** 394
 general anesthesia **P:** 393
 historical aspects **P:** 392
 indications **P:** 393
 patient discomfort **P:** 394

- Gasserian ganglion (*continued*)
 results **P:** 394
 side effects **P:** 394
 technique **P:** 393–4, **P:** 393 *F*
 tunnel-vision technique **P:** 393
- gastric emptying times,
 prolonged **C:** 108
- gastric erosions,
 NSAID-induced **C:** 128–9
Helicobacter pylori **C:** 128
- gastric outlet obstruction **C:** 318
- gastric stasis, opioid-induced **P:** 129
- gastric ulcers **Ch:** 565
- gastritis **Ch:** 42
- gastroenterological pain
 chronic pelvic pain **Ch:** 573 *T*,
Ch: 579
 HIV infection **Ch:** 358–9
- gastroesophageal reflux disease **Ch:** 543
- gastrointestinal bleeding
 aspirin-induced **C:** 129
 NSAID-induced **C:** 129
 paracetamol-induced **C:** 125
- gastrointestinal surgery, neuraxial
 analgesia **A:** 263–4
- gastrointestinal system
 COX-2 selective agent adverse
 effects **A:** 71
 drug absorption **P:** 304
 ibuprofen adverse effects **A:** 76–7
 nonpain-related symptom control,
 cancer patients **C:** 316–7
 NSAIDs adverse effects *see* NSAID-
 induced gastrointestinal effects
 opioid-induced effects **C:** 155, **C:** 189;
P: 110
 paracetamol adverse effects **Ch:** 201
- gastrointestinal ulcers,
 NSAID-induced **A:** 70–1; **Ch:** 196
- gate control theory of pain
 descending inhibition **P:** 146
 manual medicine **P:** 235
 neurostimulation **Ch:** 269
 nociception **A:** 15 *F*, **A:** 17
 SCS **P:** 405
 TENS stimulation **P:** 194
- gating function, nociception **A:** 13–4
- gender
 acute postoperative pain **A:** 157
 CPSP **A:** 157
 low back pain **A:** 447
 NSAID-induced gastrointestinal
 effects **C:** 131 *T*
 pain definition **Ch:** 91
 pain perception **P:** 13
 pediatric CRPS **Ch:** 626
 tension-type headache **Ch:** 452
- gene expression, peripheral
 sensitization **A:** 21
- gene expression analysis **Ch:** 57–9
 microarrays *see* microarrays
 quantitative PCR **Ch:** 57
 RNA expression **Ch:** 59
- gene polymorphisms, mu opioid
 receptors **A:** 54
- general anesthesia
 burn pain **A:** 404
 children, CBT *vs.* **C:** 306
 Gasserian ganglion radiofrequency
 lesioning **P:** 393
 local anesthetic procedures,
 children **P:** 469
- generalized anxiety disorder, chronic
 pain **Ch:** 170, **Ch:** 616–7
- general spasticity *see* spasticity/
 spasticity pain
- genes **Ch:** 49
 coding region **Ch:** 49–51
 exons **Ch:** 49–51
 expression **Ch:** 49–51
 heterozygosity **Ch:** 49
 homozygosity **Ch:** 49
 organization **Ch:** 49, **Ch:** 52 *F*
 promoter region **Ch:** 49
- genetic markers, pain diagnosis **P:** 70–1
- genetics **Ch:** 48–64
 chronic pancreatitis **Ch:** 553
 complex multifactorial
 disorders **Ch:** 53, **Ch:** 60,
Ch: 61 *T*
 environmental effects **Ch:** 53
 familial clustering **Ch:** 53, **Ch:** 60–1
- cosegregating gene
 identification **Ch:** 55–7
- CPSP **A:** 561
- elderly patient pain **Ch:** 642–3
- epidemiology **Ch:** 55
- fibromyalgia syndrome **Ch:** 603
- heritability evidence **Ch:** 55
- historical aspects **Ch:** 87
- human diversity **Ch:** 51–3
- inheritance patterns **Ch:** 55
 segregation analysis **Ch:** 55
- methods/techniques **Ch:** 62 *T*, **Ch:** 63;
see also individual techniques
- mitochondria genome **Ch:** 49
- opioid addiction risk **Ch:** 654
- pain sensitivity **Ch:** 56 *T*, **Ch:** 60
- phantom pain **Ch:** 418
- phenotype, definition **Ch:** 53
- studies **Ch:** 53–7
 experimental **Ch:** 53–5, **Ch:** 56 *T*
 observational **Ch:** 53–5, **Ch:** 56 *T*
 study approaches **Ch:** 53–7
- systems biology **Ch:** 60
 transcription **Ch:** 49, **Ch:** 50 *F*
- genetic tests, hereditary
 neuropathies **P:** 79
- genitofemoral nerve **P:** 278
 chronic pelvic pain **Ch:** 581
- genitofemoral nerve block **P:** 278–9
 anatomy **P:** 278
 children **P:** 470
 complications **P:** 279
 indications **P:** 278
 landmarks **P:** 278
 practical steps/technique **P:** 278,
P: 279 *F*
- genitofemoral neuralgia,
 block-induced **P:** 333, **P:** 334 *F*
- genomaps, psychological
 evaluation **C:** 51
- genome, definition **Ch:** 48–9
- Geriatric Pain Measure **P:** 20
- Geriatric Research Education Clinical
 Center (GRECC) **A:** 145–6
- German Commission E, herbal
 medicine **Ch:** 313
- germander **Ch:** 315 *T*
- ghrelin **C:** 328
- ginger **Ch:** 314 *T*
- ginkgo **Ch:** 314 *T*
- girdle zone spinal pain *see* spinal cord
 injury (SCI) pain, at-level
 neuropathic pain
- glial cell(s)
 activation **A:** 27
 neuropathic pain **Ch:** 13
- glial-derived neurotrophic factor
 (GDNF), peripheral nerve
 injury **Ch:** 9
- gliomas **C:** 252–3
- Global Year Against Pain **P:** 655
- Global Year Against Pain in Older
 Persons **P:** 655
- glove anesthesia technique **C:** 300–1
- glucocorticoid(s), postoperative pain
 management **A:** 334
- glucosamine sulfate,
 osteoarthritis **Ch:** 527
- glutamate, nociception **A:** 9–10; **Ch:** 12
- glutamate receptor(s), postnatal
 development **A:** 33
- glutamate receptor antagonists **Ch:** 232
- glutamine, chemotherapy-induced
 peripheral neuropathy **C:** 402
- glutathione, chemotherapy-induced
 peripheral neuropathy **C:** 402
- gluteus medius tendon tears **P:** 356
- glycerol neurolysis **C:** 228, **C:** 228 *T*;
P: 337–8

- trigeminal ganglion **P**: 344
glycine, nociception modulation **A**: 15;
Ch: 12–3
NMDA receptors **Ch**: 12
glycine receptor, postnatal
development **A**: 34 *T*, **A**: 35–6
P-glycoprotein, cerebral drug
uptake **A**: 507
P-glycoprotein, opioid response
variability **C**: 170–3
glycopyrronium bromide **C**: 335
goal attainment scaling,
physiotherapy **P**: 226
goal setting, CBT **Ch**: 295
goal-setting charts,
physiotherapy **P**: 226
The Goals of Medicine - Setting New
Priorities **Ch**: 101
golfer's elbow *see* medial epicondylitis
Go Medical patient-controlled
intranasal analgesia device **P**: 307,
P: 308 *F*, **P**: 308 *T*
gonadotropin-releasing hormone
(GnRH) agonists
chronic pelvic pain, cyclic **Ch**: 584
endometriosis **Ch**: 575–6
ovarian remnant syndrome **Ch**: 577–8
Good Clinical Practice (GCP)
Guidelines, clinical trials **P**: 554
gout **A**: 434
government policy
cancer pain management **C**: 82
opioid availability, developing
world **A**: 392
G-protein coupled receptors (GPCRs)
dorsal horn plasticity **A**: 25–6
intracellular signaling **A**: 22
somatic nociceptors **A**: 6
graded activity, graded exposure *in vivo*
vs. **P**: 179, **P**: 186
graded exposure *in vivo*, pain-related
fear **P**: 177–90
behavioral experiments **P**: 184
case illustrations **P**: 183 *T*,
P: 185
complicating factors **P**: 186
increased pain **P**: 186, **P**: 186 *F*
maintenance of change **P**: 186
education **P**: 183–4
effectiveness **P**: 186–7, **P**: 187 *F*
at home activities **P**: 186–7
exposure **P**: 184
fear-avoidance model
explanation **P**: 183–4
graded activity *vs.* **P**: 179, **P**: 186
systematic desensitization **P**: 184
technique **P**: 184–6
grand mal seizures, stellate ganglion
block-induced **P**: 329
granisetron **C**: 320 *T*
granulation tissue, tissue healing/
repair **A**: 528
grapeseed extract **Ch**: 314 *T*
graphic rating scale (GRS) *see* verbal
rating scale (VRS)
greater auricular nerve (GAN) **P**: 383
greater occipital nerve **P**: 259, **P**: 383
groin pain **Ch**: 549–69
cryoanalgesia **P**: 386–7
etiology **Ch**: 549–51
see also individual diseases/disorders
group psychotherapy, distress **C**: 303
growth factors
cancer-induced bone pain **C**: 5
peripheral nerve injury **Ch**: 9
growth hormone (GH), fibromyalgia
syndrome **Ch**: 603, **Ch**: 608
guanethidine, intravenous regional
sympathetic block **P**: 333
duration **P**: 334
local anesthetics and **P**: 333
guanine **Ch**: 49
guided imagery
cancer pain **C**: 277, **C**: 299–300
children **A**: 316–7
evidence **A**: 316–7
fMRI **A**: 316
relaxation techniques **A**: 316
success **A**: 316
techniques **A**: 316
mindfulness *vs.* **P**: 170
*Guidelines for the Assessment of Herbal
Medicine* **Ch**: 313
Guidelines for the provision of
anesthetic services **P**: 667–8
Guillain-Barré syndrome
acute pain **A**: 411–2
chronic pain **Ch**: 327
comfort measures **A**: 412
definition **A**: 411
disease-modifying therapy **A**: 412
etiology **Ch**: 335, **Ch**: 342
headache **A**: 412
ICUs **A**: 352
pain descriptions **A**: 411;
Ch: 327
gut transit time **C**: 323
gynecologic pain
cyclic **Ch**: 572, **Ch**: 573 *T*
HIV-associated **Ch**: 359
noncyclic **Ch**: 573 *T*,
Ch: 578–9
physical examination **Ch**: 583
see also chronic pelvic pain (CPP)
H1 antihistamines **C**: 330
H2 blockers **C**: 133
habituation, manual medicine **P**: 236
Hahnemann, Samuel **Ch**: 310–1
haloperidol
delirium **C**: 187, **C**: 334
migraine **A**: 366
nausea and vomiting **C**: 191, **C**: 320 *T*
opioid-induced bowel
dysfunction **P**: 129
hamstring tear (ischial enthesitis), soft-
tissue injection **P**: 356
hand, soft-tissue injection **P**: 355–6
hands-on care provision, family
caregiver **C**: 67 *T*
harm, clinical trials **P**: 562
Harm Scale **P**: 180
Hawthorne effect **P**: 502
hazard rate ratio, depression **Ch**: 241–2
hazard ratio (HR) **P**: 572
H channel (*HCN* gene) **Ch**: 9
HCN gene (H channel) **Ch**: 9
headache **Ch**: 450–66
base of skull metastases **C**: 29–30,
C: 31 *T*
biofeedback **P**: 486
case example **P**: 488–9
cervicogenic **P**: 396
children *see* pediatric headache
classification **Ch**: 450–1
clinical features **Ch**: 452
cluster *see* cluster headache
diagnosis **Ch**: 454–5
imaging **Ch**: 454
differential diagnosis **Ch**: 454,
Ch: 454 *T*
epidemiology **Ch**: 451–2
Guillain-Barré syndrome **A**: 412
HIV patients **Ch**: 357–8, **Ch**: 358 *T*
meningeal carcinomatosis **C**: 32
orthostatic **Ch**: 455
pathophysiology **Ch**: 452–4
postdural puncture **P**: 422
primary **Ch**: 450
prophylaxis **Ch**: 459–62
radiotherapy **C**: 252–3
secondary **Ch**: 450
tension-type *see* tension-type
headache (TTH)
treatment **Ch**: 202, **Ch**: 455
acute episodes **Ch**: 455–7
nonpharmacological **Ch**: 462
see also individual drugs
see also migraine
head and neck
chronic pain syndromes **P**: 383
myofascial trigger points **P**: 210 *F*

- head and neck (*continued*)
 peripheral nerve blocks **P**: 258–64
- healing *see* therapeutic touch (healing)
- healthcare costs, substance abuse/
 misuse **Ch**: 653
- healthcare delivery systems
 pain and **P**: 654–62
 third-party payers **P**: 659
 treatment “carve out” practices **P**: 659
 clinical outcomes **P**: 659
- healthcare organizations
 education **P**: 658–9
 pain and **P**: 654–62
- healthcare professionals/providers
 chronic pain development
 beliefs **A**: 296
 decision-making, cancer pain **C**: 96
 education **P**: 658–9
 analgesic drug use **C**: 82
 pain control issues **C**: 94
 PCA **A**: 221
 postoperative pain
 preventability **A**: 297
 elderly cancer pain control, attitudes
 to **C**: 362–3
 ethical issues, cancer pain **C**: 97
 opioid use fears **C**: 115
 postoperative pain, influences
 on **A**: 295
 postoperative pain
 underestimation **A**: 295
 safety provision, field/disaster
 situations **A**: 377
- healthcare records, opioid addiction
 risk **Ch**: 655
- health-related quality of life, clinical
 trials outcomes **P**: 523
- heart, innervation **Ch**: 538–9
- heart rate, biofeedback **P**: 487 *T*
- heat
 chronic lower back pain
 treatment **Ch**: 509–10
 transient receptor potential ion
 channel V1 **Ch**: 9
see also entries beginning *thermal*
- heat-foil technology, thermal
 stimulation **P**: 52–3, **P**: 52 *F*
- heat hyperalgesia, neuropathic
 pain **Ch**: 135, **Ch**: 141 *T*
- heat pain
 ex-neonatal ICU patients **A**: 43
 thermotest **P**: 48–9, **P**: 49 *F*
- heat therapy
 sickle cell disease pain **A**: 421
see also cryotherapy
- heat wrap therapy **P**: 224
- heavy metal neuropathy **Ch**: 151 *T*
- Helicobacter pylori*, NSAID-induced
 gastric erosions **C**: 128
- helium/oxygen mixtures,
 dyspnea **C**: 314
- helplessness **P**: 145
- hemarthrosis **A**: 436
- hematological disorders, acute pain
 and **A**: 419–22
- hematological malignancy,
 children **C**: 346
- hematoma
 cervical, stellate ganglion
 block-induced **P**: 329
 cryoanalgesia complication **P**: 386
 epidural *see* epidural hematoma
 SCS-induced **P**: 411
- hematoma block, forearm
 fractures **A**: 367–8
- hematuria syndrome **Ch**: 564–5
- heme arginate, porphyria **A**: 421
- hemibody radiotherapy, bone pain *see*
 wide field irradiation, bone pain
- hemochromatosis **P**: 68
- hemoglobin, functional magnetic
 resonance imaging **P**: 85, **P**: 85 *F*
- hemophilia **A**: 419
 continuous peripheral neural
 blockade **A**: 242
 factor VIII replacement **A**: 419
- hemophilia A **A**: 419
- hemophilia B **A**: 419
- hemoptysis **C**: 315
- hemostasis
 epidural blocks **A**: 349–50
 NSAID-induced **A**: 72
- heparin
 epidural analgesia
 contraindication **A**: 518
 interstitial cystitis **Ch**: 557
- hepatic drug clearance **C**: 108
 elderly **A**: 508
- hepatic pain
 cancer-induced **C**: 35
 hemorrhage **C**: 35
 radiotherapy **C**: 253
 toxicity **C**: 253
- hepatitis C, HIV-associated
 musculoskeletal pain **Ch**: 357
- hepatomegaly, cancer patients **C**: 35
- hepatotoxicity, paracetamol **A**: 332–3,
A: 482
- herbal medicine **Ch**: 313–5
 adverse effects **Ch**: 313–5
 antitumor potential **C**: 274
 applications **Ch**: 313–5
 cancer patients **C**: 274–5
 category I herbs **Ch**: 314 *T*
- historical aspects **Ch**: 313
- history taking **P**: 5–6
- preparation quality **C**: 275
- prevalence **Ch**: 313
- side effects **C**: 275
- unsafe agents **Ch**: 315 *T*
see also *individual medicines*
- hereditary coproporphyrria **Ch**: 562–3
- hereditary erythromelalgia **Ch**: 342
- hereditary neuropathies **Ch**: 342; **P**: 79
- hereditary sensory and autonomic
 neuropathy (HSAN) type
 I **Ch**: 342; **P**: 79
- hereditary sensory and autonomic
 neuropathy (HSAN) type
 IV **Ch**: 344
- hereditary sensory and autonomic
 neuropathy (HSAN) type
 V **Ch**: 344
- hernia(s)
 chronic pelvic pain **Ch**: 579
 intervertebral discs *see* intervertebral
 discs, herniation
 Spigelian **Ch**: 579
- hernia repair (herniorrhaphy)
 children **A**: 489
 inguinal blocks **A**: 490
 local anesthetics **A**: 489
 CPSP **Ch**: 408–9
 age-related **A**: 560–1
 incidence **A**: 559 *T*, **A**: 560–1
 laparoscopic vs. open **A**: 562
 preoperative pain effects **A**: 562
 recurrent hernia **A**: 562–3
- herniorrhaphy *see* hernia repair
 (herniorrhaphy)
- heroin *see* diamorphine
- herpes simplex virus infection, HIV-
 associated anorectal pain **Ch**: 359
- herpes zoster **Ch**: 429–39
 acute, management **Ch**: 433
 complications **Ch**: 430
 costs **Ch**: 431
 diagnosis **Ch**: 431
 disease course **Ch**: 430 *F*
 elderly patients **Ch**: 430–1, **Ch**: 436
 epidemiology **Ch**: 430–1
 HIV infection **Ch**: 357
 latency **Ch**: 429–30
 management **Ch**: 432–3
 antiviral drugs **Ch**: 432, **Ch**: 433
 guidelines **Ch**: 435–6, **Ch**: 436 *T*
 local anesthetic blocks **Ch**: 432
 pain phases **Ch**: 431
 chronic *see* postherpetic neuralgia
 (PHN)
 prevention **Ch**: 431–2

- prodrome management **Ch:** 432
see also postherpetic neuralgia (PHN)
- herpetic infections, oral **C:** 317
- heterotopic bone formation, NSAIDs **A:** 70
- heterozygosity, genes **Ch:** 49
- high-density genome-wide screening, chronic pain epidemiology **Ch:** 71
- highly active antiretroviral treatment (HAART) **Ch:** 352
- highly selective COX-2 inhibitors *see* cyclooxygenase 2 (COX-2) selective inhibitors
- high-molecular weight dextrans, local anesthetics and **A:** 119
- high thoracic epidural anesthesia (HTEA), refractory angina pectoris **Ch:** 540
- high-threshold receptor stimulation, acupuncture **A:** 280–1
- hip (joint)
 anatomy **P:** 353
 intra-articular injection **P:** 353
 myofascial trigger points **P:** 212 *F*
 osteoarthritis **Ch:** 526; **P:** 353
 pain, acute **A:** 439
 soft-tissue injection **P:** 356
- hip adductor spasticity **Ch:** 443
- hip arthroplasty, NSAIDs **Ch:** 199
- hip joint disease **Ch:** 505
- hip replacement surgery
 CPSP **Ch:** 406–7
 femoral nerve blocks **A:** 241
 neuraxial analgesia **A:** 264
 three-in-one blocks **A:** 240
- histamine H2 receptor antagonists (H2RAs) **A:** 71
- histone protein complexes **Ch:** 49
- history-taking
 acute pain *see* acute pain
 cancer pain *see* cancer pain
 chronic pain *see* chronic pain
 expert opinion *see* expert medicolegal report
- HIV-associated pain **Ch:** 352–61
 abdominal **Ch:** 358
 acute **A:** 412–3
 disease-specific therapy **A:** 413
 drug interactions **A:** 413
 etiology **A:** 412
 multiple sites **A:** 412
 presentation **A:** 412
 treatment **A:** 413
 under-treatment **A:** 413
 anorectal **Ch:** 359
- antiretroviral toxic neuropathy *see* antiretroviral toxic neuropathy (ATN)
- causes **Ch:** 354
- classification **Ch:** 354
- diffuse infiltrative
 lymphocytosis **Ch:** 357
- esophageal **Ch:** 358, **Ch:** 359 *T*
- exclusion diagnosis **Ch:** 356
- gastroenterological **Ch:** 358–9
- gynecological **Ch:** 359
- headaches **Ch:** 357–8, **Ch:** 358 *T*
- herpes zoster infection **Ch:** 357
- immunological status **Ch:** 356
- locality **Ch:** 353–4
- mononeuritis multiplex **Ch:** 342, **Ch:** 357
- musculoskeletal **Ch:** 357
- neuropathic **Ch:** 342, **Ch:** 354–6, **Ch:** 355
 as clinical trial model **P:** 558
 models **Ch:** 5–6
- oral **Ch:** 358, **Ch:** 359 *T*
- patient assessment **Ch:** 356–7
- poor recognition of **Ch:** 354
- prevalence **Ch:** 353, **Ch:** 353–4
- radiculopathy **Ch:** 357
- treatment **Ch:** 353–4, **Ch:** 356–7
 barriers to **Ch:** 354
- HIV gp120, distal symmetrical polyneuropathy **Ch:** 355
- HIV infection
 antiretroviral treatment **Ch:** 353, **Ch:** 353 *T*
 CD4 T-cells **Ch:** 352–3
 characteristics **Ch:** 352
 immunosuppression **Ch:** 352–3
 mortality **Ch:** 352
 pain in *see* HIV-associated pain
see also AIDS
- HMG CoA reductase inhibitors (statins), rheumatoid arthritis **Ch:** 524
- holistic assessment framework **C:** 51 *F*
- holistic medicine *see* complementary and alternative medicine (CAM)
- homecare service, palliative care
 India **C:** 87
 Middle East **C:** 87
- home care team (HCT) **C:** 418
- home environment, pain management
 difficulties **C:** 66, **C:** 66 *T*
- homeopathy **Ch:** 310–1
 cancer pain **C:** 275
 fibromyalgia syndrome
 management **Ch:** 607
 historical aspects **Ch:** 310–1; **C:** 275
- research **Ch:** 311
 risks **Ch:** 311
- homozygosity **Ch:** 49
- honey, burn wound dressings **A:** 405
- hormone analyses **P:** 68
- hormone therapy
 bone pain **C:** 265–6
 ovarian remnant syndrome **Ch:** 577–8
- Horner's syndrome
 stellate ganglion block sign **P:** 329
 vertebral metastases **C:** 28–9
- hospice movement development **C:** 85, **C:** 412
 Africa **C:** 88–9
 poorer countries **C:** 85
- Hospital Anxiety and Depression Scale (HADS)
 cancer patients **C:** 39, **C:** 56–7
 chest pain **Ch:** 538
 quality of life effects **Ch:** 79
- hot flashes *see* hot flushes
- hot flushes
 acupuncture **C:** 274
 cancer patients
 clinical findings **C:** 331
 management **C:** 331
- 5-HT receptors *see* serotonin receptor(s)
- Human Genome Project **Ch:** 49
 chronic pain epidemiology **Ch:** 70
- human immunodeficiency virus (HIV) *see* HIV infection
- human leukocyte antigen-B27 (HLA-B27) **P:** 70–1
 spondylarthropathies
P: 70–1
- humeral epicondylitis *see* lateral epicondylitis
- humidity, pain perception **P:** 13–4
- Hunner's ulcers **Ch:** 556
- Hurwitz, William **Ch:** 111
- hyaluronan injections,
 osteoarthritis **Ch:** 527; **P:** 359
- hyaluronidase, local anesthetic additive **A:** 119
- hydration
 opioid-induced delirium **C:** 187
 pediatric headache **Ch:** 630
- hydrocele **Ch:** 563
- hydrocodone, children **A:** 485; **P:** 466 *T*, **P:** 468
 administration **A:** 485
 adverse effects **A:** 485
 pharmacokinetics **A:** 485
- hydrocortisone
 epidural injections **P:** 419
 osteoarthritis **Ch:** 527

- hydrodistension, interstitial
cystitis **Ch:** 557
- hydrogels, rectal drug
administration **A:** 204
- hydromorphone **A:** 60; **C:** 161, **C:** 169 *T*
adverse effects **A:** 485; **C:** 161
breakthrough pain **C:** 291
cancer patients **C:** 161; **P:** 127
children **A:** 484–5; **C:** 349, **C:** 352 *T*;
P: 466 *T*, **P:** 468
headache **Ch:** 631, **Ch:** 632 *T*
elderly **C:** 368
equianalgesic doses **A:** 547 *T*
intranasal administration **A:** 208 *T*
pharmacodynamics **C:** 161
pharmacokinetics **A:** 59 *T*; **C:** 161
children **A:** 484
routes of administration/
formulations **A:** 60; **C:** 161
children **A:** 484
spinal administration **Ch:** 286–7
subcutaneous drug infusion, cancer
patients **P:** 127 *T*
- hydronephrosis, unilateral **A:** 44
- hydrophilic opioids **A:** 257; **Ch:** 286
- hydroxychloroquine, rheumatoid
arthritis **Ch:** 522–4 *T*
- 5-hydroxytryptamine receptors *see*
serotonin receptor(s)
- hydroxyzine, pediatric
headache **Ch:** 631 *T*
- hygiene, spasticity pain **Ch:** 443
- hyoscine butylbromide
end of life care **C:** 335
renal colic **A:** 364, **A:** 415
- hyoscine hydrobromate **C:** 191,
C: 320 *T*
- hyoscine hydrobromide **C:** 335
- hyperalgesia
C fibers **A:** 39
CPSP **A:** 560; **Ch:** 407
cryoanalgesia-induced **P:** 381
definition **A:** 20–1, **A:** 21 *F*; **Ch:** 135,
Ch: 375; **P:** 44
descending modulation **A:** 27
fibromyalgia syndrome **Ch:** 599–600,
Ch: 604
history-taking **P:** 8
neuropathic pain *see* neuropathic pain
opioid-induced *see* opioid-induced
hyperalgesia (OIH)
peripheral neuropathies **Ch:** 336
primary **A:** 21
burn pain **A:** 400
residual limb pain **Ch:** 419
secondary **A:** 21
burn pain **A:** 400–1
- persistent musculoskeletal
pain **Ch:** 30
- persistent visceral pain **Ch:** 37–8
secondary testing **P:** 47–8
vibration **P:** 48
- hyperbaric oxygen therapy, sports
injuries **A:** 537
- hypercalcemia, cancer
patients **C:** 319–21
management **C:** 319–21
symptoms **C:** 319
- hyperesthesia,
postsympathectomy **P:** 333
- hyperexcitability, spasticity **Ch:** 441
- hyperhidrosis, postsympathectomy
pain **P:** 322–3
- hyperkalemia, NSAID-induced **A:** 71
- hyperkinetic movement
disorders **Ch:** 327, **Ch:** 328–9
classification **Ch:** 328
- hypermobility, juvenile fibromyalgia
syndrome **Ch:** 625
- hyperoxaluria, vulvodinia **Ch:** 591
- hyperpathia **Ch:** 135; **P:** 8
- hypersensitivity reactions,
NSAID-induced **Ch:** 198
- hypertension, NSAID-induced **C:** 135
- hyperthermia, therapeutic **C:** 231–2
- hypertonic solution neurolysis **C:** 228
- hyperventilation **C:** 311
- hypnoanalgesia
children **P:** 483–4
case example **P:** 484
endorphins in **P:** 492
pain switch/magic glove
technique **P:** 483
- hypnosis **P:** 147–8
acute pain **A:** 299
analgesia mechanisms **P:** 149
burn pain **A:** 404
cancer pain **C:** 275–7, **C:** 299–300
efficacy **C:** 301–2
elderly **C:** 369–70
individual studies **C:** 301, **C:** 305
non-pain symptoms **C:** 276
systemic reviews/meta-
analyses **C:** 301–2, **C:** 305
cerebral bloodflow changes **P:** 492
children **A:** 315–6; **P:** 148–9, **P:** 482–5
acute procedural pain **P:** 483
cancer pain **C:** 304–5, **C:** 305,
C: 347
contraindications **P:** 493
direct suggestions **C:** 304
distraction *vs.* **P:** 148–9
emergency situations **P:** 484
hypnoanalgesia *see* hypnoanalgesia
- indirect suggestions **C:** 305
individual variation **A:** 315–6
i.v. pain **P:** 484–5
neodissociative model **A:** 315
postoperative pain **A:** 315–6
preschool age **P:** 484–5
procedure-related pain **C:** 276,
C: 305
school-age **P:** 485
self-management **P:** 148–9
social-cognitive model **A:** 315
success criterion **P:** 483–4
suitability **A:** 315
techniques **A:** 315; **C:** 304–5
components **C:** 300
controlled dissociation **P:** 147
definitions **A:** 299; **C:** 275, **C:** 299;
P: 480 *T*, **P:** 482–3
goals **P:** 482
mechanism of action **C:** 276–7; **P:** 492
midazolam *vs.* **P:** 483
muscle relaxation **P:** 147
nomenclature confusion **C:** 276
not fighting pain techniques **P:** 147–8
pain relief aims **C:** 275
pain treatment components **P:** 148
perceptual alteration **P:** 147
postamputation pain **Ch:** 423–4
procedure-related pain **C:** 216
side effects **C:** 276, **C:** 302
stages **P:** 482 *T*
states **P:** 146
subject's hypnotic ability **P:** 147
“switch off” of pain perception **P:** 147
techniques **C:** 300–1
temperature metaphors **P:** 147
- hypnotic drugs, fibromyalgia
syndrome **Ch:** 608
- hypnotic imagery, painful
procedures **P:** 148
- hypnotic responsiveness **C:** 300
- hypnotic suggestibility **C:** 300
- hypnotic trance state **P:** 482
adolescents **P:** 485
- hypnotizability **C:** 300
- hypocarbica, labor pain **A:** 465
- hypochondriacal disorder **Ch:** 619
- hypoesthesia, residual limb
pain **Ch:** 419
- hypogastric nerve, inferior **Ch:** 572
- hypogastric pain, central **C:** 35
- hypoglossal nerve pain syndrome **C:** 30
- hypogonadotrophic hypogonadism,
opioid-induced **C:** 192
- hypokinetic movement
disorders **Ch:** 327
- hyponatremia

- carbamazepine-induced **Ch**: 256
 NSAID-induced **A**: 71
 oxcarbazepine-induced **Ch**: 256
- hypotension
 clonidine-induced **A**: 487
 epidural analgesia **A**: 350; **P**: 591
 fluid restriction and **P**: 592–3
 monitoring, APS **P**: 591–3
- hypothalamic–pituitary–adrenal (HPA) axis
 fibromyalgia syndrome **Ch**: 603
 placebo effect **P**: 505–6
 postnatal development **A**: 38, **A**: 39
- hypothalamo–pituitary axis
 suppression, opioids **Ch**: 216
- hypothalamus
 persistent visceral pain **Ch**: 40
 temperature regulation **C**: 331
- hypothermia, therapeutic **C**: 231
- hypothyroid neuropathy **Ch**: 340
- hypotonic solution neurolysis **C**: 228
- hysterectomy
 with bilateral salpingo-
 oophorectomy **Ch**: 577
- chronic pelvic pain **Ch**: 585–6
 adverse effects **Ch**: 585–6
 contraindications **Ch**: 585
 efficacy **Ch**: 586
 indications **Ch**: 585
 endometriosis **Ch**: 576
- IASP *see* International Association for
 the Study of Pain (IASP)
- ibandronate **C**: 321
- IBCS (Infamy Body Coding
 System) **A**: 479 *T*
- ibuprofen **A**: 76–7
 children **P**: 464, **P**: 465 *T*
 doses **A**: 483 *T*
 clinical use **A**: 75
 gastrointestinal system adverse
 effects **A**: 76–7; **C**: 131–3
 intravenous administration **A**: 205–6
 noninflammatory joint pain **A**: 435
 numbers needed to treat **A**: 89 *T*
 oral administration **A**: 202
 surgery **A**: 202–3
 pediatric headache **Ch**: 630
 pharyngitis **A**: 418
 preparations **A**: 76–7
 properties **A**: 75 *T*
 rectal administration **A**: 204
 liquid gels **A**: 204
 sports injuries **A**: 533–4
 structure **A**: 76
 tension-type headache **Ch**: 458
 thrombogenicity **C**: 137–8
- topical, soft-tissue injuries **Ch**: 235
 transdermal administration **A**: 206–7
 WHO essential drug list **A**: 395 *T*
- ice, sports injury management **A**: 532
- ice massage **A**: 536
- ice packs **A**: 536
- ICUs *see* intensive care units (ICUs)
- ignition hypothesis, trigeminal
 neuralgia **Ch**: 473
- ileitis, persistent visceral pain **Ch**: 42
- iliac fossae pain **C**: 35
- iliohypogastric nerve **P**: 278, **P**: 470
 chronic pelvic pain **Ch**: 581
 cryoanalgesia **P**: 386 *F*
- iliohypogastric nerve block **P**: 278–9
 anatomy **P**: 278, **P**: 470
 complications **P**: 279, **P**: 470
 indications **P**: 278, **P**: 470
 landmarks **P**: 278
 local anesthetic solution **P**: 470
 practical steps/technique **P**: 278,
P: 279 *F*, **P**: 470
- ilioinguinal nerve **P**: 278, **P**: 470
 chronic pelvic pain **Ch**: 581
 cryoanalgesia **P**: 386 *F*
- ilioinguinal nerve block **P**: 278–9
 anatomy **P**: 278, **P**: 470
 children **P**: 470
 complications **P**: 279, **P**: 470
 indications **P**: 278
 landmarks **P**: 278
 practical steps/technique **P**: 278,
P: 279 *F*
- iliopsoas bursitis, soft-tissue
 injection **P**: 356
- iliotibial band friction syndrome
 (runner's knee) **P**: 356
- illicit drug users, opioids **C**: 106–7
- illumina, high-density genome-wide
 screening **Ch**: 71
- image intensifiers, sympathetic
 blocks **P**: 327
- imagery
 biofeedback and **P**: 160
 cancer pain **C**: 299–300
 children **C**: 304–5
 efficacy **C**: 301
 elderly **C**: 369–70
 guided *see* guided imagery
- imaginative involvement
 (protohypnosis) **P**: 484
- imaging
 CRPS **Ch**: 149, **Ch**: 367–8
 neuropathic pain **Ch**: 16
 nonarticular pain **A**: 433
 novel techniques **P**: 83–92
 second somatosensory cortex **Ch**: 16
- spinal cord injury
 musculoskeletal pain **Ch**: 391
 neuropathic pain **Ch**: 392
 visceral pain **Ch**: 391
- sports injuries **A**: 531
- visceral hypersensitivity
 disorders **Ch**: 38
see also individual techniques
- imipramine **Ch**: 244 *T*
 dosage/treatment schedule **P**: 138
 peripheral neuropathic pain **Ch**: 345,
Ch: 345 *T*
- immediate release tablets **C**: 110–1
- immobilization
 fractures **A**: 528–9
 ligament injuries **A**: 530
 sports injuries **A**: 532
- IMPACT *see* Initiative on Methods,
 Measurement, and Pain
 Assessment in Clinical Trials
 (IMPACT)
- immune reconstitution inflammatory
 syndrome, HIV-associated
 pain **Ch**: 354
- immune system
 cancer-induced bone pain **C**: 5
 nociception **A**: 3–4
 NSAIDs
 adverse effects **A**: 73
 beneficial effects **A**: 70
 opioid effects **C**: 156, **C**: 192
 placebo effect **P**: 507
- immunoglobulin A nephritis **Ch**: 564–5
- immunosuppression
 HIV-associated pain **Ch**: 352–3
 associated damage **Ch**: 354
- inflammatory bowel disease **Ch**: 561
- interstitial cystitis **Ch**: 557
- opioid-induced **Ch**: 216; **C**: 156
- IMPACT (Inpatient Management of
 Acute pain and Advice Clinical
 Treatment) **P**: 582
- impairment
 as construct **Ch**: 116
 definition **Ch**: 119
 measurement **Ch**: 119–20
- implanted pacemakers, SCS
 contraindication **P**: 407
- incident pain
 bone **C**: 258
 definition **Ch**: 220–1; **C**: 287; **P**: 539
 epidemiology, cancer patients **C**: 288
 rescue analgesics **C**: 114
see also breakthrough pain
- India
 cancer incidence **C**: 86
 opioid use regulations **C**: 84

- India (*continued*)
- palliative care services **C:** 86–7
 - government-funded centers **C:** 87
 - historical aspects **C:** 86
 - homecare service **C:** 87
 - sources of provision **C:** 86
 - Indian Association of Palliative Care (IAPC) **C:** 87
 - “individual” **C:** 50, **C:** 51 *F*
 - individual ethics **P:** 547–8
 - indometacin **A:** 78
 - CNS adverse effects **A:** 72, **A:** 78
 - intravenous administration **A:** 205–6
 - properties **A:** 75 *T*
 - sports injuries **A:** 533–4
 - induction, hypnosis **P:** 482 *T*, **P:** 483
 - induction heating **C:** 231–2
 - Infamy Body Coding System (IBCS) **A:** 479 *T*
 - infant(s)
 - nurse-controlled analgesia **P:** 467 *T*
 - pain assessment **A:** 480, **A:** 481 *T*; **P:** 456–7
 - measures **P:** 457
 - procedural pain **A:** 493–4
 - see also* children
 - infection(s)
 - cancer pain induction **C:** 36
 - continuous peripheral neural blockade **A:** 243, **A:** 247
 - cryoanalgesia-induced **P:** 381
 - intra-articular injection
 - contraindication **P:** 350
 - intrathecal drug
 - delivery-induced **P:** 376
 - lumbar spine diseases/ disorders **A:** 446
 - musculoskeletal chest pain **Ch:** 544
 - neck pain **Ch:** 488, **Ch:** 490
 - neuraxial analgesia **A:** 262
 - neuropathic pain **Ch:** 4 *T*
 - pharyngitis **A:** 418
 - postnatal development effects **A:** 43
 - SCS-induced **P:** 411
 - spinal pain **Ch:** 155, **Ch:** 156 *T*
 - treatment, breakthrough pain **C:** 289
 - see also individual infections*
 - infectious cystitis, recurrent **Ch:** 579–80
 - inferior hypogastric nerve **Ch:** 572
 - inferior mesenteric plexus, neurolytic block **C:** 230
 - inflammation
 - characteristics **A:** 21, **A:** 27
 - COX-2 **A:** 174
 - joint pain *see* joint pain, acute
 - lumbar spine diseases/ disorders **A:** 446
 - mediators
 - neuropathic pain **Ch:** 10
 - peripheral nociceptor sensitization **Ch:** 28–9
 - musculoskeletal pain **A:** 431
 - spinal cord injury **Ch:** 393
 - neuropathic pain **Ch:** 4 *T*, **Ch:** 133
 - orofacial pain **Ch:** 471
 - NSAIDs **A:** 533
 - peripheral nociceptors **Ch:** 27, **Ch:** 28
 - peripheral sensitization **A:** 21, **A:** 23 *F*
 - persistent musculoskeletal pain **Ch:** 24–5, **Ch:** 25, **Ch:** 26, **Ch:** 30
 - persistent visceral pain **Ch:** 42
 - phospholipase A₂ **A:** 174
 - postnatal nociception
 - development **A:** 39
 - remodeling/maturation phase **A:** 533–4
 - rheumatoid arthritis **Ch:** 520
 - septic arthritis **A:** 434–5
 - signaling systems **A:** 174
 - sports injuries **A:** 527, **A:** 527 *F*
 - visceral hypersensitivity disorders **Ch:** 38
 - inflammatory bowel disease (IBD) **A:** 416–7; **Ch:** 561
 - acute pain **A:** 416–7
 - differential diagnosis **Ch:** 561
 - presentation **A:** 416; **Ch:** 561
 - treatment **A:** 417; **Ch:** 561
 - inflammatory hyperalgesia **A:** 20–31
 - inflammatory mediators, peripheral sensitization **A:** 21, **A:** 23 *F*
 - infliximab, rheumatoid arthritis **Ch:** 521, **Ch:** 522–4 *T*
 - informal carers **C:** 52–3
 - informational support, professional teams **C:** 75
 - informed consent
 - cancer patients **C:** 94
 - cognitive aspects **P:** 548
 - expert medicolegal report **P:** 680
 - intrathecal drug delivery **P:** 373
 - patient’s risk/harm assessment **C:** 95
 - peripheral neurolysis **P:** 338
 - side effects **C:** 94
 - terminal illness **P:** 548
 - zygapophyseal joint blocks **P:** 363
 - infraclavicular block **A:** 238 *T*; **P:** 264–5, **P:** 268
 - complications **P:** 270 *T*
 - continuous **P:** 268
 - field/emergency situations **A:** 382 *T*
 - landmarks **P:** 268
 - practical steps/technique **P:** 268, **P:** 268 *F*
 - infraorbital nerve **P:** 260, **P:** 260 *F*, **P:** 471
 - cryoanalgesia **P:** 384–5
 - infraorbital nerve block **P:** 261
 - anatomy **P:** 260, **P:** 471
 - children **A:** 490; **P:** 471
 - intraoral technique **P:** 471
 - landmarks **P:** 260 *F*, **P:** 261
 - percutaneous technique **P:** 471
 - practical steps/technique **P:** 261
 - infusion pumps
 - APS **P:** 587
 - pediatric APS **P:** 642
 - inguinal nerve block,
 - children **A:** 489–90
 - herniorrhaphy **A:** 490
 - orchidopexy **A:** 490
 - inguinal paravascular block *see* fascia iliaca compartment block
 - inhalational anesthesia, burn pain **A:** 402, **A:** 404
 - inhalational drug
 - administration **A:** 209; **P:** 304
 - children **P:** 464
 - labor pain **A:** 469–70
 - opioids **A:** 209
 - see also individual drugs*
 - inheritance patterns **Ch:** 55
 - inhibitory interneurons, nociception **A:** 15
 - inhibitory pathway depression, local anesthetics **A:** 122–3, **A:** 123 *T*
 - inhibitory systems, neuropathic pain **Ch:** 12–3
 - Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
 - chronic pain clinical trial recommendations **P:** 29
 - clinical trial outcome
 - measures **Ch:** 182, **Ch:** 182 *T*; **P:** 560–1, **P:** 560 *T*
 - numerical rating scale
 - recommendations **P:** 14–5
 - verbal rating scale
 - recommendations **P:** 15
 - injection therapy
 - chronic lower back pain **Ch:** 511
 - chronic pelvic pain **Ch:** 584
 - corticosteroids *see* corticosteroid injections
 - see also* intramuscular drug administration; intravenous drug administration
 - injury *see* trauma

- innovation
 key attributes **P:** 607–8
 professional autonomy and **P:** 611
 resistance to **P:** 611
- Inpatient Management of Acute pain and Advice Clinical Treatment (IMPACT) **P:** 582
- insoles, osteoarthritis **Ch:** 528
- instrumental support, professional teams **C:** 75
- insula
 affective-motivational dimension of pain **Ch:** 242–3
 imaging, neuropathic pain **Ch:** 16
- insulin-like growth factor-1, fibromyalgia syndrome **Ch:** 603
- Integrated Formulary and Drug Use Committee, herbal medicine **Ch:** 313–5
- integrative therapies *see* complementary and alternative medicine (CAM)
- intelligence quotient (IQ), TENS caution **P:** 196
- intense TENS **A:** 272, **A:** 273 *F*; **C:** 238, **C:** 239 *T*, **C:** 240 *F*
- intensity, of pain *see* pain intensity
- intensive care units (ICUs) **A:** 343–59
 aims **A:** 344
 analgesics **A:** 347–8
 broadening categories **A:** 347
 non-opioids **A:** 347–8
 opioids **A:** 347
 cardiac surgery **A:** 351
 costs **A:** 344
 drug-withdrawal symptoms **A:** 348
 elderly **A:** 517
 emergency resuscitation **A:** 351
 epidural analgesia **A:** 349–50, **A:** 517; **P:** 318
 Guillain-Barré syndrome **A:** 352
 historical aspects **A:** 343
 neuropathic pain **A:** 351–2
 pain assessment **A:** 344–5
 behavioral indicators **A:** 345, **A:** 346 *T*
 children **P:** 453
 physical barriers **A:** 344–5
 pain monitors **A:** 345
 pain scores **A:** 345, **A:** 346 *T*
 pain sources **A:** 344
 physiology **A:** 348
 regional blocks **A:** 349–50
 renal replacement therapy **A:** 349
 sedation **A:** 345–7
 analgesia *vs.* **A:** 347
 daily interruption of **A:** 346
 deep **A:** 346–7
 ventilators **A:** 346
 thoracic surgery **A:** 351
see also end of life care
- intention, ethical issues **C:** 98
- intention-to-treat (ITT) analysis clinical trials **P:** 524–5, **P:** 525 *T*, **P:** 554–5
- intercostal nerve(s) **P:** 275
 branches **P:** 276 *T*
 cryoanalgesia
 acute/postoperative pain **P:** 383
 chronic pain **P:** 385–6
- intercostal nerve block **P:** 276
 anatomy **P:** 276, **P:** 472
 anterior approach **P:** 276
 children **A:** 491–2; **P:** 471–2
 catheter technique **P:** 472
 method **P:** 472
 complications **P:** 276
 continuous **A:** 242
 ICU patients **A:** 350
 indications **A:** 238 *T*; **P:** 276
 landmarks **P:** 276
 midaxillary approach **P:** 276, **P:** 472
 posterior approach **P:** 276
 practical steps/technique **P:** 276, **P:** 277 *F*
 sensory **P:** 277
- intercostal nerve cryoneurolysis **C:** 231
- intercostobrachial nerve **P:** 276
- intercostobrachial nerve block **P:** 268
- intercostobrachial neuralgia, postbreast cancer surgery pain **Ch:** 409; **C:** 403
- interdisciplinary care, cancer patients **C:** 74
- interferential therapy, TENS **P:** 194
- interleukin(s), cancer-induced bone pain **C:** 5
- interleukin-1B (IL-1B)
 arthritis **Ch:** 29
 neuropathic pain **Ch:** 10, **Ch:** 11 *F*
- interleukin 1 inhibitors, rheumatoid arthritis **Ch:** 521, **Ch:** 522–4 *T*
- interleukin-6 (IL-6)
 arthritis **Ch:** 29
 microglia activation **Ch:** 14
 neuropathic pain **Ch:** 10, **Ch:** 11 *F*, **Ch:** 14
- intermediate cervical ganglion **P:** 327
- intermediolateral cell column, persistent visceral pain **Ch:** 40
- intermittent acute porphyria (IAP) **Ch:** 562–3
- intermittent bolus, loading dose calculation **C:** 108
- intermittent hemodialysis and filtration (IHD) **A:** 349
- internal carotid artery dissection, neck pain **Ch:** 488
- internal consistency, pain measures **P:** 36
- International Association for the Study of Pain (IASP)
 CRPS diagnostic criteria **Ch:** 277, **Ch:** 363, **Ch:** 626
 developing world **A:** 391
 Ethical Guidelines for Pain Research in Humans **P:** 555
 headache diagnosis, children **Ch:** 628, **Ch:** 629 *T*
 low back pain taxonomy **A:** 450
 neuropathic pain definition **Ch:** 374
 pain definition **A:** 135–6; **Ch:** 87, **Ch:** 117, **Ch:** 503; **P:** 588
 psychiatric diagnosis **Ch:** 615, **Ch:** 615 *T*
 trigeminal neuralgia
 definition **Ch:** 472
 website **P:** 564
- International Classification of Diseases, 10th edition (ICD-10) **Ch:** 615, **Ch:** 615 *T*
- International Classification of Functioning, Disability and Health (ICF) holistic model **P:** 221
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use **P:** 564
- International HapMap Project **Ch:** 71
- International Narcotics Control Board (INCB) **C:** 82–3
 drug control *vs.* pain relief **Ch:** 112
 opioids for nonmalignant pain **P:** 110
 undertreated cancer pain
 findings **Ch:** 102
- International Observatory on End of Life Care (IOELC), access to cancer pain relief findings **C:** 85–6
- International Society for the Study of Vulvovaginal Disease, vulvodynia **Ch:** 587
- International Spinal Intervention Society **P:** 624
- International Statistical Classification of Diseases (ICSD)-10, delirium definition **C:** 186
- International Symposium on Cancer Pain, first **C:** 82
- International Symposium on Pediatric Pain, first **P:** 630
- internet-based resources
 clinical trials **P:** 564

- internet-based resources (*continued*)
 patient information, APS **P**: 585
- interphalangeal joints, intra-articular
 injection **P**: 352, **P**: 353
- interpleural block **A**: 241–2; **P**: 276–8
 anatomy **P**: 277
 cancer pain **P**: 277
 chronic pain **P**: 277
 complications **P**: 278
 contraindications **P**: 277
 definition **A**: 241
 ICU patients **A**: 350
 indications **P**: 277
 landmarks **P**: 277
 paravertebral block *vs.* **A**: 242
 postoperative analgesia **P**: 277
 practical steps/technique **P**: 277–8,
P: 278 *F*
 thoracotomy **A**: 241–2
- interscalene brachial plexus block *see*
 brachial plexus blocks
- interscalene catheters **P**: 265
 placement (Meier's approach) **P**: 266
- interscalene groove **P**: 265
- interstitial cystitis (IC) **Ch**: 556–8,
Ch: 580
 anti-proliferative factor **Ch**: 557–8
 diagnostic criteria **Ch**: 557 *T*
 hydrodistension **Ch**: 557
 disease association **Ch**: 556
 evaluation **Ch**: 38, **Ch**: 556–7
 Hunner's ulcers **Ch**: 556
 pathology **Ch**: 556
 prevalence **Ch**: 556
 symptoms **Ch**: 556, **Ch**: 580
 treatment **Ch**: 557, **Ch**: 558, **Ch**: 560
 behavioral therapies **Ch**: 557
 food avoidance **Ch**: 557
 immunosuppression **Ch**: 557
 intravesical therapy **Ch**: 557
 neurolysis **Ch**: 557–8
 opioids **Ch**: 557
 pharmacological **Ch**: 557
- interstitial fibrositis *see* fibromyalgia
 syndrome (FMS)
- interval therapy, gout **A**: 434
- interventional practices/
 procedures **P**: 243–4
 modality-based **P**: 624
see also individual procedures
- intervertebral discs
 herniation **P**: 418
 chiropractic therapy **Ch**: 313
 epidural steroid injections **P**: 420
 removal, chronic lower back
 pain **Ch**: 512
 whiplash **Ch**: 489–90
- intervertebral foramina **P**: 417
- interview, pain-related fear **P**: 180–2
- intestinal cystitis **Ch**: 42
- intestinal linitis plastica **C**: 321
- intimacy, cancer patients **C**: 55
- intra-articular injections **A**: 210;
P: 349–60
 contraindications **P**: 350
 corticosteroids **P**: 350
 historical aspects **P**: 349–50
 indications **P**: 350 *T*
 nonopioid analgesics **A**: 210
 NSAIDs **A**: 210, **A**: 331
 opioids **A**: 210
 patient's fears **P**: 350
 postoperative pain
 management **A**: 331
 procedure **P**: 351–3
 joint fluid examination **P**: 351
 sterile technique **P**: 351–3
 steroid preparations **P**: 351 *T*
 ultrasound-guided **P**: 351
see also individual joints
- intracellular cascades, spinal cord pain
 transmission **A**: 35
- intracranial pressure
 headache **Ch**: 455
 raised, nausea and vomiting **C**: 318,
C: 321 *F*
- intracranial stimulation **Ch**: 279–80
 deep brain *see* deep brain stimulation
 (DBS)
 motor cortex *see* motor cortex
 stimulation (MCS)
- intractable angina, TENS **P**: 201
- intractable pain, definition **Ch**: 100–1
- Intractable Pain Treatment
 Acts **Ch**: 100–1
- intra-dermal saline injections, labor
 pain **A**: 469
- intradiscal electrothermal therapy
 (IDET) **P**: 439, **P**: 439 *F*
 complications **P**: 442
 discTRODE *vs.* **P**: 441
 economic costs **P**: 442
 effectiveness **P**: 441
 efficacy **P**: 441
 randomized controlled trial **P**: 441
- intradiscal radiofrequency annuloplasty
see intradiscal thermal
 annuloplasty (IDTA)
- intradiscal thermal annuloplasty
 (IDTA) **P**: 438–44
 considerations **P**: 442
 contraindications **P**: 440–1
 controversies **P**: 441
 diagnostic considerations **P**: 440–1
- effectiveness **P**: 441
 efficacy **P**: 441
 emerging modalities **P**: 441
 pain relief mechanisms **P**: 439–40
 annulus fibrosis collagen
 denaturation **P**: 440
 nociceptors, thermal
 coagulation **P**: 439–40
 paraspinal muscles, altered
 sensorimotor control **P**: 440
 placebo response **P**: 439
 radiofrequency-based **P**: 439
 recommendations **P**: 442
 technique **P**: 440
- intra-lesional injection *see* soft-tissue
 injections
- intramuscular drug
 administration **A**: 204–5
 adverse effects **C**: 110
 children **A**: 485; **C**: 350; **P**: 464
 developing world **A**: 395
 elderly **A**: 505–7
 nonopioid analgesics **A**: 205
 opioids **A**: 205
 elderly **A**: 505–7
 preventive analgesia **A**: 184
see also individual drugs
- intranasal drug administration **A**: 207,
A: 208
 children **A**: 485; **P**: 463–4
 field/disaster situations **A**: 383
 opioids **A**: 208, **A**: 208 *T*
 emergency department **A**: 362
 PCA *see* patient-controlled intranasal
 analgesia (PCINA)
see also individual drugs
- intraoperative systemic heparinization,
 spinal hematoma **A**: 261
- intrapelvic pain, cancer
 patients **C**: 35–6
- intraspinous muscles, cervical referred
 pain **Ch**: 486
- intrathecal baclofen
 delivery complications **P**: 377
 overdose **P**: 377
 spasticity pain **Ch**: 285–6, **Ch**: 288,
Ch: 445–6
- intrathecal drug administration/
 delivery **A**: 209–10; **P**: 370–8,
P: 244
 cardiac surgery **A**: 263
 catheter placement **P**: 374, **P**: 374 *F*
 spinal level **P**: 374
 subcutaneous tunnel **P**: 375,
P: 375 *F*
 suturing **P**: 374, **P**: 374 *F*
 catheters **P**: 371

- malfunction **P**: 377
 tip inflammatory masses **P**: 376, **P**: 377
- central neuropathic pain **Ch**: 380
 complications **P**: 376–7
 drug-related **P**: 377
 management **P**: 377
 neurological **P**: 376, **P**: 377
 technique-related **P**: 376
- conduct of technique **P**: 373
 constant flow pumps **P**: 371
 advantages/disadvantages **P**: 372 *T*
 programmable pumps vs. **P**: 372
CRPS Ch: 370
- elderly **A**: 507, **A**: 518–9
 endocrine screening **P**: 377
 equipment malfunction **P**: 377
 implantation equipment **P**: 371–2
 informed consent **P**: 373
 intrathecal **Ch**: 184
 local anesthetics **A**: 257
 nonopioid analgesics **A**: 210
 operative technique **P**: 373–6
 preoperative phase **P**: 373
 preoperative planning **P**: 373
 preparation **P**: 373–4
 opioids **A**: 210, **A**: 258, **A**: 518–9
 polyanalgesic algorithm **P**: 376 *T*
 power source **P**: 371
 preimplantation trialling **P**: 372
 programmable pumps **P**: 371
 advantages/disadvantages **P**: 372 *T*
 constant flow pumps vs. **P**: 372
 pump malfunction **P**: 377
 pump placement **P**: 375–6, **P**: 375 *F*
 catheter connection **P**: 375
 filling regimes **P**: 375, **P**: 375 *F*
 location decisions **P**: 373
 pocket for **P**: 375, **P**: 376 *F*
 system types **P**: 370–1
 team composition **P**: 373
 therapeutic context **P**: 372–3
see also individual drugs
- intrathecal neurolysis **C**: 230; **P**: 339–41
 complications **C**: 230, **C**: 231 *T*;
P: 340–1
 hyperbaric solutions **P**: 339
 indications **P**: 339
 pain relief **P**: 339
 patient positioning **C**: 230
 perineal area blockade **P**: 340
 technique **C**: 230; **P**: 339–40, **P**: 340 *F*
- intravenous drug
 administration **A**: 205–6; **C**: 110
 children **A**: 481–2, **A**: 482 *T*, **A**: 485;
C: 350; **P**: 464
 developing world **A**: 395
 dying person **C**: 393–4
 loading dose calculation **C**: 108
 nonopioid analgesics **A**: 205–6
 NSAIDs **A**: 205–6, **A**: 335
 opioids *see* opioid(s)
 postoperative pain
 management **A**: 335
see also individual drugs
- intravenous ketamine test **P**: 61–2
 adverse effects **P**: 62
 contraindications **P**: 61
 doses **P**: 62
 efficacy **P**: 62
 fibromyalgia syndrome **P**: 62
 indications **P**: 61
 pain scores **P**: 62
 paradigms **P**: 62
 phantom limb pain **P**: 62
 pharmaceutical considerations **P**: 62
 practical tips **P**: 62
- intravenous lidocaine trial **P**: 57–9
 adverse effects **P**: 59
 bolus regimen **P**: 58
 contraindications **P**: 57
 doses **P**: 58–9
 efficacy **P**: 59
 extended six-hour infusion **P**: 58
 four-hour infusion **P**: 58–9
 indications **P**: 57
 mexiletine following **P**: 57, **P**: 59
 monitoring **P**: 58
 paradigms **P**: 58–9
 practical tips **P**: 59
 repeated infusions **P**: 59
 short infusion regimen **P**: 58
- intravenous opioid drug
 challenges **Ch**: 214–5; **P**: 62–4
 adverse effects **P**: 63
 chronic noncancer pain **P**: 115
 contraindications **P**: 63
 doses **P**: 63
 efficacy **P**: 63–4
 indications **P**: 63
 limitations **P**: 63
 paradigms **P**: 63
 practical tips **P**: 63
- intravenous patient-controlled analgesia
see patient-controlled analgesia
 (PCA)
- intravenous phentolamine test **P**: 59–61
 adverse effects **P**: 60–1
 complex regional pain
 syndrome **P**: 325
 contraindications **P**: 60
 doses **P**: 60
 efficacy **P**: 61
 indications **P**: 60
- pain relief onset **P**: 60
 paradigms **P**: 60
 pharmaceutical considerations **P**: 61
 placebo response **P**: 60
 practical tips **P**: 61
 propranolol in **P**: 60
 quantitative sensory testing and **P**: 60
- intravenous phenytoin infusion
 test **P**: 135–6
- intravenous regional anesthesia (Bier's
 block) **A**: 128
CRPS Ch: 369
 forearm fracture reduction **A**: 368
- intra wound drug administration **A**: 210
 intrinsic activity (efficacy), drugs **A**: 54;
C: 105
- introducers, Western medical
 acupuncture **P**: 216
- invasive interventions, trials of **P**: 542
- iodine, metastatic bone pain **C**: 263–4
 [131I]iodine-metaiodobenzylguanidine
 ([131I]MIGB) **C**: 354
- ion channels, somatic
 nociceptors **A**: 4–6
- ionotropic (P2X) nociceptors **A**: 6
IONSYS A: 219; **P**: 304–5, **P**: 305 *F*
 characteristics **P**: 306
- iontophoresis
 corticosteroids **A**: 534
 fentanyl **A**: 207, **A**: 219
 lidocaine **A**: 128
 patient-controlled transdermal
 system **P**: 304–5
 sports injuries **A**: 534
- iontophoretic transdermal system
 (ITS) **P**: 304–5
- ion trapping, NSAIDs **C**: 130
- ipratropium bromide **C**: 314
- iron deficiency **P**: 68
- irritable bowel syndrome (IBS)
 acute pain **A**: 416–7
 management **A**: 416–7
 prevention **A**: 416
 chronic pain **Ch**: 558–60
 pelvic **Ch**: 579
 clinical presentation **Ch**: 558–9
 diagnosis **Ch**: 559
 exacerbation **Ch**: 559
 fibromyalgia syndrome **Ch**: 602
 prevalence **A**: 416; **Ch**: 558
 spontaneous resolution **Ch**: 559
 surgery **A**: 564
 treatment **Ch**: 559, **Ch**: 560
 visceral hypersensitivity **Ch**: 38; **P**: 88
- Isador **C**: 274
- ischemia
 human visceral pain models **Ch**: 41

- ischemia (*continued*)
 neuropathic pain **Ch**: 4 *T*
 persistent visceral pain **Ch**: 38
 spinal cord stimulation **Ch**: 273
 temporomandibular disorders **Ch**: 469
- ischemic cardiac chest pain *see* chest pain
- ischemic colitis **Ch**: 561–2
- ischemic pain, TENS **P**: 201–2
- ischial bursitis, soft-tissue injection **P**: 356
- ischial enthesitis (hamstring tear), soft-tissue injection **P**: 356
- Island Hospice **C**: 88–9
- isobologram **P**: 518 *F*
- Israel, palliative care services **C**: 87
- ISRCTN register, clinical trials **P**: 525
- Italy, opioid use regulations **C**: 83–4
- itch *see* pruritus
- itraconazole **C**: 316–7
- IT support, pediatric APS **P**: 643
- jaw muscle pain, temporomandibular disorders **Ch**: 468–9
- joint(s)
 immobilization, rheumatoid arthritis **Ch**: 524–5
 innervation **Ch**: 26
 “normal” movement **A**: 431
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO) **P**: 629
- chronic pain measurement **Ch**: 117
- pain as fifth vital sign **P**: 655
- pain assessment guidelines **Ch**: 117; **P**: 656
- pain management standards **Ch**: 109; **P**: 629, **P**: 669
- joint manipulations **P**: 231
- joint mobilizations **P**: 230
- sciatica **P**: 234
- joint pain, acute
 diagnosis **A**: 432–3
 blood tests **A**: 432–3
 imaging **A**: 433
 synovial fluid aspiration **A**: 432
- hemarthrosis **A**: 436
- inflammation
 chronic exacerbations **A**: 434–5
 management **A**: 433–5
- “mechanical” **A**: 436
- noninflammatory **A**: 435–6
 activity modification **A**: 435
 drug therapy **A**: 435
 exercise **A**: 435
 injections **A**: 435–6
- rest **A**: 435
- supports **A**: 435
- trigger points **A**: 436
- osteonecrosis **A**: 436
- see also individual diseases/disorders; individual joints*
- joint pain, chronic **Ch**: 518–36
 assessment **Ch**: 518–9
 classification **Ch**: 519 *T*
 osteoarthritis *see* osteoarthritis
- regional soft-tissue disorders **Ch**: 528–31
- rheumatoid arthritis *see* rheumatoid arthritis
- see also individual joints*
- joint replacement,
 osteoarthritis **Ch**: 528
- joint surgery, postoperative pain management **A**: 331
- Joule–Thompson effect **P**: 379–80
- jugular foramen syndrome **C**: 31 *T*
- jumper’s knee (patellar tendonosis) **P**: 357
- juvenile fibromyalgia syndrome (JFS) **Ch**: 624–6
 clinical presentation **Ch**: 625
 etiology **Ch**: 625
 management **Ch**: 625–6
 prevalence **Ch**: 624–5
 prognosis **Ch**: 625
- juvenile rheumatoid arthritis, NSAIDs **A**: 483
- juxta-articular hyperemia, bone scans **Ch**: 149
- kainate receptor(s)
 central sensitization **A**: 25; **Ch**: 12
- persistent musculoskeletal pain **Ch**: 31
- postnatal development **A**: 33
- kallidin **A**: 23
- Kaposi’s sarcoma **Ch**: 358
- kappa opioid receptor agonists **Ch**: 554
- kappa (κ) opioid receptors **A**: 54; **C**: 152
 endogenous ligands **A**: 55
 location **A**: 55
 neuraxial analgesia **A**: 256
 spinal cord **A**: 15
- karaya pads, TENS **P**: 196
- karyotypes **Ch**: 49, **Ch**: 51 *F*
- Katz Activities of Daily Living, elderly **C**: 361
- KCNQ gene/protein (M channel), neuropathic pain **Ch**: 9
- ketamine
 abdominal pain, acute **A**: 414
- acute pain **A**: 100 *T*
- acute pancreatitis **A**: 416
- adverse effects **C**: 207
 CNS **A**: 99, **A**: 486
 nausea and vomiting **A**: 99
- atypical odontalgia **Ch**: 475
- bioavailability **C**: 208
- burn pain **A**: 403, **A**: 404
- cancer pain use **C**: 208
 elderly **C**: 368
 intravenous “burst” **C**: 208
- central neuropathic pain **Ch**: 379, **Ch**: 380
- chemical properties **A**: 98
- children **A**: 486; **P**: 468–9
 doses **P**: 469 *T*
 postoperative pain **P**: 469
 procedural pain **P**: 469
- chronic pain **P**: 61
- CPSP prevention **A**: 565
- developing world **A**: 395
- emergency departments **A**: 363
- epidural analgesia **A**: 184, **A**: 259; **P**: 469
 preventive analgesia **A**: 184
- fibromyalgia syndrome **Ch**: 604, **Ch**: 607
- field/disaster situations, intranasal administration **A**: 383
- flare-up pain **Ch**: 221
- fracture reduction **A**: 367
- ICUs **A**: 348
- intrathecal administration **A**: 259
- intravenous administration **A**: 184
- intravenous testing *see* intravenous ketamine test
- mechanism of action **A**: 259; **C**: 207
- neuraxial analgesia **A**: 259
- neurotoxicity **A**: 486
- opioids and **Ch**: 213–4
- opioid sensitivity and **C**: 202–3
- opioid-tolerant patients **A**: 100, **A**: 548
- PCA **A**: 224; **P**: 295
 morphine and **A**: 224
 opioid tolerant patients **P**: 298
- perioperative pain
 management **A**: 100
- pharmacodynamics **C**: 207
- pharmacokinetics **A**: 99 *T*; **C**: 207–8
 children **A**: 486
- physical properties **A**: 98
- postamputation pain **Ch**: 423
- postoperative pain
 management **A**: 334–5
- preventive analgesia **A**: 100, **A**: 175, **A**: 175–84, **A**: 180

- administration **A:** 184
 epidural **A:** 184
 intravenous **A:** 184
 opioid-tolerant patients **A:** 548
 surgical procedures **A:** 175–84,
A: 184
 procedure-related pain, cancer
 patients **C:** 218
 advantage/disadvantages **C:** 218
 psychomimetic effects **A:** 548
 routes of administration,
 children **A:** 486
 sickle cell disease pain **A:** 420
 spinal administration **Ch:** 287
 spinal cord injury pain **Ch:** 395,
Ch: 396 *T*
 subcutaneous drug infusion, cancer
 patients **P:** 130
 as substance of abuse **A:** 99
 terminal sedation, children **C:** 354
 topical preparations
 CRPS **Ch:** 369
 mechanism of action **P:** 61
 mucositis-associated pain **Ch:** 237
 neuropathic pain **Ch:** 234
 WHO essential drug list **A:** 395 *T*
 ketoconazole **C:** 316–7
 ketoprofen **A:** 77
 noninflammatory joint pain **A:** 435
 rectal administration **A:** 204
 soft-tissue injuries **Ch:** 235
 tension-type headache **Ch:** 458
 topical **Ch:** 235
 transdermal administration **A:** 206–7
 ketorolac **A:** 77
 adverse effects, tissue healing **A:** 72
 biliary colic **A:** 364
 burn pain **A:** 403
 cancer pain **C:** 181–2
 subcutaneous infusion **P:** 130–1
 children **A:** 482–3; **P:** 465 *T*
 doses **A:** 483 *T*
 dislocations/fractures **A:** 367
 intra-articular analgesia **A:** 331
 intramuscular administration **A:** 205
 intravenous administration **A:** 205–6
 migraine **A:** 365, **A:** 366 *T*
 PCA
 children **P:** 297
 morphine co-administration **A:** 224
 pediatric headache **Ch:** 631
 postoperative myocardial infarction
 reduction **A:** 70, **A:** 71–2
 postoperative pain **A:** 331
 properties **A:** 75 *T*
 renal colic **A:** 364
 transdermal administration **A:** 206–7
 ketorolac trometamol *see* ketorolac
 kidney(s)
 age-related changes **A:** 506 *T*
 dialysis **A:** 349, **A:** 349 *T*
 local anesthetic elimination **A:** 120
 NSAID adverse effects **A:** 71; **C:** 128 *T*,
C: 135–6, **C:** 135 *F*
 NSAID elimination **A:** 70
 organ failure **A:** 348–9
 paracetamol adverse effects **Ch:** 201
entries beginning renal
 kidney stones, topiramate-
 induced **Ch:** 260–2
 kinesophobia **P:** 178
 CRPS **Ch:** 370–1
 rehabilitation **P:** 621
 Kleinman, Arthur **Ch:** 103–4
 knee, intra-articular block **P:** 288–9
 complications **P:** 289
 indications **P:** 289
 landmarks **P:** 289
 practical steps/technique **P:** 289,
P: 290 *F*
 knee hyperextension **Ch:** 442
 knee nerve blocks **P:** 287–8
 anatomy **P:** 288
 indications **P:** 287
see also individual blocks
 knee pain
 acute **A:** 439–41
 clinical features **A:** 440
 entities **A:** 439
 investigations **A:** 440
 management **A:** 440–1, **A:** 440 *T*
 chronic **Ch:** 530
 intra-articular injection **P:** 353,
P: 353 *F*
 osteoarthritis **Ch:** 526, **Ch:** 530
 soft-tissue injections **P:** 356–7
 anterior pain **P:** 356–7
 lateral pain **P:** 356
 medial pain **P:** 356
 spasticity **Ch:** 442
 knee surgery, femoral nerve
 blocks **A:** 240
 knockout mice, mu opioid
 receptors **A:** 54
 kyphosis **Ch:** 580
 labor **A:** 463–4
 pain during *see* labor pain
 stages of **A:** 463 *T*
 laboratory examination/tests **P:** 67–74
 algorithm **P:** 71
 CRPS **Ch:** 367–8
 general considerations **P:** 71
 hormone analyses **P:** 68
 neuropathic pain **Ch:** 138–9
 nutritional deficiencies **P:** 68
see also individual tests
 labor pain **A:** 463
 biofeedback **A:** 468
 clinical presentation **A:** 463–5
 continuous abdominal pain **A:** 465
 description **A:** 463, **A:** 463 *F*
 latent phase, prolonged **A:** 464
 magnitude **A:** 463
 management **A:** 467–72
 acupuncture **A:** 283 *T*, **A:** 284,
A: 468
 breakthrough pain **A:** 469
 continuous labor support **A:** 468
 epidural analgesia **A:** 470, **A:** 471 *T*;
P: 318
 inhalational analgesics **A:** 469–70
 neuraxial analgesia *see* neuraxial
 analgesia
 neuraxial regional
 anesthesia **A:** 470–2
 nitrous oxide **A:** 98
 nonneuraxial regional
 anesthesia **A:** 470
 nonpharmacological **A:** 468–9
 patient positioning **A:** 469
 pharmacology **A:** 469–72
 psychoprophylaxis **A:** 468
 spinal epidural/neuraxial regional
 anesthesia **A:** 472, **A:** 472 *T*
 systemic analgesics **A:** 469
 TENS **A:** 277–80, **A:** 278; **P:** 195,
P: 200
 maternal factors **A:** 466–7
 obstetric factors **A:** 467
 dysfunctional labor **A:** 467,
A: 467 *F*
 fetal position **A:** 467
 pain pathways **A:** 465, **A:** 465 *F*
 physiological response **A:** 465–6
 psychological/social factors **A:** 466
 somatic **A:** 464
 variability **A:** 460, **A:** 461 *F*,
A: 464–5
 visceral pain **A:** 464
 lacosamide **Ch:** 263
 adverse effects **Ch:** 257 *T*
 diabetic neuropathy **Ch:** 257 *T*,
Ch: 263
 doses **Ch:** 257 *T*
 efficacy **Ch:** 261 *T*
 lactation
 NSAID use **A:** 73; **Ch:** 198
 paracetamol **A:** 86
 lactic acidosis,
 antiretroviral-induced **Ch:** 358

- lactose intolerance, functional
abdominal pain **Ch:** 634
- lacuna musculorum **P:** 470
- Lamaze, labor pain treatment **A:** 468
- lamotrigine **Ch:** 256 *T*, **Ch:** 262
adverse effects **Ch:** 257 *T*, **Ch:** 262;
P: 137
central neuropathic pain
treatment **Ch:** 379, **Ch:** 379–82 *T*
central poststroke pain **Ch:** 262,
Ch: 380
contraindications **P:** 135
diabetic neuropathy **Ch:** 262
dosage/treatment schedule **Ch:** 257 *T*;
P: 136
efficacy **Ch:** 261 *T*
HIV-related neuropathy **A:** 413;
Ch: 262, **Ch:** 356
metabolism **P:** 135
pediatric headache **Ch:** 632, **Ch:** 633 *T*
peripheral neuropathic pain **Ch:** 346
spasticity pain **Ch:** 445
spinal cord injury **Ch:** 262, **Ch:** 394,
Ch: 396 *T*
trigeminal neuralgia **Ch:** 262
- lancet-induced trauma, TENS **P:** 195,
P: 200
- lanreotide **C:** 320 *T*
- Laos, healthcare spending **A:** 391 *T*
- laparoscopic cholecystectomy,
intraperitoneal local
anesthetics **A:** 331
- laparoscopic uterine nerve ablation
(LUNA), chronic pelvic
pain **Ch:** 586–7
adverse effects **Ch:** 586
contraindications **Ch:** 586
efficacy **Ch:** 586–7
indications **Ch:** 586
presacral neurectomy *vs.* **Ch:** 586
- laparoscopy
adhesions **Ch:** 578
chronic pelvic pain **Ch:** 584–5
adverse effects **Ch:** 585
efficacy **Ch:** 585
indications **Ch:** 585
medication failure **Ch:** 585
pain mapping **Ch:** 585
endometriosis **Ch:** 576
diagnostic **Ch:** 575
- laparotomy
adhesions **Ch:** 578
endometriosis **Ch:** 576
diagnostic **Ch:** 575
- large intestine
obstruction, cancer patients *see* bowel
obstruction, advanced cancer
opioid effects **C:** 155
toxicity, NSAID-induced **C:** 135
- laryngeal nerve block, recurrent
P: 329
- Lasegue's test **P:** 7
- laser(s)
acupuncture **C:** 272
neurolysis **C:** 232
thin-fiber activator **P:** 53, **P:** 53 *F*
- laser Doppler, peripheral
neuropathy **P:** 79
- laser Doppler flowmetry, CRPS **Ch:** 365
- laser-evoked potentials **P:** 51
central pain syndromes **P:** 51
fibromyalgia syndrome **P:** 51
peripheral neuropathy **P:** 79
- laser therapy
refractory angina pectoris **Ch:** 541
rotator cuff disorders **Ch:** 529
- last observation carried forward
(LOCF) **P:** 525
- lateral atlantoaxial joints, neck
pain **Ch:** 152
- lateral cutaneous nerve of the
forearm **P:** 271
- lateral cutaneous nerve of the forearm
block **P:** 272
- lateral cutaneous nerve of the
thigh **P:** 284
- lateral cutaneous nerve of the thigh
block **P:** 284, **P:** 284 *F*
- lateral epicondylitis **P:** 355
diagnosis **Ch:** 529 *T*, **Ch:** 530
epidemiology **Ch:** 529
natural history **A:** 438
steroid injections **P:** 355
- lateral femoral cutaneous nerve
(LFCN), entrapment
neuropathy **P:** 358
- lateral medullary infarctions
(Wallenberg's syndrome) **Ch:** 377
- lateral thalamus, nociception **A:** 12–3
- Latin America, palliative care
services **C:** 86
- Latin American and Caribbean Health
Sciences Literature
(LILACS) **P:** 570 *T*
- laxatives
constipation **C:** 190, **C:** 324, **C:** 325 *T*
dying person **C:** 394–5
opioid therapy and **C:** 113, **C:** 190
rectal **C:** 324
- learned responses, nausea and
vomiting **C:** 318
- learned tolerance **C:** 105
- Leeds Assessment of Neuropathic
Symptoms and Signs
(LANSS) **Ch:** 137, **Ch:** 140,
Ch: 374–5
- leflunomide, rheumatoid
arthritis **Ch:** 522–4 *T*
- legal issues/perspectives **Ch:** 99–114
accountability, lack of **Ch:** 109
“controlled substances”
prescription **Ch:** 111
drug control *vs.* pain relief **Ch:** 111–2
excessive prescribing
practices **Ch:** 105–6
inappropriate treatment
prosecutions **Ch:** 107
pain and suffering **Ch:** 89
physician-assisted suicide **Ch:** 110
psychoactive substances **Ch:** 652–3
quality of palliative care **Ch:** 110–1
suffering relief **Ch:** 110
undertreatment cases **Ch:** 110
undertreatment prosecutions **Ch:** 107
- leg pain, lumbar radiculopathy **Ch:** 505,
Ch: 511
- leg surgery, combined spinal–epidural
analgesia **A:** 260
- leg weakness, epidural analgesia-
induced **P:** 313
- leiomyomata, uterine **Ch:** 578–9
- lemniscal sensory pathway, central
neuropathic pain **Ch:** 378
- leprosy **Ch:** 344–5
- lesser occipital nerve **P:** 259, **P:** 383
- leucopenia, paracetamol **Ch:** 200–1
- leukemia inhibitory factor (LIF) **Ch:** 10
- levels of care **P:** 656–8
- levetiracetam
central neuropathic pain **Ch:** 379–80
pediatric headache **Ch:** 632, **Ch:** 633 *T*
- levobupivacaine **A:** 127
children **A:** 491, **A:** 492
continuous peripheral neural
blockade **A:** 245
elderly **A:** 517
epidural analgesia
caudal **A:** 491
children **A:** 492; **P:** 474 *T*
elderly **A:** 517
lumbar, labor **A:** 471–2, **A:** 472 *F*
labor **A:** 471–2, **A:** 472 *F*
neuraxial analgesia **A:** 256
peripheral nerve blocks **P:** 256
ropivacaine *vs.* **A:** 127
- levomepromazine
agitation **C:** 335
nausea and vomiting **C:** 320 *T*
- levonorgestrel-releasing intrauterine
system (Lng-IUS),
endometriosis **Ch:** 575

- levorphanol **C**: 162
 cancer pain **C**: 162
 central neuropathic pain **Ch**: 381–2 *T*
- Leyden jar **P**: 193–4
- Lhermitte's phenomenon **Ch**: 326; **P**: 8
- lichen planus, vulvar **Ch**: 588
- lichen sclerosus, vulvar **Ch**: 588
- lichen simplex chronicus,
 vulvar **Ch**: 588
- licofelone **C**: 138
- licorice extract **Ch**: 315 *T*
- lidocaine **A**: 119 *T*, **A**: 124, **A**: 125;
P: 139
 acute pain **A**: 107
 adverse effects **A**: 107; **C**: 208; **P**: 140
 anti-inflammatory effects **A**: 107
 burn pain **A**: 107, **A**: 400–1, **A**: 404
 central neuropathic pain **Ch**: 379,
Ch: 380
 clinical uses **P**: 139
 continuous peripheral neural
 blockade **A**: 244–5
 contraindications **P**: 139
 cough **C**: 315
 CRPS **Ch**: 368–9
 dosing/treatment schedule **P**: 139–40
 dyspepsia, acute **A**: 417
 dyspnea **C**: 314
 elderly, pharmacokinetics **A**: 505
 fibromyalgia syndrome **Ch**: 604,
Ch: 607
 historical aspects **A**: 107, **A**: 113–4
 HIV-associated neuropathic
 pain **Ch**: 356
 intravenous trials *see* intravenous
 lidocaine trial
 iontophoresis **A**: 128
 mechanism of action **Ch**: 9,
Ch: 263
 metabolism **A**: 120, **A**: 121 *F*
 microaerosols **A**: 128
 migraine **A**: 366
 morphine and, PCA **A**: 224
 neuraxial analgesia **A**: 257
 neuropathic pain, cancer
 patients **C**: 208
 neurotoxicity **A**: 121–2
 parenteral **A**: 107
 PCA **A**: 224
 penile block **A**: 490
 peripheral nerve blocks **P**: 255–6
 peripheral neuropathic
 pain **Ch**: 346 *T*
 postamputation pain **Ch**: 423
 postherpetic neuralgia **Ch**: 435
 shoulder dislocation **A**: 368
 sodium channel blockade **Ch**: 263
- spinal cord injury pain **Ch**: 395,
Ch: 396 *T*
- subcutaneous administration **A**: 107
- sympathetic blocks **P**: 326–7
- systemic **A**: 107; **Ch**: 263; **P**: 139
- topical **A**: 128; **Ch**: 233
 central neuropathic itch **Ch**: 237
 FDA approval **Ch**: 231
 low back pain **Ch**: 236–7, **Ch**: 508
 myofascial pain **Ch**: 236–7
 neuropathic pain **Ch**: 233; **C**: 209
 peripheral neuropathic
 pain **Ch**: 347
 postherpetic neuralgia **Ch**: 9,
Ch: 233, **Ch**: 434 *T*, **Ch**: 435
 soft-tissue injuries **Ch**: 236
- transient radicular irritation
 induction **A**: 122
- vulvodynia **Ch**: 590
- WHO essential drug list **A**: 395 *T*
- wounds **A**: 367
- LIDS (Liverpool Infant Distress
 Scale) **A**: 479 *T*
- life root **Ch**: 315 *T*
- lifting, fear of **P**: 180–1
- ligament injuries **A**: 530
- ligand-gated ion channels
 dorsal horn plasticity **A**: 25–6
 intracellular signaling **A**: 22
- lignocaine *see* lidocaine
- LILACS (Latin American and
 Caribbean Health Sciences
 Literature) **P**: 570 *T*
- limb(s)
 lower *see* lower limb(s)
 upper *see* upper limb(s)
- limbic system
 acupuncture **C**: 273
 pain modulation **P**: 146
- limb salvage, peripheral vascular
 disease **Ch**: 275
- linear analog scale (LAS), elderly **C**: 361
- linkage studies **Ch**: 55–6
- lipid solubility, age-related
 changes **C**: 365
- lipid-soluble drugs, transdermal
 administration **A**: 206
- lipophilic opioids **A**: 257; **Ch**: 286
- liposomes, local anesthetics and **A**: 129
- lipoyxygenase (LOX) **C**: 125 *F*, **C**: 138
- liquid gels, ibuprofen **A**: 204
- listening skills
 healthcare provider education **A**: 297
 narrative analysis **Ch**: 93–4
- literature, low back pain **Ch**: 507–8
- lithium, NSAID interactions **A**: 74 *T*
- litigation
- sources **P**: 678 *T*
 trends in **P**: 677–8
- “litigious” patient **P**: 683
- liver
 age-related changes **A**: 506 *T*, **A**: 508
 local anesthetic metabolism **A**: 121
 NSAID-induced adverse effects **A**: 71;
Ch: 197
 paracetamol adverse effects **Ch**: 201
see also entries beginning hepatic
- liver disease, chronic
 opioid bioavailability **C**: 108
 pharmacokinetic effects **C**: 108
- liver failure **A**: 349
 contraindicated drugs **A**: 349
 paracetamol-induced **A**: 92, **A**: 349
- Liverpool Infant Distress Scale
 (LIDS) **A**: 479 *T*
- living wills **C**: 96–7
- load bearing, biofeedback **P**: 156
- loading dose **C**: 108
 PCA **A**: 220; **P**: 294
- local anesthetic(s) **A**: 113–34; **P**: 139–40
 absorption **A**: 119–20
 partition coefficient **A**: 120
 p*K_a* **A**: 120
 tissue vascularity **A**: 120
- acute pain treatment, long-term
 opioid therapy patients **P**: 116
- additives **A**: 118–9
 adverse effects **P**: 140
 differential diagnosis **A**: 124
- age-related effects **A**: 120–1
 children **A**: 120–1
 elderly **A**: 121, **A**: 515
 liver **A**: 121
 newborns **A**: 120–1
- alkalinization **A**: 119
- allergy/allergic reactions **A**: 123
- anti-inflammatory effects **A**: 124
- antioxidants in **A**: 118
- blocks *see* local anesthetic blocks
- burn pain **A**: 400–1, **A**: 404
- cancer-induced/related neuropathic
 pain **C**: 208–9
 systemic agents **C**: 208–9
- carbonated salt preparations **A**: 118–9
- cardiotoxicity **A**: 122
- cardiovascular effects **A**: 257
- children **A**: 487
 administration **A**: 487
 adverse effects **A**: 487
 techniques **A**: 489–92
- clinical uses **A**: 127–8; **P**: 139
- complications **A**: 121–4
 local **A**: 121–2, **A**: 122 *T*
 systemic **A**: 122–4

local anesthetic(s) (*continued*)

contraindications **A:** 127–8, **A:** 128 *T*;
P: 139
 CPSP prevention **A:** 564
 CRPS **Ch:** 368–9, **Ch:** 369
 cryoanalgesia **P:** 382
 definition **A:** 113
 the dental pain model **P:** 531–2
 dental surgery **A:** 489
 dental surgery, children **A:** 489
 developing world *see* developing world
 differential sensitivity **A:** 116–7,
A: 116 *T*
 distribution **A:** 119–20
 dosing/treatment schedule **A:** 119;
P: 139–40
 drug interactions **A:** 123–4
 efficacy **P:** 134–5
 elimination **A:** 120
 epidural analgesia
 children **A:** 492
 elderly **A:** 517
 postoperative complication
 reduction **P:** 312
 epidural steroid injections **P:** 419
 epinephrine and **A:** 118
 frequency-dependent actions **A:** 116
 open ion channel binding **A:** 116
 small fibers **A:** 116–7
 future directions **A:** 129
 herniorrhaphy **A:** 489
 historical aspects **A:** 113–4, **A:** 114 *T*
 hyaluronidase and **A:** 119
 hydrophilicity **A:** 117
 hydrophobicity **A:** 115, **A:** 117
 indications **A:** 127–8
 intra-articular injections **P:** 351
 intraperitoneal instillation **A:** 331
 intrathecal **A:** 257
 delivery complications **P:** 377
 long-release formulations, field/
 disaster situations **A:** 383
 maximum safe dose **A:** 119
 mechanism of action **A:** 114–9
 potassium conductance **A:** 114
 sodium influx **A:** 114
 voltage-dependent actions **A:** 116
 metabolism **A:** 120
 myofascial pain **Ch:** 608
 myotoxicity **A:** 124
 neuraxial analgesia **A:** 256
 adverse effects **A:** 257
 mechanisms of action **A:** 256
 motor nerve block **A:** 256
 opioids and **A:** 258
 sensory nerve block **A:** 256

neurologic disease pain **Ch:** 329
 neurotoxicity **A:** 121–2, **A:** 257
 ophthalmic anesthesia **A:** 128
 pattern of offset **A:** 117
 pattern of onset **A:** 117
 peripheral nerve blocks **P:** 255–6
 agents **P:** 255–6
 differential blockade **P:** 255
 pharmacokinetics **A:** 119–21, **A:** 119 *F*
 children **A:** 487
 pH effects **A:** 117–8, **A:** 118 *F*,
A: 119 *T*
 pK_a dependence **A:** 117, **A:** 118 *F*
 postoperative pain
 management **A:** 330, **A:** 330 *T*
 potassium channel blockers
 and **A:** 119
 in pregnancy **A:** 462
 preventive analgesia **A:** 168, **A:** 169
 surgical procedure types **A:** 168
 procedure-related pain **C:** 217
 practical aspects **C:** 217
 toxicity **C:** 217
 pruritus **C:** 330
 rotator cuff disorders **Ch:** 529
 site of action **A:** 114–6
 equilibrium **A:** 115
 neutral types **A:** 115
 steric interactions **A:** 115
 voltage-gated Na⁺
 channels **A:** 114–5
 spinal analgesia **A:** 257
 spinal cord injury pain **Ch:** 395,
Ch: 396 *T*
 squint (strabismus) surgery **A:** 489
 stabilizers **A:** 118
 structure **A:** 117, **A:** 117 *F*
 tonsillectomy **A:** 489
 topical
 adverse effects **Ch:** 232
 mechanisms of action **Ch:** 232
 neuropathic pain **Ch:** 233–4
 toxicity **A:** 122–3
 continuous peripheral neural
 blockade **A:** 245, **A:** 247
 inhibitory pathway
 depression **A:** 122–3, **A:** 123 *T*
 treatment **A:** 122–3, **A:** 123 *T*
 transient neurologic symptoms **A:** 257
 types **A:** 128
 amino amides **A:** 124–7
 amino-esters **A:** 124
 vasoconstrictors and **A:** 118
 vulvodinia **Ch:** 590
 WHO essential drug list **A:** 395 *T*
 wounds **A:** 366–7, **A:** 489
see also individual compounds

local anesthetic blocks
 children **A:** 489–91, **A:** 491–2;
P: 469–74
 ultrasound guidance **P:** 469
 chronic pelvic pain **Ch:** 584
 herpes zoster **Ch:** 432
 neurologic disease pain **Ch:** 331
 opioid sensitivity screening **Ch:** 215
 postherpetic neuralgia
 prevention **Ch:** 432
 refractory angina pectoris **Ch:** 540
 spinal cord injury pain **Ch:** 390,
Ch: 390–1
see also individual blocks
 local immersion, cryotherapy **A:** 536
 lockout interval
 local anesthetics **A:** 245
 PCA **A:** 219–20; **P:** 294
 locus coeruleus **A:** 12; **Ch:** 40
 loin pain
 hematuria syndrome **Ch:** 564–5
 radiotherapy **C:** 253
 long-term depression (LTD),
TENS A: 273–4
 long-term potentiation (LTP) **A:** 24–5
 definition **A:** 24
 high-frequency stimuli **A:** 25
 low-frequency stimuli **A:** 25
 manual medicine **P:** 236
 loperamide
 burn pain **Ch:** 237
 diarrhea **C:** 326
 lorazepam
 burn pain **A:** 403
 dyspnea **C:** 314
 nausea and vomiting **C:** 320 *T*
 opioid-induced delirium **C:** 187
 lordosis
 chronic pelvic pain **Ch:** 580
 neck pain radiography **Ch:** 492
 loss of resistance (LORT), pediatric
 epidural analgesia **P:** 473
 loss to follow-up, cancer pain clinical
 trials **P:** 547
 low back pain (LBP) **A:** 444–59
 age **A:** 447
 age and **A:** 447
 cauda equina syndrome **A:** 448–9
 chronic *see* chronic lower back pain
 (CLBP)
 clinical approach to **A:** 448–50
 clinical evaluation **A:** 446–8, **A:** 449 *T*
 diagnostic labeling **A:** 450
 discogenic *see* discogenic low back
 pain
 distress contributors **A:** 449
 economic costs **Ch:** 77

- epidemiology **A:** 445–6
 developed countries **A:** 445
 epiduroscopy **P:** 428–9
 gender **A:** 447
 incidence **A:** 445
 inflammation **P:** 416
 investigations **A:** 449–50
 labor **A:** 464–5
 lower limb pain **A:** 448–9
 low job satisfaction and **A:** 445
 lumbar spine diseases/
 disorders **A:** 446
 lumbar spine neuroanatomy **A:** 446,
A: 449
 management **A:** 450–3, **A:** 453–4
 active physical therapy **A:** 450–2,
A: 451 *T*
 acupuncture **A:** 282–4, **A:** 283 *T*,
A: 451 *T*, **A:** 452
 analgesics **A:** 451 *T*, **A:** 452–3
 bed rest **A:** 451, **A:** 451 *T*
 cognitive modalities **A:** 453
 evidence-based medicine **A:** 451 *T*,
A: 453–4
 guidelines **A:** 453–4
 injections **A:** 451 *T*, **A:** 453
 lumbar supports **A:** 451 *T*, **A:** 452
 mechanical back pain **A:** 454
 multidisciplinary
 programs **A:** 451 *T*, **A:** 453
 muscle relaxants **A:** 451 *T*, **A:** 453
 NSAIDs **A:** 70, **A:** 451 *T*, **A:** 452,
A: 453
 opioids **A:** 452–3
 paracetamol **A:** 452
 passive physical therapy **A:** 451 *T*,
A: 452
 pharmacotherapy **A:** 452–3
 printed information **A:** 451 *T*,
A: 453
 spinal manipulation **A:** 451 *T*,
A: 452
 TENS **A:** 451 *T*, **A:** 452
 traction **A:** 451 *T*, **A:** 452
 manual medicine **P:** 237
 mechanical problems **A:** 448, **A:** 449 *T*
 mechanisms **A:** 444–5
 multiple sclerosis **Ch:** 326
 pelvic girdle pain **A:** 448–9
 physical examination **A:** 448
 prevalence **A:** 292, **A:** 445
 prevention **A:** 447
 primary care **A:** 447
 prognosis **A:** 447–8
 psychosocial factors **A:** 445, **A:** 446–7
 outcome predictors **A:** 446
 red flag conditions **A:** 445
 self-limitation **A:** 445
 smoking and **A:** 446
 spondylosis **A:** 448
 work deferment effects **A:** 447
 within workforce **A:** 445
 yellow flags **A:** 446–7
 lower limb(s)
 continuous peripheral neural
 blockade **A:** 239–41
 adverse effect avoidance **A:** 239
 nerve blocks **P:** 279–91
 pain, low back pain **A:** 448–9
 postoperative epidural
 analgesia **P:** 318, **P:** 320
 soft-tissue disorders **Ch:** 530–1
 diagnosis **Ch:** 530
 epidemiology **Ch:** 530
 treatment **Ch:** 530–1
see also individual disorders
 lower limb asymmetric motor
 neuropathy (diabetic
 amyotrophy) **Ch:** 339
 low-molecular weight heparin
 (LMWH), spinal hematoma
 induction **A:** 261, **A:** 518
 low-threshold (LT) neurons **A:** 9
 LOX-COX inhibitors **C:** 138
 loxiglumide, chronic pancreatitis
 pain **Ch:** 554
 Luer lock needles
 neurolytic blocks **P:** 338
 zygapophyseal joint injections **P:** 364
 luetic disease **Ch:** 134
 lumbar disk herniation,
 electromyography **Ch:** 150,
Ch: 150 *T*
 lumbar dorsal root ganglion
 pain symptoms **P:** 400
 radiofrequency lesioning **P:** 400–1
 contraindications **P:** 400
 diagnostic root blocks **P:** 400
 indications **P:** 400
 L5 **P:** 401
 S1 **P:** 401
 technique **P:** 400–1, **P:** 401 *F*
 treatment efficacy **P:** 401
 lumbar epidural analgesia **P:** 312–3
 children **A:** 491–2; **P:** 473–4
 complications **A:** 491–2
 insertion **A:** 491–2
 management **A:** 491–2
 interstitial cystitis **Ch:** 557
 labor **A:** 470, **A:** 471 *T*
 lumbar medial branch blocks, lower
 back pain **Ch:** 152
 lumbar metastatic pain **C:** 28–9, **C:** 29 *T*
 lumbar plexopathies **P:** 76
 lumbar plexus **P:** 280
 lumbar plexus block **P:** 279–81
 anatomy **P:** 280
 complications **P:** 280–1
 continuous **P:** 281
 postoperative pain **A:** 332
 distal technique **P:** 280
 elderly **A:** 519
 field/emergency situations **A:** 382 *T*
 indications **A:** 238 *T*; **P:** 279
 landmarks **P:** 280
 paravertebral technique **P:** 280
 practical steps/technique **P:** 280,
P: 280 *F*
see also psoas compartment blocks
 lumbar puncture
 children, hypnosis **P:** 483
 peripheral neuropathy **P:** 80–1
 lumbar radiculopathy **Ch:** 505
 analgesia **Ch:** 511
 disc herniation **P:** 419–20
 epidural steroid injections **P:** 419–21
 caudal approach **P:** 421
 interlaminar approach **P:** 419–20,
P: 420 *T*
 transforaminal approach **P:** 420–1
 trial quality **P:** 420
 natural history **Ch:** 511
 physical therapy **Ch:** 511
 radicular leg pain **Ch:** 511
 treatment **Ch:** 511–2
 lumbar spine diseases/disorders *see* low
 back pain (LBP)
 lumbar supports, low back
 pain **A:** 451 *T*, **A:** 452
 lumbar sympathetic block **P:** 323,
P: 331–3
 anatomy **P:** 331, **P:** 331 *F*
 continuous **P:** 332
 local anesthetic dose **P:** 332
 neurolytic **P:** 331, **P:** 332
 agents **P:** 333
 complications **P:** 333
 technique **P:** 333
 technique **P:** 331, **P:** 332 *F*
 single needle **P:** 332
 lumbar sympathetic chain **P:** 280
 lumbar sympathetic ganglia,
 radiofrequency lesioning **P:** 401–2
 complications **P:** 402
 contraindication **P:** 401
 indication **P:** 401
 side effects **P:** 402
 technique **P:** 401–2
 treatment efficacy **P:** 402
 lumbar zygapophyseal blocks **P:** 364–5
 intra-articular blocks **P:** 364, **P:** 365 *F*

- lumbar zygapophyseal blocks
(*continued*)
patient positioning **P:** 364, **P:** 364 *F*
lower back pain diagnosis **Ch:** 152,
Ch: 157, **Ch:** 158–9
medial branch blocks **P:** 362 *F*,
P: 365 *F*
results **P:** 367
- lumbosacral back pain,
pregnancy **A:** 462
- lumbosacral nerve roots, phenol
“saddle” blocks **C:** 230
- lumbosacral plexopathy, cancer
patients **C:** 33–5
presacral recurrence **C:** 35
upper **C:** 33
- lumbosacral plexus
peripheral branch blocks **P:** 282
radiotherapy infiltration **C:** 254
see also individual branches
- lumiracoxib **A:** 79
serum transaminase levels **A:** 71
thrombogenicity **C:** 137
withdrawal **A:** 79; **C:** 127
- lung(s), local anesthetics **A:** 120
- lung cancer, elderly **C:** 360
- lupus erythematosus, peripheral
neuropathy **Ch:** 342
- Lyell syndrome, NSAID-induced **A:** 73
- Lyme disease **P:** 70
- lymphangitis carcinomatosa **C:** 312
- lymphedema **C:** 329
- lysine salts, oral NSAIDs **A:** 202
- machinery operation, TENS
caution **P:** 195–6
- macrophage colony-stimulating factor
(MCSF) **Ch:** 14
- magnesium
field/disaster situations **A:** 380
migraine **A:** 366
PCA **A:** 224; **P:** 295
- magnetic resonance imaging
(MRI) **Ch:** 147–8
adenomyosis **Ch:** 574
atypical facial pain **Ch:** 474–5
cancer patient assessment **C:** 40
chronic lower back pain **Ch:** 148,
Ch: 157
chronic pain **Ch:** 147–8
chronic pelvic pain **Ch:** 583
CRPS **Ch:** 367
disk-related pain **P:** 440
epiduroscopy *vs.* **P:** 432 *T*
functional *see* functional magnetic
resonance imaging (fMRI)
headache **Ch:** 454
historical aspects **Ch:** 86–7
joint pain **A:** 433
knee pain **A:** 440
malignant bone tumors **C:** 257
meningeal carcinomatosis **C:** 33 *F*
neck pain **Ch:** 159, **Ch:** 492
osteoarthritis **Ch:** 25
osteonecrosis **A:** 436
painful neuropathies **P:** 80
pelvic congestion **Ch:** 577
rheumatoid arthritis **Ch:** 520
shoulder pain **A:** 437
spinal cord compression **C:** 31,
C: 32 *F*
syringomyelia **Ch:** 154–5
temporomandibular
disorders **Ch:** 469
Tolosa–Hunt syndrome **Ch:** 154–5
trigeminal neuralgia **Ch:** 473
vertebral metastases **C:** 28, **C:** 30 *F*
- magnetic resonance volumetry **P:** 89
chronic back pain **P:** 89
- magnetoencephalography (MEG) **P:** 84
- Ma huang (ephedra) **Ch:** 315 *T*
- maintenance dose calculation **C:** 108
- maintenance strategies, CBT **Ch:** 297
- major depressive episode **C:** 56
- maladaptive behaviors, opioids **Ch:** 217
- maladaptive pain, field/disaster
situations **A:** 383
- Malawi
acute pain management **A:** 391 *T*
healthcare spending **A:** 391 *T*
- malignant bone pain *see* cancer-induced
bone pain (CIBP)
- malignant pericardial
effusions **C:** 312–3
- malignant pleural effusions **C:** 312–3
- malignant psoas syndrome **C:** 34–5
features **C:** 34, **C:** 34 *F*
pain distribution **C:** 34
- malingering **Ch:** 620; **P:** 680
- malnutrition, elderly **C:** 361
- Manchester Triage Scale **A:** 140
- mandibular movement changes,
temporomandibular
disorders **Ch:** 468
- manual medicine **Ch:** 307, **Ch:** 307 *T*;
P: 230–9
acute neck pain treatment **Ch:** 494
assessment **P:** 231
biopsychosocial model, case
history **P:** 231–5
chronic neck pain treatment **Ch:** 494
clinical trial evidence **P:** 237
CNS-based mechanisms **P:** 235–7
bottom-up effects **P:** 235
clinical trial results **P:** 237
counter-irritation effects **P:** 235–6
descending inhibition **P:** 235
diffuse noxious inhibitory
control **P:** 235–6
extinction **P:** 236
facilitation **P:** 236
gate control theory **P:** 235
habituation **P:** 236
motor responses **P:** 236
sympathetic nervous system
responses **P:** 236–7
top-down effects **P:** 235
definitions **P:** 230–1
examination **P:** 231
exercise therapy and **P:** 237
multidimensional approaches **P:** 237
physical testing **P:** 231
placebo response **P:** 237
red flags **P:** 231
sciatica, case history **P:** 231–5
body chart **P:** 232 *F*
continuing management **P:** 234–5
explanation **P:** 233–4
initial physiotherapy input **P:** 234
management **P:** 233–5
physical assessment **P:** 232–3
presentation **P:** 231–2, **P:** 232 *F*
psychosocial factors **P:** 232
reassurance **P:** 233–4
recovery agenda setting **P:** 233–4
yellow flag assessment **P:** 232,
P: 233 *T*
yellow flags **P:** 231
- manual muscle tests, sciatica **P:** 232–3
- massage
cancer pain **C:** 277–8, **C:** 278, **C:** 370
definition **C:** 277
dying person **C:** 394
low back pain **A:** 451 *T*, **A:** 452;
Ch: 509; **P:** 224
physical effects **C:** 278
sciatica **P:** 234
techniques **P:** 231
see also individual techniques
- mass spectrometry,
proteomics **Ch:** 59–60
- mast cells
pruritus **C:** 329
visceral hypersensitivity **Ch:** 42
- mastectomy
nerve trauma/damage **C:** 7
postoperative pain *see* postbreast
cancer surgery pain (PBCSP)
- MASTER trial, neuraxial
analgesia **A:** 265
- mastery model, surgical patients **P:** 252

- masticatory muscle pain,
temporomandibular
disorders **Ch:** 468
- match/mismatch model of pain **P:** 179
- Materia Medica* **Ch:** 310–1
- maternal separation, postnatal
development effects **A:** 43
- MAVERICK artificial disk **P:** 242
- maxillary sinusitis **Ch:** 155
- maximal androgen blockade, prostate
cancer **C:** 265
- maximum safe dose (MSD), local
anesthetics **A:** 119
- MC1R* gene/protein **Ch:** 62 *T*
- McGill Pain Questionnaire
(MPQ) **A:** 144; **P:** 16–7,
P: 18 *F*
- acute pain **A:** 144
- advantages **A:** 144
- burn pain **A:** 401
- cancer pain **C:** 42
- chronic pain patients **Ch:** 125
- confirmatory factor analyses **Ch:** 125
- disadvantages **A:** 144
- elderly **C:** 361–2
- English as first language
issues **Ch:** 125
- phantom pain **Ch:** 417
- presurgical assessment **P:** 248
- short form *see* Short-Form McGill
Pain Questionnaire (SF-MPQ)
- visceral hypersensitivity
disorders **Ch:** 38–9
- M channel (*KCNQ* gene) **Ch:** 9
- meaning response **P:** 500
- mean transit time (MMT-S),
opioid-induced
constipation **C:** 189–90
- measurement of pain *see* pain measures
- mechanical evoked pain, clinical trial
outcomes **P:** 521, **P:** 522 *T*
- “mechanical failure,” disability
measurement **Ch:** 119
- “mechanical” joint pain **A:** 431, **A:** 436
- mechanical/manipulative therapies *see*
manual medicine
- mechanical stimuli
ex-neonatal ICU patients **A:** 43
- human visceral pain models **Ch:** 41
- neuropathic pain assessment
Ch: 138, **Ch:** 139 *T*
- somatic vs. visceral
nociception **A:** 6–7
- mechanical/stretch distension,
persistent visceral pain **Ch:** 38
- mechanical-type neuropathic
pain **Ch:** 135
- mechanoreceptors, somatic
nociceptors **A:** 4–6
- Meckel’s diverticulum **Ch:** 562
- media, end of life issues reporting **C:** 97
- medial branch blocks **P:** 361–9
cervical **P:** 366, **P:** 366 *F*, **P:** 367 *F*
lower back pain diagnosis **Ch:** 159
lumbar **P:** 362 *F*, **P:** 364–5, **P:** 365 *F*
neck pain diagnosis **Ch:** 493,
Ch: 493 *F*
- medial collateral ligament strain **P:** 356
- medial cutaneous nerve of the
forearm **P:** 271
- medial cutaneous nerve of the forearm
block **P:** 272
- medial epicondylitis
diagnosis **Ch:** 529 *T*
epidemiology **Ch:** 529
soft-tissue injection **A:** 438; **P:** 355
- medial tennis elbow *see* medial
epicondylitis
- medial thalamus, nociception **A:** 12–3
- median nerve
arm **P:** 265
axilla **P:** 269, **P:** 269 *F*
compression **Ch:** 342
elbow **P:** 270
wrist **P:** 273
- median nerve block
elbow **P:** 272
landmarks **P:** 272
practical steps/technique **P:** 272,
P: 272 *F*
forearm fractures **A:** 368
wrist **P:** 273–4
landmarks **P:** 273
practical steps/technique **P:** 273–4,
P: 274 *F*
- medical gases, dyspnea **C:** 314
- medical negligence
legal standing **P:** 681–2
Woolf recommendations **P:** 682
see also expert medicolegal report
- medical oncologists, elderly pain
control **C:** 362
- Medical Outcomes Study 36-Item Short
Form (SF-36) *see* Short-Form 36
(SF-36)
- Medical Research Council
website **P:** 564
- medical staff
education
APS **P:** 585–6
pediatric APS **P:** 643
pediatric persistent pain
services **P:** 648–9
- medical undertreatment of pain **Ch:** 94
- medication overuse headache
(MOH) **Ch:** 455
- Medicines and Healthcare Products
Regulatory Agency website **P:** 564
- medicolegal report, expert *see* expert
medicolegal report
- meditation **Ch:** 315; **P:** 480 *T*
- MEDLINE **P:** 570 *T*
- medroxyprogesterone **C:** 328
- medroxyprogesterone acetate
(MPA) **Ch:** 577
- Medtronic “restore,” SCS
system **P:** 406 *T*
- medulla, persistent visceral pain **Ch:** 40
- medulla-radicular irritation,
epiduroscopy-induced **P:** 435
- mefenamic acid **A:** 75 *T*, **A:** 78
- megestrol acetate
anorexia cachexia syndrome **C:** 328
hot flushes **C:** 331
- melanocortin -1 receptor **Ch:** 62 *T*
- melatonin **C:** 328
- meloxicam **A:** 75 *T*, **A:** 78
thrombotic risk **C:** 136
- memantine
elderly **A:** 516
pediatric headache **Ch:** 632
postamputation pain **Ch:** 423
- membrane stabilizers, spinal
administration **Ch:** 287
- Memorial Delirium Assessment Scale
(MDAS) **C:** 40, **C:** 186
- Memorial Pain Assessment Card **C:** 42
- Memorial Symptom Assessment Scale
10-18 (MASAS 10-18),
children **C:** 346
- memory, children **A:** 311, **A:** 313
- meningeal carcinomatosis **C:** 31–2
causes **C:** 31
diagnosis **C:** 32
pain syndromes **C:** 29 *T*, **C:** 31–2
radiological investigation **C:** 32,
C: 33 *F*
spinal symptoms/signs **C:** 32 *T*
- meningitis, SCS-induced **P:** 411
- Mental Capacity Act 2005,
England **C:** 96
- mental exercises, children **A:** 313
- mental imagery
biofeedback, children **P:** 488
needle phobia **P:** 489
see also hypnosis
- mental nerve **P:** 260, **P:** 260 *F*
cryoanalgesia **P:** 384–5
- mental nerve block **P:** 260
anatomy **P:** 260
landmarks **P:** 260, **P:** 260 *F*

- mental nerve block (*continued*)
 practical steps/technique **P:** 260
- mental training *see* biofeedback
- menthol **C:** 330
- meperidine *see* pethidine
- mepivacaine **A:** 127; **P:** 326–7
 characteristics **A:** 125
 clearance **A:** 120
 dental surgery, children **A:** 489
 transient radicular irritation
 induction **A:** 122
- meralgia paresthetica **Ch:** 342–3; **P:** 358
 pregnancy **A:** 462
- mercury poisoning **Ch:** 341
- merperthidine *see* pethidine
- mesencephalon **Ch:** 40
- mesenteric ischemia, chronic (ischemic colitis) **Ch:** 561–2
- mesocorticolimbic dopaminergic pathways, opioid addiction **A:** 544
- mesothelioma **C:** 252
- messenger RNA (mRNA) **Ch:** 49
- meta-analysis **P:** 571
 acute pain assessment **A:** 149
 CAM **Ch:** 305
 CBT in chronic pain **Ch:** 297–300
 absolute efficacy **Ch:** 297
 clinical significance **Ch:** 298
 data analysis **Ch:** 299, **Ch:** 299 *F*
 effect sizes **Ch:** 298
 multiple outcomes **Ch:** 298,
Ch: 298 *T*
 multiple trial arms **Ch:** 298–9
 outcomes **Ch:** 298
 quality scales **Ch:** 299–300
 relative efficacy **Ch:** 297
 treatment controls **Ch:** 298–9
 treatment effects **Ch:** 298–9
 trial quality issues **Ch:** 299–300
 waiting list controls **Ch:** 298–9
- chiropractic therapy efficacy **Ch:** 312
- confidence intervals **A:** 149
- definition **A:** 149
- PCA analgesic efficacy **A:** 222
- reliability **P:** 571–2
- summary statistic choice **P:** 572
- topical NSAIDs **Ch:** 235–6
- metabolic bone disease, spinal pain **Ch:** 156
- metabolic disorders
 acute pain and **A:** 419–22
 neck pain **Ch:** 488
- metabolic neuropathies **Ch:** 339–40
- metabotropic glutamate receptors (mGluR)
 central sensitization **Ch:** 12
 early development **A:** 34 *T*
- orofacial neuropathic pain **Ch:** 471
- metacarpal fractures **A:** 528
- metacarpophalangeal joint,
 intra-articular injection **P:** 352
- metaclopramide, pediatric
 headache **Ch:** 631 *T*
- metamizole *see* dipyrone (metamizole)
- MetaRegister of Current Controlled Trials **P:** 570 *T*
- meta-regression **P:** 573
- metastatic bone pain
 breakthrough **C:** 290
 NSAIDs **C:** 128
 radiotherapy **C:** 259, **C:** 260 *F*
- metastatic disease, children **C:** 346
- metatarsal fractures **A:** 528
- metatarsophalangeal joints, intra-articular injection **P:** 353
- methadone **A:** 61; **C:** 160–1
 accumulation **C:** 160
 adverse effects **C:** 160
 sedation **C:** 184
 torsade de pointes **Ch:** 216
 breakthrough pain **C:** 291
 cancer pain **A:** 61; **C:** 160–1, **C:** 169 *T*
 neuropathic **C:** 204
 children **P:** 466 *T*, **P:** 468
 “as needed” dosing **C:** 349
 cancer pain **C:** 349, **C:** 352 *T*
 headache **Ch:** 632 *T*
- chronic noncancer pain **Ch:** 210–1
- cough **C:** 315
- dose conversion **Ch:** 210–1;
C: 393
- dying person **C:** 393
- equianalgesic doses **A:** 547 *T*
- intranasal administration **P:** 307
- mechanism of action **A:** 550; **Ch:** 210
 mu opioid receptor
 endocytosis **Ch:** 214
- morphine vs. **Ch:** 210; **C:** 393
- neuropathic pain **Ch:** 208
- nociceptive pain **Ch:** 208
- opioid-tolerant patients **A:** 550
- oral bioavailability **A:** 58; **C:** 160
- PCA, opioid-dependent patients **P:** 297–8, **P:** 298 *T*
- pharmacodynamics **C:** 160
- pharmacokinetics **A:** 59 *T*, **A:** 550;
Ch: 210; **C:** 160
 clearance **Ch:** 210
 pharmacology **C:** 204
 redistribution **A:** 61
 routes of administration/
 formulations **C:** 160
 single-dose studies **Ch:** 210
 spinal cord injury pain **Ch:** 394
- subcutaneous drug infusion, cancer patients **P:** 127 *T*
- substance abuse/misuse **A:** 550; **C:** 385
- toxicity **Ch:** 211
- unacceptability **C:** 393
- volume of distribution **A:** 58
- methemoglobin, EMLA-induced **A:** 488
- methionine therapy, paracetamol overdose **A:** 92
- method-effectiveness, clinical trials **P:** 525
- methotrexate
 NSAID interactions **A:** 74 *T*
 rheumatoid arthritis **Ch:** 521,
Ch: 522–4 *T*
- methotrimeprazine **C:** 354
- methoxyflurane, burn pain **A:** 404
- methylnaltrexone
 cholestasis **C:** 330
 constipation **C:** 324
- methylphenidate
 cancer patients
 children **C:** 353–4
 fatigue **C:** 329
 opioid-induced sedation **C:** 184
- methylprednisolone
 epidural injection **P:** 419
 osteoarthritis **Ch:** 527
 sports injury **A:** 535
- methysergide, migraine **Ch:** 459–61,
Ch: 461 *T*
- metimazole *see* dipyrone
- metoclopramide
 migraine **Ch:** 455
 emergency department
 management **A:** 365, **A:** 366 *T*
 nausea and vomiting **C:** 320 *T*
 opioid-induced bowel
 dysfunction **P:** 129
- metoprolol, ischemic cardiac chest pain **A:** 365
- mexiletine **Ch:** 263; **P:** 139
 adverse effects **P:** 140
 central neuropathic pain **Ch:** 379–80,
Ch: 380
 contraindications **P:** 139
 dosing/treatment schedule **P:** 140
 HIV-associated neuropathy **Ch:** 355–6
 post-intravenous lidocaine trial **P:** 57,
P: 59
 sodium channel blockade **Ch:** 263
 spinal cord injury pain **Ch:** 395,
Ch: 396 *T*
- microaerosols **A:** 128
- microarrays **Ch:** 57–8, **Ch:** 58–9,
Ch: 58 *F*, **Ch:** 62 *T*
 interpretation **Ch:** 59

- microcatheters, continuous spinal analgesia **A:** 261
- microfatigue, overuse injuries **A:** 527
- microglia
ERK **Ch:** 14–5
neuropathic pain **Ch:** 11 *F*, **Ch:** 13
activation **Ch:** 14
nociception **A:** 11
p38 MAP kinase **Ch:** 14–5
- microneurography **P:** 51–2
CRPS vasomotor changes **Ch:** 365
limitations **P:** 52
- microvascular decompression, trigeminal neuralgia **Ch:** 473
- midazolam
agitation **C:** 335
delirium
cancer patients **C:** 334
opioid-induced **C:** 187
epidural analgesia **A:** 259
hypnosis vs. **P:** 483
neuraxial analgesia **A:** 259
procedure-related pain **C:** 218
- midbrain reticular formation, central sensitization **P:** 88
- middle cervical ganglion **P:** 327
- Middle East
opioid availability **C:** 88
palliative care services **C:** 86, **C:** 87–8
education/training **C:** 88
home care services **C:** 87
hospice inpatient care units **C:** 88
service development barriers **C:** 88
- Middle East Cancer Consortium (MECC) **C:** 87
opioid availability **C:** 88
physician prescribing powers **C:** 88
- migraine
abdominal *see* abdominal migraine
age-related prevalence **Ch:** 452
aura **Ch:** 450–1
cortical hyperexcitability **Ch:** 452–3
biofeedback **P:** 164, **P:** 488
children
diagnosis **Ch:** 629 *T*
differential diagnosis **Ch:** 629–30
prevalence **Ch:** 628
classification **Ch:** 450–1, **Ch:** 451 *T*
clinical features **Ch:** 452
cortical spreading depression **Ch:** 453
diagnosis **Ch:** 454
emergency department
management **A:** 365–6
epidemiology **Ch:** 451–2
age-related **Ch:** 452
genetics **Ch:** 452
pathophysiology **Ch:** 452–3
nitroglycerin model **Ch:** 453
precipitating factors **Ch:** 452
visual stimuli **Ch:** 452–3
precipitating factors **Ch:** 452
prevalence **A:** 104
prophylaxis **A:** 104–5; **Ch:** 459–61, **Ch:** 461 *T*
skin temperature-assisted relaxation **P:** 158
treatment **Ch:** 455–7
clinical trials **Ch:** 455, **Ch:** 456 *T*
as trigeminovascular disease **Ch:** 453
triptans *see* triptan(s)
- Military Advanced Regional Anesthesia and Analgesia (MARAA) **A:** 377
- milk thistle **Ch:** 314 *T*
- Million Visual Analog Scale (MVAS) **Ch:** 118
- milnacipran **Ch:** 244 *T*
peripheral neuropathic pain **Ch:** 346
pharmacology **Ch:** 245
- Milwaukee shoulder **Ch:** 526
- mind/body skills **P:** 145–52
certification **P:** 493
children **P:** 478–95
benefits **P:** 481
clinical applications **P:** 481–90
developmental issues **P:** 479–80
holistic approach **P:** 480
indications **P:** 479
integration **P:** 491–2
integrative approaches **P:** 480
quality of life **P:** 493–4
sequential training model **P:** 490–1
strategy designs **P:** 490–3
cognitive reframing, pain **P:** 493
contraindications **P:** 493
concurrent medication use **P:** 493
definitions **P:** 478–9
expectancy management **P:** 150
limitations **P:** 493
nonspecific pain control
mechanisms **P:** 492
“rehabilitation” model **P:** 150
therapeutic change
mechanisms **P:** 492–3
sympathetic nervous system activity **P:** 492
training **P:** 493
see also individual skills/techniques
- Mindful Attention Awareness Scale (MAAS) **P:** 170–1
- mindfulness **P:** 170–1
acceptance of pain and **P:** 170–1
definition **P:** 170
guided imagery vs. **P:** 170
relaxation vs. **P:** 170
research lack **P:** 170
- mindfulness-based stress reduction (MBSR) **P:** 149
- mindful therapies **Ch:** 307, **Ch:** 307 *T*, **Ch:** 315–6
research **Ch:** 315–6
see also individual techniques
- minimal intervention strategies, CBT **A:** 300
- Mini-Mental State Examination (MMSE) **C:** 39–40, **C:** 186
- minimum clinically important change (MCIC) **Ch:** 185
- minimum effective analgesic concentration (MEAC)
elderly physiological simulations **A:** 509
opioids **A:** 206
PCA **A:** 220
- minimum local analgesic concentration (MLAC)
labor pain **A:** 471
ropivacaine **A:** 127
- Minnesota Multiphasic Personality Inventory (MMPI) **Ch:** 126, **Ch:** 126 *F*
lumbar surgery success prediction **Ch:** 128
personality disorders **Ch:** 618
- miosis, opioid-induced **C:** 155
- mirror image areas, neuropathic pain **Ch:** 137–8
- mirtazepine
depression **C:** 332
pruritus **C:** 330
- misoprostol **A:** 71; **C:** 133
- mistletoe **Ch:** 315 *T*; **C:** 274
- mitochondria-dependent apoptosis **Ch:** 10
- mitochondria genome **Ch:** 49
mutations **Ch:** 60
- mitogen-activated protein kinase (MAPK), central sensitization **A:** 26–7
- Mittelschmerz **A:** 417
- mixed pain syndromes **A:** 560
- mobilization, pediatric CRPS **Ch:** 626–7
- “Model Guidelines for the Use of Controlled Substances for the Treatment of Pain” **Ch:** 106–7
- modeling
CBT in children **A:** 317
preprocedural **P:** 252
children **P:** 252
- molecular imaging **P:** 84, **P:** 90–1
metabolic change **P:** 90–1
- monitoring, coping style **A:** 310–1

- mono-amine oxidase inhibitors,
fibromyalgia syndrome **Ch:** 607
- monoclonal gammopathy, serum
protein electrophoresis **P:** 67
- mononeuritis multiplex **P:** 76, **P:** 76 *T*
HIV-associated pain **Ch:** 342, **Ch:** 357
- mononeuropathies **Ch:** 335; **P:** 76,
P: 76 *T*
- mood disorders
cancer patients, history taking **C:** 39
pain and **P:** 147
see also individual disorders
- morbid obesity
PCA **A:** 225; **P:** 298
SCS contraindication **P:** 407
- morphine **A:** 59; **C:** 158–9
abdominal pain, acute **A:** 414
acute coronary syndrome **A:** 418
addiction, field/disaster
situations **A:** 378
adverse effects **A:** 484; **C:** 158
delayed **C:** 158
respiratory depression **A:** 514;
C: 191
sedation **C:** 184
affective response changes **C:** 158
analgesic action onset **C:** 158
benztropine vs. **Ch:** 211
brachial plexus neuropathy,
radiotherapy-induced **C:** 406
breakthrough pain **C:** 291
buccal administration **A:** 208
burn pain **A:** 400–3
cancer-induced bone pain **C:** 5
cancer-induced/related neuropathic
pain **C:** 202, **C:** 203
clinical studies **C:** 203
cancer pain **C:** 159, **C:** 169 *T*
cardiac pain **A:** 418
central neuropathic pain **Ch:** 380
children **A:** 484; **C:** 348; **P:** 466–7
clearance **C:** 348
dosages **C:** 348, **C:** 352 *T*; **P:** 466 *T*
headache **Ch:** 631, **Ch:** 632 *T*
parenteral **P:** 466
chronic noncancer pain **Ch:** 211–2
conjugation **C:** 158
consumption per capita **A:** 391–2,
A: 392 *F*
continuous subcutaneous
administration **C:** 110
controlled-release
preparations **Ch:** 211–2
cough **C:** 315
developing world **A:** 391–2, **A:** 392 *F*
dying person **C:** 393
dyspnea **C:** 313
starting dose **C:** 313
effects, in absence of pain **C:** 158
elderly **A:** 513; **C:** 367
adverse effects **A:** 514; **C:** 367
doses **A:** 514
PCA **P:** 298–9
prescription **C:** 362
emergency departments **A:** 362
dose adjustments **A:** 362
epidural analgesia **P:** 319
children **P:** 474 *T*
equianalgesic doses **A:** 547 *T*
femoral neck fractures **A:** 366
fentanyl vs. **Ch:** 209
field/disaster situations **A:** 375
fracture reduction **A:** 367
gabapentin and **Ch:** 258
half-life, individual variability **A:** 58
inhalational administration **A:** 209
intermittent intravenous bolus
administration chart **P:** 638–9 *F*
intra-articular administration **A:** 210
postoperative pain
management **A:** 331
intramuscular administration **A:** 205
intrathecal administration **A:** 210
intravenous challenges **P:** 63
ischemic cardiac chest pain **A:** 365
ketamine and **A:** 224
ketorolac and **A:** 224
lidocaine and **A:** 224
magnesium and **A:** 224
metabolism **A:** 59; **C:** 158
children **C:** 348
methadone vs. **Ch:** 210; **C:** 393
naloxone and **A:** 224
neonates **P:** 466–7, **P:** 467 *T*
neuraxial administration **A:** 484
neuropathic pain **Ch:** 208, **Ch:** 209
nociceptive pain **Ch:** 208
nurse-controlled analgesia **A:** 484
oral administration **A:** 203, **A:** 484
potency ratio **A:** 203, **A:** 203 *T*
osteoarthritis **Ch:** 209
oxycodone and **Ch:** 214
parenteral administration
children **A:** 484
elderly **A:** 505
PCA
children **A:** 484; **P:** 466
co-administered drugs **A:** 224
pharmacodynamics **C:** 158
pharmacokinetics **A:** 59 *T*; **C:** 158
children **A:** 484
developmental **P:** 466–7
pharmacology **C:** 203
children **C:** 348
postherpetic neuralgia **Ch:** 434–5
postoperative pain
management **A:** 335
rectal administration **A:** 204; **C:** 110
hydrogels **A:** 204
renal colic **A:** 363–4
routes of administration/
formulations **A:** 59; **C:** 159
children **A:** 484
sickle cell disease pain **A:** 420
spinal administration **Ch:** 286,
Ch: 288
spinal cord injury pain **Ch:** 394,
Ch: 395, **Ch:** 396 *T*
subcutaneous infusion, cancer
patients **P:** 126, **P:** 127 *T*
alternative drugs **P:** 126
metabolism **P:** 126
switching **C:** 169
therapeutic limitations **C:** 113
topical application **Ch:** 237
tramadol and **Ch:** 214
transdermal, nausea induction **C:** 191
WHO analgesic ladder **C:** 113
WHO essential drug list **A:** 395 *T*
morphine-3-glucuronide (M3G) **C:** 158,
C: 203
elderly **C:** 367
renal failure **P:** 129
subcutaneous drug infusion, cancer
patients **P:** 126
morphine-6-glucuronide (M6G) **C:** 158,
C: 203
renal failure **P:** 129
subcutaneous drug infusion, cancer
patients **P:** 126
morphine glucuronides, kidney
failure **A:** 348–9
Morton metatarsalgia **Ch:** 342–3
motility disorders, cancer
patients **C:** 321
motivational interviewing
techniques **P:** 100
physiotherapy **P:** 225
motivational system, substance abuse/
misuse **Ch:** 654
motor axons, peripheral
neuropathy **P:** 77 *T*
motor (nerve) block
cryoanalgesia-induced **P:** 381
local anesthetics **A:** 256
monitoring, APS **P:** 593–5
neuraxial analgesia **A:** 256
thoracic epidural analgesia **A:** 260
motor cortex stimulation
(MCS) **Ch:** 279
central neuropathic pain **Ch:** 383

- clinical effectiveness **C**: 246
 definition **Ch**: 279
 localization **Ch**: 279
 prophylactic antiseizure drugs **Ch**: 279
- motor end-plate, myofascial pain **Ch**: 605
- motor nerve damage, herpes zoster **Ch**: 430
- motor paresis, neurolysis-induced **C**: 231 *T*
- motor power, peripheral neuropathy **P**: 78
- movement-based therapies **Ch**: 307, **Ch**: 307 *T*
- movement disorders **Ch**: 327
 CRPS **Ch**: 367
 hyperkinetic *see* hyperkinetic movement disorders
 hypokinetic **Ch**: 327
 pain underestimation **Ch**: 327
 terminology **Ch**: 327
- movement fears, questionnaires **P**: 180
- moxibustion **P**: 216
- mucolysis **C**: 315
- mucositis **A**: 418–9
 cancer-related **A**: 418–9; **C**: 317
 topical pain therapy **Ch**: 237
- multiarmed trials, CBT **Ch**: 298–9
- Multidimensional Pain Inventory (MPI) **Ch**: 127; **P**: 17, **P**: 33–4 *T*
 advantages **Ch**: 173
 cancer pain **P**: 21
 chronic pain **Ch**: 127
 daily functioning
 assessment **Ch**: 172 *T*, **Ch**: 173
 coverage **P**: 32
 patient classification **Ch**: 173; **P**: 17
- multidisciplinary teams
 chronic pelvic pain **Ch**: 587
 continuous peripheral neural blockade **A**: 237
 low back pain management **A**: 451 *T*, **A**: 453
- multidrug resistance gene 1 (MDR-1), opioid response
 variability **C**: 170–3
- multimodal analgesia
 breakthrough pain **Ch**: 221
 children **A**: 480–1
 definition **P**: 668
 field/disaster situations *see* field/disaster situations
 inflammatory bowel disorders **A**: 417
 NSAIDs **A**: 70
 preoperative **A**: 185, **A**: 186
 definition **A**: 185
- negative effects **A**: 185
 surgical procedures **A**: 185
- Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) program **Ch**: 195–6; **C**: 366
- multiple myeloma **C**: 264
- multiple sclerosis (MS) **Ch**: 324–7, **Ch**: 375–6
 acute pain **A**: 411
 anticonvulsant drugs **A**: 411; **Ch**: 330
 CAM **Ch**: 332
 central neuropathic pain **Ch**: 375–6
 nociceptive pain *vs.* **Ch**: 376
 as presenting feature **Ch**: 376
 prevalence **Ch**: 376
 severity **Ch**: 376
 treatment **Ch**: 380
 characteristics **Ch**: 325
 clinical course **Ch**: 325
 definition **Ch**: 375–6
 epidemiology **Ch**: 325
 epileptiform seizures **Ch**: 326
 etiology **Ch**: 325
 lesion distribution **Ch**: 376
 Lhermitte's phenomenon **Ch**: 326
 mechanical neuropathic pain **Ch**: 326–7
 musculoskeletal pain **Ch**: 325, **Ch**: 326, **Ch**: 376
 central neuropathic pain *vs.* **Ch**: 376
 myelopathic pain **Ch**: 325
 pain classification **Ch**: 326
 pain presentation patterns **Ch**: 325–7
 iatrogenic **Ch**: 327
 incidence **Ch**: 325
 nonspecific exacerbation **Ch**: 327
 prevalence **Ch**: 375–6
 primary neurogenic pain **Ch**: 326–7
 nonparoxysmal **Ch**: 326
 paroxysmal **Ch**: 326
 spasticity in **Ch**: 376
 trigeminal neuralgia **Ch**: 326
- multiplex protein analysis **Ch**: 62 *T*
- mu (μ) opioid receptors **A**: 54
 A118G nucleotide
 substitution **C**: 173–4
 endocytosis **Ch**: 214
 endogenous ligands **A**: 55
 gene polymorphisms **A**: 54, **A**: 223
 knockout mice **A**: 54; **C**: 173
 location **A**: 55
 methadone **Ch**: 214
 morphine binding **A**: 59
 neuraxial analgesia **A**: 256
 opioid-tolerance **A**: 543–4
- pharmacogenetics **Ch**: 62 *T*
 placebo effect **P**: 506
 postnatal development **A**: 45
 response variability **C**: 173–4
 single nucleotide
 polymorphisms **A**: 54
 spinal cord **A**: 15
 stimulation **C**: 152
 structure **C**: 152
 subtypes **A**: 54; **C**: 152
 TENS **C**: 238
- muscarinic receptors, TENS **A**: 275
- muscle(s)
 cryotherapy **A**: 536
 discrimination assessment **P**: 157
 fibromyalgia syndrome **Ch**: 603
 innervation **Ch**: 26
 mass, age-related changes **A**: 506 *T*, **A**: 508
 residual limb pain **Ch**: 419
 spasticity **Ch**: 441, **Ch**: 442
 sports injuries **A**: 530–1
 ultrasound **Ch**: 148
- muscle biopsy, peripheral neuropathies **Ch**: 337
- muscle bulk examination, peripheral neuropathy **P**: 78
- muscle discrimination training **P**: 161–2
- muscle pain
 experimental research
 approaches to **P**: 45
 hypertonic saline injection **P**: 46
 models **P**: 45–6
 stimulus paradigm **P**: 45
 neural mechanisms **P**: 45
 referred **P**: 45
see also musculoskeletal pain
- muscle relaxants
 cancer-induced/related neuropathic pain **C**: 209
 local anesthetics **A**: 124
 low back pain
 acute **A**: 451 *T*, **A**: 453
 chronic **Ch**: 508
- muscle relaxation techniques
 children **P**: 481
 chronic tension headaches **P**: 488
 progressive *see* progressive muscle relaxation training
- muscle spasms
 spinal cord injury **Ch**: 389, **Ch**: 393
 spinal pain **Ch**: 157
- muscle tension, chronic pain **P**: 155
- muscle tone, opioid effects **A**: 57; **C**: 155
- muscular rheumatism *see* fibromyalgia syndrome (FMS)

- musculocutaneous nerve **P**: 265
 axilla **P**: 269, **P**: 269 *F*
- musculoskeletal pain
 acupuncture **A**: 281
 acute **A**: 430–43
 articular *see* joint pain, acute
 clinical assessment **A**: 431
 clinical diagnosis **A**: 431–2
 clinical presentation **A**: 431–2
 diagnostic tests **A**: 432–3
 examination **A**: 432
 mechanism-based
 taxonomy **A**: 431, **A**: 432 *T*
 nonarticular, diagnosis **A**: 433
 regional approach **A**: 436–41
 central poststroke pain **A**: 411
 chest **Ch**: 544
 children **Ch**: 624–8
 diagnosis **Ch**: 624
 etiology **Ch**: 624
 history taking **Ch**: 624
 chronic pelvic pain **Ch**: 573 *T*,
 Ch: 580–1
 Guillain–Barré syndrome **A**: 412
 HIV infection **Ch**: 357
 multiple sclerosis **Ch**: 376
 persistent **Ch**: 24–36
 chest **Ch**: 544
 deep referred pain **Ch**: 30
 etiology **Ch**: 25–6
 inflammation **Ch**: 25, **Ch**: 26,
 Ch: 30
 nociceptive system
 activation **Ch**: 26, **Ch**: 27 *F*
 secondary hyperalgesia **Ch**: 30
 sensations **Ch**: 25
 site of injury **Ch**: 24–5
 spinal cord nociceptors **Ch**: 29–30
 spinal hyperexcitability **Ch**: 27 *F*,
 Ch: 30–1
 spinal processing **Ch**: 29–31
 spinal sensitization, molecular
 mechanisms **Ch**: 31
 supraspinal neurons **Ch**: 32
 spasticity **Ch**: 444
 spinal cord injury *see* spinal cord
 injury (SCI) pain
 TENS **P**: 195, **P**: 201
 vitamin D deficiency **P**: 68
 see also individual diseases/disorders
- music therapists, pediatric APS **P**: 643
 music therapy **C**: 278–9
 MUST-EECP study **Ch**: 541
 myalgia *see* fibromyalgia syndrome
 (FMS)
 myelin sheath **A**: 114
 myelography **Ch**: 148
- myelopathic disorders **Ch**: 136
 myelopathic pain, multiple
 sclerosis **Ch**: 325
 myeloperoxidase (MPO) **P**: 70
 myocardial ischemia, acute **A**: 417
 myoclonus
 definition **Ch**: 327; **C**: 187
 opioid-induced **C**: 187–8
 children **C**: 353 *T*
 clinical presentation/
 findings **C**: 188
 diagnostic criteria **C**: 188, **C**: 188 *T*
 epidemiology **C**: 187–8
 etiology **C**: 187
 management **C**: 188
 pathophysiology **C**: 187
 patterns **C**: 187
- myofascial pain (MFP) **Ch**: 599–613
 acupuncture research **P**: 208
 chronic pelvic pain *see* chronic pelvic
 pain (CPP)
 diagnosis **Ch**: 601
 modified criteria **Ch**: 601, **Ch**: 602
 trigger points **Ch**: 601
 enhanced pain sensitivity **Ch**: 605
 epidemiology **Ch**: 602
 management **Ch**: 608
 topical analgesics **Ch**: 236–7
 needling **P**: 208
 pathophysiology **Ch**: 605, **Ch**: 606 *F*
 persistent musculoskeletal
 pain **Ch**: 26
 prognosis **Ch**: 609
 risk factors **Ch**: 603
 temporomandibular
 disorders **Ch**: 469
 TENS **P**: 195, **P**: 201
 see also fibromyalgia syndrome (FMS);
 individual diseases/disorders
- myofascial trigger points
 acupuncture point overlap **C**: 273;
 P: 206–7, **P**: 207 *F*
 back **P**: 211 *F*
 head and neck **P**: 210 *F*
- myofasciitis *see* fibromyalgia syndrome
 (FMS)
 myositis **Ch**: 26, **Ch**: 30
- nabilone **C**: 320 *T*
 nabumetone **A**: 78; **C**: 133
 gastrointestinal adverse effects **C**: 133
 metabolism **A**: 70
 properties **A**: 75 *T*
 safety profile **C**: 133
- N-acetyl aspartate (NAA) **P**: 89–90
 N-acetylcysteine therapy, paracetamol
 overdose **A**: 92
- Na⁺-K⁺ ATPase **A**: 114
 nalbuphine
 acute pain **A**: 61
 burn pain **A**: 403
 cancer pain **C**: 162
 opioid-related pruritus **A**: 228, **A**: 258
 pharmacokinetics **A**: 59 *T*
- nalfurafine **C**: 331
 nalmefene
 cancer pain **C**: 163
 PCA **A**: 228
- naloxone
 cancer patients **C**: 162
 children **P**: 297, **P**: 468
 intravenous opioid drug challenge
 reversal **P**: 63
 opioid-induced pruritus **A**: 228
 opioid-tolerant patients **A**: 549
 PCA **A**: 224; **P**: 295
 children **P**: 297
 morphine and **A**: 224
 nausea and vomiting
 reduction **A**: 228
 placebo effect neurochemistry **P**: 505
- naltrexone **C**: 163
 cancer patients **C**: 163
 mechanism of action **A**: 550
 opioid-induced pruritus **A**: 228,
 A: 258
 opioid-tolerant patients **A**: 550
- NAPI (Neonatal Assessment of Pain
 Inventory) **A**: 479 *T*
- naproxen **A**: 77
 cardiovascular risks **C**: 136–7
 clinical use **A**: 75
 elderly **C**: 366
 metastatic bone pain **C**: 258
 migraine prophylaxis **Ch**: 461 *T*
 numbers needed to treat **A**: 89 *T*
 properties **A**: 75 *T*
 rheumatoid arthritis **Ch**: 198
 subcutaneous infusion, cancer
 patients **P**: 130
 temporomandibular
 disorder **Ch**: 469–70
 tension-type headache **Ch**: 458
 thrombogenicity **C**: 137–8
- naratriptan, migraine **Ch**: 455–6,
 Ch: 460 *T*
- narcosis, subcutaneous drug
 infusion **P**: 128
- narcotic drugs
 export regulations **C**: 83
 import regulations **C**: 83
 international regulations **C**: 82–3
 manufacture regulations **C**: 83
 see also individual drugs

- Narcotic Drugs and Psychotropic Substances Act 1985, India **C:** 84
- narrative analysis **Ch:** 93–5
 definition **Ch:** 93
 listening skills **Ch:** 93–4
 meaning of pain **Ch:** 93
- nasal transmucosal drug absorption **P:** 304
- nasogastric tubes, drug administration **C:** 110–1
- National Cancer Control Programme, India **C:** 86
- National Council for Palliative Care, psychosocial care definition **C:** 50–1
- National Health and Medical Research Council (NHMRC), Australia acute pain management clinical practice guidelines **P:** 666
- National Health Service (NHS) as challenging organizational context **P:** 609
 organization turbulence **P:** 609
 trust mergers **P:** 609–10
- National Institutes of Health Consensus Criteria, interstitial cystitis **Ch:** 580
- national opium agency **C:** 83
- National Research Register **P:** 570 *T*
- natural history, definition **P:** 501–2
- natural medicine *see* complementary and alternative medicine (CAM)
- naturopathy *see* complementary and alternative medicine (CAM)
- nausea and vomiting
 cancer patients **C:** 318–9
 bowel obstruction **C:** 322, **C:** 323 *F*
 causes **C:** 318, **C:** 319 *T*
 clinical findings **C:** 318
 management **C:** 319
 management plans **C:** 321 *F*, **C:** 322 *F*
 nonpharmacological management **C:** 319
 pathophysiology **C:** 318, **C:** 318 *F*
 pharmacological management **C:** 320 *T*
 prevalence **C:** 318
- chemotherapy-induced *see* chemotherapy-induced nausea and vomiting
- ketamine-induced **A:** 99
- morphine-induced **A:** 484
- opioid-induced **A:** 56, **A:** 258; **C:** 155, **C:** 190–1; **P:** 129
 children **C:** 353 *T*; **P:** 468
 elderly **A:** 514–5
 epidemiology **C:** 190
- etiology **C:** 190
 management **C:** 190–1
 pathophysiology **C:** 190
- PCA-induced **A:** 227–8; **P:** 296
- postoperative *see* postoperative nausea and vomiting (PONV)
- near-infrared spectroscopy, postnatal cortical activity **A:** 38
- neck pain **Ch:** 484–500
 acute, treatment **Ch:** 494, **Ch:** 495
 chronic, diagnosis **Ch:** 159–62
 atlas transverse ligament **Ch:** 159
 cervical medial branch blocks **Ch:** 162
 cervical zygapophyseal joint pain **Ch:** 162
 contralateral alar ligament **Ch:** 159
 disk stimulation **Ch:** 160
 invasive techniques **Ch:** 492–3
 pain maps **Ch:** 162, **Ch:** 162 *F*
 synovial joints **Ch:** 161
 upper vs. lower cervical pain **Ch:** 162
 chronic, treatment **Ch:** 494, **Ch:** 495
 clinical assessment **Ch:** 490
 associated features **Ch:** 490, **Ch:** 491 *T*
 definition **Ch:** 484–5
 diagnostic algorithm **Ch:** 161–2, **Ch:** 161 *F*
 disk stimulation **Ch:** 492–3
 epidemiology **Ch:** 486
 etiology **Ch:** 488–9, **Ch:** 488 *T*
 fractures **Ch:** 488
 infections **Ch:** 488
 metabolic disorders **Ch:** 488
 trigger points **Ch:** 488–9
 tumors **Ch:** 488
 history taking **Ch:** 490, **Ch:** 490 *T*
 investigations **Ch:** 491–3
 natural history **Ch:** 486
 neurological symptoms **Ch:** 490
 physical examination **Ch:** 490–1
 plain radiography **Ch:** 491–2
 prognostic factors **Ch:** 488
 referred *see* cervical referred pain
 rheumatoid arthritis **Ch:** 488
 risk factors **Ch:** 486, **Ch:** 488 *T*
 TENS **A:** 278
 treatment **Ch:** 493–5
 radiofrequency neurotomy **Ch:** 495
 recommendations **Ch:** 495
 surgical therapy **Ch:** 494
see also whiplash
- needle phobia
 biofeedback, children **P:** 489–90
 prevention **P:** 490
- needles
 acupuncture **A:** 281; **Ch:** 309
 indwelling **C:** 272, **C:** 273
 placebo **P:** 208
 combined spinal–epidural analgesia **A:** 260
 continuous peripheral neural blockade **A:** 243–4
- nefopam **C:** 126
- negative imagery **P:** 155
- negative reinforcement **Ch:** 296
- Neighbourhood Network in Palliative Care (NNPC), India **C:** 87
- neodissociative model, hypnosis **A:** 315
- Neonatal Assessment of Pain Inventory (NAPI) **A:** 479 *T*
- Neonatal Facial Coding System (NFCS) **A:** 145, **A:** 479 *T*, **A:** 480; **P:** 457
- Neonatal Infant Pain Scale (NIPS) **A:** 479 *T*
- neonate(s)
 analgesia response *see* analgesia/analgesics, age-related changes
 epidural analgesia **P:** 473
 epidural space estimation **P:** 473
 local anesthetic sensitivity **A:** 120–1
 nurse-controlled analgesia **P:** 467 *T*
 pain assessment **A:** 479 *T*, **A:** 480; **P:** 456–7
 measures **P:** 457
 persistent visceral pain **Ch:** 43
 procedural pain management **A:** 493
 Reye's syndrome, aspirin adverse effects **A:** 73
- neostigmine bromide
 epidural analgesia **A:** 259
 field/disaster situations **A:** 380
 intra-articular analgesia **A:** 331
 intrathecal analgesia **A:** 259
 neuraxial analgesia **A:** 259
- nephrotic syndrome, NSAID-induced **C:** 135
- nephrotoxicity, NSAID-induced **A:** 483; **Ch:** 197
- Nernst equation **A:** 114
- nerve biopsy
 amyloid neuropathy **P:** 79–80, **P:** 80 *F*
 morbidity **P:** 79–80
 peripheral neuropathies **Ch:** 337; **P:** 79–80
 small-fiber neuropathies **P:** 79–80
- nerve blocks
see individual blocks
- nerve compression
 peripheral neuropathies **Ch:** 342–3
 pregnancy **A:** 462

- nerve conduction studies **Ch:** 149–50
 CRPS **Ch:** 367
 diabetic neuropathy **Ch:** 149
 false positives **Ch:** 150
 large fiber neuropathy **Ch:** 149
 nerve compression **Ch:** 149–50
 peripheral neuropathies **Ch:** 337
 techniques **Ch:** 149
- nerve conduction velocity,
 cryotherapy **A:** 536
- nerve growth factor (NGF)
 peripheral nerve injury **Ch:** 9
 peripheral sensitization **A:** 24
- nerve injury
 abdominal pain **Ch:** 565
 CPSP **Ch:** 407
 transient receptor potential ion
 channels **Ch:** 9–10
- nerve of Arnold, bronchial cancer
 pain **C:** 32
- nerve pain, pregnancy **A:** 262
- nerve pain, radiotherapy
 treatment **C:** 254
 indications **C:** 252, **C:** 252 *T*
- nerve transection, chronic pelvic
 pain **Ch:** 581
- nerve trauma
 neuropathic pain **Ch:** 4
 surgery-induced **C:** 7
- neuralgic amyotrophy **Ch:** 343
- neural tension tests, sciatica
P: 232–3
- neuraxial analgesia **A:** 255–70
 cardiac surgery
 anticoagulation **A:** 262
 risk–benefit evaluation **A:** 262
 children **P:** 464
 clinical uses **A:** 256
 complications **A:** 261–2
 infectious complications **A:** 262
 postdural puncture
 headache **A:** 262
 spinal hematoma **A:** 261–2
 contraindications **A:** 256
 cost-effectiveness **A:** 264–5
 drugs used **A:** 256–9
 efficacy **A:** 264
 postoperative pain **A:** 264
 future work **A:** 266
 insertion techniques **A:** 266
 gastrointestinal surgery **A:** 263–4
 historical aspects **A:** 255
 labor pain **A:** 470–2
 adverse effects **A:** 471 *T*
 combined spinal epidural
 technique **A:** 472, **A:** 472 *T*
 contraindications **A:** 470, **A:** 470 *T*
 minimum local analgesic
 concentration **A:** 471
 patient-controlled epidural
 anesthesia **A:** 471
 spinal **A:** 470
 long-term, opioid-tolerant
 patients **A:** 549–50
 mechanisms **A:** 256
 morbidity **A:** 265–6
 mortality **A:** 265–6
 orthopedic surgery **A:** 264
 outcomes **A:** 264–6
 nontraditional measures **A:** 266
 patient-centered outcomes **A:** 266
 pharmacokinetics **A:** 256
 safety **A:** 264
 sterile techniques **A:** 262
 thoracic surgery **A:** 263
 timing **A:** 259–61
 preemptive analgesia **A:** 259–60
 vascular surgery **A:** 263
see also combined spinal–epidural
 (CSE) analgesia; continuous
 spinal analgesia (CSA); epidural
 analgesia; patient-controlled
 epidural analgesia (PCEA); spinal
 analgesia
- neuraxial neurolysis **P:** 339–41
 indications **P:** 339
 repeat blockade **P:** 339
- neuritis, zygapophyseal joint
 block-induced **P:** 367
- neurochemical imaging **P:** 89–91
- neurodegeneration,
 ketamine-induced **A:** 486
- neurofeedback **P:** 487 *T*
- neurography **P:** 51
- neurokinin(s), opioid-tolerant
 patients **A:** 544
- neurokinin **A Ch:** 26, **Ch:** 31
- neuroleptics
 children **C:** 354
 elderly **C:** 368
 neurologic disease pain **Ch:** 330
- neurological examination
 abdominal pain, chronic **Ch:** 551
 chronic pelvic pain **Ch:** 583
 neck pain **Ch:** 491
- neurologic disease/disorders **Ch:** 323–34
 acute pain **A:** 411–3
 chronic pain prevalence **Ch:** 324
 classification **Ch:** 324, **Ch:** 324 *T*,
Ch: 325 *T*
 neuropathic pain
 direct **Ch:** 323
 indirect **Ch:** 323
 nociceptive pain **Ch:** 323
- pain assessment **Ch:** 323–4
 pain management **Ch:** 329–32
 CAM **Ch:** 332
 invasive treatments **Ch:** 331–2
 neurolytic procedures **Ch:** 332
 pharmacologic **Ch:** 329–31
 physical treatments **Ch:** 331
 psychological treatment **Ch:** 332
 surgery **Ch:** 332
 topical treatments **Ch:** 329
see also individual diseases/disorders
- neurolysis
 chemical *see* chemical neurolysis
 interstitial cystitis **Ch:** 557–8
 neurologic disease pain **Ch:** 332
 pathophysiology **C:** 226–7
 selective **C:** 226–7
- neurolytic agents **P:** 256–7, **P:** 337
- neurolytic blocks **P:** 337–48, **P:** 244
 cancer pain **P:** 338
 indications **P:** 338
 sympathetic **C:** 229–30; **P:** 327
 complications **P:** 327
 stellate ganglion **P:** 329
see also individual blocks
- neurolytic celiac plexus block
 (NCPB) **C:** 228–9
 alcohol use **C:** 228
 chronic pancreatitis **Ch:** 554–5
 complications **C:** 229
 controversies **C:** 229, **C:** 230 *T*
 efficacy **C:** 229, **C:** 229 *T*
 indications **C:** 229
 pancreatic cancer pain **Ch:** 552
 procedure **C:** 229
- neuromas, cryoanalgesia **P:** 381
- neuromatrix, mind/body
 techniques **P:** 492
- neuromodulation **P:** 405
 central neuropathic pain
 treatment **Ch:** 383
 neuropathic pain **Ch:** 346 *T*
- neuron(s), classification **A:** 4, **A:** 4 *T*,
A: 5 *F*
- neuronal plasticity
 CPSP **Ch:** 407
 fibromyalgia syndrome *see*
 fibromyalgia syndrome (FMS)
- neuropathic pain **Ch:** 133
 persistent musculoskeletal
 pain **Ch:** 31
- neuropathic hypersensitivity
 mechanisms **Ch:** 4 *T*, **Ch:** 7–16
 chemokines **Ch:** 10
 compression **Ch:** 4 *T*
 cytokines **Ch:** 10
 death receptors **Ch:** 10

- demyelination **Ch:** 4 *T*
disease states **Ch:** 3, **Ch:** 4 *T*
disordered regeneration **Ch:** 3–4
drugs **Ch:** 4 *T*
HIV infection *see* HIV-associated pain
infection **Ch:** 4 *T*
inflammation **Ch:** 4 *T*
ischemic injury **Ch:** 4 *T*
mitochondria-dependent apoptosis **Ch:** 10
peripheral mechanisms **Ch:** 7–10, **Ch:** 7 *T*, **Ch:** 133 *T*
 calcium channels **Ch:** 6 *F*, **Ch:** 9, **Ch:** 12
 inflammatory mediators **Ch:** 10
 nerve trauma **Ch:** 4
 peripheral cell death **Ch:** 10
 potassium channels **Ch:** 9
 primary afferent excitability **Ch:** 7–9
 sensitivity alteration **Ch:** 9–10
 sodium channels **Ch:** 6 *F*, **Ch:** 7–9
 transient receptor ion channels **Ch:** 9–10
 see also individual types
spinal cord mechanisms **Ch:** 7 *T*, **Ch:** 10–5
 anatomical reorganization **Ch:** 13
 cannabinoid system **Ch:** 13
 excitatory mechanisms **Ch:** 11–2
 GABA **Ch:** 12–3
 glycine **Ch:** 12–3
 inhibitory systems **Ch:** 12–3
 nonneuronal cells **Ch:** 13–5
 opioid system **Ch:** 13, **Ch:** 14 *F*
neuropathic inhibition loss, persistent musculoskeletal pain **Ch:** 31
neuropathic itch **C:** 329
neuropathic orofacial pain **Ch:** 470–2
 differential diagnosis **Ch:** 471–2
 epidemiology **Ch:** 470–1
 management **Ch:** 472
 pathophysiology **Ch:** 471
 symptoms **Ch:** 471
 electrophysiology **Ch:** 471, **Ch:** 472 *F*
 trauma **Ch:** 470
neuropathic pain **Ch:** 3–23
 abnormal pain radiation **Ch:** 136
 acupuncture **A:** 281
 aftersensations **Ch:** 136, **Ch:** 141 *T*
 anesthesia dolorosa **Ch:** 375
 animal models **Ch:** 4–7
 active escape **Ch:** 7
 avoidance of preferred environments **Ch:** 7
 behavioral tests **Ch:** 5, **Ch:** 6–7, **Ch:** 6 *F*
 cancer-induced pain **C:** 7–8
 chronic constriction injury of sciatic nerve **Ch:** 4–5
 disadvantages **Ch:** 5
 drug-induced neuropathies **Ch:** 5–6
 HIV-associated pain **Ch:** 5–6
 open-field paradigm **Ch:** 6
 partial sciatic nerve ligation model **Ch:** 4–5
 peripheral diabetic neuropathy **Ch:** 5–6
 place preferment paradigms **Ch:** 7
 recent developments **Ch:** 5–6
 rodent models **Ch:** 4–5
 spared nerve injury model **Ch:** 4–5
 spinal nerve ligation transection model **Ch:** 4, **Ch:** 5 *F*, **Ch:** 7–8
 trigeminal neuralgia **Ch:** 5–6
assessment **Ch:** 132–44; **P:** 46–7
 cancer patients **C:** 43
 chemical stimuli **Ch:** 138–9, **Ch:** 139 *T*
 clinical examination **Ch:** 137–8, **Ch:** 137 *F*
 electrical stimuli **Ch:** 139 *T*
 mechanical stimuli **Ch:** 138, **Ch:** 139 *T*
 outcome measures **Ch:** 139–40
 pain measures **Ch:** 139–40
 pain relief scores **Ch:** 140
 quality of life **Ch:** 140
 sensory abnormality distribution **Ch:** 137
 sympathetic activity **Ch:** 139
 tactile sensibility **P:** 47
 thermal stimuli **Ch:** 138, **Ch:** 139 *T*; **P:** 44
 treatment as tool **Ch:** 140
biological changes **Ch:** 133
bone metastasis **C:** 260
 radiotherapy **C:** 260, **C:** 261 *F*
burns patients **A:** 401
cancer-related *see* cancer-induced/related neuropathic pain
causes **Ch:** 4 *T*
central *see* central neuropathic pain
characteristics **A:** 138 *T*; **P:** 46 *T*
chemotherapy-induced *see* chemotherapy-induced peripheral neuropathy (CIPN)
chronic, cryoanalgesia **P:** 381
chronic pelvic **Ch:** 573 *T*, **Ch:** 581
classification **Ch:** 133–4, **Ch:** 133 *T*
 etiologic-based **Ch:** 133
 mechanism-based **Ch:** 133
 pharmacological **Ch:** 134
clinical trials *see* neuropathic pain clinical trials
definitions **Ch:** 3, **Ch:** 132, **Ch:** 374; **C:** 41, **C:** 200
descriptors **Ch:** 374–5, **Ch:** 375
diagnostic blocks **Ch:** 152
dysesthesiae **Ch:** 136, **Ch:** 138
elderly **Ch:** 647
evoked **Ch:** 134; **P:** 46 *T*
findings **Ch:** 134–6
heterogenous conditions **Ch:** 132–3
history taking **Ch:** 136–7
hyperalgesia **Ch:** 135, **Ch:** 138, **Ch:** 141 *T*
 chemical **Ch:** 141 *T*
 dynamic **Ch:** 135, **Ch:** 141 *T*
 punctate **Ch:** 135, **Ch:** 141 *T*
 static **Ch:** 135, **Ch:** 141 *T*
 thermal **Ch:** 135, **Ch:** 141 *T*
hyperesthesia **Ch:** 375
hyperpathia **Ch:** 135, **Ch:** 375
ICUs **A:** 351–2
imaging **Ch:** 16
laboratory examination **Ch:** 138–9
mechanisms *see* neuropathic hypersensitivity mechanisms
musculoskeletal pain **A:** 431
myelopathic disorders **Ch:** 136
neurologic diseases **Ch:** 323
nociceptive vs. deafferentation **P:** 46
ongoing pain **Ch:** 134
opioid efficacy **Ch:** 208–9; **P:** 112
orofacial *see* neuropathic orofacial pain
paresthesiae **Ch:** 136
Parkinson's disease **Ch:** 328
paroxysms **Ch:** 135–6
pathological **C:** 200
patterns **Ch:** 3, **Ch:** 4 *F*
periaqueductal gray **Ch:** 15
peripheral, definition **C:** 200
peripheral neurolysis-induced **P:** 256
physiological **C:** 200
plasticity **Ch:** 133
referred pain **Ch:** 136
rostral ventromedial medulla **Ch:** 15, **Ch:** 15 *F*
sensory abnormalities **P:** 46, **P:** 46 *T*
sensory deficit **Ch:** 134–5
spontaneous **P:** 46 *T*
spontaneous paroxysmal **P:** 46, **P:** 46 *T*
stimulus-dependent pain **Ch:** 134, **Ch:** 134 *T*
stimulus-independent pain **Ch:** 134, **Ch:** 134 *T*

- neuropathic pain (*continued*)
 substance P **Ch:** 10, **Ch:** 14
 sympathetically maintained **Ch:** 141 *T*
 symptoms **C:** 7
 symptoms/findings–mechanisms
 relationship **Ch:** 140–1,
Ch: 141 *T*
 TENS *see* transcutaneous electrical
 nerve stimulation (TENS)
 transient postsympathectomy **P:** 333
 trauma **Ch:** 4 *T*
 treatment
 alpha-2 adrenoceptor
 agonists **A:** 102
 anticonvulsants **A:** 104
 bupropion **Ch:** 247
 fracktalkine **Ch:** 14
 galanin **Ch:** 10
 NMDA receptor
 antagonists **A:** 100–1
 protein kinase C inhibitors **Ch:** 12
 selective serotonin reuptake
 inhibitors **Ch:** 246
 serotonin-norepinephrine reuptake
 inhibitors **Ch:** 245
 topical analgesics **Ch:** 233–5
 topical local anesthetics **Ch:** 233–4
 wind up-like pain **Ch:** 136, **Ch:** 141 *T*
- neuropathic pain clinical
 trials **P:** 552–65
 active treatment
 comparators **P:** 559–60
 bias elimination **P:** 553–5
 concurrent drug use **P:** 557–8
 controls **P:** 559–60
 external **P:** 560
 multiple **P:** 560
 crossover studies **P:** 555–7, **P:** 556 *F*
 dissemination **P:** 562–3
 duration **P:** 561–2
 adverse effects and **P:** 562
 enriched enrollment **P:** 558
 equivalence trials **P:** 559–60
 ethics **P:** 553
 exclusion criteria **P:** 557–8
 hypersensory groups **P:** 557
 hyposensory groups **P:** 557
 hypothesis **P:** 553
 inclusion criteria **P:** 557–8
 recruitment populations **P:** 558
 long-term safety data
 collection **P:** 562
 models **P:** 558–9
 monitoring **P:** 562
 multiple dose comparisons **P:** 560
 outcome measures **P:** 560–1
 “nonpain” features **P:** 561
- primary **P:** 561
 secondary **P:** 561
 parallel studies **P:** 555–7, **P:** 556 *F*
 placebo **P:** 559
 post-trial access to treatment **P:** 563
 question **P:** 553
 sample size **P:** 557
 termination **P:** 562
 trial design **P:** 553–62
- Neuropathic Pain
 Questionnaire **Ch:** 374–5
 Neuropathic Pain Scale (NPS) **Ch:** 137,
Ch: 140, **Ch:** 374–5
 postherpetic neuralgia **Ch:** 233–4
 Neuropathic Pain Symptom
 Inventory **Ch:** 374–5
 neuropathies, diagnosis **Ch:** 151
 neuropeptide Y
 joint innervation **Ch:** 26
 peripheral nociceptor
 sensitization **Ch:** 29
 neurophysiology **P:** 43–55
 conventional techniques **P:** 50–1
 neuropathies **P:** 79
see also individual techniques
 neuroplasty **P:** 431, **P:** 431 *F*
 low back pain with sciatica **P:** 433
 neurostimulation **Ch:** 268–83
 complications **Ch:** 280
 computer models **Ch:** 270–1,
Ch: 271 *F*, **Ch:** 272 *F*
 dorsal root stimulation **Ch:** 270–1,
Ch: 273 *F*
 intraspinal element
 conductivity **Ch:** 270, **Ch:** 270 *T*
 mechanism of action **Ch:** 269–70,
Ch: 269 *F*
 animal studies **Ch:** 269
 ascending tract conduction
 block **Ch:** 270
 descending modulation **Ch:** 270
 gate control theory **Ch:** 269
 neurotransmitter effects **Ch:** 269
 periaqueductal gray **Ch:** 270
 supraspinal mechanisms **Ch:** 270
 programming **Ch:** 271–9
 multiple electrodes **Ch:** 271,
Ch: 274 *F*
 supraspinal mechanisms **Ch:** 270
 technical considerations **Ch:** 270–1
 intraspinal element
 conductivity **Ch:** 270,
Ch: 270 *T*
see also peripheral nerve stimulation;
 spinal cord stimulation (SCS)
- neurotransmitters
 neurostimulation **Ch:** 269
- opioid-tolerant patients **A:** 544
 persistent musculoskeletal
 pain **Ch:** 31
 TENS **A:** 274–5
see also individual neurotransmitters
- neurotrophic factors
 nociception **A:** 10–1
 sensitization **A:** 24
 neurotrophins, persistent visceral
 pain **Ch:** 43
 neutral cells, rostral ventromedial
 medulla **A:** 27
 neutropenia, paracetamol-
 induced **Ch:** 200–1
 New Zealand Acute Low Back Pain
 Guidelines **A:** 454, **A:** 455 *F*
 New Zealand Guide to Assessing
 Psychosocial Yellow Flags in Acute
 Low Back Pain **A:** 446–7
 NeXus Biofeedback System **P:** 486 *F*
 NFCS (Neonatal Facial Coding
 System) **A:** 145, **A:** 479 *T*, **A:** 480;
P: 457
 NHS *see* National Health Service
 (NHS)
 niacin deficiency **Ch:** 341
 NIH-based register, clinical trials **P:** 525
 nimesulide **A:** 75 *T*, **A:** 79
 NIPS (Neonatal Infant Pain
 Scale) **A:** 479 *T*
 nitric acid, NSAID-induced peptic
 ulceration **C:** 134
 nitric oxide (NO)
 migraine **Ch:** 453
 nociception effects **A:** 15
 peripheral vascular disease **Ch:** 275–6
 sickle cell disease pain **A:** 420
 nitric oxide synthase (NOS), postnatal
 development **A:** 35
 nitrogen/oxygen mixtures,
 dyspnea **C:** 314
 nitroglycerine
 cardiac pain **A:** 418
 emergency departments **A:** 365
 ischemic cardiac chest pain **A:** 365,
A: 418
 preventive analgesia **A:** 185
 nitroglycerin model, migraine **Ch:** 453
 nitrous oxide (N₂O) **A:** 97–8
 acute ischemic chest pain **A:** 418
 acute pain **A:** 98
 adverse effects **A:** 97–8, **A:** 488
 hematological **A:** 98
 neurological **A:** 98
 burn pain **A:** 98, **A:** 402, **A:** 404
 cannula insertion **A:** 98
 cardiac pain **A:** 418

- chemical properties **A:** 97
 children **A:** 488; **P:** 464
 administration **A:** 488
 procedural pain **A:** 98, **A:** 493–4
 clinical effects **A:** 97
 contraindications **A:** 97–8
 vitamin B12 deficiency **A:** 98
 emergency settings **A:** 98, **A:** 363
 forearm fractures **A:** 368
 historical aspects **A:** 97
 labor pain **A:** 98, **A:** 469
 mechanism of action **A:** 97
 pharmacokinetics **A:** 97
 physical properties **A:** 97
 sickle cell disease pain **A:** 420
 nitrous oxide mixture *see* entonox
 nitrovasodilators **C:** 134
 NMDA receptor(s) **A:** 98–9
 activation **A:** 35; **C:** 207
 anticonvulsants effects **A:** 103
 central sensitization **Ch:** 12
 chronic pain **P:** 61
 development **A:** 486
 fibromyalgia syndrome **Ch:** 604
 methadone effects **Ch:** 210
 neuropathic orofacial pain **Ch:** 471
 neuropathic pain **Ch:** 12
 nociception **A:** 9–10
 opioid-induced hyperalgesia **A:** 544
 opioid-tolerant patients **A:** 544
 persistent musculoskeletal pain **Ch:** 31
 postamputation pain **Ch:** 420
 postnatal development **A:** 33, **A:** 34 *T*
 NMDA receptor antagonists **A:** 98–101
 acute pain **A:** 99–101, **A:** 100 *T*
 adverse effects **A:** 99
 burn pain **A:** 400–1, **A:** 403
 cancer-induced/related neuropathic pain **C:** 207–8
 chemical properties **A:** 98
 clinical effects **A:** 98–9
 CPSP prevention **A:** 565
 elderly **A:** 516
 field/disaster situations **A:** 379
 mechanism of action **A:** 98–9, **A:** 175
 neurologic disease pain **Ch:** 330
 neuropathic pain
 acute **A:** 100–1
 assessment **Ch:** 140
 neuropathic pain assessment **Ch:** 140
 opioid-tolerant patients **A:** 548–9
 pediatric headache **Ch:** 632
 dosages **Ch:** 632
 perioperative analgesia **A:** 100
 pharmacokinetics **A:** 99 *T*
 physical properties **A:** 98
 postamputation pain **Ch:** 423
 postherpetic neuralgia **Ch:** 435
 postoperative pain
 management **A:** 334–5
 preventive analgesia **A:** 175–85, **A:** 180
 procedural pain, acute **A:** 100
 spinal administration **Ch:** 287
 spinal cord injury pain **Ch:** 395
 see also individual drugs
 N-methyl-D-aspartate receptors *see*
 NMDA receptor(s)
 nocebo **P:** 500
 nocebo effect
 clinical implications **P:** 507
 negative expectancy **P:** 150
 neuroanatomy **P:** 506
 neurochemistry **P:** 504–6
 nociceptin/orphanin FQ
 receptor **A:** 55–6
 distribution **A:** 56
 effects **A:** 56
 functions **A:** 56
 nociception modulation **A:** 15
 nociception **A:** 3–19
 in brain **A:** 12–4, **A:** 13 *F*
 cancer patients **P:** 540
 definition **P:** 540
 dorsal horn
 neurotransmitters **A:** 9–11,
 A: 10 *T*
 immune system interactions **A:** 27–8
 modulation **A:** 3–4, **A:** 14–7
 segmental (spinal) control **A:** 12 *F*,
 A: 14–7
 supraspinal/descending
 control **A:** 16 *F*, **A:** 17
 perception **A:** 3–4
 peripheral aspects **A:** 4–6
 postnatal development *see*
 nociception, postnatal
 development
 referred pain **A:** 11, **A:** 12 *F*
 somatic *vs.* visceral **A:** 6–8, **A:** 8 *T*
 spinal cord **A:** 8–11, **A:** 8 *F*
 A δ fibers **A:** 8–9
 nociceptive fibers **A:** 8–9, **A:** 9 *F*
 projection neurons **A:** 9
 wide dynamic range neurons **A:** 9
 spinal cord to brain **A:** 11–2
 spinobulbar pathways **A:** 5 *F*,
 A: 11–2
 spinothalamic pathways **A:** 11
 transduction **A:** 3–4
 transmission **A:** 3–4
 visceral nociceptors **A:** 7–8, **A:** 9
 nociception, postnatal
 development **A:** 32–52, **A:** 478
 analgesic response changes *see*
 analgesia/analgesics, age-related
 changes
 higher centers **A:** 38
 ascending pathways **A:** 38
 descending pathways **A:** 38
 human neonates **A:** 38
 hyperalgesia **A:** 39
 clinical studies **A:** 39
 laboratory investigations **A:** 39
 injury response **A:** 39–45, **A:** 40–2 *T*
 full thickness skin wounding **A:** 44
 inflammation **A:** 39
 nerve injury **A:** 44–5
 clinical studies **A:** 45
 laboratory investigations **A:** 44
 peripheral responses **A:** 33
 processing **A:** 32–8
 spinal cord pain transmission **A:** 33–6
 afferent input **A:** 33
 excitatory modulation **A:** 33,
 A: 34 *T*
 inhibitory modulation **A:** 35–6
 intracellular cascades **A:** 35
 surgical incision **A:** 39–43
 clinical studies **A:** 43
 laboratory investigations **A:** 39–43
 visceral injury **A:** 43–4
 clinical studies **A:** 44
 laboratory investigations **A:** 43–4
 withdrawal reflexes **A:** 36–8
 clinical studies **A:** 36–8, **A:** 36 *F*
 laboratory studies **A:** 36
 nociceptive pain **P:** 45–6
 acupuncture **A:** 281
 burn patients **A:** 401
 characteristics **A:** 138 *T*
 chronic, opioid treatment **P:** 116–7
 deep brain stimulation **Ch:** 279–80
 definition **C:** 41
 labor **A:** 465, **A:** 465 *F*
 neurologic diseases **Ch:** 323
 opioid responsiveness **Ch:** 208–9
 sensory testing **P:** 45–6
 spinal cord injury **Ch:** 389
 nociceptor(s)
 deep tissue **Ch:** 26–9
 definition **A:** 3
 fibromyalgia syndrome **Ch:** 604
 low back pain **A:** 446
 peripheral *see* peripheral nociceptors
 sensitization
 neuropathic pain **Ch:** 133
 nociceptive pain **P:** 45
 persistent musculoskeletal
 pain **Ch:** 30–1
 spinal cord neurons **Ch:** 29–30

- nociceptor(s) (*continued*)
 temporomandibular disorders **Ch:** 468–9
 tumor-related pain **C:** 345–6
 “N of 1” studies, chronic pain outcome measurement **Ch:** 183
 noncardiac chest pain *see* chest pain
 Non-Communicating Children’s Pain Checklist (NCCPC) **P:** 456
 Non-Communicating Children’s Pain Checklist-Revised (NCCPC-R) **P:** 456, **P:** 457 *T*
 noncommunicative patients, pain assessment **A:** 512
 noncompetitive antagonist **C:** 105
 Non-Government Organization (NGO), palliative care services
 Israel **C:** 87
 Palestinian Authority **C:** 87
 non-Hodgkin’s lymphoma, HIV-associated abdominal pain **Ch:** 358
 noninflammatory joint pain *see* joint pain, acute
 non-intended recipient use, opioids **Ch:** 656–7
 nonneuronal cells, neuropathic pain **Ch:** 13–5
 nonopioid analgesics **C:** 123–50
 buccal administration **A:** 207–8
 cancer pain **C:** 123–50
 end of life care **C:** 334–5
 intra-articular administration **A:** 210
 intramuscular administration **A:** 205
 intrathecal administration **A:** 210
 intravenous administration **A:** 205–6
 oral administration **A:** 202–3
 rectal administration **A:** 204
 subcutaneous administration **A:** 205
 sublingual administration **A:** 207–8
 transdermal administration **A:** 206–7
 WHO analgesic ladder **C:** 111–2
see also individual drugs
 nonpeptidergic somatic nociceptors **A:** 4
 nonprofessional caregivers *see* family caregiver
 NO-NSAIDs (CINODs) **C:** 138
 nonsmall cell lung cancer (NSCLC) **C:** 264
 nonsteroidal anti-inflammatory drugs (NSAIDs) **A:** 68–83; **Ch:** 193–5; **C:** 126–38
 abdominal pain, acute **A:** 414
 absorption **A:** 69
 acute pain **A:** 68–83
 clinical uses **A:** 69
 acute pancreatitis **A:** 416
 adverse effects **A:** 70–3; **Ch:** 195; **C:** 128, **C:** 128 *T*
 asthma **A:** 71, **A:** 483; **Ch:** 196–7
 bleeding **A:** 483
 cardiovascular **A:** 71–2, **A:** 334, **A:** 516; **Ch:** 195–8; **C:** 136–8
 children **A:** 73, **A:** 483
 CNS **A:** 72, **A:** 516
 cognitive dysfunction **A:** 515
 economic effects **Ch:** 79
 elderly **A:** 515–6; **C:** 366
 gastrointestinal risks *see* NSAID-induced gastrointestinal effects
 hemostasis **A:** 72
 hepatic **A:** 71; **Ch:** 197
 immune system **A:** 73
 nephrotoxicity **A:** 483
 perioperative period **A:** 333, **A:** 333 *T*
 platelets, effects on **A:** 483; **Ch:** 197–8
 renal **A:** 71, **A:** 515; **Ch:** 197; **C:** 128 *T*, **C:** 135–6, **C:** 135 *F*
 respiratory **Ch:** 196–7
 surveys **Ch:** 194
 thrombotic risks **C:** 136–8
 tissue healing **A:** 72–3
see also individual adverse effects
 analgesic efficacy **A:** 70
 anorexia cachexia syndrome **C:** 328
 arthritic pain **Ch:** 198–9
 elderly **Ch:** 199
 global preferences **Ch:** 198–9
 biliary colic **A:** 415
 emergency departments **A:** 364
 bone pain **C:** 258
 breakthrough pain **C:** 289–90
 rescue dosing **C:** 290
 burn pain **A:** 403
 cancer pain **C:** 126–38
 clinical uses **C:** 128
 future developments **C:** 138
 subcutaneous infusion **P:** 130–1
 children **A:** 482–3, **A:** 483 *T*; **C:** 348; **P:** 464
 administration routes **A:** 483
 adverse effects **A:** 483
 doses **A:** 483 *T*
 parenteral administration **A:** 492
 pharmacokinetics **A:** 483
 systemic analgesia **A:** 492
 choice of **A:** 73–9
 cyclooxygenase selectivity **A:** 71, **A:** 75 *T*
 half-life **A:** 71
 hemostasis **A:** 73–5
 preparations **A:** 75
 chronic pain **Ch:** 193–5
 administration **Ch:** 194–5
 clinical uses/indications **Ch:** 194
 dosage **Ch:** 194–5
 effectiveness **Ch:** 199 *T*
 chronic pelvic pain **Ch:** 583–4
 classification **C:** 127–8, **C:** 127 *T*
 as coanalgesics
 opioid toxicity **C:** 181
 positive effects **C:** 181–2
 contraindications **A:** 73, **A:** 74 *T*; **Ch:** 194
 epidural analgesia **A:** 518
 COX-2 selective agents *see* cyclooxygenase 2 (COX-2) selective inhibitors
 CRPS, children **Ch:** 627
 distribution **A:** 69–70
 drug interactions **A:** 73, **A:** 74 *T*
 dysmenorrhea, primary **Ch:** 572–4
 elbow pain **A:** 438
 elderly
 acute pain **A:** 73, **A:** 515–6
 cancer pain **C:** 365–6
 chronic pain **Ch:** 647
 elimination **A:** 70
 emergency departments **A:** 363
 endometriosis **Ch:** 575
 fibromyalgia syndrome **Ch:** 608
 field/disaster situations **A:** 379
 forearm soft-tissue disorders **Ch:** 530
 future developments **C:** 138
 gout **A:** 434
 hemophilia **A:** 419
 herpes zoster **Ch:** 433
 hip arthroplasty **Ch:** 199
 ICUs **A:** 347–8
 intra-articular **A:** 210, **A:** 331
 intravenous **A:** 205–6, **A:** 335
 intrawound **A:** 210
 juvenile rheumatoid arthritis **A:** 483
 knee pain **A:** 440
 lactation **A:** 73; **Ch:** 198
 low back pain **A:** 451 *T*, **A:** 452, **A:** 453; **Ch:** 508
 mechanism of action **A:** 69–70, **A:** 482–3, **A:** 533, **A:** 533 *F*; **C:** 125 *F*, **C:** 126–7
 cyclooxygenase inhibition **A:** 69
 prostaglandin synthesis **A:** 174, **A:** 364, **A:** 379
 prostaglandin synthesis blocking **Ch:** 29, **Ch:** 631
 single nucleotide polymorphisms **C:** 127
 splice variants **C:** 127

- metabolism **A:** 70
metastatic bone pain **C:** 128
migraine
 prophylaxis **Ch:** 459–61, **Ch:** 461 *T*
 treatment **Ch:** 455
musculoskeletal pain **Ch:** 198
 chronic lower back pain **Ch:** 198,
 Ch: 199 *T*
nausea and vomiting **A:** 227
neuropathic pain **Ch:** 199, **Ch:** 199 *T*
noninflammatory joint pain **A:** 435
opioid combination **Ch:** 213
opioid-tolerant patients **A:** 548
oral administration **A:** 202, **A:** 203 *T*
 arginine salts **A:** 202
 β-cyclodextrin linkage **A:** 202
 lysine salts **A:** 202
osteoarthritis **Ch:** 199, **Ch:** 199 *T*
paracetamol and **A:** 89
paracetamol vs. **C:** 124
parenteral administration **A:** 492
PCA **P:** 296
 opioid tolerant patients **P:** 298
pediatric headache **Ch:** 630–1
pericarditis **Ch:** 542
pharmaceutical issues **Ch:** 198
pharmacological issues **Ch:** 198
pharmacology **A:** 69–70
porphyria **A:** 73
postoperative pain
 management **A:** 333–4
 administration route **A:** 333
 intra-articular analgesia **A:** 331
 post discharge **A:** 335
in pregnancy **A:** 73, **A:** 461; **Ch:** 198
prevalence of use **Ch:** 194
preventive analgesia **A:** 174–5,
 A: 440 *T*
procedure-related pain **C:** 218
protein binding **A:** 70
pulpitis **Ch:** 477
rectal administration **A:** 204
renal colic **A:** 70, **A:** 415
 emergency departments **A:** 363,
 A: 364
response to, interindividual
 variability **C:** 127
rheumatoid arthritis **Ch:** 198,
 Ch: 199 *T*, **Ch:** 521
rotator cuff disorders **Ch:** 529
shoulder pain **A:** 437
sickle cell disease pain **A:** 420
spinal cord injury pain **Ch:** 393
sports injuries **A:** 533–4
 inflammation **A:** 533
 peripheral nerve damage **A:** 534,
 A: 534 *F*
 soft-tissue trauma **A:** 533
 transdermal **A:** 534
 subcutaneous infusion, cancer
 patients **P:** 130–1
 sweating **C:** 331
 systemic analgesia **A:** 492
 temporomandibular
 disorder **Ch:** 469–70
 tension-type headache **Ch:** 458
 terminology **A:** 68–9
 therapeutic benefits **A:** 70
 chronic pain transition
 prevention **A:** 70
 heterotopic bone formation **A:** 70
 immune competence
 preservation **A:** 70
 topical
 adverse effects **Ch:** 232–3
 clinical uses/indications **Ch:** 235–6
 meta-analysis **Ch:** 235–6
 mechanisms of action **Ch:** 232
 neurologic disease pain **Ch:** 329
 osteoarthritis **Ch:** 235–6, **Ch:** 526–7
 soft-tissue injuries **Ch:** 235
 transdermal administration **A:** 206–7
 soft-tissue injuries **A:** 207
 uroolithiasis, recurrent **Ch:** 564
 WHO essential drug list **A:** 395 *T*
 worldwide usage **C:** 126
 see also individual drug classes;
 individual drugs
non-ulcer dyspepsia (NUD) **A:** 417
nonverbal behavior, pain assessment
 cancer pain, elderly **C:** 370–1
 dying person **C:** 392
noradrenaline *see* norepinephrine
 (noradrenaline)
norepinephrine (noradrenaline)
 labor pain **A:** 466
 postnatal development effects **A:** 45–6
 release
 intravenous regional sympathetic
 block **P:** 326 *F*, **P:** 333, **P:** 335
 sympathetic nervous
 system **P:** 326 *F*
norketamine **C:** 208
“normal” joint movement **A:** 431
normeperidine **C:** 349
normochromic normocytic anemia,
 joint pain **A:** 432
norpethidine
 kidney failure **A:** 348–9
 toxicity, PCA **A:** 228–9
North America, palliative care
 services **C:** 86
nortriptyline **Ch:** 244 *T*
 central neuropathic pain **Ch:** 379–80
 elderly **A:** 516; **Ch:** 647
 pediatric headache **Ch:** 632
 postherpetic neuralgia **Ch:** 433
Nottingham Health Profile
 (NHP) **Ch:** 140; **P:** 33–4 *T*
noxious stimuli, peripheral
 nociceptors **Ch:** 27
NSAID-induced gastrointestinal
 effects **A:** 70–1; **Ch:** 196; **C:** 128–9,
 C: 128 *T*
 damage mechanisms **C:** 129–30
 elderly **A:** 515; **C:** 366
 ion trapping **C:** 130
 lower tract **Ch:** 196
 peptic ulcers *see* peptic ulceration,
 NSAID-induced
 risk factors **C:** 130–3
 age **C:** 131 *T*
 concomitant conditions **C:** 132 *T*
 concomitant medicine use **C:** 132 *T*
 gender **C:** 131 *T*
 identification **C:** 130, **C:** 131 *T*,
 C: 132 *T*
 peptic ulcers **C:** 131 *T*
 risk management **C:** 130
 risk reduction strategies **C:** 130–4
 COX-2 inhibitors **C:** 130, **C:** 133
 drug choice **C:** 130, **C:** 132 *T*
 lowest effective dose **C:** 132 *T*
 safe drugs **C:** 131–3, **C:** 132 *T*
 topical theory **C:** 130
nucleoside reverse transcriptase
 inhibitors, antiretroviral toxic
 neuropathy **Ch:** 355
number needed to harm (NNH)
 neuropathic pain assessment **Ch:** 140
 opioids, chronic noncancer
 pain **Ch:** 216
number needed to treat (NNT) **P:** 572
 acute postoperative pain **A:** 328
 definition **A:** 149
 neuropathic pain assessment **Ch:** 140
 NSAIDs **Ch:** 194–5
 opioids, neuropathic pain **Ch:** 347
numerical rating scale (NRS) **A:** 140–1,
 A: 140 *F*; **P:** 14–5
 accident/emergency **A:** 140
 advantages **A:** 140
 cancer pain clinical trials **C:** 14;
 P: 540–1
 chronic pain intensity **Ch:** 125
 clinical correlates **A:** 141
 dental pain model **P:** 532
 disadvantages **A:** 140–1
 elderly **A:** 512
 11-point **A:** 141; **P:** 15
 clinical trial outcomes **P:** 521

- numerical rating scale (NRS)
(*continued*)
data analysis problems **P:** 561
neuropathic pain clinical trial
outcomes **P:** 561
neuropathic pain
assessment **Ch:** 139–40
101-point scale **P:** 15
point box scale (PS-11) **A:** 140,
A: 140 *F*
variants **A:** 141
nurse-controlled analgesia (NCA)
children **A:** 484, **A:** 493; **P:** 467,
P: 467 *T*
morphine **A:** 484
nurse(s)/nursing staff
APS
certification/accreditation **P:** 586
education **P:** 585–6
reaccreditation **P:** 586
attitudes to pain in elderly **C:** 362–3
pain estimation **C:** 364
nonverbal assessment **C:** 371
pediatric APS **P:** 642
competency assessment **P:** 643
education **P:** 643
pediatric persistent pain
services **P:** 649
nurse practitioner model, APS **P:** 582–3
nursing homes, elderly pain **Ch:** 642
assessment **Ch:** 645
nursing procedure protocols,
PCA **A:** 221
nursing staff *see* nurse(s)/nursing staff
nutriceutical therapies **Ch:** 307,
Ch: 307 *T*
nutritional deficiencies **P:** 28
nystatin **C:** 316
- obesity
elderly **A:** 508
morbid *see* morbid obesity
object focusing, children **A:** 313
observability, innovations **P:** 608
observer bias **P:** 554
obsessive-compulsive disorder (OCD),
chest pain **Ch:** 538
obstetric pain **A:** 460–76
combined spinal–epidural
analgesia **A:** 260
developing world **A:** 390
epidural analgesia **P:** 316–8
labor *see* labor pain
see also pregnancy
obstructive sleep apnea, PCA **A:** 220;
P: 296–9, **P:** 298 *T*
obturator nerve **P:** 283
- obturator nerve block **P:** 283–4
anatomy **P:** 283
complications **P:** 283–4
indications **P:** 283
landmarks **P:** 283
practical steps/technique **P:** 283,
P: 283 *F*
occipital condyle syndrome **C:** 31 *T*
occipital hyperalgesia **P:** 381
occipital nerve(s) **P:** 259
cryoanalgesia **P:** 383–4
anatomical landmarks **P:** 384 *F*
complications **P:** 384
entry points **P:** 384 *F*
technique **P:** 384, **P:** 385 *F*
occipital nerve block **P:** 258–9
anatomy **P:** 259
complications **P:** 259
indications **P:** 258–9
landmarks **P:** 259, **P:** 259 *F*
practical steps/technique **P:** 259,
P: 259 *F*
occipital neuralgia **P:** 259
peripheral nerve stimulation **Ch:** 278
occupational therapists, pediatric
persistent pain services **P:** 649
occupational therapy,
osteoarthritis **Ch:** 528
Oceania, palliative care services **C:** 86
octreotide
diarrhea **C:** 326
migraine **A:** 366
nausea and vomiting **C:** 320 *T*
odds ratios (OR) **Ch:** 69, **Ch:** 69 *T*;
P: 572
odontalgia, atypical *see* atypical
odontalgia
odontoid process fracture **C:** 29 *T*
OFF cells, rostral ventromedial
medulla **A:** 27; **Ch:** 15
Office of Alternative Medicine
(OAM) **Ch:** 305
“off-label” prescribing, children **A:** 478
“off licence” drugs, developing
world **A:** 396
olanzapine
nausea and vomiting **C:** 320 *T*
opioid-induced delirium **C:** 187
older people *see* elderly
olecranon bursitis **A:** 437; **P:** 355
oligodendrocytes, nociception **A:** 11
omega-3 fatty acids, rheumatoid
arthritis **Ch:** 525
omeprazole **C:** 366
ON cells, rostral ventromedial
medulla **A:** 27; **Ch:** 15
ondansetron
- cholestasis **C:** 330
fibromyalgia syndrome **Ch:** 607
nausea and vomiting **C:** 320 *T*
opioid-induced **A:** 258; **C:** 191
PCA **P:** 296
children **P:** 297
renal colic **A:** 415
open-field paradigm, neuropathic pain
models **Ch:** 6
open-hidden paradigm (overt-covert
design), placebo response **P:** 503 *F*,
P: 504, **P:** 507–8, **P:** 508 *F*
operant behavioral approach **P:** 167–8
operant behavioral therapy
(OBT) **P:** 224–5
operant principles, CBT **Ch:** 296
operator errors, PCA **A:** 225–6
ophthalmic anesthesia, local
anesthetics **A:** 128
opiate(s)
definition **A:** 54; **C:** 202
endogenous **P:** 149
opioid(s)
aberrant use risks **P:** 112
screening **P:** 112, **P:** 113
acute pain **A:** 53–67
acute pancreatitis **A:** 416
addiction *see* opioid addiction
adjuvant drugs **C:** 113–4
adverse effect
management **C:** 181–2
administration, problematic
prescription use **P:** 110–1, **P:** 111
adverse effects **A:** 56, **A:** 329–30;
Ch: 216–21; **C:** 179–99, **C:** 156–7;
P: 110
addiction *see* opioid addiction
administration route
changes **C:** 183
cancer pain clinical trials **P:** 547
cardiovascular **A:** 57
children **C:** 351, **C:** 353 *T*; **P:** 468
classification **C:** 180
cognitive effects **A:** 515; **Ch:** 216
combination drugs **C:** 183
constipation *see* constipation
cutaneous **A:** 57
dose response **C:** 180
elderly **A:** 514
epidemiology **C:** 180, **C:** 181 *T*
etiology **C:** 180
fear of **C:** 151–2
gastrointestinal dysfunction **P:** 110,
P: 129
genetic variability **C:** 180
hypothalamic–pituitary axis
suppression **Ch:** 216

- incidence **Ch**: 216
management strategies **C**: 180–3
nausea and vomiting *see* nausea and vomiting
nonopioid receptors in **C**: 180
numbers needed to harm **Ch**: 216
pathophysiology **C**: 180
patient information **P**: 113
renal impairment **A**: 513
respiratory depression *see* respiratory depression
sedation **A**: 258, **A**: 514, **A**: 515 *T*
symptomatic management **C**: 182
urinary **A**: 57
urinary retention **A**: 258
see also individual effects
agonist–antagonists **C**: 154
as antidiarrheals **C**: 326
availability regulation **Ch**: 102
biliary colic **A**: 364, **A**: 415
blood–brain barrier and **C**: 154;
P: 110
breakthrough pain **C**: 289, **C**: 290 *F*
induction **P**: 113
buccal administration **A**: 208
burn pain **A**: 400–3
cancer-induced bone pain **C**: 258
cancer-induced/related neuropathic pain **C**: 202–4; **P**: 63
controversies in **C**: 202–3
dosing schedules **C**: 201 *T*
genetic variations **C**: 202–3
cancer pain **Ch**: 288; **C**: 157–63
mild to moderate pain **C**: 157–8
moderate to severe pain **C**: 158–62
children **P**: 465–8
adverse effects **C**: 351, **C**: 353 *T*
dose escalation **C**: 350, **C**: 351
dosing schedules **C**: 350, **C**: 352 *T*
monitoring **P**: 466 *T*, **P**: 468
chronic back pain **P**: 117
chronic non cancer pain *see* opioids, chronic noncancer pain (CNCP)
chronic prescribing, risks/outcome prediction **Ch**: 129
classification **A**: 56, **A**: 56 *T*; **C**: 153–4
functional **A**: 56, **A**: 56 *T*
context-sensitive half-times **A**: 58
controlled-release preparations
HIV-associated pain **A**: 413
substance abuse/misuse **C**: 384–5
cough suppression **C**: 315
cross-tolerance **C**: 106
definition **A**: 54; **C**: 153
dependence **A**: 62
in developing world *see* developing world
- dose conversion tables **C**: 183 *T*,
C: 184 *T*
dose escalation **Ch**: 217–9
decreased analgesia **Ch**: 217
maladaptive behaviors **Ch**: 217
driving and **Ch**: 216; **C**: 185
drug interactions **Ch**: 216
dual pharmacology **C**: 115
dying person **C**: 392–3
dyspnea **C**: 313
elderly **A**: 513–5; **C**: 366–8
at home delivery systems **C**: 368
cardiac output effects **A**: 507–8
continuous infusion **C**: 368
doses **A**: 513, **A**: 514
drug combinations **C**: 367
hepatic clearance effects **A**: 508
intermittent regimens **A**: 516–7
metabolites **A**: 513
renal impairment **A**: 513
short half-life drugs **A**: 513
slow-release preparations **A**: 513
suitable types **A**: 513
titration **A**: 514, **A**: 514 *T*
emergency departments **A**: 361–2
addiction risks **A**: 362
age-adjustments **A**: 362
dose adjustments **A**: 362
dose variability **A**: 362
opioid-tolerance **A**: 362
respiratory depression **A**: 362
end of life care **C**: 334–5
endogenous *see* endogenous opioids
ethics **Ch**: 100
fear of
drug unresponsiveness **P**: 129
dying person **C**: 393
elderly **C**: 366
by healthcare professionals **C**: 115
by patients **C**: 115
field/disaster situations **A**: 375
full agonists **A**: 59–61
half-life **A**: 58, **A**: 59 *T*
hepatic clearance **A**: 508
HIV-associated pain, acute **A**: 413
hyperalgesia induction *see* opioid-induced hyperalgesia (OIH)
ICU patients **A**: 347
illicit use **Ch**: 207; **C**: 106–7
in individuals without pain **C**: 154
inhalational administration **A**: 209
breakthrough pain **C**: 286
intra-articular administration
A: 210
intramuscular administration **A**: 205,
A: 505–7
- intranasal administration **A**: 208,
A: 208 *T*, **A**: 362
breakthrough pain **C**: 292
intrathecal administration **A**: 210,
A: 257–8, **A**: 518–9
delivery complications **P**: 377
outcome studies **Ch**: 184
intravenous administration **A**: 206,
A: 239
challenges *see* intravenous opioid drug challenges
interscalene brachial plexus block vs. **A**: 239
sickle cell crisis **A**: 420
labor pain **A**: 470
long-acting, dying person **C**: 393
long-term use guidelines **P**: 110–1
low back pain **A**: 452–3
mixed agonist–antagonists **A**: 61–2
cancer pain **C**: 162
neuraxial analgesia **A**: 257
adverse effects **A**: 257–8
hydrophilic opioids **A**: 257
lipophilic opioids **A**: 257
local anesthetics and **A**: 258
mechanism of action **A**: 256
respiratory depression **A**: 257
neuropathic pain **Ch**: 208–9; **P**: 117
nociception modulation **A**: 15
nociceptive pain **Ch**: 208–9; **P**: 116–7
noninflammatory joint pain **A**: 435
non-intended recipient use **Ch**: 656–7
NSAIDs and **A**: 70
oral administration **A**: 203–4
chronic pain **P**: 112 *T*
oral bioavailability **A**: 58, **A**: 58 *T*
osteoarthritis **Ch**: 212; **P**: 116
paracetamol and **A**: 87–9; **Ch**: 200–1,
Ch: 213
parenteral administration
children **A**: 492
emergency departments **A**: 362
labor pain **A**: 469
partial agonists **A**: 61; **C**: 153–4
PCA *see* patient-controlled analgesia (PCA)
perineural administration **A**: 209
peripheral neuropathic pain **Ch**: 347
pharmacodynamics **A**: 56–8, **A**: 57 *T*
individual variability **A**: 58
pharmacokinetics **A**: 58
pharmacological effects **C**: 154–6
age-related changes **C**: 367
cardiovascular system **C**: 155
central nervous system **C**: 154–5
gastrointestinal system **C**: 155
immune system **C**: 156, **C**: 192

- opioid(s) (*continued*)
- increased muscular tone **C:** 155
 - neuroendocrine **C:** 155
 - renal system **C:** 155–6
 - respiratory system **C:** 154–5
 - skin **C:** 156
 - pharmacology **A:** 59–62; **C:** 151–67
 - actions on other systems **A:** 62
 - physical dependence **A:** 544; **Ch:** 222; **C:** 156–7, **C:** 191; **P:** 113
 - porphyria **A:** 421–2
 - in pregnancy **A:** 462
 - prescribing practice **A:** 53–4
 - prescription charts, infusion
 - standardization **P:** 632–3 *F*
 - preventive analgesia **A:** 168–74, **A:** 172, **A:** 189
 - central sensitization effects **A:** 168
 - spinal postinjury
 - hyperexcitability **A:** 168
 - problematic use **P:** 114
 - behaviors **P:** 114, **P:** 117
 - pseudoaddiction **P:** 113, **P:** 118
 - pure agonists **C:** 153
 - pure antagonists **C:** 154
 - receptors *see* opioid receptor(s)
 - rectal administration **A:** 204
 - regulations/legislation
 - Indian **C:** 84
 - Italian **C:** 83–4
 - release, TENS **A:** 275
 - renal colic **A:** 363, **A:** 415
 - rescue dosing *see* rescue analgesia/dosing
 - response, interindividual
 - variability **A:** 58; **C:** 170
 - candidate genes **C:** 170–4
 - causes **C:** 170
 - drug metabolism **C:** 173
 - drug transporters **C:** 170–3
 - genetics **C:** 170–4
 - pain pathway interactions **C:** 174
 - receptors **C:** 173–4
 - receptor signaling **C:** 174
 - rotation *see* opioid rotation (switching)
 - routes of administration, dying
 - person **C:** 393
 - sickle cell disease **A:** 420
 - spinal administration **Ch:** 286–7, **Ch:** 286 *F*
 - cancer pain **Ch:** 288
 - mechanism of action **Ch:** 286
 - monitoring **Ch:** 286
 - pharmacokinetics **Ch:** 286–7
 - spinal cord injury pain **Ch:** 393, **Ch:** 394, **Ch:** 396 *T*
- strong
- adverse effects **C:** 113
 - elderly **C:** 367
 - immediate use **C:** 116
 - procedure-related pain **C:** 217
 - respiratory depression **C:** 113
 - sedation **C:** 113
 - starting dose **C:** 114
 - WHO analgesic ladder **C:** 113
- subcutaneous administration **A:** 205
- cancer patients *see* subcutaneous drug infusion, cancer pain
 - elderly **A:** 505–7
- sublingual administration **A:** 208
- substance abuse/misuse **C:** 384–5
- switching *see* opioid rotation (switching)
- systemic
- children **A:** 492
 - continuous paravertebral blockade
 - vs.* **A:** 241
 - continuous peripheral neural blockade
 - vs.* **A:** 237
- tolerance *see* opioid tolerance
- topical
- epidermolysis bullosa **Ch:** 237
 - malignant wounds **C:** 217
 - mechanisms of action **Ch:** 232
- toxicity, subcutaneous drug
 - infusion **P:** 125, **P:** 128
- transdermal administration **A:** 207; **P:** 304–6
- adverse reactions/complications **P:** 309
 - chronic pain **P:** 112 *T*
 - contraindications/limitations **P:** 309
 - ideal drug properties **P:** 307
- transmucosal administration **A:** 208; **P:** 306–8
- adverse reactions/complications **P:** 309
 - contraindications/limitations **P:** 309
 - ideal drug properties **P:** 307
 - see also* patient-controlled intranasal analgesia (PCINA)
- underprescription **C:** 115
- volume of distribution **A:** 58; **C:** 107
- weak
- elderly **C:** 366–7
 - legislation **C:** 112
 - WHO essential drug list **A:** 395 *T*
 - withdrawal symptoms **C:** 156–7; **P:** 113
 - see also individual drugs*
- opioid addiction
- acute pain patients **A:** 62
 - cancer patients **C:** 157, **C:** 191
 - characteristics **P:** 113
 - children **C:** 354–5
 - chronic pain patients **P:** 114
 - behavioral signs **P:** 114, **P:** 118
 - prevalence **P:** 114
 - risk factors **Ch:** 654–7; **P:** 114
 - fear of causing **Ch:** 104–5
 - pain therapy in **Ch:** 657
 - recovering addicts **Ch:** 657
 - parental fears **C:** 355
 - pathophysiology **A:** 544
 - prevalence **Ch:** 654
 - recognition of **Ch:** 656
 - risk identification **Ch:** 653 *T*, **Ch:** 655–6
 - behavioral changes **Ch:** 656, **Ch:** 656 *T*
 - clinical examination **Ch:** 655
 - laboratory tests **Ch:** 656
 - medical history **Ch:** 655
 - screening instruments **Ch:** 655
- opioid antagonists **C:** 162–3
- cholestasis **C:** 330
 - constipation **C:** 324
 - newer compounds **C:** 163
- “opioid contracts” **P:** 622
- opioid dose escalation rate (ODER) **Ch:** 217
- opioid escalation index (OEI) **Ch:** 217
- opioid-induced hyperalgesia (OIH) **Ch:** 218–9; **C:** 188–9
- animal models **Ch:** 219
 - capsaicin model **A:** 543
 - clinical features **A:** 543; **C:** 189
 - cold pressor testing **Ch:** 219
 - definition **Ch:** 218
 - diagnostic criteria **C:** 189
 - dose reduction studies **Ch:** 219
 - epidemiology **C:** 189
 - etiology **Ch:** 210, **Ch:** 218 *T*; **C:** 188
 - management, evidence-based
 - evaluation **C:** 189
 - neuropsychological
 - mechanisms **Ch:** 218
 - pain scores **A:** 540
 - pathophysiology **A:** 544; **C:** 188
 - timing **Ch:** 218–9
- opioid irrelevant pain **C:** 116
- opioid receptor(s) **A:** 54–6; **C:** 152–3
- acupuncture **Ch:** 310; **C:** 273
 - delta (δ) *see* delta (δ) opioid receptors
 - distribution/location **A:** 55; **C:** 152, **C:** 202
 - peripheral tissue **A:** 55
 - endogenous ligands **A:** 55

- epsilon (ϵ) **A:** 54
kappa (κ) *see* kappa (κ) opioid receptors
mechanism of action **A:** 55; **C:** 152–3
neurotransmitters **A:** 55
mu (μ) *see* mu (μ) opioid receptors
nociception **A:** 15
nomenclature **A:** 55, **A:** 55 *T*
opioid activities at **C:** 202 *T*
peripheral sensitization **A:** 24
receptor-specific actions **C:** 152
sigma (σ) **A:** 54
signaling response variability **C:** 174
signal transduction **C:** 153
structure **C:** 152
subtypes **C:** 152
TENS **C:** 238
see also specific receptors
opioid receptor antagonists,
opioid-tolerant patients **A:** 549
opioid rotation (switching) **C:** 168–78,
C: 182–3
adverse effect profiles **C:** 169–70
cancer pain clinical trials **P:** 542
children **C:** 350–1
equianalgesic dose **C:** 350–1
chronic noncancer pain **Ch:** 219–20;
P: 116
administration routes **Ch:** 220
adverse effects reduction **Ch:** 220
analgesia improvement **Ch:** 220
equipotent doses **Ch:** 220
metabolites **Ch:** 219
pharmacodynamics **Ch:** 219
pharmacokinetics **Ch:** 219
clinical rationale **C:** 169–70
cross-tolerance **C:** 106
definition **Ch:** 219; **C:** 182
delirium **C:** 187
dose calculations **C:** 169
dose conversions **C:** 183 *T*,
C: 184 *T*
dose-ratio ranges **C:** 169
effectiveness **C:** 182
evidence base **C:** 170
studies **C:** 171
guidelines **C:** 183
opioid-induced myoclonus **C:** 188
opioid rotation *vs.* **C:** 169
opioid switching *vs.* **C:** 169
opioid-tolerant patients **A:** 547–8,
A: 547 *T*
refractory nausea **C:** 191
subcutaneous drug infusion, cancer
patients **P:** 125
substance abuse/misuse **Ch:** 657
WHO analgesic ladder in **C:** 182
- opioids, chronic noncancer pain
(CNCP) **Ch:** 207–29, **Ch:** 223 *T*;
P: 109–20
acute pain treatment **P:** 115–6
as-needed *vs.* by-the-clock **Ch:** 212–3
breakthrough pain **Ch:** 220–1; **P:** 116
ceiling dose **Ch:** 217–8; **P:** 116
central neuropathic pain **Ch:** 380
chronic pancreatitis pain **Ch:** 554
chronic pelvic pain **Ch:** 584
combinations **Ch:** 213–4
combined opioid–opioid
analgesia **Ch:** 214
gabapentin **Ch:** 213
ketamine **Ch:** 213–4
long-acting opioids *vs.* **Ch:** 213–4
NSAIDs **Ch:** 213
compliance monitoring **P:** 113
consent **Ch:** 221–2; **P:** 112–3
contraindications **P:** 112, **P:** 114
CRPS **Ch:** 369
children **Ch:** 627
doctor problems, case
history **P:** 117–8
dose adjustments **P:** 115
efficacy, evidence for **Ch:** 208–14;
P: 110
individual drugs **Ch:** 210–2
long-acting drugs **Ch:** 209–10
meta-analyses **Ch:** 208
reviews **Ch:** 208
short-acting drugs **Ch:** 210
failed treatments **P:** 117
herpes zoster **Ch:** 433
HIV-associated neuropathic
pain **Ch:** 356
indications **P:** 114
inflammatory bowel disease **Ch:** 561
interstitial cystitis **Ch:** 557
long-term use indications **P:** 111–2
lower back pain **Ch:** 508
monitoring **Ch:** 222–3
aberrant behavior **Ch:** 222,
Ch: 223 *T*
analgesic effect review **Ch:** 222
dose reviews **Ch:** 222
starting dose **Ch:** 222
timing **Ch:** 222
tolerance **Ch:** 222
neurologic disease pain **Ch:** 329
neuropathic pain **Ch:** 13, **Ch:** 14 *F*
pancreatic cancer pain **Ch:** 551
patient information **P:** 112–3
patient problems, case
history **P:** 117–8
patient selection **Ch:** 207, **Ch:** 214–6,
Ch: 224 *T*
- biophysical approach **Ch:** 215–6
intravenous opioid
testing **Ch:** 214–5
local anesthetic blocks **Ch:** 215
presentation **Ch:** 208
previous conservative
therapy **Ch:** 215
psychological assessments **Ch:** 215
pediatric headache **Ch:** 631–2,
Ch: 632 *T*
period reviews **P:** 115
postamputation pain **Ch:** 423
postherpetic neuralgia **Ch:** 434–5,
Ch: 434 *T*
prescribers **P:** 113
problematic prescription
use **P:** 110–1, **P:** 114
refractory angina pectoris **Ch:** 541
rotation *see* opioid rotation
(switching)
treatment guidelines **P:** 114–5
treatment objectives **P:** 115
treatment plan **P:** 115
treatment protocols **P:** 109–20
trial period **P:** 115
unresolved questions in **P:** 111
opioid substitution *see* opioid rotation
(switching)
opioid switching *see* opioid rotation
(switching)
opioid tolerance **A:** 539–57
acute **A:** 543
adverse effects **A:** 540
behavioral conditioning **Ch:** 218
cancer patients **C:** 156, **C:** 191; **P:** 539
assessment **A:** 545
persistent pain **A:** 542
children **C:** 354–5
clinical features **Ch:** 218 *T*; **C:** 106
cold pressor testing **Ch:** 219
definition **A:** 62, **A:** 540; **Ch:** 218;
P: 113
development, timing of **Ch:** 218–9
identification **A:** 544
management **A:** 545–6
additional opioids **A:** 546–7
adjuvants **A:** 548–9
collaborative approach **A:** 546
goals **A:** 545–6
neuraxial blockade,
long-term **A:** 549–50
nonpharmacological **A:** 549
opioid rotation **A:** 547–8, **A:** 547 *T*
opioids **A:** 546–8
PCA **A:** 547
pharmacological **A:** 549–51
planning **A:** 544–5

- opioid tolerance (*continued*)
 psychiatric/behavioral disorders **A:** 546
 regional analgesia **A:** 548
 step-down analgesia **A:** 548
 neurobiological mechanisms **Ch:** 218; **C:** 156
 neuropsychological mechanisms **Ch:** 218
 obstetrics **A:** 551
 opioid consumption and **A:** 540
 pain tolerance **A:** 543
 pathophysiology **A:** 543–4
 patient assessment **A:** 544–5
 nonjudgmental approaches **A:** 544–5
 pain history **A:** 545
 patient concerns **A:** 541
 PCA **P:** 297–8, **P:** 298 *T*
 persistent noncancer pain **A:** 541–2; **Ch:** 218–9
 pathophysiological factors **A:** 541
 patient assessment **A:** 545
 psychological factors **A:** 541
 sociocultural factors **A:** 541
 prevalence **A:** 539
 staff knowledge/attitudes **A:** 541
 workload impact **A:** 541
see also substance abuse disorder (*SAD*); substance abuse/misuse
- opioid-unresponsive pain, chronic nonmalignant **P:** 112
- opioid withdrawal **C:** 156–7; **P:** 113, **P:** 622
- opiophobia **Ch:** 104; **C:** 115
- OPRM1 gene/protein **Ch:** 62 *T*
- optic neuritis, multiple sclerosis **Ch:** 325
- oral bedside PCA **P:** 309
- oral contraceptives
 chronic pelvic pain **Ch:** 584
 dysmenorrhea, primary **Ch:** 574
 endometriosis **Ch:** 575
- oral drug administration **A:** 202–4; **P:** 304
 absorption rates **A:** 202; **P:** 304
 advantages **A:** 210
 children **C:** 349; **P:** 463
 developing world **A:** 395
 dying person **C:** 393–4
 loading dose calculation **C:** 108
 nonopioid analgesics **A:** 202–3
 onset of effect delay **A:** 202
 opioid analgesics **A:** 203–4
 postoperative pain management **A:** 335
- WHO guidelines, efficacy **C:** 109–11, **C:** 116
see also individual drugs
- oral pain
 HIV infection **Ch:** 358, **Ch:** 359 *T*
 neuropathic *see* neuropathic orofacial pain
- oral problems, cancer patients **C:** 316–7
- oral splints, temporomandibular disorder management **Ch:** 469
- oral transmucosal fentanyl citrate (OTFC) **P:** 308, **P:** 308 *F*
 breakthrough pain **C:** 203, **C:** 291–2
 cancer pain **C:** 160
 children **A:** 484; **C:** 349
 field/disaster situations **A:** 382
 lollipops **A:** 208; **P:** 308, **P:** 308 *F*
 procedure-related pain **C:** 217
- oral ulceration, acute **A:** 418
- orbitofrontal cortex (OrbF), placebo effect **P:** 506
- orchialgia **Ch:** 563
- orchidopexy, inguinal nerve block **A:** 490
- order (period) effect **P:** 520, **P:** 543–4, **P:** 556
- Orebro Musculoskeletal Pain Screening Questionnaire **P:** 223
- orexin **C:** 328
- organ donation, end-of-life care **A:** 351
- organ dysfunction, clinical trial exclusion criteria **P:** 545
- organ failure **A:** 348–9
 edema **A:** 349
 kidney **A:** 348–9
 liver **A:** 349
 plasma level surveillance **A:** 349
- organ function testing **P:** 67
- organic hallucinosis
 definition **C:** 185
 opioid-induced **C:** 185
 children **C:** 353 *T*
 clinical presentation **C:** 185
 management **C:** 185
- organ perfusion, critical illness **A:** 348
- orofacial pain
 acute **A:** 418–9
 causes **A:** 418
 neuropathic *see* neuropathic orofacial pain
- oromandibular dysfunction, headache **Ch:** 454
- oropharyngeal pain, cancer-related mucositis **A:** 418–9; **C:** 317
- orphanin NQ/nociceptin **C:** 153
- orthognathic surgery, neuropathic orofacial pain **Ch:** 470
- orthopedic surgery
 continuous spinal analgesia **A:** 260–1
 neuraxial analgesia **A:** 264
 orthostatic headache **Ch:** 455
 orthostatic phenomena, drug-induced **P:** 139, **P:** 335
 osmic acid **P:** 359
 osmotic laxatives **C:** 325 *T*
 osteoarthritis **Ch:** 525–8
 acute pain **A:** 436
 age-related **Ch:** 526
 cartilage deterioration *vs.* **A:** 436
 clinical features **Ch:** 25, **Ch:** 519, **Ch:** 526, **Ch:** 526 *T*
 definition **A:** 436; **Ch:** 525
 epidemiology **Ch:** 526
 first carpometacarpal joint **P:** 352
 fractures **Ch:** 146
 hip joint **P:** 353
 investigations **Ch:** 526
 MRI **Ch:** 25
 knee pains **Ch:** 530
 prevalence **Ch:** 518
 shoulder joint **P:** 351
 symptomatic **A:** 436
 treatment **Ch:** 526–8
 chondroprotective agents **Ch:** 527
 clinical guidelines **Ch:** 526
 exercise therapy **Ch:** 527
 intra-articular injections **Ch:** 527; **P:** 359
 nonpharmacological **Ch:** 527–8
 occupational therapy **Ch:** 528
 patient education/self management **Ch:** 527
 pharmacological **Ch:** 526–7
 physical therapy **Ch:** 527–8
 surgery **Ch:** 528
 systemic therapies **Ch:** 527
 TENS **Ch:** 528
 topical therapies **Ch:** 526–7
see also individual drugs/treatments
- osteoarthroses, neck pain **Ch:** 488
- osteoblasts, bone metastases **C:** 256–7
- osteoclast-activating factors (OAFs) **C:** 256–7
- osteoclasts, bone metastases **C:** 256–7
- osteonecrosis
 joint pain **A:** 436
 MRI **Ch:** 148
- osteopathy, neurologic disease pain **Ch:** 331
- osteoporosis
 persistent musculoskeletal pain **Ch:** 26
 vertebral metastases *vs.* **C:** 28

- osteoporotic vertebral crush fractures **A:** 107
- osteoprotogerin (OPG) **C:** 256–7
- Oswestry Disability Index (ODI) Charité artificial disk **P:** 442 coverage **P:** 32 intradiscal electrothermal therapy **P:** 441
- Oswestry Low Back Pain Disability Questionnaire **P:** 33–4 *T*
- otitis media **A:** 419
- Ottawa Ankle Rule **Ch:** 146 *T*
- Ottawa Knee Rule **A:** 440; **Ch:** 146 *T*
- Oucher self-report pain scale, children acute pain assessment **A:** 142–3; **P:** 449, **P:** 450 *F* cultural/ethnic considerations **P:** 458 “The Ouchless Place” **P:** 647
- outcome evaluation, treatment **P:** 102–4 aims **P:** 102 daily measurement **P:** 103 outcome selection **P:** 102–4, **P:** 103 *T* program evaluation **P:** 104 single-subject designs *see* single-subject designs, outcome evaluation weekly measurement **P:** 103
- outcome reporting bias **P:** 574
- outcome stress, surgery **P:** 248–9
- outpatients, continuous peripheral neural blockade **A:** 246
- ovarian cancer, radiotherapy **C:** 254
- ovarian remnant syndrome **Ch:** 577–8
- overload, persistent musculoskeletal pain **Ch:** 26
- oversedation, PCA **A:** 225
- overt-covert design (open-hidden paradigm), placebo response **P:** 503 *F*, **P:** 504, **P:** 507–8, **P:** 508 *F*
- overuse injuries, sports-related **A:** 527 bone **A:** 529–30 clinical presentation **A:** 531 NSAIDs **A:** 534, **A:** 534 *F* repetitive friction **A:** 527 repetitive microfatigue **A:** 527
- oxaliplatin **C:** 401
- oxcarbazepine **Ch:** 255–6, **Ch:** 256 *T* adverse effects **Ch:** 256, **Ch:** 257 *T*; **P:** 137 central neuropathic pain **Ch:** 379–80 clinical trials **Ch:** 255 contraindications **P:** 135 diabetic polyneuropathy **Ch:** 255, **Ch:** 257 *T* dosage/treatment schedule **P:** 136 doses **Ch:** 257 *T*
- efficacy **Ch:** 256, **Ch:** 261 *T* indications **Ch:** 257 *T*; **P:** 135 metabolism **Ch:** 255; **P:** 135 pediatric headache **Ch:** 633 *T* pharmacokinetics **Ch:** 255 pharmacology **Ch:** 254–5 sodium channel blockade **Ch:** 254–5 trigeminal neuralgia **Ch:** 256, **Ch:** 256 *T*, **Ch:** 257 *T*, **Ch:** 473
- oxicams **A:** 78; *see also individual drugs*
- oxidative stress, chronic pancreatitis **Ch:** 553
- oxycodone **A:** 60; **C:** 161 adverse effects **A:** 485; **C:** 161, **C:** 190, **C:** 191 breakthrough pain **C:** 291 cancer pain **C:** 161, **C:** 169 *T* neuropathic **C:** 204 children **A:** 485; **P:** 466 *T*, **P:** 468 cancer pain **C:** 348, **C:** 352 *T* headache **Ch:** 632 *T* chronic noncancer pain **Ch:** 211 constipation induction **C:** 190 controlled release **A:** 203–4, **A:** 335–6 diabetic neuropathy **Ch:** 211 elderly **A:** 513; **C:** 368 intermittent use guidelines **P:** 596–7 *F* intranasal administration **A:** 208 *T* intravenous administration **A:** 485 morphine and **Ch:** 214 nausea induction **C:** 191 neuropathic pain **Ch:** 208, **Ch:** 211 nociceptive pain **Ch:** 208 oral administration **A:** 203 children **A:** 485 controlled-release preparations **A:** 203–4 paracetamol and **Ch:** 213 pharmacodynamics **C:** 161 pharmacokinetics **A:** 59 *T*; **C:** 161 children **A:** 485 pharmacology **C:** 204 postherpetic neuralgia **Ch:** 211, **Ch:** 434–5 postoperative pain management **A:** 335–6 rectal administration **A:** 204 routes of administration/formulations **C:** 161 children **A:** 485 spinal cord injury pain **Ch:** 394 subcutaneous infusion, cancer patients **P:** 127 *T* substance abuse disorder **A:** 542
- oxygen cluster headache treatment **Ch:** 462
- dyspnea, cancer patients **C:** 314 withholding treatment **C:** 314 opioid-induced respiratory depression **A:** 514 sickle cell disease pain **A:** 420
- oxygen consumption, labor pain **A:** 465–6
- oxygen saturation PCA **A:** 221 respiratory depression monitoring **P:** 591
- oxymorphone **A:** 203–4; **C:** 161
- oxyphenbutazone **A:** 76
- oxytocin, acupuncture **C:** 273
- p38 MAP kinase, microglia activation **Ch:** 14–5
- paclitaxel, neuropathy induction **C:** 7, **C:** 402 animal models **C:** 8
- PADT (Pain Assessment and Documentation Tool) **Ch:** 128
- pain anticipation **P:** 154 assessment *see* pain assessment attention to **P:** 146 biopsychosocial perspective **P:** 619, **P:** 655 components **C:** 50 *F* as construct **P:** 13 cortical modulation **P:** 146 cultural effects **Ch:** 91–2, **Ch:** 92 beliefs about **Ch:** 92 emotional effects **Ch:** 92 psychosocial factors **Ch:** 92 definition **C:** 13; **P:** 540 definitions **Ch:** 87–90 brain multiplicity **Ch:** 91 Cartesian definitions **Ch:** 88 ethical concerns **Ch:** 88 experiences, psychological factors **P:** 145 gender effects **Ch:** 91 as malignant force **P:** 619 management barriers to *see* pain relief barriers ethics *see* ethical issues psychological interventions *see* psychological interventions/therapy meaning of **P:** 146–7 mood disorders **P:** 147 neurophysiological mechanisms **P:** 44 perception *see* pain perception as pleural concept **Ch:** 90 psychology **C:** 297 somatosensory evaluation **P:** 45

- pain (*continued*)
 as subjective state **Ch:** 87–8
 syndrome-specific **Ch:** 90–1
 traumatic dissociation **P:** 146
 undertreatment, ethics **Ch:** 94
see also individual types
Pain after Surgery **P:** 605
 recommendations **P:** 581
 Pain and Palliative Care Clinic,
 Kerala **C:** 87
 Pain and Policy Study Group
 (PPSG) **C:** 84
 opioid policy assessment
 guidelines **Ch:** 112; **C:** 84
 workshop approach **C:** 84
 research areas **C:** 84
 Romanian work **C:** 84–5
 Pain Anxiety Symptoms Scale **P:** 180
 chronic pain-related
 anxiety **Ch:** 172 *T*, **Ch:** 173–4
 fibromyalgia syndrome **P:** 178–9
 pain appraisal, cognitive processes
 in **C:** 297
 pain assessment
 acute pain *see* acute pain assessment
 cancer pain clinical trials *see* cancer
 pain clinical trials
 children *see* children
 cognitive impairment **A:** 511–2
 dementia patients **A:** 145–7; **C:** 43
 developing world **A:** 394
 Down syndrome **C:** 371
 dying person **C:** 392, **C:** 392 *F*
 elderly *see* elderly
 guidelines **P:** 656
 ICU patients *see* intensive care units
 (ICUs)
 infants **P:** 456–7
 intensity *see* pain intensity
 measurement
 measures *see* pain measures
 neuropathic pain *see* neuropathic pain
 nonverbal behavior **C:** 370–1, **C:** 392
 by nurses **C:** 364, **C:** 371
 presurgical **P:** 248
 underestimation by health
 professionals **P:** 248
 preventive analgesia **A:** 189
 subcutaneous drug infusion
 monitoring **P:** 124
 substance abuse disorder **A:** 545
 Pain Assessment and Documentation
 Tool (PADT) **Ch:** 128
 Pain Assessment in Advanced Dementia
 (PAINAD) **A:** 145–6, **A:** 512;
C: 371
 Pain Assessment Tool (PAT) **A:** 479 *T*
 pain behavior *see* behavior(s)
 pain catastrophizing *see* catastrophizing
 Pain Catastrophizing Scale, presurgical
 patients **P:** 248
 Pain Catastrophizing Scale for Children
 (PCS-C), chronic pain
 assessment **P:** 455–6
 pain center pain questionnaire **Ch:** 123,
Ch: 124 *T*
 pain clinics, India **C:** 87
 pain complexity, chronic pain outcome
 measurement **Ch:** 181
 pain conditions, classification **P:** 45
 pain control exercises, self-
 hypnosis **P:** 148
 Pain Coping Questionnaire
 (PCQ) **P:** 455–6
 “pain diary”
 cancer pain **P:** 21
 chronic noncancer pain **P:** 21
 outcome evaluation **P:** 103
 Pain Disability Index (PDI) **Ch:** 172 *T*,
Ch: 173; **P:** 33–4 *T*
 Pain Disability Questionnaire
 (PDQ) **Ch:** 118
 pain drawings **A:** 143–4
 advantages **A:** 143
 disadvantages **A:** 143
 ICUs **A:** 143
 pain flare *see* breakthrough pain
 pain hypervigilance, pain-related
 fear **P:** 178–9
 pain intensity
 clinical trial end points **P:** 520, **P:** 521
 definition **P:** 13
 generalized anxiety disorder **Ch:** 616
 measurement *see* pain intensity
 measurement
 pain intensity difference
 (PID) **A:** 148–9; **P:** 21, **P:** 517 *F*,
P: 522 *F*
 pain intensity measurement **P:** 12–27
 advantages **P:** 12–3
 age extremes **P:** 20
 assessor “status” **P:** 14
 cancer patients **C:** 41–2, **C:** 43 *T*; **P:** 21
 graphic display **C:** 42
 instruments **C:** 41
 children *see* children
 chronic pain trials **Ch:** 184
 composite measures **P:** 17
 elderly **P:** 20
 pain memory **P:** 14
 pictures **P:** 15–6, **P:** 16 *F*
 questionnaires **P:** 16–20
 results
 handling **P:** 21–3
 interpretation **P:** 21–3
 sample size **P:** 22
 scales **P:** 14–6
 acute pain assessment **A:** 136 *T*,
A: 139–47
 anchor points **P:** 14
 cancer pain clinical trials **P:** 540–1
 descriptive terms **P:** 14
 single ratings **P:** 14
see also individual scales
 serial measures **P:** 21, **P:** 22 *T*
 toys **P:** 15–6, **P:** 17 *F*
see also individual instruments
 pain management inventory (PMI),
 elderly **C:** 362
*Pain management services - good
 practice* **P:** 667–8
 pain maps
 cervical referred pain **Ch:** 485–6,
Ch: 485 *F*, **Ch:** 486 *F*, **Ch:** 487 *F*
 neck pain diagnosis **Ch:** 162,
Ch: 162 *F*
 pain matrix **P:** 85–6
 pain measures
 application **P:** 28–42
 associated variable measurement **P:** 29
 behavioral **P:** 29
 change/difference estimation **P:** 38–9
 clinical significance **P:** 38
 meaningfulness **P:** 22–3, **P:** 38
 raw data plots **P:** 39, **P:** 39 *F*
 reliable **P:** 38
 researcher/clinician tension **P:** 39
 type I error **P:** 38
 type II error **P:** 38
 compound measures **P:** 32–5
 content **P:** 29–36
 domains of outcome **P:** 28–9,
P: 29–35
 activity **P:** 31–2
 behavior **P:** 31–2
 biomedical **P:** 30
 healthcare resources **P:** 35
 pain experience **P:** 30
 pain relief **P:** 30
 significant others **P:** 35
 third party-defined outcomes **P:** 35
 welfare provision **P:** 35
 intensity *see* pain intensity
 measurement
 methods **P:** 29
 nonoutcome variables **P:** 35–6
 output interpretation **P:** 36–9
 psychometric properties **P:** 29, **P:** 36
 psychosocial outcomes **P:** 30–1
 acceptance **P:** 31
 affect/emotion **P:** 30–1

- anxiety **P**: 30–1
 cognitive **P**: 31
 constructs **P**: 30
 coping **P**: 31
 fear **P**: 31
 frustration **P**: 30–1
 satisfaction ratings **P**: 35
 social roles, interference with **P**: 35
 quality **P**: 36–9
 quality of life **P**: 32–5, **P**: 33–4 *T*
 reliability **P**: 36–7
 error variance **P**: 36
 internal consistency **P**: 36
 interrater reliability **P**: 36, **P**: 37
 intraclass correlation **P**: 37
 low **P**: 36
 test–retest reliability/
 repeatability **P**: 36–7
 selection **P**: 28–42
 considerations in **P**: 29–36
 self-report methods **P**: 29
 sensitivity to change/
 responsiveness **P**: 38
 treatment aims and **P**: 29, **P**: 39
 treatment process assessment **P**: 35–6,
 P: 40
 adherence **P**: 35–6
 validity **A**: 148; **P**: 37–8
 concurrent **P**: 37
 construct **P**: 37
 cutpoints **P**: 37–8
 definition **P**: 37
 divergent **P**: 37
 estimation **P**: 37
 “gold standards” **P**: 37
see also individual measures
 Pain Medication Questionnaire **Ch**: 656
 pain memory, manual medicine **P**: 236
 pain monitors, ICUs **A**: 345
 Pain Outcomes Questionnaire-VA
 (POQ-VA) **P**: 20
 pain perception
 attention in **P**: 146
 consciousness state **P**: 146
 elderly *see* elderly
 factors affecting **P**: 13–4
 climatic conditions **P**: 13–4
 demographic **P**: 13
 ethnicity **P**: 13
 gender **P**: 13
 psychosocial **P**: 13
 time of day **P**: 13–4
 genetics in **P**: 85–6
 neck pain **Ch**: 484–5
 pain processing
 dopaminergic pathways **P**: 90
 neuroanatomy **P**: 85–6, **P**: 88 *F*
 pain progression model **P**: 655–6
 sick role **P**: 655–6
 stage 1 **P**: 655
 stage 2 **P**: 655
 stage 3 **P**: 655–6
 pain provocative discography **P**: 441
 pain quality, clinical trial
 outcomes **P**: 521
 pain rehabilitation programs
 chronic lower back pain **Ch**: 503
 North American *see* comprehensive
 pain rehabilitation programs,
 North America
 pain-related fear
 acquisition pathways **P**: 184
 attention and **P**: 178–9
 behavioral performance **P**: 178
 characteristics **P**: 178
 children **P**: 480–1
 assessment **P**: 453
 cognitive-behavioral
 assessment **P**: 179–83
 behavioral tests **P**: 183
 future expectations **P**: 181
 graded hierarchies **P**: 182–3,
 P: 183 *T*
 interview **P**: 180–2, **P**: 181
 pain severity estimation **P**: 181
 questionnaires **P**: 179–80
 reinjury fears **P**: 180–1
 treatment goals **P**: 181–2
 cognitive-behavioral model **P**: 180–1,
 P: 181 *F*
 disconfirmations of harm
 beliefs **P**: 179
 graded exposure *in vivo see* graded
 exposure *in vivo*, pain-related
 fear
 informational transmission **P**: 185
 traumatic experience in **P**: 184
 pain relief, as outcome **P**: 30, **P**: 521
 pain relief and intensity difference
 (PRID) **A**: 148–9
 pain relief barriers **Ch**: 102–9
 cancer pain
 international perspective **C**: 81–92
 service development
 patterns **C**: 85–9
 developing world **A**: 390–3
 drug availability **C**: 82–4
 economic factors **C**: 82
 Indian regulations **C**: 84
 Italian regulations **C**: 83–4
 narcotic drug regulations
 C: 82–3
 family caregivers **C**: 64–5
 principle of balance **C**: 84–5
 pain relief scores, neuropathic
 pain **Ch**: 140
 pain reporting reluctance, patient
 beliefs **A**: 295
 pain resource nurse programs **P**: 643
 pain scales, cognitive impaired **C**: 392 *F*
 pain scores
 ICUs **A**: 345, **A**: 346 *T*
 postoperative pain
 management **P**: 606
 pain services
 acute *see* acute pain service(s) (APS)
 birth of **P**: 629
 children *see* pediatric pain services
 historical aspects **P**: 628–9
 national guideline
 development **P**: 629
 Palestinian Authority, palliative care
 services **C**: 87
 palliative care **C**: 412–3; **P**: 658
 acute care–palliative care
 interface **C**: 412, **C**: 413 *F*
 definition **A**: 350–1
 double effect principle *see* doctrine of
 double effect
 emotional pain alleviation,
 ethics **C**: 95
 global development **C**: 85
 ICU patients, analgesia **A**: 351
 model **Ch**: 101 *T*; **C**: 389–90, **C**: 390 *F*
 pancreatic cancer **Ch**: 551
 quality, legal perspectives **Ch**: 110–1
 services, worldwide distribution **C**: 86
 social pain alleviation, ethics **C**: 95
 United States **C**: 412
 WHO definition **C**: 412
 see also end of life care; *individual*
 countries
 Palliative Care Formulary, non-licensed
 drug use **C**: 415–6
 palliative home care teams
 team members roles **C**: 413
 United Kingdom **C**: 412–3
 United States **C**: 413
 Palmer, D. D. **Ch**: 311–2
 palonsetron **C**: 320 *T*
 palpation, abdominal pain **Ch**: 551
 pamidronate **C**: 265–6
 Pancoast tumor **C**: 254
 pancreatic cancer **Ch**: 551–2
 characteristics **Ch**: 551
 diagnosis **Ch**: 551
 exocrine tissue **Ch**: 551
 pain **Ch**: 551, **Ch**: 552; **C**: 35
 celiac plexus block **Ch**: 552; **P**: 341
 treatments **Ch**: 552, **Ch**: 560

- pancreatic cancer (*continued*)
 videothoracoscopic
 splanchnicectomies **Ch:** 552
 palliative therapy **Ch:** 551
 presentation **Ch:** 551
 risk factors **Ch:** 551
- pancreatic enzymes, chronic
 pancreatitis **Ch:** 554
- pancreatic pain, cancer-induced **C:** 35
- pancreatic pseudocysts **Ch:** 556
- pancreatitis, acute **A:** 415–6
 causes **A:** 416
 chronic, development of **A:** 416
 treatment **A:** 416
- pancreatitis, chronic **Ch:** 553–6
 acute vs. **Ch:** 553
 alcohol consumption **Ch:** 553
 animal models **Ch:** 553
 classification **Ch:** 553
 diffuse intraductal calcium
 deposition **Ch:** 553
 genetics **Ch:** 553
 histopathology **Ch:** 553
 HIV-associated abdominal
 pain **Ch:** 358
 hypersensitivity **Ch:** 38
 idiopathic types **Ch:** 553
 imaging **Ch:** 553
 intraparenchymal pressure **Ch:** 553
 oxidative stress **Ch:** 553
 pain therapy **Ch:** 553–4, **Ch:** 555 *F*,
Ch: 560
 alcohol abstinence **Ch:** 554
 antioxidants **Ch:** 554
 opioids **Ch:** 554
 spinal cord stimulation **Ch:** 276
 surgery **Ch:** 556
 presenting complaints **Ch:** 553
 steatorrhea **Ch:** 553
- pancytopenia, paracetamol-
 induced **Ch:** 200–1
- panic disorder
 chest pain **Ch:** 538
 chronic pain patients **Ch:** 170,
Ch: 617
- para-aortic lymphadenopathy
C: 253–4
- parabrachial area, nociception **A:** 11–2
- parabrachial nucleus, persistent visceral
 pain **Ch:** 40
- paracentesis **C:** 215 *F*
- paracetamol (acetaminophen) **A:** 84–95;
Ch: 199–200; **C:** 124–5
 abdominal pain **A:** 414
 absorption **Ch:** 201
 acute pain, indications **A:** 85
 administration **A:** 89–92; **Ch:** 200
- adverse effects **A:** 87; **Ch:** 200–1;
C: 125
 children **A:** 482
 gastrointestinal **Ch:** 201; **C:** 125
 hepatotoxicity **A:** 332–3, **A:** 482;
Ch: 201
 renal **Ch:** 201; **C:** 125
- analgesic ceiling **A:** 332–3
- breakthrough pain **C:** 289–90
- cardiac surgery **A:** 351
- children **A:** 481–2; **P:** 464, **P:** 465 *T*
 acute postoperative pain **A:** 481
 administration **A:** 481–2
 adverse effects **A:** 482
 cancer pain **C:** 347–8
 contraindications **C:** 347–8
 dosages **A:** 85, **A:** 482 *T*; **C:** 347–8
 pharmacokinetics **A:** 481–2
 safety **C:** 348
 systemic analgesia **A:** 492
- chronic pain **Ch:** 199–200
 effectiveness **Ch:** 201–2
- codeine and **A:** 87–8; **Ch:** 200
- compound analgesics and **A:** 87–9,
A: 90–1 *T*
- contraindications **A:** 86
 kidney failure **A:** 349
 lactation **A:** 86
 liver failure **A:** 349
- development **C:** 124
- dextropropoxyphene and **A:** 88
- dosages **A:** 85–6
 chronic pain **Ch:** 200
- drug interactions **A:** 86–7
 alcohol **A:** 87
 liver-metabolized drugs **A:** 87
 warfarin **A:** 86, **A:** 86 *F*, **A:** 452
- elderly **A:** 515; **C:** 365, **C:** 367
 chronic pain **Ch:** 646–7
 NSAIDs alternative **A:** 515
 oral absorption **A:** 505
 renal impairment **A:** 515
- extent of use **A:** 86
- field/disaster situations **A:** 379
- headache **Ch:** 202
- historical aspects **A:** 85
- ICUs **A:** 347
 cardiac surgery **A:** 351
- intravenous administration **A:** 89–92
 children **A:** 481–2, **A:** 482 *T*
- low back pain **A:** 452; **Ch:** 202
- mechanism of action **A:** 86, **A:** 332–3,
A: 481; **Ch:** 200; **C:** 124–5,
C: 125 *F*
 COX-3 **C:** 124
 COX inhibition **Ch:** 200; **C:** 124
- metabolism **Ch:** 200
- migraine **A:** 365
- nausea and vomiting **A:** 227
- noninflammatory joint pain **A:** 435
- NSAIDs and **A:** 89
- NSAIDs vs. **C:** 124
- number needed to treat **A:** 89 *T*
- opioids and **A:** 87–9; **Ch:** 200–1,
Ch: 213
- opioid-tolerant patients **A:** 548
- oral administration **A:** 87–9,
A: 481–2, **A:** 482 *T*
 children **A:** 481–2, **A:** 482 *T*
 efficacy measurement **A:** 87
 as single agent **A:** 87, **A:** 88 *T*,
A: 89 *T*
- osteoarthritis **A:** 87; **Ch:** 201–2,
Ch: 527
- overdose **A:** 92, **A:** 92 *T*; **C:** 125
- oxycodone and **Ch:** 213
- parenteral administration **A:** 492
 children **A:** 492
- PCA **P:** 295–6
- pediatric headache **Ch:** 630–1
- pharmaceutical issues **Ch:** 201
- pharmacokinetics **A:** 86
- pharmacological issues **Ch:** 201
- popularity **C:** 124
- porphyria **A:** 422
- postoperative pain **A:** 332–3, **A:** 481
 in pregnancy **A:** 86, **A:** 461
- preparations **A:** 85
- profile **A:** 85 *T*
- pulpitis **Ch:** 477
- rectal administration **A:** 92, **A:** 204
 children **A:** 481–2, **A:** 482 *T*
- rectal pharmacokinetics **P:** 463
- rheumatoid arthritis **A:** 87;
Ch: 521
- spinal cord injury pain **Ch:** 393
- sports injuries **A:** 532–3
- sweating **C:** 331
- systemic analgesia **A:** 492
- tension-type headache **Ch:** 458
- toxicity **P:** 464
- tramadol and **Ch:** 213
- WHO essential drug list **A:** 395 *T*
- parallel studies **P:** 520
 advantages **P:** 556–7
 cancer pain clinical trials **P:** 543,
P: 543 *F*
 drug safety evaluation
 limitations **P:** 557
 neuropathic pain clinical
 trials **P:** 555–7, **P:** 556 *F*
- paralytic scoliosis, spasticity **Ch:** 444
- paraneoplastic neuropathies **Ch:** 344
- paraplegia **P:** 422–3

- parasympathetic nervous system,
heart **Ch:** 538–9
- parathyroidectomy, uremic itch **C:** 330
- parathyroid hormone-related peptide
(PTHrP), hypercalcemia **C:** 319
- paravertebral blockade **P:** 345
children **A:** 491; **P:** 471–2
anatomy **P:** 472
catheter technique **P:** 472
method **P:** 472
continuous **A:** 241
indications **A:** 241
systemic opioids vs. **A:** 241
thoracotomy **A:** 241
elderly **A:** 519
field/emergency situations **A:** 382 *T*
interpleural blockade vs. **A:** 242
postoperative pain **A:** 332, **A:** 332 *T*
- paravertebral space, children **A:** 491;
P: 472
- parecoxib **A:** 78–9
intramuscular administration **A:** 205
postoperative pain
management **A:** 334
- parent(s)
acute pain management role **A:** 481
biofeedback, involvement in **P:** 488
child pain assessment **A:** 478–9;
P: 458
concerns of **A:** 318–9
distress reduction **P:** 252
education, pediatric APS **P:** 644
empowerment, procedural pain
management services **P:** 647
presurgical behavioral
effects **A:** 312–3; **P:** 252–3
psychological preparation of
child **P:** 252–3
surgical psychological preparation,
child **P:** 252–3
see also family
- parenteral drug administration **C:** 110
central neuropathic pain **Ch:** 380
PCA **A:** 218
- parenteral gold, rheumatoid
arthritis **Ch:** 522–4 *T*
- parenteral lidocaine **A:** 107
- Parents' Postoperative Pain Measure
(PPPM) **A:** 481 *T*; **P:** 20, **P:** 453,
P: 453 *T*
- paresthesiae
definition **Ch:** 375
neuropathic pain **Ch:** 136
peripheral neuropathies **Ch:** 336
topiramate-induced **Ch:** 260–2
- parieto-occipital orienting
system **P:** 146
- parkinsonism **Ch:** 328
causes **Ch:** 327, **Ch:** 328
pain prevalence **Ch:** 328
placebo effect **P:** 507
- Parkinson's disease
communication in **C:** 370–1
pain in **Ch:** 328
treatment **Ch:** 328
- paroxetine **Ch:** 244 *T*
mechanism of action **Ch:** 246
neuropathic pain **Ch:** 246
cancer-induced/related **C:** 205
pharmacology **Ch:** 246
pruritus **C:** 330
- paroxysms, neuropathic pain **Ch:** 135–6
- partial agonist
ceiling effect **C:** 105
definition **C:** 105
- partial sciatic nerve ligation (PNL)
model, neuropathic pain **Ch:** 4–5
- participation
ICF definition **P:** 221
restrictions, physiotherapy
evaluation **P:** 222
- partition coefficient, local
anesthetics **A:** 120
- passive movements **P:** 230
- passivity, patient beliefs **A:** 295
- PAT (Pain Assessment Tool) **A:** 479 *T*
- patch clamp recordings, peripheral
nociceptor sensitization **Ch:** 28–9
- patellar tendonosis (jumper's
knee) **P:** 357
- pathological coagulopathies, continuous
peripheral neural blockade **A:** 242
- pathological fractures **C:** 266–7
- pathological neuropathic pain **C:** 200
- pathway-based association test, chronic
pain epidemiology **Ch:** 72
- patient(s)
analgesics, reluctance to take **C:** 94
drug use misunderstandings **C:** 94
education *see* patient education
mindset, lower back pain **Ch:** 507,
Ch: 507 *T*
- patient-centered interviewing
technique **P:** 4
- patient-controlled analgesia
(PCA) **A:** 217–35; **P:** 293–302
abdominal pain **A:** 414
acute pancreatitis **A:** 416
addiction fears **A:** 295
adjustable parameters **A:** 219–20;
P: 294
adolescents **A:** 222
advanced error-reduction
features **P:** 294
- anxiety **A:** 222
APS **P:** 295
background infusion **A:** 220
barcoding **A:** 226; **P:** 294
bolus dose **A:** 219; **P:** 294
buccal delivery systems **P:** 308
burn pain **A:** 402–3
cancer patients **P:** 123
children **A:** 492–3; **C:** 350; **P:** 296–7,
P: 467, **P:** 467 *T*
clinical trials **P:** 516–8
validity **P:** 518
complications **A:** 225–9
concurrent medications **A:** 226
masking **A:** 229
costs **A:** 223
definition **A:** 206, **A:** 217–8
delivery routes **P:** 293–4
delivery systems/equipment **A:** 218–9;
P: 294
alternatives **P:** 303–10, **P:** 304 *T*
applied anatomy **P:** 304
see also individual systems
developing world **A:** 395
disposable devices **A:** 218; **P:** 304
dose error reduction systems **A:** 225;
P: 294
dose limit **A:** 220; **P:** 306
drug delivery routes **A:** 206
drugs **P:** 295–6
adjuvants/coadministered **A:** 224;
P: 295–6
coadministered **P:** 307
efficacy **A:** 222–4
analgesic **A:** 222
other routes vs. **A:** 223–4
elderly **A:** 517; **P:** 298–9
contraindications **A:** 517
dose reductions **A:** 517
i.v. vs. epidural **A:** 517
monitoring **P:** 299
electronic devices **P:** 294
emergency department **A:** 362
equipment-related problems **A:** 226–7
syringe/cartridge damage **A:** 226–7
equipment types **A:** 218–9
transdermal **A:** 219
transmucosal **A:** 218–9
field/disaster situations **A:** 377, **A:** 383
flow sheets, preprinted **P:** 590–1 *F*
historical aspects **A:** 218
incorrect checking **A:** 225–6
infusion devices **P:** 294
infusion systems **P:** 294
loading dose **A:** 220; **P:** 294
lockout interval **A:** 219–20; **P:** 294
locus of control **P:** 293

- patient-controlled analgesia (PCA)
 (*continued*)
 management **P**: 294–5
 as measure of analgesia
 consumption **A**: 190
 modes **P**: 294
 monitoring **A**: 221; **P**: 294–5
 morbidly obese patients **A**: 225;
P: 298
 mortality **A**: 225
 nausea and vomiting
 induction **A**: 227–8; **P**: 296
 nursing procedure protocols **A**: 221
 obstructive sleep apnea **A**: 224–5;
P: 296–9, **P**: 298 *T*
 operator errors **A**: 225–6
 opioids **A**: 222–3; **P**: 295, **P**: 295 *T*
 adverse effects **A**: 222–3
 complications **A**: 227–8
 dosage drop **A**: 222
 parenteral **A**: 223
see also individual opioids
 opioid-tolerant patients **A**: 547;
P: 297–8, **P**: 298 *T*
 oral bedside **P**: 309
 oversedation **A**: 225
 pain assessment **A**: 149
 patient-control module **P**: 294
 patient education **A**: 220–1
 patient-related errors **A**: 225, **A**: 226
 deliberate tampering **A**: 226
 misunderstanding **A**: 226
 proxy use **A**: 226
 patient satisfaction **A**: 221, **A**: 222
 lower pain ratings *vs.* **A**: 222
 patient selection **P**: 296
 inappropriate **A**: 226
 perioperative use **A**: 102
 porphyria **A**: 421–2
 postbreast cancer surgery pain **C**: 404
 postoperative pain **A**: 221, **A**: 332
 preoperative information **P**: 296
 children **P**: 296–7
 preparation for **A**: 220–1
 prescriptions **P**: 294–5
 programmable pumps **A**: 218
 programming errors **A**: 225–6
 incidence **A**: 225
 pruritus-induction **A**: 228
 psychological factors **A**: 221–2
 control **A**: 221
 pumps **P**: 587–8
 reluctance of use **A**: 295
 renal disorder patients **P**: 298
 respiratory depression **A**: 225, **A**: 227
 incidence **A**: 227
 NSAID use **A**: 227
 risk factors **A**: 227
 “run-away” pump **A**: 226
 side effect management **P**: 296
 children **P**: 297
 special applications/patient
 groups **A**: 224–5; **P**: 296–9
 staff education **A**: 221
 standard orders **A**: 221
 preprinted **P**: 590–1 *F*
 step-down analgesia **A**: 224
 syringe drivers **P**: 294
 techniques **P**: 293–4
 urinary retention **A**: 228–9
 valves **P**: 294
see also individual drugs
 patient-controlled epidural analgesia
 (PCEA) **A**: 260; **P**: 317
 analgesic efficacy **A**: 264
 PCA *vs.* **A**: 222
 cardiac surgery **A**: 263
 children **P**: 474
 cost-effectiveness **A**: 265
 labor pain **A**: 471
 patient-centered outcomes **A**: 266
 pumps **P**: 587–8
 patient-controlled intranasal analgesia
 (PCINA) **A**: 218–9
 adverse reactions/
 complications **P**: 306, **P**: 309
 analgesic efficacy **A**: 223
 bidirectional system **P**: 307–8
 children **P**: 306
 devices **P**: 307–8, **P**: 308 *F*, **P**: 308 *T*
i.v. PCA *vs.* **P**: 306, **P**: 307
 patient-controlled transdermal system
 (PCTS) **A**: 207, **A**: 219; **P**: 304–6,
P: 305 *F*
 bolus dose **P**: 305–6
 characteristics **P**: 306
 clinical trials **P**: 306
 dose-current relationship **P**: 306
 field/disaster situations **A**: 381–2
 side effects **P**: 306
 patient education
 APS **P**: 585
 discharge information **P**: 585,
P: 586
 information accuracy **P**: 585
 pretreatment **P**: 585
 atypical facial pain **Ch**: 475
 biofeedback **P**: 158–9
 cancer pain clinical trials **P**: 548–9
 cancer pain control issues **C**: 94
 CBT **Ch**: 295
 information provision levels **A**: 297
 juvenile fibromyalgia
 syndrome **Ch**: 625
 myofascial pain **Ch**: 608
 nonpharmacological
 interventions **C**: 297
 opioid fear reductions **C**: 298
 osteoarthritis **Ch**: 527
 pain assessment **C**: 297
 PCA **A**: 220–1
 pediatric APS **P**: 644
 pediatric headache **Ch**: 630
 pharmacological **C**: 297
 physiotherapy **P**: 223
 postoperative pain **A**: 328–9
 psychological interventions *see*
 psycho-education
 rheumatoid arthritis **Ch**: 525
 sickle cell disease pain **A**: 421
 patient-operated stopwatches, onset of
 analgesia **P**: 522
 Patient Outcome Questionnaire
 (POQ) **P**: 672
 revision **P**: 672
 patient-physician relationship, irritable
 bowel syndrome **Ch**: 559–60
 patient record card, controlled
 drugs **C**: 414
 patient refusal, continuous peripheral
 neural blockade **A**: 242
 Patients Global Impression of Change
 (PCIG) **P**: 523–4
 patients without capacity
 clinical trial consent **P**: 555
 decision-making **C**: 96–7
 patient uniformity myth **P**: 96
 PBCL (Procedure Behavior Check
 List) **A**: 481 *T*; **P**: 453
 PDI (Pain Disability Index) **Ch**: 172 *T*,
Ch: 173; **P**: 33–4 *T*
 PDQ (Pain Disability
 Questionnaire) **Ch**: 118
 pediatric acute pain
 assessment **A**: 145, **A**: 478–80,
A: 479 *T*; **P**: 447–54
 age appropriate tests **A**: 145
 approaches **P**: 447–8
 behavioral measures **A**: 480;
P: 450–3, **P**: 451 *T*
 communication impaired
 child **A**: 480
 family/cultural effects **A**: 478–9
 indirect methods **A**: 480
 physiological measures **A**: 312,
A: 480; **P**: 453–5, **P**: 455 *T*
 self-report measures **A**: 145, **A**: 479;
P: 448–50, **P**: 448 *T*
*see also individual measures/
 instruments*
 management **A**: 477–503

- analgesic pharmacology **A:** 481–8
 complementary therapies **A:** 493
 epidural analgesia *see* epidural analgesia
 multimodal analgesia **A:** 480–1
 NSAIDs **A:** 73, **A:** 492
 nurse controlled analgesia **A:** 484, **A:** 493
 off-label prescriptions **A:** 478
 parenteral analgesia **A:** 492–3
 parent/family roles **A:** 481
 PCA **A:** 492–3
 plans **A:** 480–1
 postoperative pain **A:** 480, **A:** 488–9
 procedural pain **A:** 98, **A:** 493–4
 systemic analgesia **A:** 492–3
see also individual methods
- model **A:** 310 *F*
- psychological interventions **A:** 308–23
 breathing techniques **A:** 314
 CRPS **Ch:** 371, **Ch:** 627
 developmental
 considerations **A:** 311, **A:** 311 *T*
 distraction *see* distraction
 guided imagery *see* guided imagery
 juvenile fibromyalgia
 syndrome **Ch:** 626
 management approach **A:** 312
 parental concerns **A:** 318–9
 parental involvement **A:** 312–3, **A:** 318–9
 patient coping strategies **A:** 313
 preparation **A:** 312–3
 procedural pain **A:** 493
 relaxation *see* relaxation
 surgical preparation **A:** 312–3
see also individual methods
- sociocultural factors **A:** 311–2
- pediatric acute pain services **P:** 630–1
 adult services *vs.* **P:** 630
 biological factors **P:** 630
 adverse events reporting **P:** 645
 after-hours cover **P:** 631
 analgesic technique selection **P:** 635
 audit **P:** 644
 clinical service delivery
 organization **P:** 631–5
 administrative aspects **P:** 635–43
 algorithms **P:** 634–5
 availability **P:** 631
 charting **P:** 634
 computerized prescribing **P:** 634
 contactability **P:** 631
 continuity of care **P:** 631
 discharge advice **P:** 635
 documentation **P:** 634
 dosage guidelines/
 standardization **P:** 632–3 *F*, **P:** 634
 follow-up **P:** 635
 multiple order avoidance **P:** 634
 pain scores **P:** 634
 patient observation
 documentation **P:** 634
 patient review, regular **P:** 631
 patient selection **P:** 631
 prescription charts **P:** 634, **P:** 638–9 *F*, **P:** 640–1 *F*
 referral capture **P:** 631–4
 referrals **P:** 634
 sedation scores **P:** 634
 treatment plans **P:** 634
 complaints **P:** 645
 core staff **P:** 642
 databases **P:** 644–5
 frequent flyer concept **P:** 645
 development factors in **P:** 630
 emotional development **P:** 630
 psychological development **P:** 631
 drug selection **P:** 635
 education **P:** 643–4
 children **P:** 644
 medical staff **P:** 643
 nursing staff **P:** 643
 parents **P:** 644
 physiotherapists **P:** 644
 equipment choice/
 management **P:** 642
 establishment **P:** 645–6
 existing resource utilization **P:** 646
 goal-orientated approach **P:** 646
 guidelines **P:** 635
 infusion standardization **P:** 630, **P:** 632–3 *F*
 institutional support **P:** 645
 minimum requirements **P:** 646
 model, ideal **P:** 631–44
 noncore staff **P:** 642–3
 pain assessment scale selection **P:** 635
 parental factors **P:** 631
 personnel **P:** 642
 protocols **P:** 635
 quality improvement **P:** 644–5
 research **P:** 644–5
 smaller organizations **P:** 646
 staffing **P:** 646
 system of governance **P:** 645, **P:** 645 *F*
- pediatric APS director **P:** 642
- pediatric cancer pain **C:** 345–58
 analgesics **C:** 347–9
 adjuvant **C:** 351–4
 postoperative pain models **C:** 347
 routes of administration **C:** 349–50
 studies **C:** 347
- anesthetic management
 approaches **C:** 354
 breakthrough pain **C:** 346
 complementary therapy use **C:** 270–1
 epidemiology **C:** 346
 etiology **C:** 345–6
 nonpharmacological control **C:** 346–7
 environmental **C:** 347
 pharmacological
 management **C:** 347–54
 psychological interventions **C:** 304–5
 terminal sedation **C:** 354
- pediatric headache **Ch:** 628–33
 assessment **Ch:** 628–9
 diagnosis **Ch:** 628, **Ch:** 629 *T*
 differential diagnosis **Ch:** 629–30
 examination **Ch:** 628
 genetics **Ch:** 630
 hypnosis, school-aged child **P:** 485
 prevalence **Ch:** 628
 secondary **Ch:** 628
 treatment **Ch:** 628, **Ch:** 630
 activity schedules **Ch:** 630
 acute **Ch:** 630–2
 adult guidelines **Ch:** 630
 analgesia overuse **Ch:** 630
 diet **Ch:** 630
 education **Ch:** 630
 hydration **Ch:** 630
 nonpharmacological
 therapy **Ch:** 633
 pharmacological **Ch:** 630
 sleep **Ch:** 630
 trigger avoidance **Ch:** 630
- Pediatric Pain Questionnaire (PPQ) **P:** 456
- pediatric pain services **P:** 628–53
 acute pain *see* pediatric acute pain services
 barriers to change **P:** 629–30
 safety concerns **P:** 630
 birth of **P:** 629
 cancer pain **P:** 650
 changing attitudes **P:** 629–30
 delegate sponsorship **P:** 650
 lesser developed countries **P:** 650
 outmoded beliefs **P:** 629
 persistent pain *see* pediatric persistent pain services
 procedural pain **P:** 630, **P:** 646–7
 barriers to improving care **P:** 647
 guidelines **P:** 647
 parental empowerment **P:** 647
- pediatric patients *see* children
- pediatric persistent pain
 services **P:** 648–50

- case managers **P**: 649
 discharge **P**: 650
 follow-up appointments **P**: 650
 initial assessment **P**: 649
 interdisciplinary model **P**: 648
 interdisciplinary pain
 assessment **P**: 649
 medical practitioners **P**: 648–9
 nurses **P**: 649
 occupational therapists **P**: 649
 personnel **P**: 648–9
 physiotherapists **P**: 649
 psychiatrists **P**: 649
 psychologists **P**: 649
 referrals **P**: 648
 role **P**: 648
 self-efficacy **P**: 648
 staff employment **P**: 649
 staff selection **P**: 649
 team communication **P**: 650
 team governance **P**: 648
 treatment plans **P**: 649
 triage systems **P**: 649
- pedigree diagrams **Ch**: 53, **Ch**: 55 *F*
 pellagra **Ch**: 341
 pelvic congestion **Ch**: 577
 pelvic inflammatory disease
 (PID) **Ch**: 579
 chronic pelvic pain **Ch**: 579
 HIV-associated gynecological
 pain **Ch**: 359
- pelvic pain
 chronic *see* chronic pelvic pain (CPP)
 cryoanalgesia **P**: 387
 low back pain **A**: 448–9
 pregnancy **A**: 462
 radiotherapy **C**: 254
- pelvis, nerve blocks **P**: 291–2
 penetrance, genetics **Ch**: 53
 penicillamine, rheumatoid
 arthritis **Ch**: 522–4 *T*
 penile block, children **A**: 490; **P**: 469–70
 anatomy **P**: 470
 circumcision **A**: 490
 complications **P**: 470
 indications **P**: 469–70
 local anesthetic solutions **P**: 470
 method **P**: 470
- pentazocine
 acute pain **A**: 61
 cancer pain **C**: 162
 mechanism of action **C**: 105
 pharmacokinetics **A**: 59 *T*
- pentosanpolysulfate, interstitial
 cystitis **Ch**: 557
- peppermint oil **Ch**: 314 *T*
 irritable bowel syndrome **A**: 416
- peptic ulceration,
 NSAID-induced **C**: 129
 absolute risk **C**: 129
 prophylaxis **C**: 130, **C**: 133–4
 drug choice **C**: 134
 prostaglandin
 replacement **C**: 133–4
 stomach acid reduction **C**: 133
 relative risk **C**: 129
 trends **C**: 129
- peptidergic somatic nociceptors **A**: 4
 peptidylarginine deiminases
 (PAD) **P**: 69–70
- perceived threat, pain **A**: 294
 percentage pain reduction **Ch**: 185
 “perception threshold,”
 neurostimulation **Ch**: 270
- percutaneous balloon
 pericardiectomy **C**: 313
- percutaneous cervical
 cordotomy **P**: 390–2
 applied anatomy **P**: 390–1
 complications **P**: 392
 historical aspects **P**: 390
 indications **P**: 391
 limitations **P**: 391
 patient discomfort **P**: 392
 results **P**: 392
 side effects **P**: 392
 technique **P**: 391–2, **P**: 391 *F*, **P**: 392 *F*
 intrathecal injection **P**: 391–2,
 P: 391 *F*
 patient positioning **P**: 391–2
- percutaneous electrical nerve
 stimulation (PENS) **Ch**: 278
 chronic lower back pain **Ch**: 510
- percutaneous radiofrequency cervical
 facetal joint denervation **P**: 396–7
 C2 level **P**: 396
 electrical stimulation **P**: 397
 indications **P**: 396
 motor stimulation **P**: 397
 results **P**: 397
 side effects **P**: 397
 technique **P**: 396–7, **P**: 396 *F*
- percutaneous radiofrequency lumbar
 facetal joint
 denervation **P**: 399–400
 electrostimulation **P**: 399
 indications **P**: 399
 side effects **P**: 400
 technique **P**: 392 *F*, **P**: 399
 entry points **P**: 399
 treatment efficacy **P**: 400
- percutaneous revascularization,
 refractory angina pectoris **Ch**: 541
- performance, ICF definition **P**: 221
- periaqueductal gray (PAG)
 acupuncture **P**: 209
 deep brain stimulation **C**: 246
 manual medicine **P**: 235, **P**: 236
 mu opioid receptors **A**: 55
 neuropathic pain **Ch**: 15
 neurostimulation **Ch**: 270
 nitrous oxide effects **A**: 97
 persistent musculoskeletal
 pain **Ch**: 31
 placebo effect **P**: 506
 postnatal development **A**: 38
- pericardial effusions,
 malignant **C**: 312–3
- pericarditis **Ch**: 542
- pericardium, chest pain **Ch**: 542
- periclavicular brachial plexus blocks *see*
 brachial plexus blocks
- pericranial myofascial tissues,
 tension-type headache **Ch**: 454
- peridiverticular abscesses **Ch**: 562
- peridol, PCA and **P**: 296
- perineal nerve **P**: 291
- perineal pain **Ch**: 549–69
 cryoanalgesia **P**: 387
 etiology **Ch**: 549–51
 see also individual diseases/disorders
- perineoplasty, vulvodynia **Ch**: 591
- perineural drug administration **A**: 209;
 see also individual drugs
- period (order) effect **P**: 520, **P**: 543–4,
 P: 556
- periodontitis, apical **Ch**: 477
- periosteum, acute injuries **A**: 529
- peripheral cell death, neuropathic
 pain **Ch**: 10
- peripheral diabetic neuropathy **Ch**: 5–6
- peripheral finger temperature,
 biofeedback **P**: 488
- peripheral ischemia, TENS **P**: 201–2
- peripheral nerve(s)
 age-related changes **P**: 20
 diabetic neuropathy **Ch**: 339
 injury
 GABA **Ch**: 12
 Na_v1.3 voltage-gated sodium
 channels **Ch**: 9
 Na_v1.9 voltage-gated sodium
 channels **Ch**: 9
 tumor-invaded **C**: 35
- peripheral nerve blocks **P**: 255–92,
 P: 243
 abdomen **P**: 275–9
 agents **P**: 255–8
 aseptic technique **P**: 258
 children **P**: 469–72
 epidural analgesia *vs.* **P**: 472

- chronic pelvic pain **Ch:** 581
differential blockade **P:** 255
elderly **A:** 507
field/disaster situations **A:** 380–1
head and neck **P:** 258–64
local anesthetics **P:** 255–6
lower limb **P:** 279–91
needles **P:** 258
neurolysis *see* peripheral neurolysis
pelvis **P:** 291–2
resuscitation equipment **P:** 258
techniques **P:** 255–8
thorax **P:** 275–9
ultrasound-guided **P:** 257–8
upper limb **P:** 264–5
see also individual blocks; individual nerve blocks
- peripheral nerve entrapment syndromes **P:** 357–8
- peripheral nerve stimulation **Ch:** 268–9, **Ch:** 278–9
indications **Ch:** 278–9
nerve location **P:** 257
end points **P:** 257
needles, insulated vs. noninsulated **P:** 257
principles **P:** 257
postherpetic neuralgia **Ch:** 278, **Ch:** 278 *F*
see also individual techniques
- peripheral nerve stimulator (PNS) **P:** 257
brachial plexus block **P:** 265
CRPS, children **Ch:** 627
femoral nerve block **P:** 282
lateral cutaneous nerve of the thigh block **P:** 284
peripheral neurolysis **P:** 338
sciatic nerve block, lithotomy approach **P:** 286
- peripheral nervous system (PNS) **Ch:** 335
- peripheral neurolysis **P:** 338–9
agents **P:** 256–7
complications **P:** 256, **P:** 339
consent **P:** 338
disadvantages **P:** 256
doses **P:** 338
indications **P:** 256, **P:** 338
neuropathic pain induction **P:** 256
permanent anesthesia **P:** 338
techniques **P:** 257, **P:** 338–9
- peripheral neuropathic pain, definition **C:** 200
- peripheral neuropathies **Ch:** 335–51
acute pain **A:** 412
allodynia **Ch:** 336
autoimmune **Ch:** 342
axonal vs. demyelinating **P:** 76–7
brachial plexus *see* brachial plexus neuropathy (BPM)
cancer patients **C:** 34–5
chemotherapy-induced *see* chemotherapy-induced peripheral neuropathy (CIPN)
classification **Ch:** 335; **P:** 76–7
anatomical **P:** 76
etiologic **Ch:** 337–9, **Ch:** 338–9 *T*
fiber type **P:** 76, **P:** 77 *T*
clinical description **Ch:** 336
clinical history taking **P:** 77–8
drugs/toxins **P:** 77
family history **P:** 78
past medical history **P:** 77
presenting complaint **P:** 77, **P:** 77 *T*
social history **P:** 78
systems review **P:** 78
deficiency states **Ch:** 340–1
diabetic *see* diabetic neuropathy
diagnostic algorithms **P:** 75–82
diagnostic points **Ch:** 336
drug-induced **Ch:** 341
dysesthesiae **Ch:** 336
etiology **A:** 412
examination **P:** 78
hereditary **Ch:** 342; **P:** 79
HIV infection *see* HIV-associated pain
hyperalgesia **Ch:** 336
idiopathic **Ch:** 344
imaging **P:** 80
investigations **Ch:** 337–9; **P:** 78–81
unmyelinated fiber function **P:** 79
large fiber **P:** 76, **P:** 77 *T*
metabolic **Ch:** 339–40
mixed fiber **P:** 76, **P:** 77 *T*
mononeuropathies **Ch:** 335
nerve compression **Ch:** 342–3
painful **Ch:** 339–48; **P:** 76 *T*
painless **Ch:** 344–5
pain mechanisms **Ch:** 336–7
paraneoplastic **Ch:** 344; **C:** 34–5
paresthesiae **Ch:** 336
pathology **P:** 76–7
polyneuropathies **Ch:** 335, **Ch:** 336
motor function **Ch:** 336
sensory loss **Ch:** 336
tendon reflexes **Ch:** 336
positive symptoms **Ch:** 336
presentation time course **P:** 77, **P:** 77 *T*
prevalence **P:** 75
signs/symptoms **P:** 77 *T*
small fiber **P:** 76, **P:** 77 *T*
spontaneous pain **Ch:** 336
stimulus-evoked pain **Ch:** 336
stimulus-independent pain **Ch:** 336
therapy
acute pain **A:** 412
principles **Ch:** 345
specific **Ch:** 345
symptomatic **Ch:** 345–8, **Ch:** 345 *T*, **Ch:** 346 *T*
see also individual drugs
toxic **Ch:** 341–2
see also individual diseases/disorders
- peripheral nociceptors, mechanosensitivity **Ch:** 26–8
A β -fibers **Ch:** 27, **Ch:** 28
A δ -fibers **Ch:** 27, **Ch:** 28
C-fibers **Ch:** 27, **Ch:** 28
electrical stimulation **Ch:** 27
inflammation **Ch:** 27, **Ch:** 28
noxious stimuli **Ch:** 27
silent nociceptors **Ch:** 28
thresholds **Ch:** 27
- peripheral paresthesiae, multiple sclerosis **Ch:** 325
- peripheral sensitization **Ch:** 28–9
extracellular signal-regulated kinases **A:** 26
inflammatory mediators **Ch:** 28–9
mechanisms **A:** 21–4
mediators **A:** 22–3
arachidonic acid metabolites **A:** 22–3
bradykinin **A:** 23
cytokines **A:** 23
neurotrophic factors **A:** 24
opioid receptors **A:** 24
patch clamp recordings **Ch:** 28–9
persistent musculoskeletal pain **Ch:** 26
postoperative pain management **A:** 329
sodium channels **A:** 23–4
transducing ion channels **A:** 21
- peripheral sensorimotor neuropathy, neuraxial analgesia **A:** 256
- peripheral temperature biofeedback training **P:** 488
- peripheral vasodilation, opioid-induced **A:** 57
- peristaltic actions, gut **C:** 323
- periventricular and periaqueductal gray matter, deep brain stimulation **Ch:** 279–80; **C:** 246
- pernicious anemia **P:** 68
- peroneal nerve **P:** 285
deep **P:** 289
knee **P:** 288
superficial **P:** 289

- peroneal nerve block
ankle **P:** 290 *F*, **P:** 291
knee **P:** 288, **P:** 289 *F*
- peroneus brevis tendonosis **P:** 357
- peroneus longus tendonosis **P:** 357
- per-protocol (PP) analysis, clinical trials **P:** 524–5, **P:** 525 *T*
- persistent idiopathic facial pain **Ch:** 474–6
- persistent pain services, children *see* pediatric persistent pain services
- persistent somatoform pain disorder **Ch:** 619
- personal data assistants (PDA), APS **P:** 597
- personality disorders **Ch:** 618
types **Ch:** 618, **Ch:** 618 *T*
- personality profiles, tension-type headache **Ch:** 453
- pes anserinus tendonosis **P:** 356
- pes cavus **P:** 78
- pethidine **A:** 62; **C:** 162
abdominal pain **A:** 414
adverse effects **C:** 162
anticholinergic actions **A:** 62
biliary colic **A:** 415
burn pain **A:** 403
cancer pain **C:** 162
children **C:** 349, **C:** 352 *T*
contraindications, elderly **A:** 513
developing world **A:** 392, **A:** 392 *T*
dying person **C:** 394–5
emergency departments **A:** 362
fracture reduction **A:** 367
intranasal administration **A:** 208; **P:** 306–7
labor pain **A:** 469
metabolism **A:** 62
neuropathic pain **Ch:** 209
PCA **A:** 223
elderly **P:** 299
pharmacodynamics **C:** 162
pharmacokinetics **A:** 59 *T*; **C:** 162
postoperative pain, elderly **Ch:** 643
procedure-related pain **C:** 217
renal colic **A:** 363–4, **A:** 415
routes of administration/formulations **C:** 162
sickle cell disease pain **A:** 420
toxicity **C:** 162
- petrissage **C:** 277–8
- P-glycoprotein
cerebral drug uptake, elderly **A:** 507
opioid response variability **C:** 170–3
- Phalen's test, carpal tunnel syndrome **P:** 357–8
- phantom bladder pain **C:** 36
- phantom breast pain **C:** 404
- phantom limb pain **Ch:** 415–8
anxiety **Ch:** 418
attention **Ch:** 418
biofeedback **P:** 149–50, **P:** 163
blood flow **Ch:** 420
central neuropathic pain *vs.* **Ch:** 378
characteristics **Ch:** 416–7
children **Ch:** 408
CPSP **Ch:** 406
definition **Ch:** 415
emotional stress **Ch:** 418
episodic nature **Ch:** 416
frequency **Ch:** 416–7
genetics **Ch:** 418
impact **Ch:** 417–8
incidence **Ch:** 414–5
intensity **Ch:** 416–7
intravenous ketamine test **P:** 62
phantom sensation *vs.* **Ch:** 419
position of **Ch:** 416–7
preamputation pain effects **Ch:** 417
prevalence **Ch:** 415, **Ch:** 416 *T*
preventive analgesia **A:** 189
psychological factors **Ch:** 417–8
residual limb pain *vs.* **Ch:** 419
TENS **P:** 195
time course **Ch:** 415–6
- phantom pain
early nerve injury effects **A:** 55
post-rectal excision **C:** 36
- phantom sensation **Ch:** 418–9
definition **Ch:** 415
limb manipulation **Ch:** 420
telescoping **Ch:** 418–9, **Ch:** 419 *F*
- phantom spinal pain *see* spinal cord injury (SCI) pain, below-level neuropathic pain
- pharmacists, pediatric APS **P:** 642–3
- pharmacodynamics **C:** 105–7
definition **C:** 364–5
elderly *see* elderly
long-term exposure effects **C:** 105–7
receptor effects **C:** 105
see also individual drugs
- pharmacodynamic synergy, definition **C:** 209
- pharmacodynamic tolerance **C:** 105
- pharmacogenetics **Ch:** 61, **Ch:** 62 *T*
- pharmacokinetics **C:** 107–8
absorption *see* absorption, drug
definition **C:** 364–5
dosing regimen calculation **C:** 108
elderly *see* elderly
factors influencing **C:** 108
terminology **C:** 107
see also individual drugs
- pharmacokinetic synergy, definition **C:** 209
- pharmacokinetic tolerance **C:** 105
- pharmacological diagnostic tests **P:** 56–66
definition **P:** 56
intravenous drug trials
advantages **P:** 56–7
disadvantages **P:** 57
side effects **P:** 57
see also individual trials
quantitative sensory testing and **P:** 56
- pharmacology **C:** 104–8
historical aspects **Ch:** 87
see also individual drugs
- pharyngitis **A:** 418–9
infections **A:** 418
- phenacetin **A:** 85
- phenobarbital **C:** 335
- phenol
focal spasticity **Ch:** 445 *F*, **Ch:** 447
neurolysis **C:** 227–8, **C:** 228 *T*; **P:** 337
alcohol neurolysis *vs.* **C:** 228
alcohol *vs.* **P:** 257
epidural blockade **C:** 230
intrathecal **P:** 339
lumbar sympathetic ganglion block **P:** 333
patient positioning **C:** 227
peripheral **P:** 256–7, **P:** 338
pruritus **C:** 330
stellate ganglion block **P:** 329
sympathetic blocks **P:** 327
toxicity **P:** 337–8
- phenothiazines
dyspnea, cancer patients **C:** 314
migraine **A:** 365
- phenotolamine
intravenous trial *see* intravenous phenolamine test
mechanism of action **P:** 59–60
- phenotype, definition **Ch:** 53
- phenylbutazone **A:** 76
sports injuries **A:** 533–4
- phenytoin
cancer-induced/related neuropathic pain **C:** 206
central neuropathic pain treatment **Ch:** 379–80
contraindications **P:** 135
dosage/treatment schedule **P:** 136
elderly cancer patients **C:** 369
long-term efficacy **P:** 135–6
metabolism **P:** 135
NSAID interactions **A:** 74 *T*
pediatric headache **Ch:** 632, **Ch:** 633 *T*

- peripheral neuropathic
 pain **Ch:** 345 *T*, **Ch:** 346
 saturation kinetics **P:** 135–6
 side effects **C:** 369; **P:** 136
 trigeminal neuralgia **P:** 135
- phobias **Ch:** 617
 subcutaneous infusion
 contraindication **P:** 122
see also individual phobias
- pholcodine **C:** 315
- phosphate, hypercalcemia **C:** 321
- phospholipase A₂, inflammation **A:** 174
- phospholipase-A₂ inhibitors
 (PLA₂) **C:** 138
- phospholipase C (PLC), intracellular
 signaling **A:** 22
- phosphorus, metastatic bone
 pain **C:** 264
- Photograph Series of Daily Activities
 (PHODA) **P:** 182–3, **P:** 182 *F*
- Photograph Series of Daily Activities,
 short electronic version
 (PHODA-SeV) **P:** 182–3
- photoplethysmography **P:** 487 *T*
- phrenic nerve **P:** 265
- phrenic nerve block **P:** 329
- physical abuse, chronic pelvic
 pain **Ch:** 582
- physical conditioning programs,
 chronic lower back pain **P:** 223
- physical deconditioning
 chronic pain **P:** 620
 CRPS, children **Ch:** 627
- physical dependence
 children **C:** 354–5
 definition **A:** 540; **C:** 106, **C:** 156–7
 opioids **A:** 544; **Ch:** 222; **C:** 156–7,
C: 191; **P:** 113
- physical examination, chronic pain
 patients **P:** 6–8
 behavioral assessment **P:** 6
 formal exam **P:** 6–8
 during interview **P:** 6
 musculoskeletal system disorders **P:** 7
 signs **P:** 7
 nervous system disorders **P:** 7–8
 motor tests **P:** 8
 sensory tests **P:** 8
 over-reaction **P:** 8
 non-organic signs **P:** 8
 pediatric musculoskeletal
 pain **Ch:** 624
- physical neurolysis **C:** 225–34
 agents **C:** 226 *T*, **C:** 231–3
 pathophysiology **C:** 226–7, **C:** 226 *T*
 surgical sectioning vs. **C:** 226,
C: 226 *T*
- see also individual agents/techniques*
- physical performance tests **P:** 222
- pain measurement **P:** 32
- pain-related fear **P:** 178
- physical reconditioning/
 rehabilitation **P:** 621
- physician-assisted suicide **Ch:** 110
- physician-patient interview, chronic
 pain **Ch:** 123–4; **P:** 4–6
 interviewing style **P:** 4
 medical history **P:** 5
 pain history **P:** 4–5
 alleviating factors **P:** 5
 current trend **P:** 5
 exacerbating factors **P:** 5
 intensity **P:** 5
 location **P:** 4–5
 number of pains **P:** 5
 onset **P:** 5
 past **P:** 5
 quality **P:** 5
 temporal pattern **P:** 5
 patient's expectations **P:** 4
 psychosocial history **P:** 6
 treatment history **P:** 5–6
 herbal medicines **P:** 5–6
 nonpain treatments **P:** 6
 nonpharmacological **P:** 6
 pharmacological **P:** 5–6
 psychological **P:** 6
- physiological measurements, pain
 research **Ch:** 61 *T*
- physiological neuropathic pain,
 definition **C:** 200
- physiotherapists
 education, pediatric APS **P:** 644
 pediatric persistent pain
 services **P:** 649
 spine care team **Ch:** 502–3
- physiotherapy **P:** 220–9
 activity limitation assessment **P:** 222
 “all or nothing” behavior **P:** 222
 behavioral approaches **P:** 224–5
 chronic pelvic pain **Ch:** 584
 clinical circumstances
 evaluation **P:** 221–3
 clinical expertise **P:** 225
 clinical reasoning processes **P:** 225
 CRPS **Ch:** 371
 children **Ch:** 626
 elderly **Ch:** 648
 evidence-based practice **P:** 220–1
 follow-up **P:** 226
 functional testing **P:** 222
 lumbar radiculopathy **Ch:** 511
 motivational interviewing
 techniques **P:** 225
- myofascial pain **Ch:** 608
- neurologic disease pain **Ch:** 331
- osteoarthritis **Ch:** 527–8
- passive modalities **P:** 224
- patient-centered clinical
 expertise **P:** 225
- patient education **P:** 223
- patient evaluation **P:** 221–3
 baseline establishment **P:** 221
 environmental factors **P:** 223
 health profile **P:** 221
 ICF domains **P:** 221, **P:** 221 *T*
 impairments **P:** 222
 participation restrictions **P:** 222
 personal factors **P:** 223
 red flags **P:** 222
 yellow flags **P:** 223
- patient goal achievement **P:** 226
- patient's preferences **P:** 225
 stages of change model **P:** 225
- physical circumstances
 evaluation **P:** 221–3
- postamputation pain **Ch:** 423–4
- provider's beliefs, effects on
 treatment **P:** 225
- psychosocial circumstances
 evaluation **P:** 221–3
- research evidence **P:** 223–5
- self-management programs **P:** 225
- spasticity **Ch:** 444
 treatment end points **P:** 226
- physostigmine **P:** 295
- phytotherapy *see* herbal medicine
- pictorial pain rating scales **A:** 142–3,
A: 143 *F*; **P:** 15–6, **P:** 16 *F*
 advantages **A:** 143
 children **P:** 20
 disadvantages **A:** 143
see also individual scales
- Pieces of Hurt Tool (Poker Chip
 Tool) **Ch:** 125; **P:** 450
- pigmentation changes,
 cryoanalgesia-induced **P:** 381
- pilocarpine **C:** 316
- piracetam, spasticity pain **Ch:** 445
- piroxicam **A:** 78
 noninflammatory joint pain **A:** 435
 numbers needed to treat **A:** 89 *T*
 oral administration **A:** 202–3
 properties **A:** 75 *T*
 transdermal administration **A:** 207
- Pittsburgh Knee Rule **Ch:** 146 *T*
- pituitary ablation **C:** 254
- pizotifen, migraine
 prophylaxis **Ch:** 459–61, **Ch:** 461 *T*
- pK_a, local anesthetics **A:** 120
- placebo **P:** 499–513

- active **P**: 520, **P**: 524
 acupuncture studies **P**: 208
 definition **P**: 499–500
 dental pain trials **P**: 534, **P**: 535 *F*
 ethics **P**: 508, **P**: 519
 cancer pain clinical trials **P**: 548
 neuropathic pain clinical trials **P**: 559
 historical aspects **P**: 500
 inadvertent unblinding **P**: 559
 long-term exposure **P**: 562
 neuropathic pain clinical trials **P**: 559
- placebo effect
 analgesic studies **P**: 501
 anticipation in **P**: 506
 clinical implications **P**: 507–9
 cognitive impairment **A**: 511–2
 as context effect **P**: 500
 CRPS management **Ch**: 369
 deception **P**: 503 *T*
 definition **P**: 500, **P**: 501
 expectation in **P**: 506
 historical aspects **P**: 500
 in laboratory setting **P**: 502
 neuroanatomy **P**: 506
 neurochemistry **P**: 504–6, **P**: 505 *F*
 historical aspects **P**: 505
 naloxone in **P**: 505
 opioid release **P**: 505
 non-pain conditions **P**: 506–7
 no treatment *vs.* **P**: 500–1
 patient's expectations in **P**: 508
 patient's power of perception and **P**: 508
 perceived **P**: 502
 quantification attempts **P**: 500–1
 spontaneous remission *vs.* **P**: 501–2
 study paradigms **P**: 502–4, **P**: 503 *F*, **P**: 519
 balanced design **P**: 503, **P**: 503 *F*
 conditioning protocols **P**: 504
 deception in **P**: 503, **P**: 503 *T*
 doctor-initiated *vs.* machine-initiated therapy **P**: 503 *F*, **P**: 504
 double-blind versus deceptive design **P**: 503, **P**: 503 *F*
 open-hidden paradigm (overt-covert design) **P**: 504, **P**: 507–8, **P**: 508 *F*
 surgical treatments **P**: 500
 true **P**: 502
- placebo flowers **P**: 507
 placebo needles, acupuncture **P**: 208
 placebo response
 definition **P**: 501
 detection **P**: 501–2
- confounding factors **P**: 501, **P**: 502 *F*
 hormonal **P**: 505 *F*, **P**: 507
 intradiscal thermal annuloplasty **P**: 439
 intravenous phentolamine test **P**: 60
 knowledge of, clinical trials **P**: 518
 manual medicine **P**: 237
 psychosocial context **P**: 508
- place preferment paradigms, neuropathic pain models **Ch**: 7
 plain radiography *see* radiography
 plain x-ray *see* radiography
 plantar fasciitis, soft-tissue injection **A**: 441; **P**: 357
 plantar spur **P**: 357
 plasma albumin *see* albumin, plasma
 plasticity *see* neuronal plasticity
 platelet(s)
 aspirin effects **A**: 76
 NSAIDs effects **A**: 483; **Ch**: 197–8
 platinum-based chemotherapy, peripheral neuropathy induction **C**: 401
 play therapists, pediatric APS **P**: 643
 pleural disease, radiotherapy **C**: 252
 pleural effusions, malignant **C**: 312–3
 pleurodesis **C**: 312–3
 plexus blockade, developing world **A**: 396
 pneumography, biofeedback **P**: 487 *T*
 pneumothorax
 acupuncture-induced **P**: 210–1
 cryoanalgesia complication **P**: 381, **P**: 386
 stellate ganglion block-induced **P**: 329
 thoracic paravertebral block-induced **A**: 350
 point box scale (PS-11) **A**: 140, **A**: 140 *F*
 “point detectors,” acupuncture **P**: 216
 Poker Chip Tool (Pieces of Hurt Tool) **Ch**: 125; **P**: 450
 policeman's heel (subcalcaneal bursitis) **P**: 357
 polyarteritis nodosa **Ch**: 342
 polycystic kidney disease **Ch**: 564
 polymorphisms **Ch**: 52–3
 candidate genes, chronic pain **Ch**: 71
 polyneuropathies **Ch**: 335, **Ch**: 336; **P**: 76
 polypharmacy
 cancer pain clinical trials **P**: 541–2
 delirium **C**: 186
 dying person **C**: 393–4
 elderly **Ch**: 642, **Ch**: 646
- polysubstance abuse, substance abuse disorder **A**: 542
 pons, persistent visceral pain **Ch**: 40
 popliteal block, continuous **A**: 332
 popliteal fossa block **P**: 288, **P**: 289 *F*
 popliteal fossa sciatic nerve block **A**: 238 *T*, **A**: 240–1
- population(s)
 chronic pain outcome measurement **Ch**: 181–2
 genetic studies **Ch**: 63
 stratification, chronic pain epidemiology **Ch**: 72
 population, intervention(s) or exposure(s), comparison group(s), and outcome(s) (PICO) **P**: 567, **P**: 567 *T*
- porphyria(s)
 abdominal pain **A**: 421
 acute pain **A**: 421–2
 management **A**: 419
 mechanisms **A**: 421
 attack precipitation **A**: 421
 chronic pain **Ch**: 562–3
 definition **A**: 421
 diagnosis **A**: 421
 management **A**: 421
 disease modification **A**: 421
 prevalence **A**: 421
 porphyric neuropathy **Ch**: 151 *T*
- portable syringe drivers **P**: 123
 positioning, labor pain **A**: 469
 positive mental images **C**: 299–300
 efficacy **C**: 301
 positive reinforcement, CBT **Ch**: 296
 positive self-statements, pediatric CBT **A**: 317
 positive self-talk **P**: 480 *T*
 positron emission tomography (PET) **P**: 84
 functional magnetic resonance imaging *vs.* **P**: 87 *T*
 guided imagery, children **A**: 316
 historical aspects **Ch**: 86–7
 hypnosis **C**: 277
 malignant bone tumors **C**: 257
 migraine **Ch**: 453
 nociception **A**: 13–4
 painful neuropathies **P**: 80
 placebo effect **P**: 506
 radioactive tracers **P**: 85, **P**: 90 *T*
 refractory angina pectoris **Ch**: 275
 technique **P**: 85–9, **P**: 87 *F*
- postamputation pain **Ch**: 414–28, **Ch**: 408
 clinical characteristics **Ch**: 415–20
 historical aspects **Ch**: 408, **Ch**: 414

- incidence **A**: 559 *T*
mechanisms **Ch**: 415, **Ch**: 420–1,
Ch: 421 *F*
cortical reorganization **Ch**: 421
peripheral **Ch**: 420
spinal factors **Ch**: 420–1
supraspinal factors **Ch**: 421
sympathetic nervous
system **Ch**: 420
thalamus **Ch**: 421
neuropathic pain **Ch**: 134
phantom *see* phantom limb pain
preemptive analgesia **A**: 565
preoperative pain effects **A**: 561–2
prevention **Ch**: 424
residual limb pain *see* residual limb
pain
supraspinal mechanisms **Ch**: 421
treatment
acute pain **Ch**: 421
analgesics **Ch**: 421
chronic pain **Ch**: 421–4, **Ch**: 422 *T*
medical **Ch**: 415, **Ch**: 422–3
nonmedical **Ch**: 415, **Ch**: 423–4
regional blockade **Ch**: 421
surgical **Ch**: 424
postbreast cancer surgery pain
(PBCSP) **Ch**: 409; **C**: 402–5
acute pain influences **C**: 403–4
axillary dissection **C**: 403
breast reconstruction **C**: 404
classification **Ch**: 409; **C**: 403
demographics **A**: 560–1
etiology **C**: 403
incidence **A**: 559 *T*
intercostobrachial neuralgia **Ch**: 409;
C: 403
PCA **C**: 404
preoperative pain effects **A**: 561–2
risk factors **C**: 403
surgical factors **A**: 562; **C**: 403–4
treatment **C**: 404–5
postcholecystectomy syndrome **Ch**: 38,
Ch: 563–4
posterior cutaneous nerve of the
forearm **P**: 271
posterior cutaneous nerve of the
forearm block **P**: 272
posterior cutaneous nerve of the
thigh **P**: 287
posterior cutaneous nerve of the thigh
block **P**: 287
posterior intervertebral joints *see*
zygapophyseal joint
posterior primary ramus
dorsal compartment
innervation **P**: 395
medial branch **P**: 362
posterior sacral foramina **P**: 281
postherpetic neuralgia
(PHN) **Ch**: 429–39, **Ch**: 343
assessment, chemical stimuli **Ch**: 138
characteristics **Ch**: 277
as clinical trial model **P**: 558
costs **Ch**: 431
definition **Ch**: 430
disease course **Ch**: 430 *F*
epidemiology **Ch**: 431
HIV infection **Ch**: 357
intravenous ketamine test **P**: 62
pathophysiology **Ch**: 431
prevention **Ch**: 431–2
acute pain **Ch**: 432
age in **Ch**: 432
local anesthetic blocks **Ch**: 432
varicella-zoster vaccine **Ch**: 343,
Ch: 431–2
time course **Ch**: 431
treatment **Ch**: 433–5, **Ch**: 434 *T*
anticonvulsants **Ch**: 433–4,
Ch: 434 *T*, **Ch**: 435
antidepressants **Ch**: 234, **Ch**: 433,
Ch: 434 *T*
guidelines **Ch**: 435–6, **Ch**: 436 *T*
lidocaine, intrathecal **Ch**: 435
NMDA receptor
antagonists **Ch**: 435
opioids **Ch**: 434–5, **Ch**: 434 *T*
peripheral nerve
stimulation **Ch**: 278,
Ch: 278 *F*
spinal cord stimulation **Ch**: 277
TENS **Ch**: 435
therapeutic indices **Ch**: 434 *T*
topical medication **Ch**: 435
“posthypnotic suggestion” **C**: 275
postinjection flare,
corticosteroids **A**: 535
postmarketing surveillance
exercise **P**: 562
postmastectomy pain syndrome
(PMPS) **Ch**: 409; **C**: 205–6
postoperative bleeding,
NSAID-induced **A**: 72
postoperative nausea and vomiting
(PONV)
acupuncture **C**: 273–4
algorithms **P**: 635
chart **P**: 640–1 *F*
children **A**: 489, **A**: 493
morbidity **A**: 493
management, improvements
needed **P**: 606
steroids **A**: 106
treatment **P**: 296, **P**: 297 *T*
postoperative pain
acute *see* acute postoperative pain
chronic *see* chronic postsurgical pain
(CPSP)
cryoanalgesia **P**: 383
elderly *see* elderly
management *see* postoperative pain
management
mood and **A**: 293–4
postoperative pain
management **P**: 665–76
epidural analgesia *see* epidural
analgesia
guidelines **P**: 665–9
clinical practice
recommendations **P**: 674–5
dissemination **P**: 669
implementation **P**: 669
research
recommendations **P**: 674–5
improvements needed **P**: 606
institutionalization **P**: 670, **P**: 671 *T*
quality improvement
initiatives **P**: 670–4
standards **P**: 669–70
TENS *see* transcutaneous electrical
nerve stimulation (TENS)
topical analgesics **Ch**: 237
*Postoperative pain management - good
clinical practice* **P**: 668
acute pain management **P**: 668
discharge **P**: 668
pain management principles **P**: 669
patient/family education **P**: 668
post-orthopedic surgery, continuous
peripheral neural blockade
A: 246
post-pain modulation
phenomenon **P**: 14
postsympathectomy
hyperesthesia **P**: 333
Posttraumatic Chronic Pain Test
(PCPT) **Ch**: 124
posttraumatic pain, cryoanalgesia
contraindication **P**: 381
posttraumatic stress disorder
(PTSD) **Ch**: 124, **Ch**: 617
children **A**: 309
posture, abnormal, spasticity **Ch**: 442,
Ch: 444
potassium (K⁺) channel blockers, local
anesthetics **A**: 119
potassium–chloride cotransporter
(KCC2), postnatal
development **A**: 34 *T*
potency, drug **A**: 54; **C**: 105

- “potentization,”
 homeopathy **Ch:** 310–1; **C:** 275
- power of the study **P:** 546
- P/Q calcium channel complex,
 migraine **Ch:** 452
- pragmatic studies **P:** 515, **P:** 515 *T*
- pramipexole, fibromyalgia
 syndrome **Ch:** 608
- prednisolone
 anorexia cachexia syndrome **C:** 327–8
 epidural injection **P:** 419
 rheumatoid arthritis **Ch:** 524
- preemptive analgesia
 administration timing **A:** 157
 amputation **A:** 565
 analgesia timing **A:** 159–60, **A:** 160 *F*
 animal models **A:** 565
 controversies **A:** 157–60
 CPSP prevention **A:** 565
 definition **A:** 154
 full control studies **A:** 158–9, **A:** 159 *F*
 historical aspects **A:** 157, **A:** 565
 mechanisms **A:** 155
 postoperative pain
 management **A:** 329
 psychosocial factors **A:** 190
 studies **A:** 157–8, **A:** 190
 study design **A:** 157–8, **A:** 190
 terminology **A:** 157
 two-group studies **A:** 157, **A:** 158–9,
A: 158 *F*
see also preventive analgesia
- preferential COX-2 inhibitors **C:** 127
- prefrontal cortex neuroimaging **P:** 86–8,
P: 88 *F*
 affective-motivational dimension of
 pain **Ch:** 242–3
 chronic pain **P:** 87
- pregabalin **Ch:** 256 *T*, **Ch:** 258–60
 adverse effects **A:** 103; **Ch:** 257 *T*,
Ch: 260, **Ch:** 394; **P:** 137
 central neuropathic pain **Ch:** 259,
Ch: 381–2 *T*
 combination therapies **Ch:** 260
 contraindications **P:** 135
 CRPS **Ch:** 369
 diabetic neuropathy **Ch:** 257 *T*,
Ch: 258–9, **Ch:** 259
 dosage/treatment schedule **Ch:** 257 *T*;
P: 136
 efficacy **Ch:** 261 *T*
 elderly **A:** 516
 fibromyalgia syndrome **Ch:** 257 *T*,
Ch: 259–60, **Ch:** 607–8
 field/disaster situations **A:** 380
 HIV-associated neuropathy **Ch:** 356
 interactions **Ch:** 260
- mechanism of action **Ch:** 346; **C:** 206
- metabolism **P:** 135
- neurologic disease pain **Ch:** 330
- neuropathic pain **Ch:** 345 *T*, **Ch:** 346
 orofacial **Ch:** 472
- pediatric headache **Ch:** 632
- perioperative use **A:** 104
- pharmacokinetics **A:** 103 *T*; **Ch:** 257
- pharmacology **Ch:** 257
- postherpetic neuralgia **Ch:** 257 *T*,
Ch: 259, **Ch:** 433, **Ch:** 434 *T*
- postoperative pain
 management **A:** 335
- spinal cord injury **Ch:** 257 *T*, **Ch:** 380,
Ch: 394, **Ch:** 396 *T*
- pregnancy **A:** 461–2
 CAM **Ch:** 316
- epidural steroid injection
 contraindication **P:** 424
- epiduroscopy **P:** 428
- erythrocyte sedimentation rate **P:** 69
- lumbosacral back pain **A:** 462
- medication and **A:** 461–2
- nerve pain **A:** 462
- NSAID use **A:** 73, **A:** 461; **Ch:** 198
- pain syndromes **A:** 462;
see also individual diseases/disorders
- paracetamol **A:** 86, **A:** 461
- pelvic girdle pain **A:** 462
- TENS contraindication **A:** 277
- Premature Infant Pain Profile
 (PIPP) **A:** 479 *T*, **A:** 480; **P:** 457
- premedication, procedure-related
 pain **C:** 214
- premorbid state, psychological
 assessment **Ch:** 123
- preoperative pain
 acute postoperative pain
 and **A:** 156–7, **A:** 190
 CPSP and **A:** 156–7, **A:** 190,
A: 561–2
- prepatellar bursitis **Ch:** 530
 soft-tissue injection **P:** 356–7
- presacral neurectomy (PNS), chronic
 pelvic pain **Ch:** 586–7
 adverse effects **Ch:** 586
 contraindications **Ch:** 586
 efficacy **Ch:** 586–7
 indications **Ch:** 586
 laparoscopic uterine nerve ablation
 vs. **Ch:** 586
- prescription costs, chronic
 pain **Ch:** 77–8
- Prescription Drug Use
 Questionnaire **Ch:** 656
- Prescription Opiate Abuse
 Checklist **Ch:** 656
- prescription opioid abuse **A:** 542,
A: 545
- pressure algometry (algometer
 testing) **P:** 48
- pressure sensation
 threshold determination **P:** 48
 transmission **P:** 47
- pressure ulcers, topical
 analgesics **Ch:** 237
- presurgical scoring cards, success
 prediction **Ch:** 128
- preventive analgesia **A:** 154–98
 definition **A:** 154, **A:** 155, **A:** 160
 future work **A:** 189–90
 analgesic consumption **A:** 190
 opioids **A:** 189
 pain measures **A:** 189
 preexisting pain effects **A:** 189
 study quality
 improvements **A:** 189–90
- intraoperative phase **A:** 156
- literature reviews **A:** 164–85
- mechanisms **A:** 155
- nonanalgesic agents **A:** 185,
A: 188 *T*
- postoperative phase **A:** 156
- post-treatment condition
 absence **A:** 160, **A:** 161 *F*
- preoperative phase **A:** 156
- studies **A:** 189–90
 drugs used **A:** 162, **A:** 163 *T*
 excluded studies **A:** 164 *T*
 experimental designs **A:** 165 *T*
 inclusion criteria **A:** 162–4
 outcomes **A:** 165 *T*
 PubMed database **A:** 162
 search strategies **A:** 162–4
 targets **A:** 156, **A:** 156 *F*
 timing **A:** 160–1, **A:** 162 *F*
see also preemptive analgesia; *specific
 drugs*
- prilocaine **A:** 127
 characteristics **A:** 119 *T*, **A:** 125
 continuous peripheral neural
 blockade **A:** 244–5
 CRPS **Ch:** 368–9
 peripheral nerve blocks **P:** 256
 transient radicular irritation
 induction **A:** 122
- primary afferent excitability,
 neuropathic pain **Ch:** 7–9
- primary afferents receptors, somatic
 nociceptors **A:** 4–6
- primary care **P:** 656–7
 low back pain **A:** 447
 stepped-care framework **P:** 657,
P: 657 *T*

- primary care physicians, pain control in elderly **C:** 362
- primary dysmenorrhea *see* dysmenorrhea
- primary efficacy variables, clinical trials **P:** 515–6
- primary somatosensory cortex **Ch:** 242–3
- principle of balance, opioid analgesics **C:** 84–5
- printed information, low back pain **A:** 451 **T, A:** 453
- problem solving
cognitive therapy **Ch:** 297
patient beliefs **A:** 295
- procaine **A:** 124
allergies to **A:** 123
characteristics **A:** 125
historical aspects **A:** 113–4
- procedural information **A:** 297;
P: 250 **T, P:** 251
- procedural stress **P:** 248–9
- Procedure Behavior Check List (PBCL) **A:** 481 **T; P:** 453
- Procedure Behavior Rating Scale-Revised (PBRs-R) **P:** 453
- procedure-related pain
burn pain *see* burn pain
cancer patients
analgesia provision **C:** 213–4
approaches to **C:** 214–5
assessment **C:** 216 **T**
control **C:** 213–21
future directions **C:** 219–20
incidence **C:** 213
local techniques **C:** 216–7
mild to moderate **C:** 214 **T**
moderate to severe **C:** 213, **C:** 214 **T**
nonpharmacological
interventions **C:** 215–6
patient factors **C:** 214, **C:** 216 **T**
physician factors **C:** 214–5
procedural preparations **C:** 216
procedures causing **C:** 214 **T**
sedating drugs **C:** 218–9
system factors **C:** 215
- children
causes **C:** 346
incidence **C:** 213
psychological interventions **A:** 313;
C: 304
definition **A:** 308
hypnotic imagery **P:** 148
NMDA receptor antagonists **A:** 100
pediatric behavioral measures **P:** 451
TENS **A:** 280; **C:** 216
topical techniques **C:** 216–7
- PROCESS study **P:** 405
- processual-contextual perspective framework **P:** 607
- prochlorperazine, migraine **A:** 365,
A: 366 **T**
- proctalgia fugax **Ch:** 564
- proctitis, persistent visceral pain **Ch:** 42
- Prodisc **P:** 442
- profile-tailored cognitive-behavioral therapy **C:** 302–3
- progabide, spasticity **Ch:** 445
- progesterone, pregnancy **A:** 461
- progestins
chronic pelvic pain **Ch:** 584
endometriosis **Ch:** 575
pelvic congestion **Ch:** 577
- progestogens
anorexia cachexia syndrome **C:** 328
side effects **C:** 328
- proglumide, placebo effect **P:** 505
- programmable pumps, PCA **A:** 218
- Programme for Cancer Pain Relief, WHO **C:** 82
- progressive muscle relaxation
training **P:** 160–2
applied relaxation **P:** 161
in CBT **Ch:** 295
definition **P:** 480 **T**
muscle discrimination training
and **P:** 161–2
muscle group combinations **P:** 161,
P: 162 **T**
muscle tensing **P:** 161
practice cycles **P:** 161
preprocedural **P:** 252
procedure **P:** 161, **P:** 162
program **P:** 161 **T**
therapist suggestions in **P:** 161
- proinflammatory cytokines,
fibromyalgia syndrome **Ch:** 604
- projection theory, referred pain **A:** 11,
A: 12 **F**
- project officers, pediatric procedural pain services **P:** 647
- prolonged release preparations, local anesthetics **A:** 129
- promethazine
dyspnea, cancer patients **C:** 314
PCA, nausea and vomiting
prevention **A:** 228
preventive analgesia **A:** 185
- promoter region, genes **Ch:** 49
- propacetamol **A:** 333, **A:** 481–2
- propranolol, pediatric
headache **Ch:** 632 **T**
- propofol
agitation **C:** 335
burn pain **A:** 404
central neuropathic pain **Ch:** 380
fracture reduction **A:** 367
ICU patients **A:** 348
opioid-related pruritus **A:** 258
PCA, nausea and vomiting and
A: 228
procedure-related pain **C:** 218
spinal cord injury pain **Ch:** 395,
Ch: 396 **T**
- propofol infusion syndrome **A:** 348
- propranolol **P:** 60
- PROSPECT group, nerve block
recommendations **A:** 241, **A:** 264
- prostaglandin(s) **A:** 69, **A:** 69 **T**
NSAID mechanism of action **A:** 174,
A: 379; **Ch:** 631
peripheral nociceptor
sensitization **Ch:** 29
- prostaglandin E₂, peripheral
sensitization **A:** 22–3
- prostaglandin synthetase inhibitors,
dysmenorrhea **Ch:** 572–4
- prostate cancer
hormone treatment **C:** 265
strontium **C:** 263
- prostate specific antigen (PSA), bone
metastasis **C:** 257
- prostatitis **Ch:** 563
- proteinase(s), nociception **A:** 17
- proteinase 3 (PR3) **P:** 70
- proteinase-activated receptors (PARs),
nociception **A:** 17
- protein binding
age-related changes **C:** 365
NSAIDs **A:** 70
- protein kinase(s)
sensitization **A:** 26–7
see also individual types
- protein kinase A (PKA)
capsaicin, effects of **A:** 26
sensitization **A:** 26
- protein kinase C (PKC)
capsaicin, effects of **A:** 26
postnatal development **A:** 35 **T**
sensitization **A:** 21, **A:** 26
- protein kinase C inhibitors,
neuropathic pain **Ch:** 12
- protein levels, genetic study **Ch:** 62 **T**
- protein synthesis
(translation) **Ch:** 48–9, **Ch:** 49–51,
Ch: 51
codons **Ch:** 51, **Ch:** 52 **F**
ribosomes **Ch:** 51
- proteomics **Ch:** 59–60, **Ch:** 63
definition **Ch:** 59
mass spectrometry **Ch:** 59–60

- proteomics (*continued*)
 two-dimensional gel
 electrophoresis **Ch**: 59
- protohypnosis (imaginative involvement) **P**: 484
- proton magnetic resonance spectroscopy (MRS) **P**: 89–90, **P**: 90 *F*
- proton pump inhibitors (PPIs)
 elderly **C**: 366
 gastroesophageal reflux disease **Ch**: 543
 NSAID-induced peptic ulcer prophylaxis **A**: 71; **C**: 133
- provocative discography **P**: 440
 controversies **P**: 441
 criteria **P**: 440
 interpretation **P**: 441
- proximal bicipital tendonosis **P**: 354
- proxy use, PCA **A**: 226
- pruritus
 cancer patients **C**: 329–31
 causes **C**: 329
 clinical findings **C**: 329–30
 management **C**: 330
 general measures **C**: 330
 systemic treatments **C**: 330–1
 topical treatments **Ch**: 232; **C**: 330
- opioid-induced **A**: 257–8; **C**: 156, **C**: 192
 children **C**: 353 *T*
 elderly **A**: 515
 PCA patients **A**: 228
- pathology **C**: 329
- pseudoadddiction **C**: 107
- analgesia prioritization
 failure **Ch**: 103–4
 causes **Ch**: 103–4
 definition **A**: 540; **Ch**: 653–4; **C**: 107; **P**: 622
- opioids **P**: 113, **P**: 118
 substance abuse/misuse **C**: 381
- pseudoclaudication, epidural steroid injections **P**: 421
- pseudocysts, pancreatic **Ch**: 556
- pseudogout **A**: 434
- pseudomembranous stomatitis **C**: 316
- pseudotolerance, definition **A**: 540
- psoas compartment blocks **A**: 238 *T*, **A**: 239–40; **P**: 280
 comparisons **A**: 239
 landmarks **A**: 239
see also lumbar plexus block
- psoriatic arthritis
 long-term opioid use **P**: 117–8
 neck pain **Ch**: 488
- psychiatric disorders
 chronic pain **Ch**: 614–22
 classification schedules **Ch**: 615, **Ch**: 615 *T*
 non-pain related, cancer patients **C**: 331–4
 substance abuse disorder **A**: 542
see also individual diseases/disorders
- psychiatrists, pediatric persistent pain services **P**: 649
- psychoactive substances,
 legislation **Ch**: 652–3
- psycho-education **C**: 297–8
 children **C**: 304
 components **C**: 297
 efficacy, evidence for **C**: 298
 individual studies **C**: 298
 meta-analysis **C**: 298
 family members **C**: 298
 medication compliance **C**: 298
 patient empowerment **C**: 297
- psychological deconditioning, chronic pain **P**: 620
- psychological dependence *see* addiction
- psychological disorders
 abdominal pain **Ch**: 549–51
 chronic pain **Ch**: 66
 groin pain **Ch**: 549–51
 perineal pain **Ch**: 549–51
- psychological distress **C**: 303
 pain interactions **C**: 48–9
- psychological evaluation
 cancer pain *see* cancer pain
 chronic pain *see* chronic pain
- psychological factor(s)
 acute pain processing **A**: 292–6
 addiction fears *see* addiction
 burning mouth syndrome **Ch**: 476
 cancer patients **C**: 21
 non-pain related **C**: 331–4
 catastrophizing *see* catastrophizing
 chest pain **Ch**: 538
 children **A**: 309
 anxiety **A**: 309
 anxiety sensitivity **A**: 309
 catastrophizing **A**: 310
 coping style **A**: 310–1
 expectancies **A**: 309–10
 memory **A**: 311
 temperament **A**: 310
- chronic pain outcome
 measurement **Ch**: 181
- chronic pelvic pain **Ch**: 583
 CPSP **Ch**: 407
 CRPS, children **Ch**: 626
 fibromyalgia syndrome **Ch**: 602
 neck pain **Ch**: 486
 pain beliefs/meanings **A**: 295
 to healthcare provider **A**: 295
 knowledge lack **A**: 295
- pain beliefs/meanings, pain reporting
 reluctance **A**: 295
- pain beliefs/meanings, to patient **A**: 295
- PCA **A**: 221–2
- persistent noncancer pain **A**: 541
- postoperative pain **A**: 293–5
- spinal cord injury pain **Ch**: 392
- syndrome X **Ch**: 542
- visceral hypersensitivity disorders **Ch**: 38–9
see also individual factors
- psychological inflexibility **P**: 168
- psychological interventions/therapy
 acute pain **A**: 291–307
 healthcare provider
 education **A**: 297–8
 information provision **A**: 296, **A**: 297
 patient satisfaction **A**: 301
- cancer pain **C**: 296–309
 adult populations **C**: 297–303
 children **C**: 304–5
 clinical trials **P**: 547
- chronic pelvic pain **Ch**: 587
 CRPS **Ch**: 370–1
 developing world **A**: 394
see also individual interventions
- psychological pain interview **P**: 9–10
 content **P**: 9–10
 daily routine, impacts on **P**: 10
 family life, impacts on **P**: 10
 inconsistent responses **P**: 9
 interpersonal skills **P**: 10
 pain history **P**: 9
 pain mechanisms **P**: 10
 psychological disorders **P**: 10
 purpose/aims **P**: 9
 rapport building **P**: 9
 social history **P**: 10
 topic areas **P**: 9
 vocational history **P**: 10
- psychological preparation, painful procedures **P**: 245–54
 anticipated pain **P**: 246
 anxiety assessment *see* anxiety, presurgical assessment
 behavioral instruction **P**: 250 *T*, **P**: 251
 children **P**: 252–3
 parental involvement **P**: 252–3
 cognitive preparation **P**: 250 *T*, **P**: 251
 communication **P**: 252
 information giving **P**: 251
 modeling **P**: 252

- peri-procedure **P**: 249
 post-procedure **P**: 249
 pre-procedure **P**: 248–9
 health outcomes **P**: 249, **P**: 250 *F*
 minor procedures **P**: 249
 relaxation **P**: 251–2
 techniques **P**: 249–52, **P**: 250 *T*
 treatment refusal **P**: 246
- psychological reconditioning, chronic pain **P**: 621–2
 psychological therapies
 functional abdominal pain **Ch**: 634
 neurologic disease pain **Ch**: 332
 vulvodynia **Ch**: 591
 psychological therapy *see* psychological interventions/therapy
 Psychological Well-being Scale **Ch**: 79
 psychologists
 pediatric APS **P**: 643
 pediatric persistent pain services **P**: 649
 psychomimetic effects, ketamine **A**: 548
 psychomotor performance,
 opioid-induced cognitive failure **C**: 185
 psycho-oncology **C**: 380
 psychophysical studies, visceral hypersensitivity disorders **Ch**: 38
 psychophysiological stress profile, biofeedback **P**: 486
 psychoprophylaxis, labor pain **A**: 468
 psychosocial care **C**: 50–1
 psychosocial factors
 adhesions **Ch**: 578
 CPSP **A**: 563
 preemptive analgesia **A**: 190
 spinal cord injury pain **Ch**: 391
 substance abuse disorder **A**: 542–3
 psychosocial support groups, substance abuse/misuse **C**: 383
 psychostimulants
 adverse effects **C**: 184–5
 children, cancer pain **C**: 353–4
 opioid-induced sedation **C**: 184
 psychotherapy
 depression, cancer patients **C**: 332
 group, distressed patients **C**: 303
 supportive *see* supportive psychotherapy
 psychotic illness, SCS
 contraindication **P**: 407–8
 PsycINFO **P**: 570 *T*
 publication bias **P**: 574
 PubMed database **A**: 162
 pudendal nerve **P**: 291
 chronic pelvic pain **Ch**: 581
 pudendal nerve block **P**: 291–2
- anatomy **P**: 291
 bilateral, labor pain **A**: 470
 complications **P**: 292
 indications **P**: 291
 landmarks **P**: 291
 practical steps/technique **P**: 291–2
 transvaginal approach **P**: 291–2,
 P: 291 *F*
- pulmonary edema,
 opioid-induced **C**: 192
 pulmonary emboli **C**: 311–2
 pulpectomy, assay sensitivity **P**: 533
 pulpitis **Ch**: 477
 pulsed radiofrequency (PRF) **P**: 257
 cervical dorsal root ganglion **P**: 398
 theoretical aspects **P**: 390
 pulse generator, TENS **P**: 196
 pulse oximetry, respiratory depression **A**: 514; **P**: 591
 pumps, continuous peripheral neural blockade **A**: 244
 punctate hyperalgesia, neuropathic pain **Ch**: 135, **Ch**: 141 *T*
 purines, nociception modulation **A**: 17
 purinoceptors, nociception modulation **A**: 17
 pyelograms, recurrent urolithiasis **Ch**: 564
 pygeum **Ch**: 314 *T*
 pyrazoles **A**: 76;
 see also individual drugs
 pyrophosphate arthropathy **Ch**: 526
- Qi Gong *see* energy healing
 qualified rehabilitation counselor (QRC) **P**: 622–3
 quality adjusted life years (QALY) **Ch**: 180–1; **P**: 659
 economic evaluation **Ch**: 80, **Ch**: 81 *F*
 quality improvement initiatives, pain management **P**: 670–4
 Swedish experience **P**: 674
 United States experience **P**: 672–4
 quality of life
 cancer patients **P**: 540
 chronic pain, economic measure **Ch**: 75–6, **Ch**: 79
 measurement **P**: 32–5, **P**: 33–4 *T*
 neuropathic pain assessment **Ch**: 140
 refractory angina pectoris **Ch**: 539
 quality scales, CBT **Ch**: 299–300
 quantitative polymerase chain reaction **Ch**: 57–8, **Ch**: 57
 quantitative sensory testing (QST) **P**: 47
 American Academy of Neurology recommendation **P**: 78
- atypical facial pain **Ch**: 474–5
 CIPN **C**: 401
 CRPS **Ch**: 150–1, **Ch**: 365
 distal symmetrical polyneuropathy **Ch**: 355
 HIV-associated pain **Ch**: 356
 intravenous phentolamine test and **P**: 60
 limitations **P**: 78
 neuropathic orofacial pain **Ch**: 471
 neuropathic pain **P**: 47
 peripheral neuropathies **Ch**: 337; **P**: 78
 pharmacological diagnostic tests and **P**: 56
 trigeminal neuralgia **Ch**: 473
 quantitative sudomotor axon reflex testing (QSART), CRPS **Ch**: 150–1, **Ch**: 277, **Ch**: 366
 Quebec Task Force on Spinal Disorders **A**: 453–4
 questioning, Socratic style **P**: 100, **P**: 101
 questionnaires
 children, chronic pain assessment **P**: 456
 movement fears **P**: 180
 outcome evaluation **P**: 103
 pain assessment **P**: 16–20
 pain-related fear **P**: 179–80
 presurgical anxiety assessment **P**: 247–8
 reinjury fears **P**: 180
 see also individual questionnaires
- radial epicondylalgia *see* lateral epicondylitis
 radial nerve **P**: 265
 axilla **P**: 269, **P**: 269 *F*
 elbow **P**: 271
 wrist **P**: 273
 radial nerve block
 elbow **P**: 272
 practical steps/technique **P**: 272, **P**: 272 *F*
 forearm fractures **A**: 368
 wrist **P**: 274
 landmarks **P**: 274
 practical steps/technique **P**: 274, **P**: 274 *F*
- radiation damage, late **C**: 259
 radiation-induced fibrosis **C**: 7
 radiation tolerance dose **C**: 259
 radicular low back pain *see* lumbar radiculopathy
 radicular pain
 cervical **P**: 399

- radicular pain (*continued*)
 spinal cord compression **C**: 30
- radiculopathic pain, chronic **P**: 428
 epiduroscopy **P**: 428
- radiculopathy
 definition **P**: 76
 epidural fibrosis **P**: 429
 HIV infection **Ch**: 357
 lumbar *see* lumbar radiculopathy
 MRI **Ch**: 148
 pathophysiology **P**: 428–9
 nerve root properties **P**: 429
 nucleus pulposus **P**: 429
 thermography **Ch**: 150
- radioactive knee synovectomy **P**: 359
- radioactive tracers, positron emission tomography **P**: 85
- radiofrequency (RF) lesioning **C**: 232;
P: 389–403, **P**: 244
 advantages/disadvantages **C**: 232,
C: 232 *T*
 cervical area **P**: 395–6
 clinical applications **C**: 232–3; **P**: 390
 complications **C**: 233
 contraindications **P**: 390
 definition **C**: 232
 electric fields **P**: 390
 epiduroscopic **P**: 435
 equipment **P**: 390
 heat generation **P**: 390
 historical aspects **P**: 389
 indications **P**: 390
 lumbar area **P**: 399
 “silent phase” **P**: 390
 spinal pain **P**: 395
 sympathetic chain **C**: 233
 theoretical aspects **P**: 390
see also individual ganglion; individual techniques
- radiofrequency neurotomy, neck
 pain **Ch**: 495
- radiography
 atypical facial pain **Ch**: 474
 bone infection **Ch**: 146
 bone tumors **Ch**: 146; **C**: 257
 cancer patient assessment **C**: 40
 chronic pain **Ch**: 145–6
 congenital abnormalities **Ch**: 146
 CRPS **Ch**: 367
 deformities **Ch**: 146
 fractures **Ch**: 146
 osteoarthritis **Ch**: 146
 pain *vs.* **Ch**: 146
 rules/guidelines **Ch**: 146, **Ch**: 146 *T*,
Ch: 147 *F*
 vertebral degeneration **Ch**: 146
 malignant psoas syndrome **C**: 34 *F*
- mechanism of action **Ch**: 145–6
 neck pain **Ch**: 491–2
 osteoarthritis **Ch**: 526
 rheumatoid arthritis **Ch**: 520
 spinal cord compression **C**: 31
- radiohumeral joint, intra-articular
 injection **P**: 352
- radioisotope therapy
 bone pain **C**: 262–4, **C**: 262 *T*
 elderly **C**: 370
see also individual radioisotopes
- radioligands **P**: 90 *T*
- radionuclides, children **C**: 354
- radionuclide scans *see* bone scans
- radiotherapy **C**: 251–5
 airway obstruction, tumors **C**: 312
 analgesic action mechanisms **C**: 251
 bone pain **C**: 258–64
 dose **C**: 259–61, **C**: 260 *F*
 efficacy **C**: 267
 elderly **C**: 370
 immobilization **C**: 258
 localization **C**: 258–9
 localized pain **C**: 258–9
 metastatic **C**: 258
 multiple sites **C**: 261
 neuropathic **C**: 260, **C**: 261 *F*
 pain relief onset **C**: 259, **C**: 260 *F*
 planning **C**: 259
 postoperative **C**: 266–7
 retreatment rates **C**: 260–1,
C: 261 *F*
 side effects/complications **C**: 259
 spine **C**: 259
 superficial bones **C**: 259
 treatment delivery **C**: 259
 wide field irradiation *see* wide field
 irradiation, bone pain
- brachial plexus neuropathy induction
see brachial plexus neuropathy
 (BPM), radiotherapy-induced
- breakthrough pain **C**: 289
 elderly **C**: 370
 hemoptysis **C**: 315
 indications **C**: 251–2
 nerve pain **C**: 254
 pain induction **C**: 405–6
 physical nature **C**: 405
 soft-tissue pain **C**: 252–4
 superior vena caval
 obstruction **C**: 312
- Radiotherapy Action Group Exposure
 (RAGE) **C**: 406
- “Raggedy Ann” doll game **P**: 481
- random effect model, statistics **P**: 572
- randomization
 allocation bias elimination **P**: 554
 clinical trials **P**: 519
 double-blind technique **P**: 520
 randomization services **P**: 519
 randomized controlled trials
 (RCT) **P**: 515
 advantages **P**: 543
 cancer pain **P**: 543
 evidence quality **P**: 567–8
 TENS **A**: 277
 range of movement assessment,
 sciatica **P**: 232–3
- ranitidine **C**: 366
- rash(es)
 lamotrigine-induced **Ch**: 262
 topical analgesic-induced **Ch**: 231
- rate, definition **P**: 572
- rate ratio **P**: 572
- Raynaud syndrome, biofeedback **P**: 486,
P: 488
- re-alerting, hypnosis **P**: 482 *T*
- recall bias, bereaved carer
 studies **C**: 14–8
- receptive fields, persistent
 musculoskeletal pain **Ch**: 29–30
- receptor(s)
 definition **C**: 105
 drug effects **C**: 105
- receptor imaging **P**: 89–91
- receptor organs, age-related
 changes **P**: 20
- receptor tyrosine kinases, intracellular
 signaling **A**: 22
- recessive alleles **Ch**: 53
- recombinant human growth factor,
 HIV-associated
 neuropathy **Ch**: 356
- rectal cancer
 case history **C**: 417–8
 postoperative pain recurrence
C: 36
- rectal distension studies, persistent
 visceral pain **Ch**: 40–1
- rectal drug administration **A**: 204
 analgesia **C**: 110
 breakthrough pain **C**: 291
 children **C**: 350; **P**: 463
 dying person **C**: 393–4
 formulations **A**: 204
 hydrogels **A**: 204
 nonopioid analgesics **A**: 204
 opioid analgesics **A**: 204
see also individual drugs
- rectal fullness sensation **C**: 36
- rectal laxatives **C**: 324
- rectal pain, malignant **C**: 36
- rectus femoris enthesitis, soft-tissue
 injection **P**: 356

- recurrent abdominal pain *see* functional abdominal pain (FAP)
- red flags
- abdominal pain, acute **A:** 413
 - low back pain
 - acute **A:** 445
 - chronic **Ch:** 504, **Ch:** 504 *T*
 - manual medicine **P:** 231
 - physiotherapy **P:** 222
- reduction, fractures **A:** 367, **A:** 528–9
- reference drugs, cancer pain trials **P:** 548
- referred pain
- cervical *see* cervical referred pain
 - chest **Ch:** 544
 - mechanisms **A:** 11, **A:** 12 *F*
 - neuropathic **Ch:** 136
- refills, early, problematic opioid use **P:** 114
- reflex arc activation, referred pain **A:** 11
- reflexology, functional abdominal pain **Ch:** 635
- reflex sympathetic dystrophy (RSD) *see* complex regional pain syndrome (CRPS)
- refractory angina pectoris **Ch:** 539–42
- assessment **Ch:** 539
 - definition **Ch:** 539
 - gene therapy **Ch:** 541–2
 - incidence **Ch:** 539
 - multidisciplinary teams **Ch:** 539
 - prevalence **Ch:** 539
 - therapy **Ch:** 539–42, **Ch:** 539 *T*
 - angina plan **Ch:** 539–40
 - enhanced external counter pulsation **Ch:** 541
 - laser revascularization **Ch:** 541
 - pharmacological **Ch:** 541
 - spinal cord stimulation *see* spinal cord stimulation (SCS)
 - sympathetic blockade **Ch:** 540
 - TENS **Ch:** 540
- refractory nausea, opioid switching **C:** 191
- refractory period, action potential **A:** 114
- reframing, pediatric CBT **A:** 317
- reframing cognitions, surgical patients **P:** 251
- regional analgesia
- opioid-tolerant patients **A:** 548
 - postamputation pain
 - prevention **Ch:** 424
- regional anesthesia
- chronic opioid therapy patients **P:** 116
 - elderly **A:** 519
 - field/disaster situations *see* field/disaster situations
 - ICUs **A:** 349–50
 - inflammatory bowel disease **Ch:** 561
- regional blocks, postamputation pain **Ch:** 421
- prevention **Ch:** 424
- regional spasticity *see* focal spasticity
- regression to the mean **P:** 501–2
- rehearsal, pediatric CBT **A:** 317
- Reiki healing **Ch:** 316; **C:** 278
- reinjury fear questionnaires **P:** 180
- reinvention, innovations **P:** 608
- APS recommendations **P:** 608
- Reiter's syndrome **Ch:** 488
- relative advantage **P:** 608
- APS recommendations **P:** 607–8, **P:** 612
- relative potency, clinical trials **P:** 516–8
- relative risk **Ch:** 69, **Ch:** 69 *T*
- relatives, as “attorney” **C:** 96
- relaxation **A:** 298–9; **Ch:** 295
- biofeedback in **P:** 157–8
 - cancer pain **C:** 277, **C:** 299–300, **C:** 300
 - efficacy **C:** 301, **C:** 302
 - elderly **C:** 369–70
 - children **A:** 313–4; **P:** 481–2
 - guided imagery **A:** 316
 - integration **P:** 491
 - older child **P:** 481
 - preprocedural **P:** 252
 - techniques **A:** 314
 - young child **P:** 481
 - chronic pelvic pain **Ch:** 587
 - electromyographic-assisted *see* electromyographic-assisted relaxation
 - mindfulness *vs.* **P:** 170
 - opioid-tolerant patients **A:** 549
 - preprocedural **P:** 251–2
 - skin conductance-assisted **P:** 158
 - skin temperature-assisted **P:** 158
- relaxation by recall **P:** 161–2
- relaxation-induced anxiety **P:** 162
- relaxed breathing *see* diaphragmatic breathing
- remifentanyl **A:** 61
- burn pain **A:** 403
 - elderly **A:** 514
 - intravenous challenges **P:** 63
 - labor pain **A:** 469
 - PCA **A:** 223
 - pharmacokinetics **A:** 59 *T*, **A:** 61
 - elderly **A:** 505
 - placebo effect **P:** 506
 - volume of distribution **A:** 58
- renal cancer
- radiotherapy **C:** 253
 - recurrence, lumbosacral plexopathy **C:** 33
- renal clearance, elderly **A:** 508
- renal colic **A:** 414–5
- emergency department management **A:** 363–4
 - HIV infection **Ch:** 358
 - pain pathology **A:** 363
 - parental analgesia **A:** 415
 - prevalence **A:** 414–5
 - TENS **A:** 415
- renal disease/disorders
- PCA **P:** 298
 - pharmacokinetic effects **C:** 108
 - see also individual diseases/disorders*
- renal failure
- dying person **C:** 394–5
 - NSAID-induced **A:** 71
 - elderly **A:** 515
 - opioid prescription **P:** 129
 - pain management **C:** 40
 - paracetamol-induced **C:** 125
- renal impairment
- opioid use, elderly **A:** 513; **C:** 367
 - pharmacokinetic effects **C:** 108
- renal replacement therapy **A:** 349, **A:** 349 *T*
- renal system, opioid effects **C:** 155–6
- repetitive colorectal distension (CRD) **Ch:** 43
- reporting bias **P:** 555
- Report of the Working Party on Pain after Surgery *see* *Pain after Surgery*
- reproductive organs, innervation **Ch:** 571–2
- reproductive organ tumors, chronic pelvic pain **Ch:** 578–9
- rescue analgesia/dosing **C:** 114
- breakthrough pain **C:** 111, **C:** 114, **C:** 290, **C:** 290 *F*, **C:** 291
 - children **C:** 350
 - oral **C:** 291, **C:** 291 *F*
 - cancer pain clinical trials
 - breakthrough pain **P:** 541–2
 - placebo-based trials **P:** 548
 - clinical trials outcomes **P:** 522, **P:** 523 *F*
 - definition **C:** 290
 - dental pain model **P:** 534–5
 - as efficacy measure, cancer pain clinical trials **P:** 541–2
 - elderly **C:** 368
 - ideal medication **C:** 290, **C:** 290 *F*
 - neuropathic pain clinical trials **P:** 553

- rescue analgesia/dosing (*continued*)
time–action relationship **C**: 291,
C: 291 *F*
- residual limb pain **Ch**: 419–20
CRPS **Ch**: 419–20
definition **Ch**: 415
description **Ch**: 419
muscle activity **Ch**: 419
phantom pain in **Ch**: 419, **Ch**: 420
phantom pain *vs.* **Ch**: 419
prevalence **Ch**: 416 *T*, **Ch**: 419
sensory abnormalities **Ch**: 419
severity **Ch**: 419–20
temperature **Ch**: 419
- residual limb trauma, phantom
pain **Ch**: 415
- residual ovary syndrome **Ch**: 578
- resource access, family caregiver **C**: 67 *T*
- resource limitations, economics **Ch**: 76
- respiratory arrest, TENS-induced **P**: 198
- respiratory depression
monitoring, APS **P**: 589–91
morphine-induced **A**: 484, **A**: 514
opioid-induced **A**: 57, **A**: 257, **A**: 258,
A: 362; **C**: 154–5, **C**: 191
children **C**: 353 *T*; **P**: 468
elderly **A**: 514, **A**: 519
neonates **P**: 468
tolerance **C**: 156
PCA *see* patient-controlled analgesia
(PCA)
- respiratory rate, respiratory depression
monitoring **A**: 221; **P**: 589–90
- respiratory system
non-pain symptoms control, cancer
patients **C**: 311
opioid effects **C**: 154–5
- Responding to patients who are
silent* **C**: 371
- response prevention, CBT **Ch**: 296
- responsiveness, pain measures **P**: 38
- rest
fractures **A**: 528
noninflammatory joint pain **A**: 435
sports injuries **A**: 532
- resting membrane potential,
neuropathic hypersensitivity
mechanisms **Ch**: 7
- resting sweat output (RSO),
CRPS **Ch**: 150–1
- restless legs syndrome **P**: 90
- Reston, James **Ch**: 308
- restrictive pericarditis **Ch**: 542
- retinal damage, epidural steroid
injections **P**: 423
- retinal hemorrhages,
epiduroscoy-induced **P**: 435
- retrograde menses,
endometriosis **Ch**: 575
- retroperitoneal sarcoma,
radiotherapy **C**: 253
- retrospective appraisals, pain
assessment **A**: 150
- return-to-work
amputees **Ch**: 418
duration of **P**: 623
programs **P**: 622–3, **P**: 658
- revised Edmonton Staging System
(rESS) **C**: 44, **C**: 45 *T*
- revised Helsinki Declaration, results
publication **P**: 525
- reward system, substance abuse/
misuse **Ch**: 654
- Rexed's laminae, spinal cord **A**: 8–9,
A: 8 *F*
- Reye's syndrome, aspirin in **A**: 73,
A: 76; **Ch**: 631
- rhodium **C**: 264
- rheumatoid arthritis (RA) **Ch**: 519–25
classification criteria **Ch**: 520
clinical course **Ch**: 525
clinical features **Ch**: 488, **Ch**: 519–20
definition **Ch**: 519
epidemiology **Ch**: 519
genetic predisposition **Ch**: 519
investigations **Ch**: 520
mortality rate **Ch**: 525
neck pain **Ch**: 488
outcome indicators **Ch**: 525
prognosis **Ch**: 525
shoulder joint **P**: 351
treatment **Ch**: 520–5
aims **Ch**: 520
analgesics **A**: 87; **Ch**: 521
antidepressants **Ch**: 521
corticosteroids **Ch**: 524; **P**: 349–50
diet **Ch**: 525
disease activity/severity
monitoring **Ch**: 520–1
DMARDs *see* disease-modifying
antirheumatic drugs
(DMARDs)
HMG CoA reductase
inhibitors **Ch**: 524
nonpharmacological **Ch**: 524–5
NSAIDs **Ch**: 198, **Ch**: 199 *T*,
Ch: 521
pharmacological **Ch**: 521–4
physical therapy **Ch**: 524–5
- rheumatoid factor (RF) **P**: 69
- rib fractures, pathological **C**: 29
- rib metastases **C**: 29
- ribosomal RNA (rRNA) **Ch**: 49
- ribosomes **Ch**: 51
- RICE regime, sports injuries **A**: 532
- Richmond Agitation-Sedation
Assessment Scale (RASS) **A**: 346 *T*
- rifampicin **C**: 330
- rigidity **Ch**: 327
- risk differences (RD) **P**: 572
- risk ratios (RR) **P**: 572
- risk-taking behavior, substance abuse
disorder **A**: 542
- risperidone **C**: 187
- ritonavir **A**: 413
- rituximab, rheumatoid
arthritis **Ch**: 522–4 *T*, **Ch**: 524
- rizatriptan, migraine **Ch**: 455–6,
Ch: 460 *T*
- RNA expression **Ch**: 59
- road traffic accidents, developing
world **A**: 389–90
- rofecoxib
cardiovascular risks **Ch**: 195–6; **C**: 137
elderly, cancer pain **C**: 366
gastrointestinal adverse effects **C**: 133
renal colic **A**: 364
withdrawal **A**: 78; **Ch**: 195; **C**: 127
- Roland–Morris Disability
Questionnaire, chronic
pain **Ch**: 172 *T*, **Ch**: 173
- Romania, opioid availability **C**: 84–5
- root canal treatment, neuropathic
orofacial pain **Ch**: 470
- root entry zone, trigeminal
neuralgia **Ch**: 473
- ropivacaine **A**: 127
caudal epidural block **A**: 491
characteristics **A**: 119 *T*, **A**: 125
continuous peripheral neural
blockade **A**: 245
toxicity **A**: 245
epidural analgesia **P**: 319
children **A**: 492; **P**: 474 *T*
elderly **A**: 517
labor **A**: 471–2, **A**: 472 *F*
half-life, elderly patients **A**: 515
inguinal blocks, children **A**: 489
levobupivacaine *vs.* **A**: 127
metabolism **A**: 121
minimum local anesthetic
concentration **A**: 127
neuraxial analgesia **A**: 256
peripheral nerve blocks **P**: 256
spinal administration **Ch**: 287
sympathetic blocks **P**: 326–7
toxicity **A**: 122
- rostral anterior cingulate cortex
(rACC), placebo effect **P**: 506
- rostral ventromedial medulla (RVM)
ON cells **A**: 27; **Ch**: 15

- hyperalgesia **A:** 27
 manual medicine **P:** 235
 neuropathic pain **Ch:** 15, **Ch:** 15 *F*
 neutral cells **A:** 27
 nociception **A:** 12
 OFF cells **A:** 27; **Ch:** 15
 pain transmission **P:** 88
 persistent musculoskeletal pain **Ch:** 31
 postnatal development **A:** 38
 rotator cuff disorders **P:** 354
 diagnosis **Ch:** 528–9; **P:** 354
 treatment **Ch:** 529; **P:** 354
 rotator cuff tears **Ch:** 148; **P:** 354
 rotator cuff tendonitis **Ch:** 528–9, **Ch:** 529 *T*
 “rugged jersey” finger **A:** 529
 rule of double effect *see* doctrine of double effect
 “run-away” pump, PCA **A:** 226
 runner’s knee (iliotibial band friction syndrome) **P:** 356
 ryodoraku **C:** 272
- sacral canal **P:** 417–8, **P:** 472
 sacral hiatus **P:** 417–8, **P:** 472
 sacral insufficiency fractures **Ch:** 505
 sacral metastases **C:** 29 *T*
 sacral parasympathetic nucleus, persistent visceral pain **Ch:** 40
 sacral plexus **P:** 281
 sacral plexus block **P:** 281–2
 anatomy **P:** 281
 complications **P:** 282
 indications **P:** 281
 landmarks **P:** 281
 practical steps/technique **P:** 281, **P:** 281 *F*
 sacrococcygeal membrane **P:** 417–8
 sacroiliac joint disease, lower back pain **Ch:** 505
 sacroiliac joint pain
 diagnosis **Ch:** 152, **Ch:** 157, **Ch:** 159
 therapy **Ch:** 163
 sacrum **P:** 417–8
Safe management of CDs **C:** 414
 salbutamol **C:** 314
 salicylates **A:** 75
 osteoarthritis **Ch:** 235–6
 sports injuries **A:** 533–4
 see also individual drugs
 salivary flow, acupuncture **C:** 274
 salpingo-oophoritis *see* pelvic inflammatory disease (PID)
 salsalate **A:** 75
 salt retention, NSAID-induced **C:** 135
 samarium
- administration **C:** 263
 bone pain **C:** 263
 gamma camera imaging **C:** 263, **C:** 263 *F*
 sample size
 cancer pain clinical trials **P:** 546
 candidate gene studies, chronic pain **Ch:** 71
 estimation **P:** 524, **P:** 524 *T*, **P:** 554
 neuropathic pain clinical trials **P:** 557
 pain intensity measurement **P:** 22
 saphenous nerve **P:** 288, **P:** 290
 saphenous nerve block
 ankle **P:** 290, **P:** 290 *F*
 knee **P:** 288, **P:** 288 *F*
 satellite DNA **Ch:** 52–3
 satisfaction scoring **A:** 137
 ranked categorical scales **A:** 150
 retrospective appraisals **A:** 150
 Saunders, Cicely **C:** 85, **C:** 412
 “total pain” concept **C:** 85
 saw palmetto **Ch:** 314 *T*
 saxitoxin **A:** 116
 Scale for Use in Newborns (SUN) **A:** 479 *T*
 scarification moxibustion **P:** 216
 scar tissue formation, sports injuries **A:** 528
 schema incongruent information **A:** 294
 schemata **A:** 294
 schemata congruent information **A:** 294
 Schwann cells **A:** 114
 sciatica
 manual medicine *see* manual medicine
 pregnancy **A:** 462
 sciatic nerve **P:** 285
 sciatic nerve block **A:** 240–1; **P:** 284–5
 anatomy **P:** 285
 anterior approach **P:** 285, **P:** 286
 landmarks **P:** 286
 practical steps/technique **P:** 286, **P:** 287 *F*
 catheter placement **A:** 240
 complications **P:** 287
 continuous **A:** 240–1, **A:** 332; **P:** 287
 postoperative pain **A:** 332
 distal **P:** 288, **P:** 289 *F*
 field/emergency situations **A:** 382 *T*
 indications **P:** 285
 lateral approach **P:** 285, **P:** 286–7
 landmarks **P:** 286
 practical steps/technique **P:** 286–7, **P:** 287 *F*
 lithotomy approach **P:** 284, **P:** 285–6
 landmarks **P:** 285
- practical steps/technique **P:** 285–6, **P:** 286 *F*
 popliteal fossa level **A:** 240–1
 posterior (classical) approach **P:** 284, **P:** 285
 practical steps/technique **P:** 285, **P:** 285 *F*
 postoperative pain **A:** 332
 proximal **A:** 238 *T*
 subgluteal approach **A:** 240
 sciatic nerve ligation **A:** 44
 Science Citation Index **P:** 568, **P:** 570 *T*
 scientific misconduct, clinical trials **P:** 562
 sclerosing cholangitis, HIV-associated abdominal pain **Ch:** 358
 SCN9A gene, hereditary erythromelalgia **Ch:** 342
 scoliosis, spasticity **Ch:** 444
 scopolamine (hyoscine hydrobromate) **C:** 191, **C:** 320 *T*
 scopolamine, renal colic **A:** 364, **A:** 415
 Screener and Opioid Assessment for Patients with Pain **Ch:** 656
 Screening Tool for Addiction Risk (STAR) **Ch:** 655
 secondary care **P:** 657
 secondary dysmenorrhea *see* dysmenorrhea
 secondary hyperalgesia *see* hyperalgesia
 secondary somatosensory cortex (S2), imaging **Ch:** 16, **Ch:** 242–3
 secretin, chronic pancreatitis **Ch:** 554
 sedation
 acupuncture-induced **P:** 210–1
 alpha-2 adrenoreceptor agonists- induced **A:** 102
 clonidine-induced **A:** 102, **A:** 487
 conscious *see* conscious sedation
 cryoanalgesia **P:** 382
 deep **C:** 219
 fracture reduction **A:** 367
 ICUs *see* intensive care units (ICUs)
 opioid-induced **C:** 154, **C:** 184–5
 children **C:** 353 *T*
 clinical presentation **C:** 184
 elderly **A:** 514
 epidemiology **C:** 184
 etiology **C:** 184
 management **C:** 184–5
 neuraxial opioids **A:** 258
 pathophysiology **C:** 184
 psychostimulants **C:** 184
 strong opioids **C:** 113
 subcutaneous drug infusion **P:** 128
 tolerance **C:** 184
 procedure-related pain **C:** 218–9

- sedation (*continued*)
 respiratory depression
 monitoring **P:** 589–90
 tricyclic antidepressant-induced **P:** 139
- sedation scoring systems **A:** 515 *T*;
P: 589 *T*
 limitation **A:** 150
 pediatric APS **P:** 634
- segmental acupuncture **P:** 212
- segmental spinal cord pain *see* spinal cord injury (SCI) pain, at-level neuropathic pain
- segregation analysis, inheritance **Ch:** 55
- seizures, opioid-induced **C:** 187–8
- selection bias **P:** 554
- selective cyclooxygenase 2 inhibitors, rheumatoid arthritis management **Ch:** 521
- selective dorsal rhizotomy (SDR), spasticity **Ch:** 446
- selective neurolysis **C:** 226–7
- selective serotonin reuptake inhibitors (SSRIs) **Ch:** 244 *T*, **Ch:** 246
 adverse effects **Ch:** 246; **P:** 139
 suicide risk **Ch:** 246
 chronic pelvic pain **Ch:** 584
 contraindications **P:** 138
 depression, cancer patients **C:** 332
 dosing/treatment schedule **P:** 138
 elderly **A:** 516
 evidence-based outcomes **Ch:** 246–7
 fibromyalgia syndrome **Ch:** 246–7, **Ch:** 607
 juvenile fibromyalgia syndrome **Ch:** 625
 low back pain **Ch:** 247
 mechanism of action **Ch:** 246, **Ch:** 346
 metabolism **P:** 138
 neurological disease pain **Ch:** 329–30
 neuropathic pain **Ch:** 246, **Ch:** 346
 cancer-induced/related **C:** 205
 panic disorder **Ch:** 617
 pharmacology **Ch:** 246
 spinal cord injury pain **Ch:** 394–5
 structure **Ch:** 246
 tension-type headache prophylaxis **Ch:** 461–2
see also individual drugs
- selective subdural nerve root block **P:** 418
 herniated disc, secondary radicular pain **P:** 420
 transforaminal epidural vs. **P:** 418
- “self,” understandings of **P:** 171
- “self-as-content” **P:** 171
- “self-as-context” **P:** 171
- “self-as-know” **P:** 171
- “self-as-knower” **P:** 171
- self-care, temporomandibular disorder **Ch:** 470
- self-efficacy, motivational interviewing techniques **P:** 100
- self-hypnosis **P:** 148
 cancer pain
 children **C:** 305
 efficacy **C:** 301
 children **A:** 315
 pediatric biofeedback and **P:** 491
- self-management
 osteoarthritis **Ch:** 527
 physiotherapy programs **P:** 225
- self-medication, costs **Ch:** 77–8
- self-monitoring **P:** 480 *T*
- self-regulation skills *see* mind/body skills
- Self-Regulation theory, children **A:** 312
- self-report measures
 acute pain assessment,
 children **A:** 479; **P:** 448–50, **P:** 448 *T*
 adherence measurement **P:** 35–6
 age-appropriate **P:** 448
 chronic pain assessment **Ch:** 118–9
 children **P:** 455–6
 clinical trial end points **P:** 520
 disability measurement **Ch:** 118–9
 elderly pain assessment **A:** 510–2, **A:** 512; **Ch:** 644
 musculoskeletal pain,
 children **Ch:** 624
 pain research **Ch:** 61 *T*
 physiotherapy activity limitation assessment **P:** 222
see also individual measures
- self-talk repertoire **P:** 488
- semistructured interview, pain-related fear **P:** 180–1
- senile pruritus **C:** 329
- senility, TENS caution **P:** 196
- senna **C:** 325 *T*
- sensitivity **Ch:** 182–3
 clinical trial exclusions **Ch:** 183
- sensitivity analysis **Ch:** 81; **P:** 573
- sensitivity to change, pain measures **P:** 38
- sensitization
 central *see* central sensitization
 peripheral *see* peripheral sensitization
 visceral hypersensitivity disorders **Ch:** 38–9
- sensory assessment
 neuropathic pain **Ch:** 137
- peripheral neuropathy **P:** 78
- sensory axons, peripheral neuropathy **P:** 77 *T*
- sensory deficit, neuropathic pain **Ch:** 134–5
- sensory-evoked potentials **P:** 51
- sensory homunculus, spinal pain syndromes **Ch:** 272, **Ch:** 274 *F*
- sensory information
 information provision **A:** 297
 presurgical **P:** 251
- sensory nerve block **A:** 256
- sensory testing **P:** 43–55
 application **P:** 47
 basis for **P:** 47
 future perspectives **P:** 52–3
 goals **P:** 47
 regimen design **P:** 47
see also individual tests
- sepsis, ICUs **A:** 350
- septic arthritis **A:** 433–4; **P:** 350
 differential diagnosis **P:** 350
 intra-articular injection
 contraindication **P:** 350
- septic bursitis **A:** 434
- sequence variation, genetics **Ch:** 51–2
- sequential trials
 cancer pain clinical trials **P:** 542–3
 multivariate **P:** 543
 stopping rules **P:** 543
- serology, pain diagnosis **P:** 69–70
- serotonin
 acupuncture **Ch:** 310; **C:** 273
 peripheral nociceptor sensitization **Ch:** 29
- serotonin-norepinephrine reuptake inhibitors (SNRIs) **Ch:** 244 *T*, **Ch:** 245
 adverse effects **Ch:** 245; **P:** 139
 cancer-induced/related neuropathic pain **C:** 205–6
 chronic pelvic pain **Ch:** 584
 contraindications **P:** 138
 depression pain symptoms **Ch:** 246
 dosing/treatment schedule **P:** 138
 evidence-based-outcomes **Ch:** 245–6
 fibromyalgia syndrome **Ch:** 245–6
 mechanism of action **Ch:** 245
 metabolism **P:** 138
 neuropathic pain **Ch:** 245
 peripheral neuropathic pain **Ch:** 346
 pharmacology **Ch:** 245
 spinal cord injury pain **Ch:** 394–5, **Ch:** 396 *T*
 structure **Ch:** 245
see also individual drugs
- serotonin receptor(s)

- neuropathic pain **Ch:** 15–6
somatic nociceptors **A:** 6
TENS **A:** 275
- serotonin receptor antagonists
irritable bowel syndrome **Ch:** 559–60
opioid-related nausea and vomiting **A:** 228, **A:** 258
opioid-related pruritus **A:** 258
postoperative nausea and vomiting **A:** 493
- serotonin syndrome **Ch:** 248; **P:** 138
diagnostic algorithm **Ch:** 248 *F*
- serous collections, SCS-induced **P:** 411
- sertraline, pediatric headache **Ch:** 632
- serum protein electrophoresis **P:** 67
- sex hormones, chronic pain epidemiology **Ch:** 66
- sexual abuse, chronic pelvic pain **Ch:** 582
- sexual counseling programs **C:** 55
- sexual history taking **C:** 55
- sexuality, cancer patients **C:** 55
- sexually transmitted infections, HIV-associated gynecological pain **Ch:** 359
- sexual problems, cancer patients **C:** 55
- SF-36 *see* Short-Form 36 (SF-36)
- sham acupuncture **P:** 208
- shamanic healing *see* energy healing
- sham procedures
ethics **P:** 509
placebo effect **P:** 500
- Shanti Avedna Ashram **C:** 87
- Shiatsu (acupressure) **C:** 272, **C:** 277–8
- shingles *see* herpes zoster
- Shingles Prevention Study (SPS) **Ch:** 431–2
- Shipman, Dr Harold **C:** 414
- shock, NSAID-induced **A:** 73
- shooting pain sensation **P:** 5
- short-acting opioids, breakthrough pain **Ch:** 221
- Short-Form 36 (SF-36) **Ch:** 118; **P:** 19–20, **P:** 33–4 *T*
chronic pain **Ch:** 79, **Ch:** 79 *T*, **Ch:** 118
clinical trial outcomes **P:** 523
neuropathic pain, “nonpain features” **P:** 561
coverage **P:** 32
daily functioning assessment, chronic pain **Ch:** 172 *T*, **Ch:** 173
- Short-Form McGill Pain Questionnaire (SF-MPQ) **P:** 17, **P:** 19 *F*
acute pain **A:** 144
chronic pain assessment **Ch:** 125
clinical trial outcomes **P:** 521
- “nonpain features” **P:** 561
- Short Pain Inventory **A:** 147
- shoulder
intra-articular injection **P:** 351
anterior approach **P:** 351, **P:** 352 *F*
patient positioning **P:** 351
posterior approach **P:** 351
osteoarthritis **P:** 351
rheumatoid arthritis **P:** 351
soft-tissue disorders **Ch:** 528–9
diagnosis **Ch:** 528–9, **Ch:** 529 *T*
differential diagnosis **Ch:** 528–9
epidemiology **Ch:** 528–9
range of movement patterns **Ch:** 528–9
treatment **Ch:** 529
see also individual disorders
- soft-tissue injection **P:** 354–5
subacromial technique **P:** 354, **P:** 354 *F*
- shoulder capsulitis **Ch:** 529 *T*
- shoulder dislocations **A:** 368
- shoulder pain, acute **A:** 436–7
clinical features **A:** 437
entities **A:** 437
investigations **A:** 437
management **A:** 432 *T*, **A:** 437
surgery **A:** 437
- shoulder surgery, interscalene brachial plexus block **A:** 239
- sickle cell crisis **A:** 419
- sickle cell disease **A:** 419–21
acute chest syndrome **A:** 419
definition **A:** 419
management **A:** 420–1
patient education **A:** 421
prevention **A:** 421
TENS **A:** 421
- Sickness Impact Profile (SIP) **P:** 33–4 *T*
daily functioning assessment, chronic pain **Ch:** 172 *T*, **Ch:** 173
- SIGLE (System for Information on Grey Literature) **P:** 570 *T*
- sigma (σ) opioid receptors **A:** 54
- signal detection theory (SDT) **P:** 501–2
- signaling cascades, inflammatory mediators **A:** 21, **A:** 22
- significance level **P:** 546
- silent nociceptors **Ch:** 28
- simple relaxation, preprocedural **P:** 252
- Single Convention on Narcotic Drugs **C:** 115
remit **C:** 82–3
- Single Convention on Narcotic Drugs 1961 (amended 1972) **C:** 82
- single nucleotide polymorphisms (SNPs) **Ch:** 52–3
- chronic pain epidemiology **Ch:** 71
high-density genome-wide screening **Ch:** 71
mu opioid receptors **A:** 54
NSAIDs and **C:** 127
- single photon emission computed tomography (SPECT) **Ch:** 149
neck pain **Ch:** 492
- single-subject designs, outcome evaluation **P:** 103–4
case study *vs.* **P:** 103
“control” condition **P:** 103–4, **P:** 104 *F*
multiple baseline approach **P:** 104, **P:** 104 *F*
treatment alterations **P:** 104
- sinusitis
acute **A:** 419
dental pain *vs.* **Ch:** 477
headache **Ch:** 454
- SIP *see* Sickness Impact Profile (SIP)
- Sjögren’s syndrome **Ch:** 151 *T*
- skeletal trauma, CPSP **Ch:** 406
- skin
blood flow, CRPS **Ch:** 365
opioid effects **C:** 156
radiotherapy side effects **C:** 259
topical analgesic sensations **Ch:** 231
topical NSAID reactions **Ch:** 232–3
- skin biopsy, neuropathies **P:** 80, **P:** 80 *F*
- skin care, lymphedema **C:** 329
- skin conditions, TENS
contraindication **A:** 277
- skin conductance, biofeedback **P:** 487 *T*
- skin conductance-assisted relaxation **P:** 158
- skin conductance response, sympathetic blocks **P:** 326
- skin irritation, TENS-induced **P:** 198
- skin patches, analgesia delivery **C:** 110
- skin potential response, sympathetic blocks **P:** 326
- skin temperature, sympathetic blocks **P:** 326
- skin temperature-assisted relaxation **P:** 158
- sleep, pediatric headaches and **Ch:** 630
- sleep disturbances
addiction **Ch:** 657
chronic pain **Ch:** 293; **P:** 146
juvenile fibromyalgia syndrome **Ch:** 625
opioid effects **C:** 154
- slippery elm **Ch:** 314 *T*
- slow low efficiency dialysis (SLED) **A:** 349

- slump technique, sciatica **P**: 234,
P: 235 *F*
- small cell lung cancer (SCLC) **C**: 264
- small-fiber neuropathy,
diabetics **Ch**: 340
- small intestine
NSAID-induced toxicity **C**: 134–5
management **C**: 135
pathophysiology **C**: 134–5
obstruction, cancer patients *see* bowel
obstruction, advanced cancer
opioid effects **C**: 155
- smoking, low back pain and **A**: 446
- smooth muscle relaxants
esophageal motor disorders **Ch**: 543
irritable bowel syndrome **A**: 416
see also individual drugs
- social–cognitive model, hypnosis **A**: 315
- social phobias **Ch**: 617
- social support
cancer patients **C**: 49
professional team **C**: 75
- Society for Developmental and
Behavioral Pediatric Workshops,
mind/body skills **P**: 493
- socioeconomics
case–control studies **Ch**: 70
chronic pain epidemiology **Ch**: 69
- Socratic style, questioning **P**: 100,
P: 101
- sodium channel(s)
nerve injury and **P**: 57
peripheral sensitization **A**: 23–4
voltage-gated *see* voltage-gated
sodium channel(s)
- sodium channel blockers
nonspecific **P**: 135
postamputation pain **Ch**: 422
specific **P**: 135
- sodium cromoglycate **C**: 330
- sodium glycocholate **A**: 208
- sodium valproate *see* valproate
- soft-tissue injections **P**: 349–60
bursitis **P**: 354–7
complications **P**: 354
enthesitis **P**: 354–7
low back pain **A**: 451 *T*, **A**: 453
procedure **P**: 353
steroid preparations **P**: 351 *T*
tendonosis **P**: 354–7
tenosynovitis **P**: 354–7
see also individual conditions/disorders;
individual joints
- soft-tissue injuries
immobilization **A**: 532
NSAIDs **A**: 533
sports-related **A**: 527
- topical analgesics **Ch**: 235–6
- soft-tissue pain, radiotherapy **C**: 252–4
indications **C**: 252, **C**: 252 *T*
- soft-tissue remodeling, spasticity
pain **Ch**: 443
- somatic focus, pain-related fear **P**: 180
- somatic nerve blockade, CRPS **Ch**: 369
- somatic nociceptors **A**: 4–6, **A**: 5 *F*
acid-sensing ion channels **A**: 4–6
chemoreceptors **A**: 4–6
classification **A**: 4–6
G-protein-coupled receptors **A**: 6
ion channels **A**: 4–6
ionotropic **A**: 6
mechanoreceptors **A**: 4–6
nonpeptidergic **A**: 4
peptidergic **A**: 4
primary afferent receptors **A**: 4–6
serotonin receptors **A**: 6
thermoreceptors **A**: 4–6
transient receptor potential
family **A**: 6, **A**: 7 *F*
- somatic pain
cancer-induced *see* cancer-induced
somatic pain
labor **A**: 464
- somatic referred pain, lumbar
spine **A**: 446, **A**: 449
- somatization, as prognostic factor **C**: 63
- somatization disorder **Ch**: 619
- somatoform disorders **Ch**: 618–9;
see also individual diseases/disorders
- somatosensory cortex
hypnotic analgesia **P**: 149
persistent musculoskeletal
pain **Ch**: 32
- somatosensory evoked potentials (SEP),
TENS **A**: 272
- somatostatin **Ch**: 26
nociception **A**: 10–1
- South African hospice
development **C**: 88–9
- Southern blots **Ch**: 62 *T*
- spared nerve injury (SNI) model **A**: 44;
Ch: 4–5
- spasmodic torticollis **Ch**: 328–9
- spasticity/spasticity pain **Ch**: 440–9
abnormal posture **Ch**: 442
contracture **Ch**: 443, **Ch**: 443 *F*
definition **Ch**: 327
focal *see* focal spasticity
general **Ch**: 441–2
management **Ch**: 444–6
spinal origin **Ch**: 442
hygiene **Ch**: 443
management **Ch**: 444
oral medications **Ch**: 444–5;
- see also individual drugs*
- principles **Ch**: 444
- spinal drug administration *see*
spinal drug administration
surgery **Ch**: 446
- in multiple sclerosis **Ch**: 376
- muscle spasms **Ch**: 442–3
extensor spasms **Ch**: 442–3,
Ch: 442 *F*
flexor spasms **Ch**: 442–3, **Ch**: 443 *F*
- musculoskeletal pain **Ch**: 444
- neuropathic pain **Ch**: 444
- pathophysiology **Ch**: 440–1
cerebral origin spasticity **Ch**: 441,
Ch: 441–2, **Ch**: 441 *T*
hyperexcitability **Ch**: 441
muscle changes **Ch**: 441
spinal origin spasticity **Ch**: 441,
Ch: 441 *T*, **Ch**: 442
upper motor neuron
syndrome **Ch**: 440–1,
Ch: 441 *T*
- skin flexure access difficulty **Ch**: 443,
Ch: 443 *F*
- TENS **P**: 195, **P**: 201
weight distribution **Ch**: 442
- spatial characteristics, neuropathic pain
assessment **Ch**: 139
- Special Prescription Form, Italy **C**: 83–4
- spermatocoele **Ch**: 563
- sphenoid sinus syndrome **C**: 31 *T*
- sphenopalatine ganglion **P**: 394
blocks **P**: 345–6
radiofrequency lesioning **P**: 394–5
applied anatomy **P**: 394
complications **P**: 395
history **P**: 394
indications **P**: 394
results **P**: 395
technique **P**: 394–5, **P**: 394 *F*,
P: 395 *F*
treatment efficacy **P**: 395
- sphincters
intrathecal neurolysis effects
C: 231 *T*
opioid effects **C**: 192
- Spigelian hernias **Ch**: 579
- spinal abnormalities, SCS
contraindication **P**: 407
- spinal accessory nerve **P**: 261
- spinal accessory nerve block **P**: 261
landmarks **P**: 261, **P**: 262 *F*
practical steps/technique **P**: 261,
P: 262 *F*
- spinal afferents, persistent visceral
pain **Ch**: 39
- spinal analgesia **A**: 256

- continuous *see* continuous spinal analgesia (CSA)
- developing world **A:** 395–6
- field/emergency situations **A:** 382 *T*
- labor pain **A:** 470
- local anesthetics **A:** 257
- spinal canal stenosis, epidural steroid injections **P:** 421–2
- caudal **P:** 421–2
- interlaminar **P:** 421
- transforaminal **P:** 421
- spinal cord
- nerve root ligation, postnatal development effects **A:** 44
- nociception *see* nociception
- nociceptive fibers **A:** 8–9, **A:** 9 *F*
- nociceptors **Ch:** 29–30
- opioid effects **C:** 152–3
- postinjury hyperexcitability, opioids **A:** 168
- radiotherapy side effects **C:** 259
- Rexed's laminae **A:** 8–9, **A:** 8 *F*
- supraspinal mechanisms **Ch:** 15–6
- descending modulation **Ch:** 15–6
- TENS segmental mechanisms **A:** 273–4
- tumor necrosis factor α **Ch:** 10
- spinal cord compression, cancer patients **C:** 30–1
- causes **C:** 30
- children **C:** 346
- imaging **C:** 31, **C:** 32 *F*
- spinal cord infarct **P:** 422–3
- spinal cord injury (SCI)
- pain **Ch:** 388–404
- above-level neuropathic pain **Ch:** 389
- management **Ch:** 393
- patient assessment **Ch:** 391–2
- at-level neuropathic pain **Ch:** 389, **Ch:** 392 *F*
- imaging **Ch:** 392
- management **Ch:** 393–7
- patient assessment **Ch:** 392
- below-level neuropathic pain **Ch:** 390, **Ch:** 392 *F*
- imaging **Ch:** 392
- management **Ch:** 393–7
- patient assessment **Ch:** 392
- spinal generator **Ch:** 390
- central neuropathic pain **Ch:** 375
- environmental effects **Ch:** 392, **Ch:** 400
- management **Ch:** 392–400
- anticonvulsant drugs **Ch:** 394, **Ch:** 396 *T*
- antidepressants **Ch:** 394–5, **Ch:** 396 *T*
- drug combinations **Ch:** 395
- exercise **Ch:** 397 *T*
- local anesthetics **Ch:** 395, **Ch:** 396 *T*
- NMDA antagonists **Ch:** 395
- nociceptive pain **Ch:** 398 *F*
- opioids **Ch:** 393, **Ch:** 394, **Ch:** 396 *T*
- physical approaches **Ch:** 397
- psychological approaches **Ch:** 397 *T*
- spinal drug administration **Ch:** 395, **Ch:** 396 *T*
- stimulation techniques **Ch:** 395–7, **Ch:** 397 *T*
- surgical approaches **Ch:** 397, **Ch:** 397 *T*
- mechanisms **Ch:** 390–1
- muscle spasms **Ch:** 389, **Ch:** 393
- musculoskeletal pain **Ch:** 389
- imaging **Ch:** 391
- inflammation **Ch:** 393
- patient assessment **Ch:** 391
- trauma **Ch:** 392–3
- neuropathic **Ch:** 389 *T*, **Ch:** 399 *F*
- nociceptive **Ch:** 389 *T*
- pain taxonomy **Ch:** 388–90, **Ch:** 389 *T*
- patient assessment **Ch:** 391–2
- environmental contribution **Ch:** 392
- psychological contribution **Ch:** 392
- visceral pain **Ch:** 391
- peripheral generator **Ch:** 390
- psychological aspects **Ch:** 390, **Ch:** 400
- spinal generator **Ch:** 390
- supraspinal generator **Ch:** 390–1
- types **Ch:** 388–90
- visceral pain **Ch:** 389
- imaging **Ch:** 391
- location **Ch:** 391
- management **Ch:** 393
- patient assessment **Ch:** 391
- physical examination **Ch:** 391
- Spinal Cord Injury Pain Task Force **Ch:** 388–9
- spinal cord lesions, spasticity **Ch:** 441
- spinal cord stimulation (SCS) **P:** 404–15, **P:** 244
- anatomy **P:** 406–7
- audits **P:** 412–3
- biopsychosocial assessment **P:** 407–8
- cancer pain **C:** 243–5
- clinical effectiveness **C:** 244
- central neuropathic pain **Ch:** 383
- clinical technique **C:** 244–6
- clonidine and **Ch:** 269
- complications **P:** 411–2
- device-related **P:** 411
- early **P:** 411
- late **P:** 411
- pain relief failure **P:** 412
- unpleasant stimulation **P:** 412
- conditions treated **Ch:** 268–9
- continuous active stimulation **P:** 412
- contraindications **C:** 245–6; **P:** 407
- cost-effectiveness **C:** 244
- CRPS **Ch:** 277, **Ch:** 370
- cycling stimulation **P:** 412
- device registration **P:** 412–3
- electrode migration **P:** 412
- electrode placement **C:** 244–5
- equipment selection **P:** 412
- complications **P:** 412
- external battery systems **P:** 412
- failed back surgery syndrome **P:** 405
- full implantation/second-stage procedure **P:** 410–1
- historical aspects **A:** 272; **Ch:** 268–9
- human studies **Ch:** 276
- implantable pulse generator (IPG)
- anchoring **P:** 411
- implantation **P:** 411
- pain at **P:** 412
- positioning **P:** 410–1
- siting decisions **P:** 409
- implantation **P:** 408–10
- topographic paresthesiae coverage screening **P:** 409–10
- indications **C:** 245 *T*; **P:** 405, **P:** 407
- internal battery systems **P:** 412
- ischemic syndromes **Ch:** 273
- lead anchoring **P:** 410
- lead breakage **P:** 412
- lead failure **P:** 411–2
- lead insertion **P:** 408–9
- deviated leads **P:** 409
- epidural space anatomical sites **P:** 407 *F*, **P:** 408–9, **P:** 409 *T*
- guide wire insertion **P:** 409
- imaging **P:** 409
- incision site **P:** 409
- lead migration **P:** 412
- lower back pain **Ch:** 272, **Ch:** 273 *F*
- mechanisms of action **C:** 243–4; **P:** 405, **P:** 405 *F*
- MRI compatibility **C:** 245–6
- national audit database needs **P:** 413
- neural interface **P:** 406–7
- pancreatitis **Ch:** 276
- paresthesia probability **P:** 406, **P:** 407 *F*
- patient selection **P:** 407–8
- patient's "sweet spot" **P:** 407

- spinal cord stimulation (SCS)
(*continued*)
peripheral neuropathic pain **Ch:** 347–8
peripheral vascular disease **Ch:** 275–6,
Ch: 276 *F*
postherpetic neuralgia **Ch:** 277
clinical trials **Ch:** 277–8
programming **P:** 412
rechargeable systems **P:** 406 *T*, **P:** 412
refractory angina pectoris **Ch:** 274–5,
Ch: 540–1
cardiac plexus neurons **Ch:** 274–5
clinical effects **Ch:** 275
electrode placement **Ch:** 275,
Ch: 275 *F*
mechanism of action **Ch:** 274–5,
Ch: 540
patient selection **Ch:** 274
technical considerations **Ch:** 275
research **P:** 412–3
spinal cord injury pain **Ch:** 395–7,
Ch: 397 *T*
spinal pain syndromes **Ch:** 271–2
other therapy failure **Ch:** 271–2
sensory homunculus **Ch:** 272,
Ch: 274 *F*
syndrome X **Ch:** 542
treatment rationale **C:** 243–4
trial/first treatment stage **P:** 408
visceral pain syndromes
animal models **Ch:** 276
human studies **Ch:** 276
- spinal cord tumors, children **C:** 346
spinal drug administration **Ch:** 284–91
blood–brain barrier **Ch:** 285,
Ch: 285 *F*, **Ch:** 286 *F*
cancer pain **Ch:** 288, **Ch:** 288–9
cost-effectiveness **Ch:** 288
chronic noncancer pain **Ch:** 288,
Ch: 289
clinical uses/indications **Ch:** 288–9
CNS blood flow **Ch:** 285, **Ch:** 286 *F*
cost-effectiveness **Ch:** 288
drugs used **Ch:** 285;
see also individual drugs
effectiveness **Ch:** 284, **Ch:** 285 *F*
historical aspects **Ch:** 284–5
membrane stabilizers **Ch:** 287
neurologic disease pain **Ch:** 331–2
pharmacology **Ch:** 286–8
physiology **Ch:** 284–6
spasticity **Ch:** 285–6, **Ch:** 288,
Ch: 289, **Ch:** 445–6
cost-effectiveness **Ch:** 288
spinal cord injury pain **Ch:** 395,
Ch: 397 *T*
- voltage-gated calcium channel
blockers **Ch:** 287
see also epidural analgesia; intrathecal
drug administration/delivery
- Spinal Function Sort (SFS) **Ch:** 119
spinal fusion surgery
chronic lower back pain **Ch:** 163,
Ch: 512
neuraxial analgesia **A:** 264
spinal gate **P:** 146
spinal hyperexcitability, persistent
musculoskeletal pain **Ch:** 27 *F*,
Ch: 30–1
spinal instability, lower back
pain **Ch:** 507
spinal manipulation, low back pain
acute pain **A:** 451 *T*, **A:** 452
chronic **Ch:** 509
spinal movement assessment,
sciatica **P:** 232–3
spinal neoplasia diagnosis **Ch:** 155,
Ch: 156 *T*
spinal nerve ligation (SNL) transection
model **Ch:** 4–5, **Ch:** 5 *F*, **Ch:** 7–8
spinal nerves **P:** 418
spinal neurons, persistent visceral
pain **Ch:** 42
spinal origin spasticity **Ch:** 441,
Ch: 441 *T*, **Ch:** 442
spinal pain
aneurysm vs. **Ch:** 155–6, **Ch:** 156 *T*
arthritis **Ch:** 156
diagnosis **Ch:** 155, **Ch:** 156 *T*
discogenic pain **Ch:** 157
fractures **Ch:** 156
infections **Ch:** 155, **Ch:** 156 *T*
metabolic bone disease **Ch:** 156
muscle spasm **Ch:** 157
sacroiliac joint pain **Ch:** 157
trigger point **Ch:** 157
zygapophyseal joint pain
Ch: 157
see also chronic lower back pain
(CLBP); low back pain (LBP)
- spinal stenosis **Ch:** 511–2
epiduroscopy **P:** 434
spinal-thalamic-cortical pathway
dysfunction **Ch:** 378
- spine
anatomy **P:** 395, **P:** 417
anterior column **P:** 417
dorsal compartment **P:** 395
middle column **P:** 417
posterior column **P:** 417
ventral compartment **P:** 395
spinobulbar pathway(s),
nociception **A:** 5 *F*, **A:** 11–2
- spinoparabrachial pathway,
nociception **A:** 11–2
spinoreticulothalamic system, central
neuropathic pain **Ch:** 378–9
spinothalamic pathway
central neuropathic pain **Ch:** 378
nociception **A:** 11
spinothalamic tract **P:** 390–1
spiral fractures **A:** 528
spiritual therapies **Ch:** 307, **Ch:** 307 *T*
spironolactone, elderly **C:** 365
splanchnicectomy, chronic
pancreatitis **Ch:** 556
splanchnic nerves, nociception **A:** 7–8
splenic pain management,
radiotherapy **C:** 253
splints, osteoarthritis **Ch:** 528
spondylosis
cervical *see* cervical spondylosis
low back pain **A:** 448
spontaneous pain
cancer patients, epidemiology **C:** 288
central poststroke pain **Ch:** 378–9
definition **P:** 539
peripheral neuropathies **Ch:** 336
sports injuries **A:** 526–38
acute **A:** 526
direct (extrinsic) **A:** 526
indirect (intrinsic) **A:** 526
presentation **A:** 531
articular cartilage **A:** 530
bone *see* bone injuries; fracture(s)
classification **A:** 526–7
by tissue **A:** 527
clinical presentation **A:** 531
cryotherapy *see* cryotherapy
granulation tissue formation **A:** 528
hard tissue **A:** 527
imaging **A:** 531
investigations **A:** 531
ligaments **A:** 530
long-term **A:** 527
management **A:** 531–7
analgesics **A:** 532–3
initial treatment **A:** 532
pharmacological therapy **A:** 532–5
prohibited substances **A:** 533
RICE regime **A:** 532
see also individual drugs
muscle **A:** 530–1
pathophysiology **A:** 527–8
inflammatory response **A:** 527,
A: 527 *F*
prognosis **A:** 529 *F*, **A:** 537
remodeling/maturation phase **A:** 528
repair/regeneration phase **A:** 528
secondary **A:** 527

- short-term **A:** 527
 soft-tissue **A:** 527
 synovial joints **A:** 530
 tendons **A:** 530
- squamous cell carcinoma,
 HIV-associated anorectal
 pain **Ch:** 359
- squashed stomach syndrome **C:** 318
 management **C:** 321 *F*
- squint (strabismus) surgery, local
 anesthetics **A:** 489
- stabilizers, local anesthetics **A:** 118
- stakeholders **Ch:** 179, **Ch:** 179 *T*; **P:** 101
- standardized mean difference
 (SMD) **P:** 572
- Standards for Reporting Interventions
 in Controlled Trials of
 Acupuncture (STRICTA) **A:** 282
- starvation, anorexia cachexia syndrome
 vs. **C:** 327
- state anxiety **A:** 293
- State-Trait Anxiety Inventory (STAI)
 chronic pain-related anxiety **Ch:** 126,
Ch: 173–4
 postoperative pain **A:** 293–4
 pre-procedural assessment **P:** 247–8
- static hyperalgesia, neuropathic
 pain **Ch:** 134 *T*, **Ch:** 135
- statins (HMG CoA reductase
 inhibitors), rheumatoid
 arthritis **Ch:** 524
- statistical heterogeneity **P:** 572–3
- stavudine, toxic neuropathy **Ch:** 341–2,
Ch: 355
- St Christopher's Hospice **C:** 85
- steatorrhea, chronic
 pancreatitis **Ch:** 553
- stellate ganglion **P:** 327
- stellate ganglion block **P:** 327–9
 adverse effects **P:** 329
 anatomy **P:** 327, **P:** 328 *F*
 clinical studies **Ch:** 152
 complications **P:** 329
 diagnostic **Ch:** 152
 life-threatening complications
P: 329
 neurolytic **C:** 229–30; **P:** 329
 refractory angina pectoris **Ch:** 540
 signs **P:** 329
 technique **P:** 327–8
 two-operator **P:** 328
 unintentional intra-arterial
 injection **P:** 329
 unintentional intrathecal
 injection **P:** 329
- step-down analgesia
 opioid-tolerant patients **A:** 548
- PCA **A:** 224
- stepped-care framework **P:** 657,
P: 657 *T*
- sternotomy, CPSP **Ch:** 406–7
- steroids *see* corticosteroid(s)
- Stevens–Johnson syndrome **A:** 73
- stimulating catheters, continuous
 peripheral neural
 blockade **A:** 243–4
- stimulation-induced analgesia
 CAM **Ch:** 307, **Ch:** 307 *T*
 cancer pain **C:** 235–50
 definition **C:** 235
 historical aspects **C:** 235
 recent techniques/
 developments **C:** 246
see also neurostimulation; *individual*
techniques
- stimulation-produced analgesia *see*
 stimulation-induced analgesia
- stimulators, TENS **P:** 196
- stimulus-dependent pain
 neuropathic pain **Ch:** 134, **Ch:** 134 *T*
 peripheral neuropathies **Ch:** 336
- stimulus-independent pain
 neuropathic pain **Ch:** 134, **Ch:** 134 *T*
 peripheral neuropathies **Ch:** 336
- St John's Wort **Ch:** 314 *T*
- “stocking-glove” distribution,
 chemotherapy-induced peripheral
 neuropathy **C:** 400
- stoicism, elderly patient pain **Ch:** 643–4
- stomach
 chest pain **Ch:** 543
 opioid effects **C:** 155
- stool analysis of transit time (SST),
 opioid-induced
 constipation **C:** 189–90
- stool samples, irritable bowel
 syndrome **Ch:** 558–9
- strabismus (squint) surgery, local
 anesthetics **A:** 489
- straight leg test **P:** 7
- stranguria, urethral syndrome **Ch:** 580
- Strategic and clinical indicators in*
postoperative pain
management **P:** 674,
P: 674 *T*
- strategy development,
 economics **Ch:** 81–3
- stratified randomization **P:** 519
- strengthening exercises,
 sciatica **P:** 234–5
- stress
 chronic pain presentation **Ch:** 293
 persistent visceral pain **Ch:** 42–3
 models **Ch:** 42–3
- reduction, chronic pelvic
 pain **Ch:** 587
 tension-type headache **Ch:** 453
- stress disorders, chronic
 pain **Ch:** 617–8;
see also individual diseases/disorders
- stress fractures **A:** 529–30; **Ch:** 149
- stress response
 field/disaster situations **A:** 383
 labor pain vs. **A:** 465
 postnatal development effects **A:** 43
- STRICTA (Standards for Reporting
 Interventions in Controlled Trials
 of Acupuncture) **A:** 282
- stroke
 central neuropathic pain *see* central
 poststroke pain (CPSP)
 communication in **C:** 370–1
 incidence **Ch:** 377
- strontium, metastatic bone pain **C:** 263
- structural imaging **P:** 84, **P:** 89
- Study to Understand Prognosis,
 Preferences for Outcomes and
 Risks of Treatment
 (SUPPORT) **Ch:** 101
- subacromial bursa, soft-tissue
 injection **P:** 354, **P:** 354 *F*
- subacromial bursitis **P:** 354
- subarachnoid infusion, children **C:** 354
- subcalcaneal bursitis (policeman's
 heel) **P:** 357
- subclavian perivascular block **A:** 238 *T*
- subcostal nerves **P:** 275, **P:** 276
- subcutaneous drug
 administration **A:** 204–5
 cancer pain *see* subcutaneous drug
 infusion, cancer pain
 children **C:** 350; **P:** 464
 dying person **C:** 393–4
 intermittent opioids,
 guidelines **P:** 594–5 *F*
 nonopioid analgesics **A:** 205
 opioids **A:** 205
 elderly **A:** 505–7
see also individual drugs
- subcutaneous drug infusion, cancer
 pain **P:** 121–33
 absorption rate variations **P:** 125
 advanced age and **P:** 129–30
 analgesics **P:** 125–6, **P:** 130–1
 “as-required” injections **P:** 122
 clinical governance **P:** 131–3
 issues **P:** 131
 complications **P:** 124–5
 contraindications **P:** 122
 dose calculation errors **P:** 125
 drug combinations **P:** 131, **P:** 132 *T*

- subcutaneous drug infusion, cancer pain
(*continued*)
 drug reactions **P**: 125
 dying patients **P**: 122
 ease of access **P**: 122
 equipment malfunction **P**: 124
 fixed rated infusions **P**: 123
 indications **P**: 122
 injection site reactions **P**: 124–5
 management **P**: 124
 monitoring **P**: 123–4
 observation **P**: 123–4
 opioid-induced bowel dysfunction
 prevention/treatment **P**: 129
 opioid-naïve subjects **P**: 128
 opioids **P**: 126–7, **P**: 126 *F*
 adverse effects **P**: 128
 conversion ratios **P**: 127 *T*
 in liver failure **P**: 129
 renal failure and **P**: 129, **P**: 130 *T*
 rescue doses **P**: 127
 switching **P**: 127 *T*, **P**: 128
 titration **P**: 127–8
 toxicity **P**: 125, **P**: 128
 unresponsiveness **P**: 129
 unwanted effects **P**: 128
 prescribing **P**: 123
 errors **P**: 125
 opioids **P**: 127
 priming **P**: 123
 risk management **P**: 125
 safety **P**: 122
 siting **P**: 123
 starting **P**: 123–4
 syringe drivers **P**: 123
- subcutaneous patient-controlled
 analgesia *see* patient-controlled
 analgesia (PCA)
- subgroup analysis **P**: 572, **P**: 573,
P: 573 *F*
- subject bias **P**: 554
- subjectivity, impairment
 measurement **Ch**: 119–20
- sublingual drug
 administration **A**: 207–8
 children **P**: 463–4
 nonopioid analgesics **A**: 207–8
 opioid analgesics **A**: 208
see also individual drugs
 “subluxation complex,” chiropractic
 therapy **Ch**: 312
- sub-Saharan Africa, analgesia
 availability **A**: 390
- substance abuse *see* substance abuse/
 misuse
- substance abuse disorder
 (SAD) **A**: 542–3
- behavior identification **A**: 545
- comorbidities **A**: 542, **A**: 545
- definition **A**: 540
- drug history **A**: 545
- drug-seeking behavior **A**: 543
- epidemiology **A**: 542
- management **A**: 546, **A**: 550–1, **A**: 550
- pain assessment **A**: 545
- pain types **A**: 542
- psychosocial issues **A**: 542–3
- relapse **A**: 541
- substance abuse/misuse **Ch**: 652–9
 analgesic therapy **C**: 384–5
 cancer pain management **C**: 379–88
 case example **C**: 385–6
 guidelines **C**: 381–5
 healthcare resources utilized **C**: 379
 history taking **C**: 39
 impact on **C**: 380–1
 incidence **C**: 383, **C**: 383 *T*
 institutional policy **C**: 381–2
 medicolegal issues **C**: 384, **C**: 386
 multidisciplinary
 program **C**: 381–2, **C**: 382 *T*
 nonpharmacologic
 approaches **C**: 382, **C**: 385
 psychosocial support
 groups **C**: 383, **C**: 384
 treatment outcomes **C**: 383
 undertreatment **C**: 380
- chronic pain management **Ch**: 657–8
 nonpharmacological intervention
 tolerance **Ch**: 657
 opioid substitution
 therapy **Ch**: 657
 team support **Ch**: 657–8
- clinician–patient trust **C**: 381
- current opioid misuse
 measure **Ch**: 620
- definitions **Ch**: 653–4; **C**: 380
- drug testing/screening **C**: 381, **C**: 382,
C: 385
 body fluids tested **C**: 385, **C**: 386 *T*
 consent **C**: 385
 result interpretation **C**: 385,
C: 386 *T*
- epidemiology **Ch**: 653
- injury risk **Ch**: 657
- multidisciplinary care team **C**: 381
- neurobiology **Ch**: 654
- pain intensity increases **Ch**: 657
- patient assessment **C**: 381, **C**: 382 *T*
- patient identification **C**: 381
- prevalence **Ch**: 619–20
- prior use effects **Ch**: 620
- psychoactive substances **Ch**: 619–20
- psychological assessment **Ch**: 128–9
- research directions **C**: 386
- secondary stimuli associated **Ch**: 654
- written care agreements **C**: 383–4
 dismissal from treatment **C**: 384
 example **C**: 384
 initiation criteria **C**: 383–4
 noncompliance
 consequences **C**: 384
 outcomes **C**: 383 *T*
see also addiction; pseudoaddiction
- substance dependence, definition **A**: 540
- substance misuse *see* substance abuse/
 misuse
- substance **P**
 capsaicin-induced release **Ch**: 232
- fibromyalgia syndrome **Ch**: 604,
Ch: 604–5
- joint innervation **Ch**: 26
- microglia activation **Ch**: 14
- muscle innervation **Ch**: 26
- neuropathic pain **Ch**: 10, **Ch**: 14
- nociception **A**: 9
- opioid-tolerant patients **A**: 544
- peripheral nociceptor
 sensitization **Ch**: 29
- peripheral sensitization **A**: 21
- persistent musculoskeletal
 pain **Ch**: 31
- postamputation pain **Ch**: 420
- sucrose, children **A**: 488
- sufentanil **A**: 60–1
 cancer patients
 procedure-related pain **C**: 217
 subcutaneous infusion **P**: 127 *T*
 context-sensitive half-times **A**: 58
- epidural analgesia **P**: 319
- intranasal administration **A**: 208 *T*;
P: 306
- neuraxial analgesia **A**: 257
- pharmacokinetics **A**: 59 *T*
- transdermal administration **A**: 207
- suffering **Ch**: 86–98
 chronic pain-related, processes
 in **Ch**: 174–5
 cultural effects **Ch**: 89–90
 cultural factors **Ch**: 89–90
 definition **Ch**: 87–90, **Ch**: 100; **P**: 540
 clinical **Ch**: 90
 controversy **Ch**: 88–9, **Ch**: 89
 individual experience **Ch**: 89–90
 as pain synonym **Ch**: 89
 as pleural concept **Ch**: 90
 relief, legal perspectives **Ch**: 110
- suicide
 cancer-related *see* cancer-related
 suicide
 physician-assisted **Ch**: 110

- risk
 depression **Ch:** 616
 elderly **C:** 363
 selective serotonin reuptake inhibitors **Ch:** 246
- sulfasalazine
 inflammatory bowel disease **Ch:** 561
 musculoskeletal chest pain **Ch:** 544
 rheumatoid arthritis **Ch:** 522–4 *T*
- sulfonyleureas, NSAID
 interactions **A:** 74 *T*
- sulindac **A:** 72, **A:** 77–8
- sumatriptan
 cluster headache **Ch:** 462
 migraine **Ch:** 455–6, **Ch:** 460 *T*
 emergency department **A:** 365, **A:** 366, **A:** 366 *T*
 pediatric headache **Ch:** 630–1
 dosages **Ch:** 631 *T*
 placebo effect **P:** 507
- summed pain intensity differences (SPID) **A:** 148–9; **Ch:** 184; **P:** 517 *F*, **P:** 522, **P:** 522 *F*
- sum of pain relief and intensity difference (SPRID) **A:** 148–9
- sum of the VAS (SUMVAS) **P:** 21
- SUN (Scale for Use in Newborns) **A:** 479 *T*
- superficial burns **A:** 400
- superficial partial thickness burns **A:** 400
- superficial peroneal nerve block **P:** 290 *F*, **P:** 291
- superior cervical ganglion **P:** 327
- superior hypogastric plexus **P:** 342
 chronic pelvic pain **Ch:** 572
- superior hypogastric plexus block **C:** 230; **P:** 342–3
 anatomy **P:** 342
 complications **P:** 343
 ganglion impar block vs. **P:** 345
 indications **P:** 343
 technique **P:** 343
- superiority studies **P:** 516, **P:** 517 *F*
- superior vena caval obstruction (SVCO) **C:** 312
- supportive care **C:** 412
- supportive psychotherapy **C:** 298–9
 breast cancer **C:** 298–9
 components **C:** 298
 definition **C:** 298
 efficacy **C:** 298–9
- supports, noninflammatory joint pain **A:** 435
- SUPPORT study **C:** 391
- suppositories *see* rectal drug administration
- supraclavicular block (subclavian perivascular technique) **P:** 266–8
 complications **P:** 270 *T*
 field/emergency situations **A:** 382 *T*
 indications **A:** 238 *T*
 landmarks **P:** 266, **P:** 267 *F*
 practical steps/technique **P:** 266–7, **P:** 267 *F*
- supraorbital nerve **P:** 260, **P:** 260 *F*
 cryoanalgesia **P:** 384
- supraorbital nerve block **P:** 260 *F*, **P:** 261
- suprascapular artery **P:** 270
- suprascapular nerve **P:** 270
 entrapment **C:** 32–3
 risk factors **C:** 32–3
- suprascapular nerve block **P:** 270
 practical steps/technique **P:** 270, **P:** 271 *F*
- suprascapular vein **P:** 270
- supraspinal neurons, persistent musculoskeletal pain **Ch:** 32
- supraspinal sites, persistent musculoskeletal pain **Ch:** 30
- suprathreshold pain sensitivity, tension-type headache **Ch:** 454
- supratrochlear nerve **P:** 260, **P:** 260 *F*
 block **P:** 261
 cryoanalgesia **P:** 384
- sural nerve **P:** 285
 ankle **P:** 290
- sural nerve block **P:** 290, **P:** 290 *F*
- surface palpation, sciatica **P:** 232–3
- surgery
 breakthrough pain **C:** 289
 breast cancer, postoperative pain *see* postbreast cancer surgery pain (PBCSP)
 central neuropathic pain **Ch:** 380–3
 chronic lower back pain **Ch:** 512
 chronic pancreatitis pain therapy **Ch:** 556
 developing world **A:** 390
 focal spasticity **Ch:** 447
 inappropriate, CPSP **A:** 559
 neck pain **Ch:** 494
 nerve trauma risk **C:** 7
 neuraxial analgesia **A:** 256
 neurologic disease pain **Ch:** 332
 peripheral neuropathic pain **Ch:** 346 *T*
 placebo effect **P:** 500
 psychological preparation *see* psychological preparation, painful procedures
 spinal cord injury pain **Ch:** 397, **Ch:** 397 *T*
- trigeminal neuralgia **Ch:** 473
- surrogate end point, clinical trials **P:** 515–6
- surrogates, behavioral pain assessment **A:** 147
Survey of Chronic Pain in Europe **Ch:** 171
Survey of Pain Attitudes (SOPA) **P:** 180
- susceptibility genes **Ch:** 53
- sustained natural apophyseal glides (SNAG)
 neuron extinction **P:** 236
 sciatica **P:** 234
- sweating
 biofeedback **P:** 158
 cancer patients **C:** 331
 investigations **C:** 331
 management **C:** 331
 pathology **C:** 331
 CRPS **Ch:** 366
 opioid-induced **C:** 156
- Swedish massage *see* massage
- symmetrical polyneuropathy **P:** 76, **P:** 76 *T*
- sympathetic activity, neuropathic pain **Ch:** 133, **Ch:** 139
- sympathetic blocks **P:** 322–36
 bilateral **P:** 326
 causalgia **Ch:** 151
 completeness testing **P:** 325
 blood flow **P:** 325
 pain **P:** 325
 pain assessment **P:** 326
 sympathetic function **P:** 325
- contraindications **P:** 326
 contrast enhancement **P:** 327
 CRPS **Ch:** 369
 children **Ch:** 627
 diagnostic **Ch:** 151–2
 indications **P:** 322, **P:** 324–5
 local anesthetic drugs **P:** 326–7
 neurolytic *see* neurolytic blocks, sympathetic
 peripheral neuropathic pain **Ch:** 346 *T*
 reflex sympathetic dystrophy **Ch:** 151
 regional intravenous **P:** 333–5
 adverse effects **P:** 335
 duration **P:** 334
 norepinephrine release **P:** 326 *F*, **P:** 333, **P:** 335
 randomized clinical trial flaws **P:** 333
 technique **P:** 334–5
- skin conductance response **P:** 326
 skin potential response **P:** 326

- sympathetic blocks (*continued*)
 skin temperature
 measurements **P**: 326
 technique **Ch**: 151
see also individual blocks
- sympathetic nervous system (SNS)
 anatomy **P**: 323–4, **P**: 323 *F*, **P**: 324 *F*
 blocks *see* sympathetic blocks
 ganglia **P**: 323
 heart **Ch**: 538–9
 manual medicine **P**: 236–7
 nerve endings **P**: 326 *F*
 norepinephrine release **P**: 326 *F*
 postamputation pain **Ch**: 420
 preganglionic fibers **P**: 323
 reproductive organ
 innervation **Ch**: 571–2
 vascular nerves **P**: 324, **P**: 324 *F*
- sympathetic skin responses,
 CRPS **Ch**: 150–1, **Ch**: 366
- symphysis pubis, ridged **P**: 185
- Symptom Checklist 90-Revised
 (SCL-90R) **Ch**: 126–7
- symptom clusters, psychological
 interventions **C**: 303–4
- symptom substitution **C**: 300
- syncope, acupuncture-induced **Ch**: 310;
P: 210–1
- syndrome X **Ch**: 542
- synergy
 CBT **Ch**: 295
 clinical trials **P**: 518, **P**: 518 *F*
- synovial fluid aspiration
 joint pain **A**: 432
 septic arthritis **A**: 434
- synovial joints
 lower back pain diagnosis **Ch**: 157,
Ch: 158–9, **Ch**: 158 *F*, **Ch**: 160 *F*
 neck pain diagnosis **Ch**: 161
 sports injuries **A**: 530
- syringe drivers
 PCA **P**: 294
 subcutaneous infusion **P**: 123
- syringomyelia
 at-level neuropathic spinal cord injury
 pain **Ch**: 389
 MRI **Ch**: 154–5
- systematic desensitization
 pain-related fear **P**: 184
 surgical treatment refusal **P**: 246
- systematic reviews **P**: 566–75
 aims **P**: 566
 data extraction **P**: 570–1
 definition **P**: 566
 duplications exclusion **P**: 570–1
 eligibility criteria **P**: 569
 evidence appraisal **P**: 569–71
- bias assessment **P**: 569–70
 eligibility assessment **P**: 569
 quality assessment **P**: 569–70,
P: 571
 quality score **P**: 569
- evidence finding **P**: 568
 citation search **P**: 568
 controlled vocabulary **P**: 568
 databases **P**: 568, **P**: 570 *T*
 free text vocabulary **P**: 568
 highly precise search **P**: 568
 highly sensitive search **P**: 568,
P: 569
- evidence quality **P**: 567–8
 evidence summarization **P**: 571–4
 features **P**: 567
 heterogeneity **P**: 572–3
 investigating **P**: 573
 process **P**: 567
 protocol **P**: 568
 publication bias **P**: 568, **P**: 574
 question formulation **P**: 567–8,
P: 567 *T*
 random vs. fixed effects **P**: 572
 validity **P**: 574
- System for Information on Grey
 Literature (SIGLE) **P**: 570 *T*
- systemic inflammatory response
 syndrome (SIRS) **A**: 350
- systemic lupus erythematosus
 (SLE) **P**: 70
- systemic sclerosis, peripheral
 neuropathy **Ch**: 342
- systemic sodium channel blockers,
 neurologic disease pain **Ch**: 330
- systems biology, genetics **Ch**: 60
- T1 constant, MRI **Ch**: 147–8
 T2 constant, MRI **Ch**: 147–8
- tachyphylaxis (acute tolerance) **C**: 105
- tactile allodynia **Ch**: 7
- tactile sensibility estimation **P**: 47–8
- “take-home packs,” children **A**: 489
- tamoxifen **C**: 265
- Tampa Scale for Kinesiophobia (TSK),
 pain-related fear **Ch**: 173–4;
P: 180
- tamsulosin, renal colic **A**: 415
- Tangier disease **Ch**: 151 *T*, **Ch**: 344
- Taoism, acupuncture **Ch**: 308
- tapotement **C**: 277–8
- TARGET trial, NSAIDs **Ch**: 196
- tarsal fractures **A**: 528
- tarsal tunnel syndrome **Ch**: 149–50;
P: 357, **P**: 358
- taste alterations, cancer patients **C**: 317
- taxanes **C**: 402
- T-cell costimulation inhibitors,
 rheumatoid arthritis **Ch**: 522–4 *T*,
Ch: 524
- TEA *see* thoracic epidural analgesia
 (TEA)
- teamworking, cancer pain
 management **C**: 71–80
 absent planning **C**: 76
 bad teamwork scenario **C**: 71–2,
C: 77–9
 Charing Cross experience **C**: 76
 colleague relationship problems **C**: 76
 communication breakdown **C**: 76
 conflicts **C**: 76
 management strategies **C**: 79 *F*
 downside/failure **C**: 76
 effectiveness **C**: 74
 experienced team scenario **C**: 72–3,
C: 79–80
 inexperienced team scenario **C**: 71–2,
C: 77–9
 maintenance problems **C**: 76
 member variety **C**: 74–5
 need for **C**: 73–4
 clinician issues **C**: 73–4
 patient issues **C**: 73
 professional companionship **C**: 73
 organizational development
 (OD) **C**: 77, **C**: 78 *T*
 definition **C**: 77
 teambuilding **C**: 77
 peer supervision **C**: 75
 planning **C**: 77
 local needs survey **C**: 77
 power/status problems **C**: 76
 roles in **C**: 75, **C**: 75 *T*
 social support **C**: 75
 successfulness **C**: 74–5, **C**: 74 *T*
 clarity **C**: 74
 development time **C**: 75–6
 support **C**: 75–6
 team definition **C**: 74
 team development **C**: 77, **C**: 77 *T*
 stages **C**: 78 *T*
 tension **C**: 76
 theory **C**: 74–7
 views on **C**: 71
- tegaserod, irritable bowel
 syndrome **Ch**: 559–60
- telescoping, phantom
 sensation **Ch**: 418–9, **Ch**: 419 *F*
- temperament, children **A**: 310
- temperature
 pain perception and **P**: 13–4
 residual limb pain **Ch**: 419
 temperature asymmetry, CRPS **Ch**: 366
 temperature regulation **C**: 331

- temporal arteritis **Ch:** 154–5
- temporal characteristics, neuropathic pain assessment **Ch:** 139
- temporal summation, abnormal **P:** 50
- temporomandibular disorders (TMD) **Ch:** 467–70
- biofeedback **P:** 164–5
- definition **Ch:** 467
- diagnosis **Ch:** 156, **Ch:** 467–8
- differential diagnosis **Ch:** 469
- epidemiology **Ch:** 468
- management **Ch:** 469–70
- pathophysiology **Ch:** 468–9
- research diagnostic criteria **Ch:** 468 *T*
- symptomatology **Ch:** 468
- temporomandibular joint
- clicks **Ch:** 468
- mechanical problems **Ch:** 467–8
- tender points
- fibromyalgia syndrome **Ch:** 600, **Ch:** 600 *F*, **Ch:** 601
- juvenile fibromyalgia syndrome **Ch:** 625
- tendon(s)
- sports injuries **A:** 530
- ultrasound **Ch:** 148
- tendonopathy, ultrasound **Ch:** 148
- tendon reflexes,
- polyneuropathies **Ch:** 336
- tennis elbow *see* lateral epicondylitis
- tenosynovitis, wrist **Ch:** 529 *T*
- tenoxicam **A:** 78
- TENS *see* transcutaneous electrical nerve stimulation (TENS)
- tension-type headache (TTH)
- children **Ch:** 629 *T*
- chronic **Ch:** 450–1, **Ch:** 452
- classification **Ch:** 450–1, **Ch:** 451 *T*
- clinical features **Ch:** 452
- diagnosis **Ch:** 454
- epidemiology **Ch:** 452
- episodic **Ch:** 450–1, **Ch:** 452
- gender ratio **Ch:** 452
- muscle relaxation techniques **P:** 488
- pathophysiology **Ch:** 453–4
- prophylaxis **Ch:** 461–2
- temporomandibular disorders **Ch:** 469
- treatment **Ch:** 458–9
- terminal sedation **C:** 391
- children **C:** 354
- tertiary care **P:** 657–8
- functional restoration programs **P:** 658
- palliative pain management **P:** 658
- positive outcomes **P:** 658
- treatment approaches **P:** 658
- testicular torsion **Ch:** 563
- test–retest reliability, pain measures **P:** 36–7
- tetracaine **A:** 124
- neuraxial analgesia, CNS toxicity **A:** 257
- topical anesthesia **A:** 128
- tetracyclines, osteoarthritis **Ch:** 527
- delta 9-tetrahydrocannabinol (THC) **C:** 328
- tetrodotoxin **A:** 116
- tetrodotoxin-sensitive (TTX-S)
- voltage-gated sodium channels *see* voltage-gated sodium channel(s)
- thalamic ablation **C:** 254
- thalamic pain syndromes **Ch:** 377, **Ch:** 379
- thalamic theory, referred pain **A:** 11, **A:** 12 *F*
- thalamocortex, persistent musculoskeletal pain **Ch:** 32
- thalamus
- affective-motivational dimension of pain **Ch:** 242–3
- persistent musculoskeletal pain **Ch:** 32
- persistent visceral pain **Ch:** 40
- postamputation pain **Ch:** 421
- supraspinal spinal cord injury pain generator **Ch:** 391
- thalidomide
- anorexia cachexia syndrome **C:** 328
- chemotherapy-induced peripheral neuropathy **C:** 402
- HIV-associated pain **Ch:** 358
- pruritus **C:** 330
- sweating **C:** 331
- thallium poisoning **Ch:** 341
- therapeutic dependence **C:** 107
- therapeutic suggestion,
- hypnosis **P:** 482 *T*
- therapeutic touch (healing)
- cancer patients **C:** 278
- principles **Ch:** 316; **C:** 278
- thermal biofeedback, phantom limb pain **P:** 149–50
- thermal stimuli
- central neuropathic pain **Ch:** 378
- heat-foil technology **P:** 52–3, **P:** 52 *F*
- human visceral pain models **Ch:** 41
- neuropathic pain assessment **Ch:** 138, **Ch:** 139 *T*
- somatic vs. visceral nociception **A:** 6–7
- thermal treatments **P:** 224
- thermography **Ch:** 150
- biofeedback **P:** 487 *T*
- CRPS **Ch:** 150
- thermoreceptors **A:** 4–6
- thermoregulatory sweat test (TST), CRPS **Ch:** 150–1, **Ch:** 366, **Ch:** 366 *T*
- thermotest **P:** 48–50
- baseline skin temperature **P:** 49–50
- contact probe size **P:** 50
- controls **P:** 50
- devices **P:** 48–9
- indications **P:** 50
- injury prevention **P:** 50
- method of limits **P:** 49
- neuropathic pain findings **P:** 48–9, **P:** 49 *F*
- normal thresholds **P:** 49 *F*
- pain tolerance threshold determination **P:** 49
- paradoxical sensations **P:** 48–9
- parameters influencing results **P:** 49–50
- skin areas tested **P:** 50
- two-alternative forced choice method **P:** 49
- The Royal College of Anesthetists *Guidelines for the Provision of Anesthetic Services* **P:** 667–8
- Pain Management Services - Good Practice* **P:** 667–8
- thioridazine **C:** 331
- third molars, surgical
- removal **P:** 529–30, **P:** 530 *F*
- clinical pain trials *see* dental pain model
- indications **P:** 532
- neuropathic orofacial pain **Ch:** 470
- Third National Audit Project (NAP III), Royal College of Anaesthetists **P:** 585
- third occipital nerve (TON) **P:** 383
- third-party assessment, dementia/delirium patients **C:** 43
- thoracic epidural analgesia (TEA) **P:** 312–3
- cardiac surgery **A:** 263
- catheter placement **A:** 260
- children **A:** 491–2; **P:** 473–4
- complications **A:** 491–2
- insertion **A:** 491–2
- management **A:** 491–2
- elderly **A:** 517
- epinephrine **A:** 258
- lumbar vs. **P:** 312–3
- motor blockade **A:** 260
- thoracic surgery **A:** 263
- complication reduction **A:** 263
- video-assisted thoracoscopy **A:** 263

- thoracic nerve root neurolysis **P**: 340
- thoracic nerves **P**: 275
- thoracic paravertebral block
(TPVB) **P**: 275–6
anatomy **P**: 275
complications **P**: 276
ICU patients **A**: 350, **A**: 351
indications **A**: 238 *T*; **P**: 275
landmarks **P**: 275
neurolytic **P**: 275
pneumothorax induction **A**: 350
practical steps/technique **P**: 275,
P: 275 *F*
refractory angina pectoris **Ch**: 540
- thoracic paravertebral nerves **P**: 275
- thoracic spine, referred chest
pain **Ch**: 544
- thoracic surgery
epidural analgesia **A**: 263
postoperative **P**: 312–3
ICUs **A**: 351
neuraxial analgesia **A**: 263
thoracic epidural analgesia *see*
thoracic epidural analgesia
(TEA)
- thoracic sympathetic block **P**: 329–31
alternative techniques **P**: 330
anatomy **P**: 329, **P**: 330 *F*
complications **P**: 331
indications **P**: 330
technique **P**: 330
- thoracic sympathetic ganglia **P**: 329,
P: 330 *F*
- thoracoabdominal radiculopathy,
diabetics **Ch**: 339–40
- thoracocentesis **C**: 312–3
- thoracotomy
continuous paravertebral
blockade **A**: 241
CPSP **A**: 559, **A**: 559 *T*, **A**: 562–3
ICU patients **A**: 351
interpleural blockade **A**: 241–2
- thorax
chronic pain syndromes **P**: 385
nerve blocks **P**: 275–9
- thought stopping, pediatric CBT **A**: 317
- threat value
perceived threat **A**: 294
postoperative pain **A**: 294
- three-in-one blocks
femoral neck fractures **A**: 366
field/emergency situations **A**: 382 *T*
hip replacement surgery **A**: 240
- thrombocytosis, joint pain **A**: 432
- thromboembolism risk reduction, local
anesthetics **A**: 124
- thrombosis
COX-2 mediated **C**: 136, **C**: 137 *F*
neuraxial analgesia **A**: 264
NSAID-induced **C**: 136–8
COX-2 inhibitors **C**: 136
epidemiology **C**: 136–7, **C**: 137 *T*
mechanism **C**: 136
non-selective NSAIDs **C**: 136
- thromboxanes **A**: 69, **A**: 69 *T*, **A**: 71–2
aspirin effects **A**: 76
- thumb flexor tenosynovitis, soft-tissue
injection **P**: 356
- thymidine **Ch**: 49
- thyroid function tests **P**: 68
- thyroid hormones, fibromyalgia
syndrome **Ch**: 603, **Ch**: 608
- thyroid-stimulating hormone
(TSH) **P**: 68
- tiaprofenic acid **A**: 77
- tibialis anterior tenosynovitis **P**: 357
- tibialis posterior tendonosis **P**: 357
- tibial nerve **P**: 285
ankle **P**: 290
knee **P**: 288
- tibial nerve block
ankle **P**: 290 *F*, **P**: 291
knee **P**: 288, **P**: 289 *F*
- tic douloureux **Ch**: 134
- ticlopidine, epidural analgesia
contraindication **A**: 518
- Tietze's syndrome **Ch**: 544
- time distortion, hypnotic
experience **P**: 485
- time-to-event data **P**: 572
- time to meaningful pain relief **P**: 522
- time to the first analgesic request
(TFA) **A**: 149
- Tinel's sign
carpal tunnel syndrome **P**: 357–8
tarsal tunnel syndrome **P**: 358
- tissue damage, visceral hypersensitivity
disorders **Ch**: 38
- tissue healing, NSAID-induced
changes **A**: 72–3
- tizanidine
fibromyalgia syndrome **Ch**: 608
neuropathic pain **C**: 209
spasticity pain **Ch**: 330, **Ch**: 445
- toe flexor spasticity **Ch**: 442
- toe pain, spasticity **Ch**: 442
- tolerance
acquired **C**: 105
acute (tachyphylaxis) **C**: 105
children **C**: 354–5
definition **Ch**: 222; **C**: 105, **C**: 156,
C: 191
fear of **C**: 106
learned **C**: 105
- opioids *see* opioid tolerance
- pharmacodynamic **C**: 105
- pharmacokinetic **C**: 105
- TENS **P**: 198
- tolfenamic acid, migraine
prophylaxis **Ch**: 461 *T*
- Tolosa–Hunt syndrome **Ch**: 154–5
- tonicaine **A**: 129
- tonsillectomy **A**: 185, **A**: 489
- tooth extraction, neuropathic orofacial
pain **Ch**: 470
- topical analgesics **Ch**: 230–40
adverse effects **Ch**: 231, **Ch**: 232–3
clinical uses/indications **Ch**: 230–1,
Ch: 233–7
definition **Ch**: 230
drug interactions **Ch**: 231
effectiveness **Ch**: 231
FDA approval **Ch**: 231
HIV-associated oral pain **Ch**: 358
individualized prescribing **Ch**: 231–2
low back pain **Ch**: 236–7
mechanisms of action **Ch**: 230–1,
Ch: 232
myofascial pain **Ch**: 236–7
neuropathic pain **Ch**: 233–5
osteoarthritis **Ch**: 235–6
pharyngitis **A**: 418
postoperative pain **Ch**: 237
pressure ulcers **Ch**: 237
soft-tissue injuries **Ch**: 235–6
systemic analgesics vs. **Ch**: 230
tissue concentration **Ch**: 230
toxicity **Ch**: 231
see also individual analgesics
- topical anesthesia
CRPS **Ch**: 368–9
local anesthetics in **A**: 128
microaerosols **A**: 128
postoperative pain **A**: 330–1
practical aspects **C**: 217
procedure-related pain
cancer patients **C**: 216
children **A**: 487–8, **A**: 493;
C: 349–50
wounds **A**: 367
see also individual drugs
- topical nonsteroidal anti-inflammatory
drugs *see* nonsteroidal
anti-inflammatory drugs (NSAIDs)
- topiramate **Ch**: 256 *T*, **Ch**: 260–2
adverse effects **Ch**: 260–2; **P**: 137
central neuropathic pain **Ch**: 379–80
contraindications **P**: 135
dosage/treatment schedule **P**: 136
elderly **A**: 516
low back pain **Ch**: 260

- mechanism of action **Ch**: 260
metabolism **P**: 135
migraine prophylaxis **Ch**: 459–61,
Ch: 461 *T*
neuropathic pain **Ch**: 260
pediatric headache **Ch**: 632, **Ch**: 633 *T*
spinal cord injury pain **Ch**: 394,
Ch: 396 *T*
“top-to-bottom” model, fibromyalgia
syndrome **Ch**: 604–5
torsade de pointes, methadone
induced **Ch**: 216
total body clearance, drugs **C**: 107
total pain
dying person **C**: 390, **C**: 392
ethical issues **C**: 95
total pain relief (TOTPAR) **P**: 22 *T*,
P: 522
touch
neuropathic pain
assessment **Ch**: 137–8
sensation transmission **P**: 47
toxic neuropathies **Ch**: 341–2
toys, pain intensity
measurement **P**: 15–6, **P**: 17 *F*
TPVB *see* thoracic paravertebral block
(TPVB)
traction
acute low back pain **A**: 451 *T*, **A**: 452
chronic lower back pain **Ch**: 510
traditional Chinese
medicine **Ch**: 307–10
Taoist philosophy **Ch**: 308
traditional medicine *see* complementary
and alternative medicine (CAM)
training lack
analgesia prioritization
failure **Ch**: 103
developing world **A**: 393
trait anxiety **A**: 293
tramadol **A**: 62; **C**: 157–8
abdominal pain **A**: 414
adverse effects **A**: 336, **A**: 486;
C: 157–8, **C**: 190
cancer pain **C**: 158
elderly **C**: 367
neuropathic **C**: 204
children **A**: 485–6; **P**: 465, **P**: 465 *T*
cancer pain **C**: 348
chronic lower back pain **Ch**: 508
chronic noncancer pain **Ch**: 212
paracetamol and **Ch**: 213
constipation induction **C**: 190
dental pain **A**: 362
elderly **A**: 513
emergency departments **A**: 362–3
equianalgesic doses **A**: 547 *T*
fibromyalgia syndrome **Ch**: 607
hyperalgesia induction **Ch**: 219
metabolism **A**: 46, **A**: 62
migraine **A**: 366 *T*
morphine and **Ch**: 214
oral administration **A**: 203
pediatric headache **Ch**: 631
peripheral neuropathic
pain **Ch**: 345 *T*, **Ch**: 347
pharmacodynamics **C**: 157
pharmacokinetics **A**: 59 *T*; **C**: 157
children **A**: 486
pharmacology **C**: 204
postherpetic neuralgia **Ch**: 434–5,
Ch: 434 *T*
postoperative pain **A**: 336
rheumatoid arthritis **Ch**: 521
routes of administration/
formulations **C**: 158
children **A**: 486
sports injuries **A**: 532–3
tolerance **Ch**: 219
trauma **A**: 362
WHO analgesic ladder **C**: 112–3
tranexamic acid **C**: 315
transacral canal **P**: 281
transcranial direct current stimulation
(tDCS), spinal cord injury
pain **Ch**: 395–7, **Ch**: 397 *T*
transcranial magnetic stimulation
(TMS) **C**: 246
transcription **Ch**: 49, **Ch**: 50 *F*
transcutaneous electrical nerve
stimulation (TENS) **P**: 193–205
acupuncture-like *see* AL-TENS
acute pain **A**: 272–7
clinical effectiveness **A**: 277–80,
A: 278; **P**: 200
clinical uses **A**: 275
indications **C**: 236 *T*; **P**: 194–5
angina pectoris **A**: 280; **P**: 195,
P: 197–8
application **P**: 197
sites **P**: 197–8
applied anatomy **P**: 194
cancer pain **C**: 236–43
clinical effectiveness **C**: 238–43,
C: 241
clinical technique **C**: 243
cautions **P**: 195–6
chemotherapy-induced nausea **C**: 243
chronic pain
evidence for use **P**: 200–1
frequency of therapy **P**: 196, **P**: 202
indications **C**: 236 *T*; **P**: 195
chronic pelvic pain **Ch**: 584
complications **P**: 198
concerns **C**: 237
continuous (conventional)
stimulation **P**: 198
application sites **P**: 197
qualities **P**: 199 *T*
contraindications/precautions **A**: 277;
C: 243, **C**: 245 *T*, **C**: 370; **P**: 195
controls **C**: 238 *F*
conventional **A**: 272, **A**: 273 *F*; **C**: 237,
C: 240 *F*
definition **A**: 272
dental pain **P**: 195, **P**: 200
devices **C**: 236, **C**: 237 *F*, **C**: 237 *T*
diabetic neuropathy **P**: 195
dosage **A**: 277
dual channel **C**: 243
dysmenorrhea, primary **A**: 278,
A: 280, **A**: 417; **Ch**: 574
elderly **C**: 370
electrical characteristics **A**: 276
electrodes **P**: 196
carbon-rubber **P**: 196–7
connection to stimulator **P**: 197
position **A**: 276, **A**: 276 *F*; **C**: 243,
C: 244 *F*; **P**: 196, **P**: 197 *F*
self-adhesive **P**: 197
equipment **A**: 272, **A**: 272 *F*; **P**: 196–7
failure **P**: 198
evidence for use **P**: 199–202
experimental **P**: 199–200
results **P**: 199, **P**: 200 *F*
frequency of therapy **P**: 196
functional abdominal pain **Ch**: 635
high vs. low-frequency **P**: 199,
P: 200 *F*
historical aspects **A**: 272; **C**: 235;
P: 193–4
indications **P**: 194–5
intense **A**: 272, **A**: 273 *F*; **C**: 238,
C: 239 *T*, **C**: 240 *F*
intractable angina **P**: 201
labor pain **A**: 277–80, **A**: 278; **P**: 195,
P: 200
limitations **P**: 196
low back pain **A**: 451 *T*, **A**: 452;
Ch: 510
mechanism of action **A**: 272–5,
A: 275 *F*
descending pathways **A**: 274
extra-segmental **A**: 274
high intensity stimulation **A**: 273–4
long-term depression **A**: 273–4
low intensity stimulation **A**: 272–3
segmental mechanisms **A**: 273
somatosensory evoked
potentials **A**: 272
musculoskeletal pain **P**: 195, **P**: 201

- transcutaneous electrical nerve stimulation (TENS) (*continued*)
 myofascial pain **P**: 195, **P**: 201
 neck pain, acute **A**: 278
 neurologic disease pain **Ch**: 331
 neuropathic pain
 evidence for use **P**: 199–200, **P**: 201
 indications **P**: 195
 neuropharmacology **A**: 274–5
 non-pain related effects **C**: 239 *T*
 optimal settings **C**: 236, **C**: 237 *T*
 osteoarthritis **Ch**: 528
 outcome determinants **A**: 276–7
 peripheral neuropathic pain **Ch**: 347
 phantom limb pain **P**: 195
 porphyria **A**: 422
 postamputation pain **Ch**: 423–4
 postherpetic neuralgia **Ch**: 435
 postoperative pain **A**: 277, **A**: 278; **P**: 195
 evidence for use **P**: 200
 frequency of therapy **P**: 196
 procedure-related pain **A**: 280; **C**: 216
 pruritus **C**: 330
 pulse amplitude **A**: 276
 pulsed (burst) stimulation **P**: 198
 application sites **P**: 197
 pulse generator **P**: 196
 rationale **C**: 237–8
 refractory angina pectoris
 Ch: 540
 renal colic **A**: 415
 sequential stimulation **P**: 198
 sham treatment **Ch**: 268–9
 short-term effects **C**: 243
 shoulder pain **A**: 437
 sickle cell disease pain **A**: 421
 side effects **P**: 199
 spasticity/spasticity pain **P**: 195, **P**: 201
 spinal cord injury pain **Ch**: 395–7, **Ch**: 397 *T*
 stimulation modality choice **P**: 198, **P**: 199
 stimulation types **P**: 197
 stimulator settings **P**: 198
 subthreshold **P**: 199
 techniques **C**: 237, **C**: 239 *T*
 TENS **P**: 200
 timing **A**: 277
 tolerance **P**: 198
 treatable conditions **C**: 239 *T*
 trial **A**: 275; **P**: 198
 tumor growth and **C**: 237
 tumor-induced pain **C**: 241
 wires **P**: 196
see also individual pain types
- transcutaneous spinal electroanalgesia (TSE) **C**: 238
- transdermal drug
 administration **A**: 206–7; **C**: 110; **P**: 304
 corticosteroids, sports injuries **A**: 535
 lipid-soluble drugs **A**: 206
 nonopioid analgesics **A**: 206–7
 NSAIDs **A**: 534
 opioids **A**: 207
 dying person **C**: 393
 physical methods **A**: 206
 see also individual drugs
- transdermal reservoir, fentanyl **A**: 207
- Transdiscal Annuloplasty (Biacuplasty) **P**: 441
- transduction, peripheral nociceptor sensitization **Ch**: 28
- TRANSFENTA **P**: 304–5
- transfer RNA (tRNA) **Ch**: 49
- transient neurologic symptoms (TNS), local anesthetics **A**: 257
- transient pain *see* breakthrough pain
- transient radicular irritation (TRI) **A**: 122
- transient receptor potential (TRP)
 family **A**: 6, **A**: 7 *F*
- transient receptor potential ion channel A1 (TRPA1)
 cold response **Ch**: 9
 nerve injury response **Ch**: 9–10
- transient receptor potential ion channel V1 (TRPV1)
 heat response **Ch**: 9
 nerve injury response **Ch**: 9–10
- transient receptor potential of vanilloid receptor 1 (TRPV1) **A**: 33
 capsaicin **Ch**: 232, **Ch**: 347
- transitional zone spinal pain *see* spinal cord injury (SCI) pain, at-level neuropathic pain
- transitory pain *see* breakthrough pain
- transmucosal drug
 administration **A**: 207–8; **C**: 111
 opioids *see* opioid(s)
- transmucosal patient-controlled analgesia **A**: 218–9
- transmyocardial revascularization (TMR), refractory angina pectoris **Ch**: 541
- transport, field/disaster situations **A**: 376–7
- transvaginal ultrasound, pelvic congestion **Ch**: 577
- transverse fractures **A**: 528
- transverse ligament of atlas tears **Ch**: 159
- trauma
 acupuncture **A**: 285
 acute pain **A**: 309
 brachial plexus neuropathies **Ch**: 343
 CRPS, children **Ch**: 626
 developing world **A**: 389–90
 musculoskeletal spinal cord injury **Ch**: 392–3
 neuropathic orofacial pain **Ch**: 470
 neuropathic pain **Ch**: 4 *T*
 persistent musculoskeletal pain **Ch**: 26
 persistent visceral pain **Ch**: 38
 response to, postnatal nociception development **A**: 39–45, **A**: 40–2 *T*
 substance abuse/misuse **Ch**: 657
 traumatic dissociation, pain **P**: 146
 traumatic neuropathy, as clinical trial model **P**: 558
- trazodone
 central neuropathic pain **Ch**: 381–2 *T*
 pediatric headache **Ch**: 632
 spinal cord injury pain **Ch**: 396 *T*
- treatment
 adherence **P**: 96
 appropriate, developmental challenges **P**: 96
 outcome evaluation *see* outcome evaluation, treatment
 selection, established evidence in **P**: 96
 treatment contracts, physiotherapy **P**: 226
 treatment guides, chronic pain **Ch**: 179
 Treatment Outcomes in Pain Survey **Ch**: 173
 treatment safety measurement **Ch**: 179
 treatment tailoring **P**: 101–2
 barriers to change identification **P**: 102
 history of failure **P**: 102
 patient vs. intervention selection **P**: 101–2
 priority order identification **P**: 102
 treatment uniformity myth **P**: 96
 trialability **P**: 608
 APS recommendations **P**: 608
 triamcinolone **P**: 419
 trichloroethylene, burn pain **A**: 404
 tricyclic antidepressants (TCAs) **Ch**: 243–4, **Ch**: 244 *T*; **P**: 137
 acute pain **A**: 105
 adverse effects **A**: 516; **Ch**: 243–4, **Ch**: 345; **P**: 139–8
 atypical facial pain **Ch**: 475

- burn pain **A:** 403–4
 children **C:** 351–3
 pre-treatment investigations **C:** 353
 chronic pelvic pain **Ch:** 584
 contraindications **P:** 137
 CRPS **Ch:** 234
 children **Ch:** 627
 depression, cancer patients **C:** 332
 dosing and treatment schedule **P:** 138
 elderly **A:** 516; **C:** 369
 evidence-based outcomes **Ch:** 244–5
 fibromyalgia syndrome **Ch:** 245,
 Ch: 607
 HIV-associated neuropathy **Ch:** 244
 juvenile fibromyalgia
 syndrome **Ch:** 625
 low back pain **Ch:** 244–5
 mechanism of action **Ch:** 243,
 Ch: 345, **Ch:** 394
 metabolism **P:** 138
 neurologic disease pain **Ch:** 329–30
 neuropathic pain **Ch:** 244
 cancer-induced/related **C:** 205
 orofacial pain **Ch:** 472
 peripheral **Ch:** 345
 pediatric headache **Ch:** 632
 pharmacokinetic variability **P:** 138
 pharmacology **Ch:** 243–4
 postamputation pain **Ch:** 244,
 Ch: 415, **Ch:** 422
 postherpetic neuralgia **Ch:** 234,
 Ch: 433, **Ch:** 434 *T*
 structure **Ch:** 243
 temporomandibular
 disorders **Ch:** 469–70
 tension-type headache
 prophylaxis **Ch:** 461–2
 therapeutic drug monitoring **P:** 138
 topical application **Ch:** 234
 case example **Ch:** 234–5
 toxicity **P:** 138
 vulvodynia **Ch:** 590
 see also individual drugs
 trigeminal ganglion **P:** 343
 migraine **Ch:** 453
 trigeminal ganglion neurolysis **P:** 343–5
 anatomy **P:** 343
 complications **P:** 345
 indications **P:** 343
 landmarks **P:** 344, **P:** 344 *F*
 results **P:** 345
 technique **P:** 343–4, **P:** 344 *F*
 trigeminal neuralgia **P:** 343
 trigeminal nerve
 cryoanalgesia **P:** 384–5
 in Gasserian ganglion **P:** 392–3
 peripheral branch blocks **P:** 259–60
 anatomy **P:** 260, **P:** 260 *F*
 indications **P:** 260 *T*
 see also individual branches
 trigeminal neuralgia **Ch:** 472–3
 definition **Ch:** 472
 differential diagnosis **Ch:** 473
 epidemiology **Ch:** 472–3
 management **Ch:** 473
 multiple sclerosis **Ch:** 326
 neuropathic pain models **Ch:** 5–6
 pathophysiology **Ch:** 473
 patient history **Ch:** 473
 radiofrequency lesioning **C:** 233;
 P: 392
 symptomatology **Ch:** 473
 trigeminal ganglion neurolysis **P:** 343
 trigeminal nucleus, migraine **Ch:** 453
 trigeminocervical convergence **P:** 383
 trigger finger **P:** 355–6
 trigger point(s)
 myofascial pain **Ch:** 601
 neck pain **Ch:** 488–9
 noninflammatory joint pain **A:** 436
 spinal pain **Ch:** 157
 trigger point injections
 chronic pelvic pain **Ch:** 584
 myofascial pain **Ch:** 608
 trigger thumb, soft-tissue
 injection **P:** 356
 triiodothyronine, fibromyalgia
 syndrome **Ch:** 603
 Trilisate (choline magnesium
 trisilicylate), children **C:** 348
 triptan(s)
 mechanism of action **Ch:** 455
 migraine **Ch:** 455–7
 contraindications **Ch:** 460 *T*
 cost **Ch:** 457
 doses **Ch:** 460 *T*
 emergency department **A:** 365
 limited use **Ch:** 457
 meta-analysis **Ch:** 455–6, **Ch:** 458 *F*
 nontriptans vs. **Ch:** 456–7,
 Ch: 456 *T*
 randomized clinical
 trials **Ch:** 455–7, **Ch:** 457 *T*
 therapeutic use **Ch:** 457
 type variations **Ch:** 457
 pediatric headache **Ch:** 630–1
 see also individual drugs
 Trivandurum Regional Cancer
 Centre **C:** 87
 Trk receptors, brain-derived
 neurotrophic factor **Ch:** 12
 trochanteric bursitis **Ch:** 530; **P:** 356
 soft-tissue injection **P:** 356
 tropisetron
 fibromyalgia syndrome **Ch:** 607
 nausea and vomiting
 cancer patients **C:** 320 *T*
 opioid-induced **C:** 191
 PCA **P:** 297
 tumor, musculoskeletal pain **A:** 431–2
 tumor-induced pain
 abdominal, HIV patients **Ch:** 358
 children **C:** 346
 chronic pelvic pain **Ch:** 578–9
 etiology **C:** 345–6
 neck pain **Ch:** 488, **Ch:** 490
 TENS **C:** 241
 see also cancer pain
 tumor necrosis factor α (TNF- α)
 arthritis **Ch:** 29
 neuropathic pain **Ch:** 10
 tumor necrosis factor- α inhibitors,
 rheumatoid arthritis **Ch:** 521,
 Ch: 522–4 *T*
 Tuohy needles, continuous peripheral
 nerve blockade **A:** 243–4; **P:** 258
 twin studies **Ch:** 55
 fibromyalgia syndrome **Ch:** 603
 two-dimensional gel electrophoresis,
 proteomics **Ch:** 59
 Uganda
 healthcare spending **A:** 391 *T*
 morphine use **C:** 89
 UGT2B7 expression, opioid response
 variability **C:** 173
 UK National Paediatric Epidural
 Audit **P:** 644–5
 ulcerative colitis (UC) **A:** 416–7;
 Ch: 561
 ulnar nerve
 arm **P:** 265
 axilla **P:** 269, **P:** 269 *F*
 elbow **P:** 270
 wrist **P:** 273
 ulnar nerve block
 elbow **P:** 271–2
 anatomy **P:** 270
 landmarks **P:** 271
 practical steps/technique **P:** 271–2,
 P: 271 *F*
 forearm fractures **A:** 368
 wrist (medial approach) **P:** 273,
 P: 273 *F*
 ulnar nerve entrapment
 nerve conduction studies **Ch:** 149–50
 neuropathic pain **Ch:** 342–3
 ultrasound
 catheter placement **A:** 332
 chronic pain **Ch:** 148–9
 chronic pelvic pain **Ch:** 583

- ultrasound (*continued*)
 continuous peripheral neural blockade **A:** 244
 joint pain **A:** 433
 postamputation pain **Ch:** 423–4
 rheumatoid arthritis **Ch:** 520
 shoulder pain **A:** 437
 ultrasound-guided nerve blocks **P:** 257–8
 brachial plexus, children **P:** 471
 ultraviolet light, pruritus **C:** 330
 understaffing, developing world **A:** 393
 undertreatment **C:** 115
 unique spinal pathway, persistent visceral pain **Ch:** 40
 United Kingdom (UK)
 acute pain service organizational models **P:** 582
 controlled drugs *see* controlled drugs (CDs)
 healthcare spending **A:** 391 *T*
 at home medication provision **C:** 414
 palliative home care teams **C:** 412–3
 United States of America (USA)
 CAM **Ch:** 305
 controlled drugs *see* controlled drugs (CDs)
 health care spending **A:** 391 *T*
 palliative care **C:** 412
 palliative home care teams **C:** 413
 quality improvement initiatives, pain management **P:** 672–4
 United States Veteran Administration **A:** 328
 upper limb(s)
 continuous peripheral neural blockade **A:** 237–9
 nerve blocks **P:** 264–74
 pain management, radiotherapy **C:** 254
 spasticity pain **Ch:** 442
 upper motor neuron syndrome (UMNS) **Ch:** 440–1, **Ch:** 441 *T*
 upside assay sensitivity **P:** 516, **P:** 534
 uremic itch **C:** 330–1
 uremic neuropathy **Ch:** 151 *T*
 ureteric contractions, opioid-induced **A:** 57
 urethral syndrome **Ch:** 580
 uridine-
 diphosphoglucuronosyltransferase (UGT) system **C:** 173
 urinary bladder distension studies **Ch:** 40–1
 urinary incontinence, strontium contraindication **C:** 263
 urinary retention
 dying person **C:** 394
 epidural analgesia **A:** 258; **P:** 474
 opioid-induced **A:** 258; **C:** 155–6
 children **C:** 353 *T*
 PCA complications **A:** 228–9
 urinary tract infections **Ch:** 393
 urokinase, refractory angina pectoris **Ch:** 541
 urolithiasis, recurrent **Ch:** 564
 urticaria, opioid-induced **A:** 57
 USA *see* United States of America (USA)
 US Headache Consortium, biofeedback evaluation **P:** 164
 US National Cancer Institute, ongoing RCT register **P:** 570 *T*
 uterine cancer, radiotherapy **C:** 254
 uterine contractions, TENS **P:** 201
 uterine leiomyomata **Ch:** 578–9
 uterosacral transection *see* laparoscopic uterine nerve ablation (LUNA)
 utility measure, chronic pain **Ch:** 180
 vaginal delivery, epidural analgesia *see* epidural analgesia
 vagus nerves **A:** 7–8
 valaciclovir, herpes zoster **Ch:** 432
 valdecoxib
 adverse effects **A:** 78
 cardiovascular risk **C:** 137
 withdrawal **A:** 78; **Ch:** 195–6; **C:** 127, **C:** 137
 valerian **Ch:** 314 *T*
 validity, pain measures *see* pain measures
 valproate
 adverse effects **A:** 103–4; **Ch:** 263; **P:** 137
 central neuropathic pain **Ch:** 379–82 *T*
 contraindications **P:** 135
 diabetic neuropathy **Ch:** 263
 dosage/treatment schedule **P:** 136
 efficacy **Ch:** 261 *T*
 emergency departments **A:** 366
 metabolism **P:** 135
 migraine
 prophylaxis **Ch:** 461 *T*
 therapy **A:** 104–5, **A:** 366
 neuropathic pain **Ch:** 256 *T*, **Ch:** 263
 cancer patients **C:** 206
 pediatric headache **Ch:** 631
 dosages **Ch:** 633 *T*
 perioperative use **A:** 104
 peripheral neuropathic pain **Ch:** 346
 pharmacokinetics **A:** 103 *T*
 postherpetic neuralgia **Ch:** 435
 pretreatment blood tests **P:** 137
 spinal cord injury pain **Ch:** 394, **Ch:** 396 *T*
 tension-type headache
 prophylaxis **Ch:** 461–2
 valproic acid *see* valproate
 values, definition **P:** 169–70
 values-based action **P:** 169–70
 values clarification **P:** 169–70
 values failure **Ch:** 174
 varicella (chickenpox) **Ch:** 429–30, **Ch:** 430 *F*
 varicella-zoster vaccine
 herpes zoster prevention **Ch:** 431–2
 postherpetic neuralgia prevention **Ch:** 343, **Ch:** 431–2
 varicella zoster virus (VZV) **Ch:** 429–30;
see also herpes zoster
 varicocele **Ch:** 563
 variegated porphyria **Ch:** 562–3
 VAS *see* visual analog scale (VAS)
 vascular amputees, phantom pain **Ch:** 417
 vascular disorders, diagnosis **Ch:** 154, **Ch:** 154 *T*
 vascular flow, axillary brachial plexus blocks **A:** 237
 vascular surgery, neuraxial analgesia **A:** 263
 vasculitic neuropathy **Ch:** 342
 vasculitis, diagnosis **Ch:** 151 *T*
 vasectomy, CPSP **Ch:** 406–7
 vasoactive intestinal peptide (VIP)
 acupuncture **P:** 209
 peripheral sensitization **Ch:** 29
 vasoconstrictor(s), local anesthetics **A:** 118
 vasomotor changes, CRPS *see* complex regional pain syndrome (CRPS)
 venipuncture, neonates **A:** 493
 venlafaxine **Ch:** 244 *T*
 adverse effects **Ch:** 245
 chemotherapy-induced neuropathy treatment **C:** 8–9
 clinical use **A:** 105
 dosage **P:** 138
 neuropathic pain **Ch:** 245
 cancer-induced/related **C:** 205–6
 peripheral **Ch:** 346
 pediatric headache **Ch:** 632
 pharmacology **Ch:** 245
 postbreast cancer surgery pain **C:** 404–5
 postmastectomy pain syndrome **C:** 205–6
 preventive analgesia **A:** 185

- spinal cord injury pain **Ch:** 394–5,
Ch: 396 *T*
- venous congestion, human visceral pain
models **Ch:** 41
- ventilator(s), ICUs **A:** 346
- venting gastrostomy
bowel obstruction **C:** 322
nausea and vomiting **C:** 319
- ventricular fibrillation,
bupivacaine-induced **A:** 127
- ventrobasal complex, persistent
musculoskeletal pain **Ch:** 32
- ventrolateral medulla, persistent visceral
pain **Ch:** 40
- ventroposteriomedial nucleus, deep
brain stimulation **Ch:** 279–80
- verapamil
cluster headache prophylaxis **Ch:** 462
migraine prophylaxis **Ch:** 461 *T*
pediatric headache **Ch:** 632 *T*
- verbal analog scales **Ch:** 124
- verbal category scales **Ch:** 139–40
- verbal descriptor scale (VDS) *see* verbal
rating scale (VRS)
- verbal numerical rating scale
(VNRS) **A:** 140
burn pain assessment **A:** 402
elderly pain assessment **A:** 512
- verbal rating scale (VRS) **A:** 139–40;
P: 15
advantages **A:** 139
burn pain **A:** 402
cancer pain clinical trials **P:** 540–1
clinical trial outcomes **P:** 521
dental pain model **P:** 532
developing world **A:** 394
disadvantages **A:** 139–40
elderly pain assessment
acute pain **A:** 512
cancer pain **C:** 361
chronic pain **Ch:** 644, **Ch:** 646
patient interpretation **P:** 15
- vertebral arteries **P:** 265, **P:** 327
unintentional stellate ganglion
block **P:** 329
- vertebral canal **P:** 417
- vertebral collapse **C:** 266
- vertebral degeneration **Ch:** 146
- vertebral metastases
C7–T1 **C:** 28–9, **C:** 29 *T*
MRI **C:** 28, **C:** 30 *F*
pain syndromes **C:** 28–9, **C:** 29 *T*
differential diagnosis **C:** 28
osteoporosis *vs.* **C:** 28
- vertebrobasilar artery ischemia,
chiropractic therapy **Ch:** 313
- vertical infraclavicular block **A:** 239
- vestibulectomy, vulvodynia **Ch:** 591
- vestibulodynia **Ch:** 589
definition **Ch:** 587
models **Ch:** 589, **Ch:** 589 *F*
symptoms **Ch:** 589
see also vulvodynia
- vibrometer testing **P:** 48
- vibration
hyperalgesia to **P:** 48
transmission **P:** 47
- vibratory threshold estimation **P:** 48
- video-assisted thoracoscopy, thoracic
epidural analgesia **A:** 263
- videothoroscopic splanchnicectomies,
pancreatic cancer pain **Ch:** 552
- Vietnam, healthcare spending **A:** 391 *T*
- VIGOR trial **C:** 133
- vincristine-induced neuropathy
animal models **C:** 8
pathophysiology **C:** 7
treatment **C:** 8–9
- visceral disorders, diagnosis **Ch:** 154,
Ch: 154 *T*
- visceral hypersensitivity
disorders **Ch:** 38–9
chronic pancreatitis **Ch:** 38
imaging **Ch:** 38
inflammation **Ch:** 38
interstitial cystitis **Ch:** 38
irritable bowel syndrome **Ch:** 38;
P: 88
markers **Ch:** 38
noncardiac chest pain **Ch:** 38
postcholecystectomy
syndrome **Ch:** 38
psychological modifiers **Ch:** 38–9
psychophysical studies **Ch:** 38
sensitization process **Ch:** 38–9
tissue damage **Ch:** 38
- visceral injury, postnatal nociception
development *see* nociception,
postnatal development
- visceral innervation, chronic pelvic
pain **Ch:** 571–2
- visceral nociceptors, spinal cord **A:** 9
- visceral pain
cancer-induced **Ch:** 560–1; **C:** 9
animal models **C:** 9
autonomic reflexes and **C:** 9
chest *see* chest pain
CPSP **Ch:** 406
definition **C:** 41; **P:** 45
diagnostic blocks **Ch:** 152
elderly patient pain **Ch:** 642,
Ch: 643
labor pain **A:** 464
persistent *see* visceral pain, persistent
- spinal cord injury *see* spinal cord
injury (SCI) pain
- spinal cord stimulation *see* spinal cord
stimulation (SCS)
- TENS **P:** 195, **P:** 201
- visceral pain, persistent **Ch:** 37–47
definition **Ch:** 37
experience of **Ch:** 37–8
chemical stimuli **Ch:** 38
functional alterations **Ch:** 38
ischemia **Ch:** 38
localization **Ch:** 37–8
mechanical/stretch
distension **Ch:** 38
secondary hyperalgesia **Ch:** 37–8
trauma **Ch:** 38
mechanisms **Ch:** 42–3
developmental changes **Ch:** 43
inflammation **Ch:** 42
neuropathic changes **Ch:** 43
peripheral pathways **Ch:** 39,
Ch: 39 *F*
stress **Ch:** 42–3
unique spinal pathway **Ch:** 40
models **Ch:** 41
animal models **Ch:** 41, **Ch:** 42–3
human models **Ch:** 41
neuropathic changes **Ch:** 43
nociceptive processing **Ch:** 43
spinal dorsal horn neurons **Ch:** 40
supraspinal terminations **Ch:** 40–1
- viscerosomatic convergent neurons,
referred pain **A:** 11
- visual analog scale (VAS) **A:** 141–2,
A: 141 *F*; **P:** 15
acute pain **A:** 141–2
advantages **A:** 141
burn pain assessment **A:** 402
cancer pain clinical trials **P:** 540–1
children
acute pain assessment **P:** 450,
P: 451 *F*
chronic pain assessment **P:** 455–6
chronic pain **Ch:** 118
clinical settings **A:** 142
clinical trial outcomes **P:** 521
dental pain model **P:** 532
depression **C:** 39
design **A:** 141
developing world **A:** 394
disadvantages **A:** 142
dying person **C:** 392
elderly pain assessment
cancer pain **C:** 361
chronic pain **A:** 512
intravenous lidocaine trial **P:** 57
neuropathic pain **Ch:** 139–40

- visual analog scale (VAS) (*continued*)
 numerical rating **A:** 142
 pain intensity measurement **P:** 15
 drawbacks/limitations **P:** 15
 phantom pain **Ch:** 416
 presurgical anxiety
 assessment **P:** 247–8
 psychological assessment **Ch:** 124,
 Ch: 125
 ratio properties **P:** 15
 reproduction, care in **P:** 15
 research **A:** 142
 types **P:** 15, **P:** 16 *F*
- visualization **C:** 277
- visual stimuli, migraine **Ch:** 452–3
- vital signs monitoring equipment, field/
 disaster situations **A:** 383
- vitamin B₁ deficiency **Ch:** 340
- vitamin B₆ deficiency **Ch:** 340–1
- vitamin B₁₂ deficiency **P:** 68
 diagnosis **Ch:** 151 *T*
 nitrous oxide contraindications **A:** 98
 nonhematological manifestation **P:** 68
- vitamin D deficiency **P:** 68
- VNRS *see* verbal numerical rating scale
 (VNRS)
- voltage-gated calcium channel(s)
 α_{2δ}-1 subunit **Ch:** 6 *F*, **Ch:** 9
 anticonvulsants **A:** 103
 blockers, spinal
 administration **Ch:** 287
 dorsal horn plasticity **A:** 25–6
 neuropathic pain **Ch:** 6 *F*, **Ch:** 9,
 Ch: 12
 N-type **Ch:** 9
- voltage-gated ion channel(s)
 peripheral sensitization **A:** 21
see also individual types
- voltage-gated potassium channel(s)
 K_v1.1 **Ch:** 9
 K_v1.2 **Ch:** 9
 K_v1.4 **Ch:** 9
 K_v1.8 **Ch:** 9
 neuropathic pain **Ch:** 9
 peripheral neuropathies **Ch:** 336–7
 peripheral nociceptor
 sensitization **Ch:** 28–9
- voltage-gated sodium channel(s)
 α subunit **A:** 114–5
 β subunit **A:** 114–5
 blockade
 antiarrhythmics **Ch:** 263
 antiepileptics **Ch:** 254–5
 postamputation pain **Ch:** 422
 local anesthetics **A:** 114–5, **A:** 115
 Na_v1.3 **Ch:** 7–8
 peripheral nerve injury **Ch:** 9
 Na_v1.7 **Ch:** 7–8
 hereditary erythromelalgia **Ch:** 342
 neuropathic pain **Ch:** 9
 pain sensitivity **Ch:** 60
 Na_v1.8 **Ch:** 7–8
 neuropathic pain **Ch:** 7–8
 peripheral neuropathies **Ch:** 336–7
 Na_v1.9 **Ch:** 7–8
 neuropathic pain **Ch:** 7–8
 peripheral nerve injury **Ch:** 9
 peripheral neuropathies **Ch:** 336–7
 neuropathic pain **Ch:** 6 *F*, **Ch:** 7–9
 peripheral **Ch:** 336–7
 peripheral nerve injury **Ch:** 9
 peripheral sensitization **A:** 23
 posttranslational
 modifications **A:** 23–4
 saxitoxin binding **A:** 116
 structure **A:** 114–5, **A:** 115 *F*
 subtypes **A:** 23–4
 tetrodotoxin-resistant **A:** 23
 postnatal development **A:** 33
 tetrodotoxin-sensitive **A:** 23, **A:** 116
 postnatal development **A:** 33
 tetrodotoxin sensitivity
 classification **Ch:** 7–8
 tissue distribution **A:** 115
 volume of distribution (*V_d*)
 definition **C:** 107
 initial-steady state differences **C:** 107,
 C: 108
 loading dose calculations **C:** 108
 opioids **A:** 58; **C:** 107
- vomiting *see* nausea and vomiting
- vomiting (emetic) pattern generator
 (VPG) **C:** 318, **C:** 318 *F*
- von Frey nylon filaments
 allodynia testing **P:** 47–8
 bending force values **P:** 47
 neuropathic pain assessment **Ch:** 138,
 Ch: 139 *T*
 secondary hyperalgesia testing **P:** 47–8
 tactile sensibility estimation **P:** 47–8
- VPL nucleus, deep brain
 stimulation **Ch:** 279–80
- ulnar dermatitis **Ch:** 587–8
- ulnar dermatoses **Ch:** 588
- ulnar vestibulitis syndrome *see*
 vestibulodynia
- ulnarodynia **Ch:** 587–9
 clinical evaluation **Ch:** 588–9
 examination **Ch:** 589
 history **Ch:** 588–9
 definition **Ch:** 587–8
 dysesthetic **Ch:** 588
 epidemiology **Ch:** 588
 etiology **Ch:** 588, **Ch:** 588 *T*
 management **Ch:** 589–91
 behavioral therapies **Ch:** 591
 biofeedback **Ch:** 591
 diet **Ch:** 591
 perineoplasty/
 vestibulectomy **Ch:** 591
 pharmacological **Ch:** 590–1
 psychological therapies **Ch:** 591
 surgery **Ch:** 591
 prognosis **Ch:** 591
 vulvovaginitis, chronic **Ch:** 587
- waiting list controls (WLC),
 CBT **Ch:** 298–9
- Wallenberg's syndrome (lateral
 medullary infarctions) **Ch:** 377
- wallerian degeneration
 neurolysis **C:** 226
 neuropathic hypersensitivity **Ch:** 7
- warfare *see* field/disaster situations
- warfarin
 drug interactions
 NSAIDs **A:** 74 *T*
 paracetamol **A:** 86, **A:** 86 *F*, **A:** 452
 elderly **C:** 365
 epidural analgesia
 contraindication **A:** 518
- warm sensations, neuropathic pain
 assessment **Ch:** 137–8
- washout periods, crossover
 studies **P:** 555–6
- water baths, labor pain
 treatment **A:** 469
- weather extremes, field/disaster
 situations **A:** 376
- Wegener's granulomatosis **Ch:** 342;
P: 70
- weight loss, depression **Ch:** 615
- Western Asia, palliative care
 services **C:** 86
- western blots **Ch:** 62 *T*
- Western Europe, palliative care
 services **C:** 86
- western medical acupuncture
 adverse effects **P:** 209
 approach **C:** 271
 clinical aspects **P:** 216–7
 definitions/interpretations **P:** 208
 “dosage” **P:** 216–7
 dry needling, trigger points
 P: 216
 introducers **P:** 216
 muscle needling **P:** 216
 needle technique **P:** 216
 patient selection **P:** 216
 periosteal needling **P:** 216
 point location **P:** 216

- point selection **P**: 207 *F*, **P**: 210 *F*,
P: 212–6, **P**: 212 *F*, **P**: 213–5 *T*
distant **P**: 212
modifications **P**: 212
repeat treatments **P**: 217
responses **P**: 216
initial **P**: 217
safety **P**: 209–11
skin impedance **P**: 216
superficial needling **P**: 216
technique **P**: 209–17
see also acupuncture
- western medicine distrust, developing
world **A**: 393
- Western Ontario and McMaster
University Osteoarthritis Index
(WOMAC) **Ch**: 212
- whiplash **Ch**: 489–91
biofeedback **P**: 149–50
diagnosis **Ch**: 156
epidemiology **Ch**: 489
etiology **Ch**: 489–90, **Ch**: 490 *F*
natural history **Ch**: 489
prognostic factors **Ch**: 489
recovery rates **Ch**: 489
risk factors **Ch**: 489
see also neck pain
- whiplash syndrome **P**: 680
- white willow **Ch**: 315 *T*
- WHO *see* World Health Organization
(WHO)
- WHO analgesic ladder **C**: 111–4,
C: 112 *F*
adjuvant drugs **C**: 111, **C**: 113–4
breakthrough pain **C**: 289
children **C**: 347
coanalgesic drugs **C**: 111, **C**: 113
developing world **A**: 394, **A**: 394 *F*
elderly pain management **Ch**: 646
HIV-associated pain treatment **A**: 413
interventional therapies **C**: 111
limitations **C**: 82
in opioid rotation **C**: 182
principles **C**: 109
step one: use of nonopioids **C**: 111–2
step two: use of weak
opioids **C**: 112–3
validity **C**: 112
step three: use of strong
opioids **C**: 113
underutilization **C**: 113
- wide dynamic range (WDR)
neurons **A**: 9
cancer-induced bone pain **C**: 5
neuropathic pain **Ch**: 136
- wide field irradiation, bone
pain **C**: 261–2, **C**: 262 *F*
- doses **C**: 261–2
efficacy **C**: 262
toxicity **C**: 262 *T*
- wind up
dorsal horn plasticity **A**: 24
features **A**: 24; **Ch**: 11–2; **P**: 44
myofascial pain **Ch**: 605
neuropathic pain **Ch**: 11–2
opioid effectiveness **C**: 202–3, **C**: 207
- wind up-like pain **Ch**: 136; **P**: 50
repetitive stimulation **Ch**: 136
- Winnie three-in-one block (distal
lumbar plexus block) *see* fascia
iliaca compartment block
- wires, TENS **P**: 196
- wire stents
airway obstruction **C**: 312
superior vena caval
obstruction **C**: 312
- Wisconsin Brief Pain Questionnaire
(WBPQ) *see* Brief Pain Inventory
(BPI)
- withdrawal of care **A**: 350–1
- withdrawal reflexes, nociceptive
development *see* nociception,
postnatal development
persistent musculoskeletal
pain **Ch**: 30
- withdrawal symptoms **C**: 106
children **C**: 355
ICU patients **A**: 348
prevention **C**: 106
see also individual drugs
- withdrawal syndrome, opioids **P**: 113
- withholding treatment **A**: 350–1
- WOMAC (Western Ontario and
McMaster University
Osteoarthritis) Index **Ch**: 212
- Wong-Baker FACES Pain Rating
Scale **A**: 145; **P**: 449, **P**: 449 *F*
- Woodruff procedure,
vulvodynia **Ch**: 591
- work deferment, low back pain **A**: 447
- work effects, disability
measurement **Ch**: 119
- Work Limitations Questionnaire
(WLQ) **Ch**: 118–9
- workload, opioid-tolerant
patients **A**: 541
- work-related activities, pain-related fear
assessment **P**: 180
- World Anti-doping Agency
(WADA) **A**: 533
- World Federation of Societies of
Anaesthesiologists (WFSA),
developing world **A**: 394, **A**: 394 *F*
- World Health Organization (WHO)
cancer pain relief guidelines **C**: 104
aims **C**: 109, **C**: 114
apparent failure **C**: 116
attention to detail **C**: 109, **C**: 114–5
availability **C**: 110 *T*
children **C**: 345
by the clock **C**: 109, **C**: 111
efficacy **C**: 115–6
evaluation **C**: 115–6
history/examination **C**: 109
implementation difficulties **C**: 115
for the individual **C**: 109, **C**: 114
by the ladder *see* WHO analgesic
ladder
by the mouth **C**: 109–11, **C**: 116
prescription
modifications **C**: 114–5
principles **C**: 108–15
reassessment **C**: 114–5
written instructions **C**: 114
- essential drug list **A**: 395, **A**: 395 *T*
“foundation measures” **C**: 82
- opioids for nonmalignant pain **P**: 110
- palliative care definition **C**: 412
- Programme for Cancer Pain
Relief **C**: 82
- World Medical Association
placebo use ethics **P**: 559
post clinical trial access to
treatment **P**: 563
website **P**: 564
- world medicine *see* complementary and
alternative medicine (CAM)
- wound(s)
analgesia, emergency
departments **A**: 366–7
depth, burns **A**: 400
infiltration
acute postoperative pain **A**: 330–1
developing world **A**: 396
- wound dressings, burns **A**: 402, **A**: 405
- wound packs, field/disaster
situations **A**: 379
- wrist
fractures **A**: 368
intra-articular injection **P**: 352,
P: 352 *F*
nerve blocks **P**: 273
anatomy **P**: 273
complications **P**: 274
indications **P**: 273
soft-tissue injection **P**: 355–6
tenosynovitis **Ch**: 529 *T*
- wrist pain **A**: 438–9
clinical features **A**: 439
entities **A**: 438
investigations **A**: 439

- wrist pain (*continued*)
management **A:** 439
- written consent, clinical trials
P: 555
- written supplements, CBT **Ch:** 295
- xerostomia
antidepressant-induced **P:** 139
cancer patients **C:** 316
causes **C:** 316 *T*
definition **C:** 192
HIV-associated oral pain **Ch:** 358
opioid-induced **C:** 192
epidemiology **C:** 192
etiology **C:** 192
management, evidence-based
evaluation **C:** 192
pathophysiology **C:** 192
treatment **C:** 316
- X-linked inheritance **Ch:** 53
- X-rays *see* radiography
- yellow flags
abdominal pain, acute **A:** 414
chronic pain development **A:** 296
low back pain **A:** 446–7;
Ch: 504
manual medicine **P:** 231
- physiotherapy patient
evaluation **P:** 223
- sciatica **P:** 232, **P:** 233 *T*
- Y-linked inheritance **Ch:** 53
- yohimbe **Ch:** 315 *T*
- zalcitabine, toxic neuropathy **Ch:** 341–2,
Ch: 355
- ziconotide
cancer pain **Ch:** 288
spinal drug administration **Ch:** 287,
Ch: 288
complications **P:** 377
- zoledronate, hypocalcemia **C:** 321
- zolmitriptan
migraine **Ch:** 460 *T*
pediatric headache **Ch:** 631 *T*
- zolpidem, fibromyalgia
syndrome **Ch:** 608
- zonisamide, pediatric
headache **Ch:** 632, **Ch:** 633 *T*
- zoster sine herpete **Ch:** 431
- zygapophyseal joint
anatomy **P:** 362, **P:** 362 *F*
innervation **P:** 362
- zygapophyseal joint blocks/
injections **P:** 361–9
aims **P:** 363
- aseptic technique **P:** 364
- cervical *see* cervical zygapophyseal
blocks
- chronic spinal pain **Ch:** 163
- complications **P:** 366–7
- contraindications **P:** 363
- evidence for **P:** 367–8
- indications **P:** 362–3
- low back pain **A:** 451 *T*, **A:** 453
- lumbar *see* lumbar zygapophyseal
blocks
- needles **P:** 364
insertion, fluoroscopy
screening **P:** 363–4
- noninvasive monitoring **P:** 364
- patient discharge **P:** 364
- preparation **P:** 363–6
- treatment limitations **P:** 363
- zygapophyseal joint pain
cervical **P:** 363
- diagnostic blocks **P:** 363
- features **P:** 362
- lumbar **P:** 363
- referred **Ch:** 486, **Ch:** 544
- spinal pain **Ch:** 157
- testing **P:** 363
- whiplash **Ch:** 489–90, **Ch:** 490 *F*
- zygomatico-orbital fractures **Ch:** 471